Allergic reactions to β-lactam antibiotics: chemical approaches for improving in vitro diagnosis by Martín-Serrano Ortiz, Ángela
TE
SI
S 
D
O
CT
O
RA
L
an
o
O
r
z
2018
Málaga, 2018
Facultad de Ciencias
Departamento de Química Orgánica
Doctorado en Química y Tecnologías Químicas. Materiales y Nanotecnología
Tesis Doctoral
Allergic reac ons to β-lactam an bio cs: 
chemical approaches for improving
in vitro diagnosis
Dirigida por: 
Mª José Torres Jaén 
Mª Isabel Montañez Vega
Ángela Mar -Serrano Or
HN NH
S
O
HH O O
O O
O
O
ON
O H
OH
O
HN NH
S
O
HH O
O
ON
O
OH
H
HO
N
NH
HN
O
O
N
NH
HN
O
O
O
OCOiBu
O
OCOiBu
NHBu
OMeO
OMe
Facultad de Ciencias 
Departamento de Química Orgánica 
Programa de doctorado: Química y Tecnologías Químicas. 
Materiales y Nanotecnología 
Tesis doctoral 
"Allergic reactions to β-lactam antibiotics: 
chemical approaches for improving  
in vitro diagnosis" 
Ángela Martín-Serrano Ortiz 
2018 
AUTOR: Ángela Martín-Serrano Ortiz
        http://orcid.org/0000-0002-2908-8910
EDITA: Publicaciones y Divulgación Científica. Universidad de Málaga
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-
SinObraDerivada 4.0 Internacional:
http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode
Cualquier parte de esta obra se puede reproducir sin autorización 
pero con el reconocimiento y atribución de los autores.
No se puede hacer uso comercial de la obra y no se puede alterar, transformar o hacer obras derivadas.
Esta Tesis Doctoral está depositada en el Repositorio Institucional de la Universidad de Málaga 
(RIUMA): riuma.uma.es
Doña María José Torres Jaén, Doctora en Medicina y Cirugía, Jefa de Servicio y Directora 
de la Unidad de Gestión Clínica de Alergología del Hospital Regional Universitario de 
Málaga y Profesora Asociada al Departamento de Medicina de la Universidad de Málaga 
y Doña María Isabel Montañez Vega, Doctora en Química e Investigadora del Instituto 
de Investigación Biomédica de Málaga (IBIMA) y del Centro Andaluz de Nanomedicina y 
Biotecnología (BIONAND), 
CERTIFICAN: 
Que el trabajo que presenta Doña Ángela Martín-Serrano Ortiz, con el título "Allergic 
reactions to β-lactam antibiotics: chemical approaches for improving in vitro 
diagnosis" ha sido realizado en el laboratorio de investigación del Hospital Regional 
Universitario de Málaga-IBIMA y en el Centro Andaluz de Nanomedicina y Biotecnología-
BIONAND bajo nuestra DIRECCIÓN y consideramos que tiene el contenido y rigor 
científico necesario para ser sometido a juicio del tribunal que ha nombrado la 
Universidad de Málaga para optar al grado de Doctor con Mención Internacional. 
Y para que así conste, firmamos el presente certificado en Málaga, a  de  de 2018. 
Fdo. Dra. María José Torres Jaén  Fdo. Dra. María Isabel Montañez Vega 

Don Ezequiel Pérez-Inestrosa de Villatoro, doctor en Química, Catedrático de 
Universidad del Departamento de Química Orgánica de la Universidad de Málaga,   
CERTIFICA: 
Que el trabajo que presenta Doña Ángela Martín-Serrano Ortiz, con el título  "Allergic 
reactions to β-lactam antibiotics: chemical approaches for improving in vitro 
diagnosis" ha sido realizado en el Laboratorio de Investigación del Hospital Regional 
Universitario de Málaga-IBIMA y en el Centro Andaluz de Nanomedicina y Biotecnología-
BIONAND bajo mi TUTORIZACIÓN y considero que tiene el contenido y rigor científico 
necesario para ser sometido a juicio del tribunal que ha nombrado la Universidad de 
Málaga para optar al grado de Doctor con Mención Internacional. 
Y para que así conste, firmo el presente certificado en Málaga, a  de  de 2018. 
Fdo. Dr. Ezequiel Pérez-Inestrosa de Villatoro 

La Dra. Mª Dolores Pérez-Sala Gozalo, Investigadora Científica del CSIC y responsable 
del grupo de Modificación Postraduccional de Proteínas del Centro de Investigaciones 
Biológicas,  
CERTIFICA: 
Que la estudiante predoctoral Dña. Ángela Martín-Serrano Ortiz, adscrita a BIONAND 
ha realizado una estancia corta en nuestro grupo, del 16 al 25 de Mayo de 2017, en el 
contexto de la RETIC Aradyal, del ISCIII, para el aprendizaje de técnicas de 
enriquecimiento en avidina de proteínas haptenizadas por fármacos biotinilados y 
análisis mediante electroforesis bidimensional.  
Y para que así conste firmo la presente en Madrid a 5 de Julio de 2018. 
Fdo. Dra. Mª Dolores Pérez-Sala Gonzalo 

Stay certificate for Ms. Ángela Martín-Serrano Ortiz 
With this letter I confirm that Ms. Ángela Martín-Serrano Ortiz did a stay at the 
Department of Fibre and Polymer Technology, KTH Royal Institute of Technology, 
Stockholm, Sweden between August 1st and October 31st 2017.  
During this period, Ángela worked on the project part of her PhD “Synthesis of 
fluorescent dendrons for secondary antibodies labeling and their application in 
detection signal amplification in microarray platforms for diagnosing allergy to drugs” 
and was guided by Prof. Michael Malkoch and PhD student Patrik Stenström.   
 Professor Michael Malkoch 

Yo, Ángela Martín-Serrano Ortiz, declaro que soy autora del presente trabajo de 
investigación cuyo título es "Allergic reactions to β-lactam antibiotics: chemical 
approaches for improving in vitro diagnosis"  y que ha sido realizado en el Laboratorio 
de Investigación del Hospital Regional Universitario de Málaga-IBIMA y en el Centro 
Andaluz de Nanomedicina y Biotecnología-BIONAND bajo la codirección de las Dras. 
María Isabel Montañez Vega y María José Torres Jaén, y la tutela del Dr. Ezequiel Pérez-
Inestrosa de Villatoro, y que he realizado una estancia corta en el grupo de Modificación 
Postraduccional de Proteínas del Centro de Investigaciones Biológicas (CIB-CSIC) de 
Madrid y otra de tres meses en el Royal Institute of Technology (KTH) de Estocolmo, 
Suecia, permitiéndome esta última optar a la Mención Internacional del Título de 
Doctor. 
Y para que así conste, firmo en Málaga, a  de  de 2018. 
Fdo. Ángela Martín-Serrano Ortiz 

The results obtained with this work leaded to the following scientific 
production and awards: 
Publications: 
1. Martín-Serrano Ortiz, A.; Stenström, P.; Mesa-Antunez, P.; Andrén, O.C.J.; Torres,
M.J.; Montañez, M.I.; Michael Malkoch. (2018) Design of multivalent fluorescent 
dendritic probes for site-specific labeling of biomolecules, Journal of Polymer Science 
Part A: Polymer Chemistry. 56(15), 1609-1616. 
2. Molina, N.; Martín-Serrano, A.; Fernandez, T.; Tesfaye, A.; Najera, F.; Torres, M.;
Mayorga, C.; Vida, Y.; Montañez, M.I.; Perez-Inestrosa, E. (2018) Dendrimeric Antigens 
for Drug Allergy Diagnosis: A New Approach for Basophil Activation Tests, Molecules. 
23(5), 997. 
3. Montañez, M.I.; Mayorga, C.; Bogas, G.; Barrionuevo, E.; Fernandez-Santamaria, R.;
Martín-Serrano, A.; Laguna, J.J.; Torres, M.J.;, Fernandez, T.D.; Doña, I. (2017) 
Epidemiology, Mechanisms, and Diagnosis of Drug-Induced Anaphylaxis, Frontiers in 
Immunology. 8, 614. 
4. Martín-Serrano, A.; Barbero, N.; Agundez, J. A.; Vida, Y.; Perez-Inestrosa, E.;
Montañez, M.I. (2016) New Advances in the Study of IgE Drug Recognition, Current 
Pharmaceutical Design. 22(45), 1-14. 
5. Ariza, A.; Mayorga, C.; Salas, M.; Doña, I.; Martín-Serrano, A.; Pérez-Inestrosa, E.;
Pérez-Sala, D.; Guzmán, A.E.; Montañez, M.I.; Torres, M.J. (2016) The influence of the 
carrier molecule on amoxicillin recognition by specific IgE in patients with immediate 
hypersensitivity reactions to betalactams, Scientific Reports. 6, 35113. 
6. Ariza, A.; Mayorga, C.; Fernández, T.D.; Barbero, N.; Martín-Serrano, A.; Pérez-Sala,
D.; Sánchez-Gómez, F.J.; Blanca, M.; Torres, M.J.; Montañez, M.I. (2015) Hypersensitivity 
Reactions to ß-Lactams: Relevance of Hapten-Protein Conjugates, Journal of 
Investigational Allergology and Clinical Immunology. 25(1), 12-25. 
Patent: 
P201731240 (October 23rd 2017). Nuevos compuestos tipo pirazolona para el 
diagnóstico de alergias a antibióticos betalactámicos (New pyrazolone-kind compounds 
for diagnosing allergy to betalactam antibiotics). Montañez, M.I.; Mayorga, C.; Martín-
Serrano, A.; Doña, I.; Torres M.J.; Pérez-Inestrosa, E. 
Communications to conferences: 
- Martín-Serrano, A.; Mayorga, C.; Barrionuevo, E.; Pérez-Inestrosa, E.; Torres M.J.; 
Montañez, M.I. New Potential Synthetic Antigenic Determinants for α-Amino-
Cephalosporins: design, synthesis and immunological evaluation. Meeting of the 
European-Academy-of-Allergy-and-Clinical-Immunology (EAACI). 2018 May 26th-30th. 
Munich, Germany. Allergy 2018 73(S105). Abstract 0590. Poster Discussion Session. 
Abstract Prize. 
- Martín-Serrano, A.; Barbero, N.; González-Morena, J.M.; Sánchez-Gómez, F.J.; 
Fernández, T.D.; Rodríguez-Nogales, A.; Pérez-Inestrosa, E.; Pérez-Sala, D.; Mayorga, C.; 
Ariza, A.; Torres, M.J.; Montañez, M.I. Study Of Protein Targets For Haptenation By 
Biotinylated Clavulanic Acid: Usefulness In Studies On Allergy Todwars Betalactams. 
Drug Hypersensitivity Meeting (DHM). 2018 April 19th-21st. Amsterdam, The 
Netherlands. Published in Clinical and Translational Allergy 2018 8(Suppl 3):P88. 
- Fernandez, T.D.; Montañez, M.I.; Barbero, N.; Martín-Serrano, A.; Bogas, G.; Ariza, A.; 
Fernández‑Santamaría, R.; Rodriguez‑Nogales, A.; Mayorga, C.;  Pérez-Inestrosa, E.; 
Torres, M.J. Improving the Diagnosis of Immediate Hypersensitivity to Clavulanic Acid 
Using Synthetic Antigenic Determinants for Basophil Activation. Drug Hypersensitivity 
Meeting (DHM). 2018 April 19th-21st. Amsterdam, The Netherlands. Published in Clinical 
and Translational Allergy 2018 8(Suppl 3):P107. 
- Martín-Serrano, A.; Mayorga, C.; Barrionuevo, E.; Rodríguez-Nogales, A.; Pérez-
Inestrosa, E.; Torres, M.J.; Montañez, M.I. Study of Specific IgE Recognition of New 
Potential Synthetic Antigenic Determinants for α-Amino-Cephalosporins. American 
Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting. 2018 March 2nd-
6th. Orlando (Florida), U.S.A. Published in Journal of Allergy and Clinical Immunology 
2018 141(2) AB34. Abstract 110. 
- Barrionuevo, E.; Pérez, N.; Gomez, F.; Salas, M.; Guerrero, M.A.; Ruiz, D.; Martín-
Serrano, A.; Torres, M.J. Descriptive Analysis of Diagnostic Methods In Betalactam 
Hypersensitivity in our Allergy Unit. American Academy of Allergy, Asthma & 
Immunology (AAAAI) annual meeting. 2018 March 2nd-6th. Orlando (Florida), U.S.A. 
Published in Journal of Allergy and Clinical Immunology 2018 141(2) AB42. Abstract 
135. 
- Martín-Serrano, A.; Stenström, P.; Mesa, P.; Malkoch, M.; Montañez, M.I. Synthesis 
and Characterization of Fluorescent Dendrimer Structures with Potential Biological 
Applications. VI Dendrimers Meeting (EDEN 6). 2018 February 22nd-23rd. Seville, Spain.  
- Martín-Serrano, A.; Barbero, N.; González-Morena, J.; Sánchez-Gómez, F.; Fernández, 
T.; Sánchez, M.; Pérez-Inestrosa, E.; Pérez-Sala, D.; Cristobalina, M.; Ariza, A.; Torres, 
M.J.; Montañez, M.I. Biotinylated Clavulanic Acid as a Tool for Identifying Serum Proteins 
Target of Haptenation by Clavulanic Acid in the Context of Allergy Studies. Meeting of 
the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI). 2017 June 17th-
21st. Helsinki, Finland. Published in Allergy 2017 72(S103). Abstract 0009. Oral Abstract 
Session. Abstract Prize.  
- Fernandez, T.D.; Montañez, M.I.; Barbero, N.; Martín-Serrano, A.; Salas, M.; Bogas, G.; 
Ariza, A.; Fernández, R.; Guerrero, M.A.; Mayorga, C.; Perez-Inestrosa, E.; Torres, M.J. 
Basophil Activation Using Synthetic Antigenic Determinants for Diagnosing Immediate 
Hypersensitivity to Clavulanic Acid. Meeting of the European-Academy-of-Allergy-and-
Clinical-Immunology (EAACI). 2017 June 17th-21st. Helsinki, Finland. Published in Allergy 
2017 72(S103). Abstract 0142. Oral Abstract Session.  Abstract Prize.  
- Martín-Serrano, A.; Barbero, N.; Ariza, A.; Fernández, T.D.; Pérez-Inestrosa, E.; Salas, 
M.; Mayorga, C.; Pérez-Sala, D.; Torres, M.J.; Montañez, M.I. Study of Protein 
Haptenation by Biotinylated Clavulanic Acid: Usefulness in Studies on Allergy Towards 
Betalactams. American Academy of Allergy, Asthma & Immunology (AAAAI) annual 
meeting. 2017 March 3rd- 6th. Atlanta (Georgia), U.S.A. Published in Journal of Allergy 
and Clinical Immunology 2017 139(2) AB46. Abstract 147. 
-Montañez M.I.; Barbero, N.; Fernandez, T.D.; Martin-Serrano, A.; Bogas, G.; Ariza, A.; 
Mayorga, C.; Pérez-Inestrosa, E.; Torres, M.J. Value of synthetic antigenic determinants 
of clavulanic acid in basophil activation test for evaluating immediate reactions to 
clavulanic acid. American Academy of Allergy, Asthma & Immunology (AAAAI) annual 
meeting. 2017 March 3rd- 6th. Atlanta (Georgia), U.S.A. Published in Journal of Allergy 
and Clinical Immunology 2017 139(2) AB46. Abstract 148. 
- Fernández, T.D.; Salas, M.; Fernández, R.; Montañez, M.I.; Martín-Serrano, A.; Barbero, 
N.; Perez-Inestrosa, E.; Mayorga, C.; Torres, M.J. Basophil Activation Test in Clavulanic 
Acid Selective Patients. Decrease of IgE Recognition over Time. American Academy of 
Allergy, Asthma & Immunology (AAAAI) annual meeting. 2017 March 3rd- 6th. Atlanta 
(Georgia), U.S.A. Published in Journal of Allergy and Clinical Immunology 2017 139(2) 
AB33. Abstract 109. 
- Ariza, A.; Fernández, T.D.; Mayorga, C.; Salas, M.; Barbero, N.; Montañez, M.I.; Martín-
Serrano, A.; Fernández, R.; Galindo, L.; Blanca, M.; Torres, M.J. The Administration of 
the Combination Amoxicillin-Clavulanic Acid can Induce Simultaneous Sensitization to 
Both Drugs. Report of two clinical cases. Meeting of the European-Academy-of-Allergy-
and-Clinical-Immunology (EAACI). 2016 June 11st-15th. Vienna, Austria. Published in 
Allergy 2016 71(S102). Abstract 762. 
- Ariza, A.; Fernández, T.D.; Mayorga, C.; Salas, M.; Barbero, N.; Montañez, M.I.; Martín-
Serrano, A.; Fernández, R.; Galindo, L.; Blanca, M.; Torres, M.J. Patients Taking 
Amoxicillin-Clavulanic Can Become Simultaneously Sensitized to Both Drugs. American 
Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting. 2016 March 4rd- 
7th. Los Angeles (California). Published in Journal of Allergy and Clinical Immunology 
2016 137(2) AB43. Abstract 137. 
- Martín-Serrano, A. Approach for Studying the Antigenic Determinants of 
Cephalosporins. I Summer School organized by Research Network for Adverse Reactions 
to Allergens and Drugs (RIRAAF). 2015 October 1st-2nd. Málaga, Spain. 
- Martín-Serrano, A.; Ariza, A.; Mayorga, C.; Fernández, T.D.; Montañez, M.I.; Torres, 
M.J. Synthesis and Characterization of Potential Antigenic Determinants of α-
Aminocehalosporins. VII Organic Chemistry Mediterranean Meeting (REQOMED). 2015 
June 10th-12th. Málaga, Spain. 
Awards: 
- Abstract Prize for the piece of work entitled “New Potential Synthetic Antigenic 
Determinants for a-Amino-Cephalosporins: design, synthesis and immunological 
evaluation”, presented at a Poster Discussion Session during the EAACI 2018 congress 
held in Munich, Germany. 
- Awarded with a FEBS Summer Fellowship in 2017 to work in the project “Synthesis of 
fluorescent dendrons for secondary antibodies labeling and their application in 
detection signal amplification in microarray platforms for diagnosing allergy to drugs” in 
collaboration with the Royal Institute of Technology (KTH) in Stockholm, Sweden.  
- Member of the team awarded with the I Unicaja Award to innovation in biomedicine 
and health (Unicaja-FIMABIS, 2017) to work in the project “Desarrollo de un microarray 
con conjugados betalactámico-proteína y betalactámico-nanoestructura para el 
diagnóstico de alergia a antibióticos”.  
- Abstract Prize for the piece of work entitled “Biotinylated Clavulanic Acid as a Tool for 
Identifying Serum Proteins Target of Haptenation by Clavulanic Acid in the Context of 
Allergy Studies”, presented at an Oral Abstract Session during the EAACI 2017 congress 
held in Finland, Helsinki. 
- Co-author of the piece of work entitled “Basophil Activation Using Synthetic Antigenic 
Determinants for Diagnosing Immediate Hypersensitivity to Clavulanic Acid”, presented 
at an Oral Abstract Session and awarded with an Abstract Prize during the EAACI 2017 
congress held in Finland, Helsinki. 
Scientific contributions not included in this thesis: 
Publications: 
1. Porret, E.; Sancey, L.; Martín-Serrano, A.; Montañez, M.I.; Seeman, R.; Yahia-Ammar,
A.; Okuno, H.; Gomez, F.; Ariza, A.; Hildebrandt, N.; Fleury, J.-B.; Coll, J.L.; Le Guével, X. 
(2017) Hydrophobicity of Gold Nanoclusters Influences Their Interactions with Biological 
Barriers, Chemistry of Materials. 29(17), 7497-7506. 
2. Fernández, T.D.; Ariza, A.; Palomares, F.; Montañez, M.I.; Salas, M.; Martín-Serrano,
A.; Fernández, R.; Ruiz, A.J.; Blanca, M.; Mayorga, C.; Torres, M.J. (2016) Hypersensitivity 
to fluoroquinolones: The expression of basophil activation markers depends on the 
clinical entity and the culprit fluoroquinolone, Medicine. 95(23), e3679. 
Communications to conferences: 
- Montañez M.I.; Mayorga C.; Nájera F.; Ariza A.; Fernández T.D.; Salas, M.; Martín-
Serrano, A.; Blanca, M.; Pérez-Inestrosa, E. Dendrimeric Antigens for Studying the 
Influence of Penicillin Determinants Orientation on IgE Recognition. 7th Drug 
Hypersensitivity Meeting (DHM, EAACI). 2016 April 21st-23rd. Málaga, Spain. Published 
in Clinical and Translational Allergy 2016, 6 (Suppl 3):P185. 
- Ariza, A.; Mayorga, C.; Montañez, M.I.; Salas, M.; Doña, I.; Martín-Serrano, A.; Pérez-
Inestrosa, E.; Pérez-Sala, D.; Blanca, M.; Guzmán, A.E.; Torres, M.J. Different Patterns of 
Recognition of Structures Derived from Amoxicillin by IgE Antibodies from Patients with 
Immediate Hypersensitivity Reactions to Betalactams. 7th Drug Hypersensitivity Meeting 
(DHM, EAACI). 2016 April 21st-23rd. Málaga, Spain. Published in Clinical and 
Translational Allergy 2016, 6 (Suppl 3):P188. 
- Montañez; M.I.; Mayorga, C.; Najera, F.; Ariza, A.; Fernández, T.D.; Salas, M.; Martín-
Serrano, A.; Blanca, M.; Pérez-Inestrosa, E.; Torres, M.J. Study of penicillin epitopes 
conformation/disposition in carrier dendrimer molecules vs sIgE molecular recognition 
relationships. Meeting of the European-Academy-of-Allergy-and-Clinical-Immunology 
(EAACI). 2015 June 6th-10th. Barcelona, Spain. Published in Allergy 70(S101). Abstract 
38.

The present study has been supported by: 
-ISCIII of MINECO; grants cofunded by European Regional Development Fund (ERDF): 
PI12/02529: “Identificación y caracterización inmunológica de conjugados 
betalactámicos con proteínas y nanoestructuras para su aplicación al diagnóstico in vitro 
de reacciones alérgicas IgE”. Principal investigator: María José Torres Jaén.  
PI15/01206: “Estudio de biomarcadores y factores de riesgo relacionados con el 
desarrollo de una respuesta alérgica diferencial frente a amoxicilina o clavulánico”. 
Principal investigator: María José Torres Jaén. 
CP15/00103: “Desarrollo de conjugados de antibióticos con nanoestructuras o 
proteínas y aplicación al diagnóstico in vitro de alergia a antibióticos”. Principal 
investigator: María Isabel Montañez Vega.  
-Andalusian Regional Ministry Health: 
PI-0699-2011: “Desarrollo de materiales nanoestructurados dendriméricos con 
aplicaciones potenciales en el diagnóstico de alergia a fármacos: inmunoensayos y test 
de activación celular”. Principal investigator: Adriana Ariza Veguillas.  
PI-0352-2012: “Papel de los linfocitos Th1/Th17 y el eje Galectin-9-Tim-3 en la 
regulación de la hipersensibilidad no inmediata a fármacos con afección cutánea”. 
Principal investigator: Tahía Diana Fernández Duarte.  
PI-0179-2014: “Desarrollo de un microarray con aductos fármaco-
proteína/nanoestructura para el diagnóstico de alergia a antibióticos”. Principal 
investigator: María Isabel Montañez Vega.  
PI-0241-2016: “Desarrollo de métodos in vitro para el diagnóstico de alergia al 
ácido clavulánico: identificación de los determinantes antigénicos implicados en la 
respuesta inmunológica”. Principal investigator: Tahía Diana Fernández Duarte. 
PI-0250/2016: “Desarrollo de nuevos nanobiosensores para el diagnóstico de 
reacciones adversas a medicamentos”. Principal investigator: Ezequiel Pérez-Inestrosa 
Villatoro. 
-RETICS RIRAAF RD12/0013/0001. 
-RETICS ARADyAL RD16/0006/0001. 
-Merck-Serono Research Grant from Fundacion Salud 2000. 
- I Unicaja Award to innovation in biomedicine and health by Unicaja-FIMABIS: 
PUNI-017-2016. “Desarrollo de un microarray con conjugados betalactámico-
proteína y betalactámico-nanoestructura para el diagnóstico de alergia a antibióticos”. 
Principal investigator: María Isabel Montañez Vega.  
- FEBS Summer Fellowship 2017. 
-PS13/12 FIMABIS-ROCHE. Estudio de reacciones de hipersensibilidad por intolerancia 
cruzada a antiinflamatorios no esteroideos con afectación cutánea: relación fenotipo-
genotipo. Principal investgator: Miguel Blanca Gómez.  
-RD07/0064/0000: Red de Investigación de Reacciones Adversas a Alérgenos y a 
Fármacos (RIRAAF). 
AGRADECIMIENTOS 

Desde mi primer contacto con la investigación en el último año de Licenciatura, he 
perseguido la oportunidad de hacer un doctorado puesto que me entusiasmaba la idea 
de aplicar toda esa teoría estudiada en la carrera para desarrollar métodos que 
permitiesen mejorar la calidad de vida de las personas. Ahora, llegado el momento de 
presentar mi tesis doctoral, debo reconocer que estoy muy contenta con el hecho de 
haber estado trabajando en un tema multidisciplinar, que me ha brindado la 
oportunidad de conocer algunas de las numerosas y prometedoras contribuciones de la 
química orgánica en el ámbito de la salud y de complementar mi formación química para 
adquirir un perfil más biológico. Durante este trayecto de cinco años, muchas son las 
personas que me han acompañado, apoyado y motivado, y por ello les doy gracias.  
En primer lugar, agradecer a la Dra. María Isabel Montañez y a la Dra. Mª José Torres la 
confiada depositada en mí para el desarrollo de este trabajo, y su apoyo.  
Continuar dando las gracias al Dr. Ezequiel Pérez-Inestrosa y a todo su grupo de 
investigación. En especial, gracias a la Dra. Nekane Barbero por toda su dedicación a la 
obtención de algunas de las estructuras utilizadas en este trabajo. También a Nekane, 
junto a Noemi, Pablo y Anjara, por toda su ayuda en el día a día del laboratorio y por 
ayudarme a disfrutar de mi tiempo en Málaga.  
No olvidar agradecer a otros compañeros de BIONAND como Rebeca, Dani, John y Xavier 
por los momentos compartidos investigando la geografía y costumbres andaluzas. 
Gracias a Patri por su ilusión y ganas de aprender, trabajar y ayudar.  
A todos mis compañeros del grupo de Alergia: Raquel, Ana, Miguel, Mª José, Mª Carmen, 
Francis, Natalia, Tahía, Alba, Jose, Jimmy… Gracias a Rubén por todo el trabajo realizado 
con los BAT y por estar siempre dispuesto a ayudar. Mil gracias a Adri por ser mi mentora 
en el Hospital Civil y estar siempre dispuesta a ayudarme y resolver mis dudas.  
A todos los compañeros de otros grupos del Hospital Civil que, de algún modo u otro 
han estado ahí. En especial, gracias a Rosa, Pablo y Antonio. También a Pepe, por 
contribuir con su experiencia en el laboratorio y tener siempre consejos y respuesta 
para solucionar los contratiempos que pudiesen surgir en los inmunoensayos.  
Agradecerle a la Dra. Pérez-Sala y a su grupo de investigación del Centro de 
Investigaciones Biológicas por la colaboración en la detección de la modificación de 
proteínas séricas por fármacos biotinilados y por acogerme en su laboratorio para el 
aprendizaje de técnicas de enriquecimiento de proteínas haptenizadas y análisis 
mediante electroforesis bidimensional. Gracias al Dr. Francisco José Sánchez por su 
tiempo y resolver mis dudas durante la estancia.  
To Professor Michael Malkoch and his research group at Royal Institute of Technology, 
for the collaboration in the design of fluorescent dendrons for antibody labeling and his 
help to publish the results obtained as outcome of my three-month stay at his laboratory. 
To the FEBS for granting me with a Summer Fellowship for my stay. To Patrik, Oliver, 
Pablo and Matthiew for your tips in the lab. To Ilona, María, Ana and Lorenzo for making 
me enjoy the city of Stockholm, and to Andrea and Nicola for treating me as one of the 
family and making me feel like at home. Tack så mycket. 
Al personal del Laboratorio de Proteómica del Hospital Vall d´Hebron y del Centro 
Nacional de Biotecnología por su ayuda en la identificación de los sitios de unión. Al 
personal de Servicio Central de Apoyo a la Investigación de la Universidad de Málaga 
encargado de los análisis de MALDI-TOF de los conjugados proteína-fármaco, y las 
medidas de absorbancia y fluorescencia de los dendrones fluorescentes y el anticuerpo 
marcado. A la Unidad de Proteómica de la Universidad Complutense de Madrid por el 
análisis de huella peptídica.  
Al personal médico y de enfermería encargado de la evaluación, diagnóstico y obtención 
de muestras biológicas de los pacientes incluidos en los diferentes estudios, así como a 
aquellas personas que han participado como pacientes y controles.  
No se me puede olvidar mi prima Natalia, por ayudarme a darle el formato final a 
esta memoria. 
A Chiqui, por los “speaking” dentro y fuera de la Escuela de Idiomas. A Lydia, Asier y 
Lidia, por los buenos momentos y por cuidarme y animarme en la etapa final, la más 
complicada de este camino.  
A Vicente, por este último año, por tratarme como a una reina, respetar como soy, 
preocuparse por mí, mostrarme su apoyo, y demostrar estar ahí no sólo para lo bueno.  
A mi amiga de toda la vida, Inma, y a una un poco más reciente, Alicia, por seguir 
brindándome su amistad y por poder seguir contando con ellas después de tantos años, 
a pesar de la distancia y las diferentes circunstancias de cada una.  
Por último, el agradecimiento más importante va dirigido a mi familia: mis padres, 
hermanos, tíos y abuelos. Por su cariño y su apoyo, por preocuparse por mí y cuidarme 
desde la distancia, por recibirme con los brazos abiertos siempre que vuelvo a casa, por 
hacerme sentir que siempre puedo contar con ellos. Gracias a mi madre por poder con 
todo y por ayudarme a levantarme en los momentos más bajos. A mi abuelo Reyes, una 
persona muy especial para mí, al que estoy segura le hubiese gustado estar presente en 
este nuevo logro de su nieta mayor, y que me ha dejado el legado de ser siempre fuerte 
y valiente.  
A mis padres 
A mis hermanos  
A mi abuelo Reyes 

TABLE OF CONTENTS 

List of Abbreviations .................................................................................................................... 33 
GENERAL INTRODUCTION ........................................................................................................... 39 
1. Definition and Classification of Adverse Drug Reactions .................................................... 41
2. Definition and Classification of Drug Hypersensitivity Reactions ....................................... 41
2.1. Immunological Classification of Allergic Reactions .................................................... 42 
2.2. Clinical Classification of Allergic Reactions ................................................................ 42 
3. Epidemiology and Prevalence of Allergic Reactions to Drugs ............................................ 44
4. Mechanisms of Allergic Reactions to Drugs ........................................................................ 44
4.1. Hapten hypothesis ..................................................................................................... 45 
4.2. Danger hypothesis ..................................................................................................... 46 
4.3. Pharmacological Interaction hypothesis .................................................................... 47 
5. Immunological Proccess Related with Immediate Allergic Reactions to β-lactam Antibiotics
 ................................................................................................................................................. 48 
5.1. Immunoglobulin E ...................................................................................................... 48 
5.2. β-lactams Chemical Structures .................................................................................. 49 
5.3. β-lactams Antigenic Determinants ............................................................................ 50 
5.4. Protein haptenation by BLs ........................................................................................ 58 
5.5. Candidate Carrier proteins for BLs ............................................................................. 58 
6. Clinical Symptoms and Diagnosis of Immediate Allergic Reactions to BLs ......................... 63
6.1. In vivo tests ................................................................................................................ 65 
6.2. In vitro tests ............................................................................................................... 67 
6.3. In vivo versus in vitro tests ......................................................................................... 70 
6.4. Limitations and future of in vitro tests ...................................................................... 70 
6.5. Nanotechnology for improving in vitro tests ............................................................. 72 
7. Dendrimeric Structures for Improving In Vitro Tests .......................................................... 73
7.1. Generalities of Dendritic Structures .......................................................................... 73 
7.2. Dendrimers as Synthetic Carriers............................................................................... 76 
7.3. Dendrimers as Fluorescent Probes for Detection Signal Amplification ..................... 77 
8. Bioconjugation Reactions for Antibodies Labeling.............................................................. 78
JUSTIFICATION AND HYPOTHESIS ............................................................................................... 83 
OBJECTIVES .................................................................................................................................. 89 
RESULTS AND DISCUSSION .......................................................................................................... 93 
I. Study of antigenic determinant structures for amino-cephalosporins ................................ 95 
I.1. Study of α-aminocephalosporins Reactivity Towards Simple Nucleophiles ............... 98 
I.2. Synthesis of New Synthetic Antigenic Determinants for α-aminocephalosporins ... 103 
I.3. Immunological Evaluation of Pyrazinone-Like Antigenic Determinants ................... 106 
I.3.1. Patient´s selection ................................................................................................ 106 
I.3.2. In Vitro Evaluation of Specific IgE Molecular Recognition by RAST Inhibition ..... 107 
II. Elucidation of antigenic determinant structures for CLV ..................................................115
II.1. Elucidation of the Chemical Structure of Antigenic Determinants for CLV ............ 118 
II.1.1. Nuclear Magnetic Resonance Studies of CLV reactivity ...................................... 120
II.1.2. Structure-Activity Relationship of Synthetic Determinant Structures ................ 123
II.1.2.1. Cellulose Discs and Nanoparticles Functionalized with CLV Derivatives ..... 123
II.1.2.2. CLV Derivatives in Free Form ....................................................................... 127
II.2. Characterization of CLV-Protein Adducts Generated In Vitro.................................. 136 
II.2.1. Mass Spectrometry Characterization .................................................................. 137
II.2.2. Identification of HSA Binding Sites ...................................................................... 138
II.3. Development of Approaches for Detection of Serum Proteins Modified by CLV.... 141 
II.3.1. Synthesis of Biotinylated Derivatives of CLV ....................................................... 142
II.3.2. Reactivity of CLV-TEG-B towards simple nucleophiles ........................................ 145
II.3.3. Comparison of Reactivity between CLV and CLV-TEG-B ..................................... 148
II.3.4. Study of CLV Biotynilated Derivatives Proteins Haptenation Capacity ............... 150
II.3.5 Mass Spectrometry Characterization of HSA-CLV-B Conjugates ......................... 157
II.3.6. Characterization of HSA-CLV-TEG-B Conjugates by LC-MS/MS .......................... 158
II.4. Detection and Identification of Serum Proteins Target of Modification by CLV-TEG-B
 ........................................................................................................................................ 159 
II.4.1. Conjugation of CLV-TEG-B with Human Serum Proteins and Detection of
Modification .................................................................................................................. 160 
II.4.2. Identification of Serum Proteins Target of Modification by Peptidic Fingerprint
 ....................................................................................................................................... 161 
III. Antibody labeling for detecting sIgE in drug allergy ........................................................ 163
III.1. Radiolabeling of a High Specific α-human IgG ........................................................ 164 
III.1.1. Labeling optimization ........................................................................................ 165
III.1.2. Labeling of α-human IgE monoclonal antibody with 125I.................................... 166 
III.1.3. Labeled IgG sensitivity evaluation by Radio Allergo Sorbent Test (RAST) ......... 166 
III.2. Multivalent fluorescent dendritic probes for immunoassays signal amplification 168 
III.2.1. Design of Fluorescent Dendrons for Site Specific Antibody Labeling with 
Application in Microarray Systems ............................................................................... 169 
III.2.2. Synthesis of Fluorescent Dendrons .................................................................... 170 
III.2.3. UV-Visible and Fluorescence Spectroscopy Characterization of Dendrons ....... 183 
III.2.4. Chemoselective Conjugation of Dendrons to a Model Antibody ....................... 184 
GENERAL DISCUSSION ............................................................................................................... 191 
CONCLUSIONS ........................................................................................................................... 197 
EXPERIMENTAL .......................................................................................................................... 201 
1. Identification of β-lactam Antibiotics Antigenic Determinants Recognized by Specific IgE
 ............................................................................................................................................... 203 
1.1. Scope of the Study ................................................................................................... 203 
1.2. Study of CLV or α-aminocephalosporins Reactivity towards Nucleophilic Species . 203 
1.3. Synthesis of structures derived from aminocephalosporins ................................... 204 
1.4. Synthesis of structures derived from CLV ................................................................ 205 
1.5. Patients and controls selection ................................................................................ 208 
1.6. Conjugation of -lactam antibiotics with different carrier molecules for in vitro studies
 ........................................................................................................................................ 209 
1.7. In vivo tests .............................................................................................................. 210 
1.8. In vitro tests ............................................................................................................. 212 
2. Study for identification of carrier proteins ....................................................................... 218
2.1. Synthesis of Biotinylated Derivatives of CLV ........................................................... 218 
2.2. Human serum proteins in vitro modification by CLV ............................................... 222 
2.3. Enrichment of biotynilated fraction ......................................................................... 223 
2.4. Characterization of modified proteins by SDS-PAGE techniques ............................ 224 
2.5. Mass spectrometry .................................................................................................. 227 
2.6. Molecular modeling ................................................................................................. 231 
3. Labeling of secondary antibodies ...................................................................................... 231
3.1. Radioactive labeling ................................................................................................. 231 
3.2. Fluorescent labeling ................................................................................................. 236 
3.2.1. Synthesis of fluorescent dendrons ...................................................................... 237 
3.2.2. IgG labeling with Cy5 decorated dendrons ........................................................ 250 
3.2.3. SDS-PAGE characterization of Cy5 labeled IgG .................................................. 251 
3.2.4. Spectroscopic Characterization of Dendrons and Labeled IgG .......................... 252
RESUMEN .................................................................................................................................253 
BIBLIOGRAPHY ..........................................................................................................................289 

List of Abbreviations 
33 
List of Abbreviations
1D One dimension 
2D Two dimension 
AAAAI American Academy of Allergy, Asthma & Immunology 
AcN Acetonitrile 
AD Antigenic Determinant 
ADR Adverse Drug Reaction 
AMP Ampicillin 
APC Antigen presenting cell 
AX Amoxicillin 
AX-B Biotinylated AX 
AXO Amoxicilloyl 
BAT Basophil Activation Test 
BL β-lactam antibiotic 
Boc Tert-butyloxycarbonyl 
BP Benzylpenicillin 
BPO Benzylpenicilloyl 
BP-OL BPO-octa-L-lysine 
BuNH2 Butylamine 
CDR Complementarity determining regions 
CH2Cl2 Dichloromethane 
CHCA α-cyano-4-hydroxycinamic acid 
CHCl3 Chloroform 
CIB Centro de Investigaciones Biológicas 
ClMs Mesyl Chloride 
ClTs Tosyl Chloride 
CLV Clavulanic Acid 
CLV-B Non water soluble biotinylated CLV 
CLV-TEG-B Water soluble biotinylated CLV 
CNB Centro Nacional de Biotecnología 
List of Abbreviations 
34 
cpm Counts per minute 
CPO Cephalosporoyl 
CSIC Centro Superior de Investigaciones Científicas 
CuAAC Copper(I)-catalyzed azide-alkyne cycloaddition 
Cy Cyanine 
DABCO Diazabicyclo[2,2,2]octane 
DCE Dichloroethane 
DCTB Trans-2-[3-(4-tert-butylphenyl)-2-methyl-2-propenylidene]-
malononitrile  
DeAns Dendrimeric antigens 
DHB 2,5-dihydroxybenzoic acid 
DHR Drug Hypersensitivity Reaction 
DMF Dimetylformamide 
DMSO Dimethyl sulfoxide 
dpm Desintegrations per minute 
EAACI European Academy of Allergy and Clinical Immunology 
ECD 
Enhanced chemiluminiscence ECL 
Electron capture dissociation 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethyleneglycoltetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
ENDA European Network on Drug Allergy 
ESI Electrospray ionization 
EtOAc Ethyl acetate 
Fab Antigen binding region 
Fc Christallizable region 
FcεRI High affinity Cell Surface receptor 
FcεRII Low affinity IgE receptors 
FEIA Fluorescence enzyme immunoassay 
HPLC High-performance liquid chromatography 
HRMS High resolution mass spectrometry 
List of Abbreviations 
35 
HRP Horseradish peroxidase 
HSA Human Serum Albumin 
iBuCOCl Isobutyl chloroformiate 
IDT Intradermal test 
Ig Immunoglobulin 
IgE Immunoglubulin type E 
IgG Immunoglubulin type G 
IgM Immunoglubulin type M 
IR Immediate reactions 
IU International units 
LC Liquid Chromatography 
LTQ Linear trap quadrupole 
Lys Lysine residues 
m/z Mass/charge 
MALDI-TOF Matrix-assisted laser desorption/ionization time of flight 
MD Minor determinant 
MDM Minor determinant mixture 
MeOH Methanol 
MHC Major histocompatibility complex 
MS Mass Spectrometry 
MW Molecular weight 
NIR Non-Immediate Reactions 
NK Natural killer 
NMM N-methyl morpholine 
NMR Nuclear Magnetic Resonance 
NSAID Non-steroidal anti-inflammatory drugs 
PAMAM Poly(amidoamine) 
PBS Phosphate buffer saline 
PI Pharmacological Interaction 
PLL Poly-L-lysine 
PO Penicilloyl 
List of Abbreviations 
36 
PPL Penicilloyl-polylysine 
ppm Parts per million 
PVDF Polyvinylidene fluoride 
QTOF Quadrupole Time of Flight 
RAST Radioallergosorbent test 
RIA Radioimmunoassay 
rpm Revolutions per minute 
RT Room temperature 
SAR Structure-activity relationship 
SCAI Central service for research support (from Spanish “Servicio 
central de apoyo a la investigación”) 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate-polyacrilamide gel electrophoresis 
SI Stimulation index 
sIgE Specific IgE 
SPA Sinapinic acid 
SPAAC Stain promoted azide-alkyne cycloaddition 
SPT Skin prick test 
ST Skin Test 
TCR T cell receptor 
TDCR Triple-to-double coincidence ratio 
TEA Triethylamine 
TFA Trifluoroacetic acid 
Th Helper T cell 
THF Tetrahydrofuran 
TMR Tetramethylrhodamine 
UMA University of Málaga 
UV Ultraviolet 
TEG Tetraethylene glycol
PS-p-Ts-OH Polystyrene supported p-toluenesulfonic acid
List of Abbreviations 
37 
WHO World Health Organization 
WTM Wortmannin 
VL Variable domains in light chains 
VH Variable domains in heavy chains 

GENERAL INTRODUCTION 

General Introduction 
41 
1. Definition and Classification of Adverse Drug Reactions
An adverse drug reaction (ADR) is defined by the World Health Organization (WHO) as 
“a response to a medicine which is noxious and unintended, and which occurs at doses 
normally used in man” (World Health Organization, 1972).  
ADRs constitute a serious public health concern since they cause considerable morbidity 
and mortality [1]. They are responsible for 3-6% of hospital admissions and 10-15% of 
hospitalized patients [2]. Among different ADRs classifications the most common is the 
proposed by Rawlins and Thompson in 1991 [3], which divided ADRs into two types: 
Type A: they are predictable, dose and pharmacological action dependent, the most 
common and account for 80% of ADRs. Reactions consequence of overdose or drug 
toxicity as well as secondary or side effects and interactions with other drugs are 
included in this group [4]. 
Type B: they are unpredictable, dose independent and comprise 15-20% of all ADRs. 
Although reactions of type B are the less common of ADRs, they are extremely 
important, because they can be cause of serious health risks and even cause death [5]. 
Type B ADRs can be sub-classified into [4]:  
    B.1. Drug intolerance: produced by a non-desired effect of the drug at therapeutic or 
subtherapeutic drug doses. 
     B.2. Idiosyncratic reactions: anomalous responses without demonstrable 
immunological response attributable to pharmacokinetic responses associated with 
genetic factors. 
     B.3. Pseudoallergic reactions: adverse responses clinically similar to an actual allergic 
reaction but with no demonstrable immunological base.  
     B.4. Drug hypersensitivity reactions (DHRs): include reactions mediated by specific 
and non-specific immunological mechanisms.  
There are also some types of infrequent reactions: 
Type C: they are time and dose dependent and are related with dose cumulation. 
Type D: they are time dependent, also related with dose and its action is only 
noticed after a latency time.  
Type E: they occur after treatment suspension. 
2. Definition and Classification of Drug Hypersensitivity Reactions
DHRs, as it was stated before, are Type B ADRs whose mechanism can be mediated by 
specific immunological mechanisms or non-specific immunological mechanisms [6]. The 
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former are called allergic reactions and may be antibody-mediated or T-cell dependent. 
The latter, non-allergic reactions, are more heterogeneous and majority of patients have 
cross-intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs). In this work, we will 
focus on allergic reactions to drugs. 
Allergic reactions take place when the immune system recognise a drug specifically and, 
as consequence, an effector response is unchained, fact that leads to a potetial serious 
damage in the organism. An important charasteristic of these reactions is that a previous 
exposure to the drug or a molecule chemically related, called sensitization phase, is 
required to stimulate the immune system. Once sensitized, allergic reactions to drugs 
are produced on drug re-exposure [7]. They represent 6-10% of all ADR and can be 
induced by a diverse range chemicals/drugs by means of the production of antibodies, 
sensitized T cells or both [5].  
2.1. Immunological Classification of Allergic Reactions 
DHRs have been traditionally classified into four groups by Gell and Coombs according 
to the trigger effector mechanism [7]. Allergic reactions to drugs can be consequence of 
any of the cited mechanisms, being types I and IV the most common. 
-Type I or immediate hypersensitivity reactions, mediated by drug specific IgE (sIgE) 
antibodies. 
-Type II or cytolytic or cytotoxic reactions, mediated by drug-specific IgG or IgM 
antibodies. 
-Type III or immune complex-mediated reactions, mediated by drug specific IgG or IgM 
antibodies. 
-Type IV or delayed hypersensitivity reactions, mediated by drug specific T cells.  Due to 
the fact that T cell mediated reactions present heterogeneity in clinical manifestations 
and mechanisms involved, a subclassification of Type IV in Type IVa, IVb, IVc and IVd 
reactions was proposed [8-10], although this classification is not completely accepted in 
clinical practice since some clinical pictures can fit in some subtypes of Type IV reactions. 
2.2. Clinical Classification of Allergic Reactions 
DHRs are difficult to catalog according to the immunological mechanism involved so, in 
daily clinical practice, a classification based on time elapsed between drug 
administration and first sympthoms is easier and more convenient. Following this 
principle, they can be included in two groups: immediate and non immediate.  
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-Immediate reactions (IR): usually occur within the first hour after drug administration 
and are generally IgE-mediated. Typical clinical manifestations are urticaria, 
angioedema, anaphylaxis, or anaphylactic shock and can be potentially fatal [5]. They 
correspond with Type I Gell and Coombs immunological classification.  
-Non-immediate reactions (NIR): they are delayed hypersensitivity reactions, occuring 
after one hour of drug administration, mediated by drug specific T cells. Maculopapular 
exanthema is the most frequent reaction [6]. They correspond with Type IV Gell and 
Coombs immunological classification. 
Figure 1. Immunological and clinical classification of DHRs. 
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3. Epidemiology and Prevalence of Allergic Reactions to Drugs
Currently, actual prevalence of allergic reactions to drugs is unknown [11], and 
morbidity and mortality data as well as economic costs are subestimated. There are few 
studies that describe both incidence and prevalence of allergic reactions to drugs in 
general population, being most of data based on hospitalized patients or emergency 
services [1], so figures are merely indicative. From these studies is deduced that allergic 
reactions to drugs represent 6-10% of every ADRs, but this values may change 
depending on the methods employed for confirming diagnosis [12-14].  
In Spain, NSAIDs are the most consumed, followed by betalactam antibiotics (BLs). 
However, only 10% of hipersensitivity reactions to NSAIDs are associated with a 
defined immunological mechanism [15], being BLs responsable for most of allergic 
reactions to drugs mediated by a well-known immunological mechanism, followed by 
quinolones and other antibiotics [15]. The prevalence and incidence of allergic 
reactions to BLs in the general population are not well known either [6].  A prevalence 
of allergic reactions to penicillin ranging from 0.7% to 10% of the population, with 
anaphylaxis occurring in 0.015% to 0.004% of cases was reported in early studies. The 
wide range of prevalence rates found in published studies, with overreporting 
occurring when patients are classified by clinical history only as well as underreporting 
of mild and severe reactions [6] is due to a considerable proportion of patients with 
suspected hypersensitivity to BLs showing good tolerance in allergy studies [6].  
Frequency of allergic reactions associated with each drug varies over time according to 
changes in prescription patterns [15]. In the study performed by Doña et al. between 
2005 and 2010 [15], it was observed that rate of allergic reactions to BLs had the same 
tendency from 80s, with a progressive decrease of reactions produced by 
benzylpenicillin (BP) and an increase of reactions produced by amoxicillin (AX). 
Nowadays, allergy to new cephalosporins are also being reported. Moreover, it is 
important to highlight an important increase of urticaria and anaphylaxis due to new 
drugs such as AX-clavulanic acid (CLV) combination, whose consumption has notably 
grown over the last years, and quinolones [16].  
4. Mechanisms of Allergic Reactions to Drugs
Drugs interaction with the immune system can be explained by 3 major working 
hypotheses: the hapten hypothesis, the danger hypothesis, and, more recently, the 
pharmacological interaction (PI) hypothesis. Hapten hypothesis explains interaction of 
the drug with the immune system after drug binding to a carrier molecule, while the 
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other 2 hypotheses try to explain the interaction without the need for covalent binding 
to proteins [17]. 
4.1. Hapten hypothesis 
Currently, the most accepted model for explaining the way the immune system 
recognizes drugs is based on the hapten hypothesis introduced by Landsteiner in 1935 
[18]. Haptens are low molecular weight molecules (<1000 Da), chemically reactive and 
too small to be able to induce an immune response by themselves but they do when 
covalently bound to a protein, proccess called haptenization [18-20]. Chemically reactive 
drugs or their metabolites can act as haptens and form covalent adducts with 
extracellular or intracellular proteins, which are able to induce the production of IgE 
antibodies or T cells that specifically recognize the adduct. The structure of the adduct 
that is recognized specifically by the components of the immune system (IgE or T cell) is 
called the antigenic determinant (AD), or epitope, and usually comprises the drug 
derivative and part of the carrier protein [5]. According to this hypothesis, antigenic 
structures must be presented to the immune system as multivalent antigens to lead to 
a specific immune response and activate immunopathological mechanisms (Figure 2, 
bottom). Hapten-carrier molecule conjugate can be proccesed and presented by 
antigen presenting cells (APCs) to lymphocytes for specific antibodies production 
which can react against AD formed by the hapten and probably by some regions of 
carrier molecule. The response induced by hapten-carrier molecule conjugates 
depends on hapten density [21] and its distribution through the carrier molecule [22]. 
The molecular weight is one of the main characteristics that determine the immune 
capacity of a molecule [21, 23] but its chemical nature and structural complexity are 
also important [24].  
BLs have been used as models of the hapten hypothesis because of their high reactivity 
or capacity to bind to proteins through the nucleophilic attack on the β-lactam ring by 
the amino groups in the protein. However, the identification of the metabolites that 
act as haptens is difficult for other non-chemically reactive drugs [17]. 
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Figure 2. Hapten hypotesis proposed by Landsteiner [18]. 
4.2. Danger hypothesis 
The danger hypothesis (Figure 3) was proposed by Matzinger [25] and is based on the 
fact that cell damage induces production of danger signals that interact with the 
immune system, thus activating APCs. The immune system only presents a response 
against antigens associated with the danger, which in this context can be defined as 
any element causing stress or cellular death [25]. Two signals are necessary for 
immunological response induction. The first signal is defined as the signal consequence 
of the contact between an antigen and its specific receptor (immunoglobulin (Ig) or T 
cell receptor (TCR)) and the second signal is a set of co-stimulating signals such as 
concurrent infections, exposure to endotoxins, stimulation by cytokines, metabolic 
alterations or drug toxicity which were called “danger signals” [26]. The presence or 
ausence of signal 2 determines whether the consequence is an immune response or a 
natural immunologic tolerance mechanism [25]. There are some studies that report 
that “danger signals” increase drug-protein adducts formation [26].  
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Figure 3. “Danger signal” hypothesis applied to the mechanism described in hapten hypothesis. Adapted 
from [25, 26]. 
4.3. Pharmacological Interaction hypothesis 
The fact that hapten hypothesis was demostrated only for some drugs leaded, in the last 
years, to the proposal of a new model in which some drugs would not need covalent 
binding to macromolecules to induce an allergic response. They could bind directly 
(without previous drug metabolization) and reversibly to immunological receptors such 
as major histocompatibility complex (MHC) or TCRs through Van der Waals forces, 
electrostatic interactions or hydrogen bonds. Thus, cells would be stimulated. This PI 
model was proposed by Pichler [27] but it has never been confirmed in the case of BLs 
[17]. It is represented in Figure 4.  
Figure 4. T lymphocytes activation in PI model. Drug binds to some TCRs (1) with enought sensitivity for 
signal triggering. Drug-TCR interaction is complemented with the interaction with MHC (2). Adapted 
from [17]. 
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5. Immunological Proccess Related with Immediate Allergic Reactions to
β-lactam Antibiotics
IRs to drugs are mediated by sIgE immune mechanisms (Figure 5). In these reactions 
IgE are produced against a hapten-carrier conjugate during a sensitization phase, these 
then attach to FcεRI on the surface of mast cells and circulating basophils. During re-
exposure, the binding of drug-carrier molecule adducts (multivalent antigen) to at least 
2 adjacent IgE molecules induces degranulation of mast cells and basophils, leading to 
the release of inflammatory mediators, including histamine, leukotrienes, and 
cytokines, resulting in the allergic symptoms [7, 28]. The drugs most frequently 
involved in these reactions are BLs, NSAIDs, quinolones and radio contrast media [5].  
Figure 5. Sequence of events in immediate allergic reactions: sensitization phase and effector phase. 
5.1. Immunoglobulin E 
IgE was discovered in 1967 by Ishizaka and Johanson [29] and it has been demonstrated 
its intervention in immediate hypersensitivity reactions as well as in immune response 
consequence of infections produced by parasites [30-32]. IgE molecular weight is 118-
196 kDa [33] and a general structure is depicted in Figure 6. Variable domains in light 
and heavy chains (VL and VH) interact between them to create a globular unit which 
contains antigen binding site. Complementarity determining regions (CDRs) comprise 
ten aminoacids which form a surface of contact complementary to the corresponding 
antigen. The rest of the domain does not take part directly in antigen recognition but it 
acts as support. 
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Figure 6. Depiction of IgE general structure with its two functional regions: the (Fab) and the 
christallizable region (Fc). The former is involved in Ig specificity and the ability to bind to the antigen 
while Fc mediates effector responses. 
IgE molecules are produced mainly by plasmatic cells in linfoid tissues associated with 
mucous [34]. Most produced IgE binds to high-affinity IgE receptors expressed in mast 
cells and basophils surface (FcεRI) [34] and the rest binds to FcεRII receptors or circulates 
free through bloodstream. IgE serum concentration is the lowest among all kind of Igs, 
which makes necessary the use of high sensitivity techniques for its detection [35]. In 
spite of IgE low concentration, its action is amplified by numerous factors such as binding 
to cellular receptors [36]. 
Total plasma IgE concentration in healthy adults is lower than 20 IU/mL and sIgE is not 
higher than 0.35 IU/mL [37]. In those people who present an allergic reaction, an 
amplified production of both non-specific IgE and sIgE against the antigen causing the 
reaction occurs, reaching IgE levels 1000 times higher than in non-allergic individuals.  
5.2. β-lactams Chemical Structures 
The basic structure of BLs consists of a four-member β-lactam ring, which provides the 
antibacterial activity. BLs are classified according to their chemical structure into 
different groups or classes: penicillins, cephalosporins, monobactams, carbapenems and 
clavams [38]   (Table 1). The core structure of every group, except for monobactams, 
consists of a bicyclic structure in which the β-lactam ring is fused to another ring: in 
penicillins this is a five-member sulphur ring (thiazolidine), in cephalosporins a six-
member sulfur ring (dihydrothiazine), in carbapenems a five-member ring 
(dihydropyrrole), and in clavams a five-member oxygen ring (oxazolidine). Every kind of 
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BL displays different side chains or R substituents. These are linked to either the β-
lactam ring (R or R1), except in the case of clavams, or to the other ring (R2, R3) except in 
the case of penicillins and monobactams. The chemical structures of these side chains 
vary greatly; however these side chains can be similar or identical between members of 
different groups of BLs [38]. 
Table 1. Chemical Structure of BLs [38]. 
5.3. β-lactams Antigenic Determinants 
As stated before, BLs represent a model of the hapten hypothesis because of their high 
reactivity towards proteins. BLs are small molecules that act as haptens and therefore 
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are able to induce an immune response only after they covalently bound to exogen or 
endogen proteins which can be proccessed and recognized by the immune system [18, 
39]. 
It is well established that the immunological behavior of BLs is determined by their 
intrinsic chemical reactivity without need of a previous metabolic proccess. Due to ring 
strain, BLs are highly reactive. The electrophilicity of the β-lactam carbonyl group 
enables binding to protein via nucleophilic attack by the ε-amino groups of their lysine 
residues (Lys), leading to the opening of the β-lactam ring and the formation of a amide 
bond to form a drug-protein conjugate [40, 41] (Figure 7). The chemical structure after 
this conjugation process depends on both the chemical properties of the BL involved, as 
well as the ring to which the β-lactam is fused, which can further increase tension to the 
β-lactam ring, leading to the formation of either stable or unstable structures [38, 42, 
43]. Haptenization degree of proteins by BLs is hapten concentration dependent [44, 
45] and there are studies that infers that binding kinetics vary depending on the nature 
of proteins, being faster for serum proteins than for cellular proteins [44]. Previously 
mentioned differences and similarities in the chemical structure of BLs, mainly in the 
core region and the side chain, among the wide range of BLs, are important for 
considering the different patterns of immunological recognition in terms of specificity 
[38].  
Identifying the drug metabolites involved in allergic reactions to BLs is important, not 
only for understanding the underlying immunological mechanisms but also for 
improving diagnostic tests. To this end, several studies have been performed with 
different BLs. 
Figure 7. Penicillins conjugation to carrier proteins and the formation of penicilloyl (PO) 
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-Penicillins 
BP was the first hapten studied in detail and it is still considered the reference model 
for the study of allergy to BLs [40, 46]. The high strain of the β-lactam ring in penicillins 
makes them highly reactive towards the nucleophilic attack of free amino groups of 
proteins and haptenization is thus a spontaneous and efficient process. This reactive 
behavior is common to all penicillins. The conjugate so formed with BP results in the 
benzylpenicilloyl (BPO) determinant [40, 46] (Figure 8A), whose stability enables the 
elucidation of its chemical structure by classical characterization techniques [47]. In fact, 
the BPO group is the major AD of BP, since it represents 95% of the penicillin molecules 
that become covalently bound to proteins under physiological conditions [46] and is 
therefore used in its acid form (benzylpenicilloic acid) and amide form (BPO linked to an 
amine functionalized compound) in diagnostic studies (Figure 8B). The remaining BP has 
been considered to form other derived structures, classified as minor determinants, 
including benzylpenicillenic acid, benzylpenicilloic acid, benzylpenilloic acid, 
benzylpenicillanyl, benzylpenamaldic acid, benzylpenaldate, penicillamine and penicoyl 
[48] (Figure 8B) although immediate IgE reactions with some of these minor 
determinants have not been demonstrated in human [49].  
With a similar behavior to BP, the major AD of AX is the amoxicilloyl (AXO) amide [50] 
(Figure 8A), whose chemical stability enabled its characterization by classical 
spectroscopic techniques [51]. Moreover, AX could form determinants similar to those 
proposed for BP. For instance, AX might generate a molecule equivalent of penicillenic 
acid (Figure 8B), which includes a free thiol group that would allow the conjugation with 
the free thiol cysteine of proteins through disulfide bonds. However, this disulfide-
conjugated structure has been neither isolated nor characterized by modern techniques. 
The difference between AX and BP structures is given by the hydroxyl and amino group 
present in the AX side chain. This amino group confers reactivity toward electrophiles, 
such as the carbonyl β-lactam ring, that can lead to different compounds, such as 
polymers through reaction of the amino group in AX side chain with the β-lactam ring in 
other AX molecule, or diketopiperazine when the amino group reacts with the β-lactam 
ring in the same AX molecule, leading to an intramolecular cyclization (Figure 8C). Thus, 
intermolecular reactions between AX molecules results in dimers [52, 53] and further 
polymers by cleavage of the β-lactam ring in aqueous solutions. This behaviour is 
common for aminopenicillins in general [54], and resulting polymers have been 
considered to be immunogenic [55]. However, further studies are needed since these 
determinants are not considered when evaluating allergy to aminopenicillins.  
The production of monoclonal antibodies against penicillins, employing the drug 
conjugated to a carrier macromolecule as immunogen, proved that both the nature of 
the carrier molecule and that of the hapten can influence IgE recognition [56, 57]. The 
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monoclonal antibodies production has provided information to characterize BP ADs with 
the identification of three different epitopes (Figure 9): the side chain, the nuclear 
structure including the thiazolidine ring, and the carbonyl group involved in the 
conjugation to the carrier protein [58], although these regions can overlap [59]. Similar 
results have been reported with AX [59] and ampicillin (AMP) [60]. In the case of these 
aminopenicillins, the majority of the generated monoclonal antibodies recognized an 
epitope in which the side chain was a major constituent, although with variable 
contributions from other regions of the molecule. 
Figure 8. A. BP and AX conjugation to carrier proteins and the formation of their major determinants. B. 
Described minor determinants for BP. C. Described minor determinants for AX. 
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Figure 9. Common ADs for penicillins. 
-Cephalosporins 
Cephalosporins are BLs derived from cephalosporanic acid. After penicillins and 
quinolones, they are the most used antibacterial agents for infectious illnesses 
treatment and prophylaxis and, due to variations in BLs prescription patterns, have 
become one of the main causes of DHRs. The number of publications on allergic 
reactions to cephalosporins is relevant and growing. However, unlike well-established 
structures responsible for penicillin allergy, metabolites involved in the immunological 
response to cephalosporins are still unknown. 
Figure 10. Structural differences between penicillins and cephalosporins. 
The main difference between penicillins and cephalosporins is the ring fused to the -
lactam, a five-membered thiazolidine ring in penicillins and a six-membered 
Thiazolidine ring
Common structure in all penicillins. Some
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dihydrotiazine ring in cephalosporins (Figure 10). These structural differences lead to 
differences in electrophilic properties of the -lactam carbonyl and, therefore, in the 
potential to bind to proteins and form a determinant [42]. The acylation capacity is 
higher in penicillins compared to cephalosporins, due to the higher tension within the 
β-lactam fused to the five-membered thiazolidine ring in the former than within the six-
membered dihydrotiazine ring in the latter.  
In cephalosporins, this lower reactivity of the -lactam ring slows carrier conjugation. 
The R2 chemical structure modulates this reactivity depending on its ability to polarize 
the electronic binding. The departure of R2 as a consequence of nucleophilic attack on 
the β-lactam has been interpreted from both theoretical [65, 66] and experimental [5] 
evidence, in terms of β-lactam ring opening concerted with the elimination of R2. 
Additionally, the non-concerted expulsion of R2 with the β-lactam ring opening has been 
described [67, 68] (Figure 11). Kinetic and spectroscopic studies have shown the 
structure resulting from the β-lactam ring opening: cephalosporoyl (CPO) [67, 68]. 
Whether the process is concerted or non-concerted, the opening of the β-lactam leads 
to a clear departure of the good R2 leaving group generating a very unstable structure 
which leads to different fragmentation of the dihydrothiazine moiety. These 
degradation products have not been identified yet, preventing from understanding the 
mechanisms of cephalosporins immunogenicity [42, 43]. 
The reaction of cephalosporins with butylamine as a simple nitrogen nucleophile has 
been chemically studied. Although the identification of the exact chemical structure was 
not possible, results suggest the CPO conjugate formation and further fragmentation of 
the dihydrothiazine ring, leading to structures including at least the remaining -lactam 
and the R1 side chain [43, 69]. Also, there is clinical and immunochemical evidence of 
the R1 side chain contribution to the sIgE production as well as to cross reactivity 
responses among different cephalosporins and penicillins. Indeed, some patients have 
selective reaction to the culprit cephalosporin, others react to some cephalosporins with 
identical or similar R1 side chain [70-72] and a third group of patients has cross reactivity 
with another BLs, specially penicillins, with identical or similar R1 side chain [64, 71, 73]. 
Figure 11. Nucleophilic ring-opening of cephalosporins by proteins and subsequent formation of ADs. 
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-Carbapenems 
Studies on the ADs of carbapenems are scarce. However, conjugation between 
carbapenems and proteins have been described. These reactions result in a stable 
structure consisting of the open BL ring bound to the carrier proteins through an amide 
linkage (Figure 12, top). The specificity of the response to carbapenems is likely to be 
related to the relatively stable dihydropyrrole ring [74]. A wide range of cross-reactivity 
between penicillins and carbapenems has been reported in various studies [75, 76]; 
however, more recent prospective studies have shown no cross-reactivity between 
penicillin and carbapenem in skin tests (STs) (around 1%) [77, 78]. 
-Monobactams 
Monobactams are the compounds in which the BL ring is not fused to a second 
heterocycle. The only commercially available monobactam is aztreonam, which has the 
same side chain as the cephalosporin ceftazidime. The conjugation of aztreonam to 
protein through amide bond formation might form relatively stable homogeneous ADs 
(Figure 12, bottom) [74]. The existing three monoclonal antibodies against aztreonam 
have identified three epitopes: nucleus, side chain and the complete structure of the 
drug with the carbonyl involved in the conjugation to the carrier protein [79]. Two of 
these monoclonal antibodies recognize both aztreonam and ceftazidime, highlighting 
the importance of the side chain as a relevant part of the determinant. The third line 
monoclonal antibody recognizes the AD which is formed by the conjugation of β-lactam 
and carrier protein, displaying broad cross-reactivity with several BLs [77]. 
Figure 12. Reactivity of carbapenems (top) and monobactams (bottom) towards nucleophiles. 
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-Clavams 
CLV is the only BL included in this group and is prescribed in combination with AX. The 
complex chemistry of CLV has made it difficult to advance our knowledge of its ADs; 
diagnosis is incomplete when an AX-CLV combination is involved in the reaction [80]. 
The reactivity of CLV can be explained by its strained bicyclic structure (β-lactam ring 
fused to an oxazolidine ring, which presumably reflects the substitution of an oxygen 
atom for sulfur), the lack of an acylamino substituent at C-6, and the presence of an exo-
p-hydroxyethylidene function at C-2 [81] (Figure 13). These structural differences 
increase chemical reactivity of the CLV structure. CLV has a more complex chemistry 
than AX [81-84] in terms of its conjugation process, and relatively little is known about 
its immunogenicity. Initial studies described a very low intrinsic immunogenicity of CLV, 
with the formation of small determinants together with other degradation products 
[74]. According to this study, CLV protein conjugates display very small and 
heterogeneous epitopes with a very low density in the carrier. Moreover, recent 
publications out of the context of allergy have described CLV binding to β-lactamases 
[54, 64, 65, 85] with protein conjugation mechanisms and proposed structures in 
agreement with those previously described [74]. 
Figure 13. Reactivity of CLV towards nucleophiles. Mechanism proposed by Edwards [74] (top) and 
Tremblay [85] (bottom). 
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5.4. Protein haptenation by BLs 
The immune response to BLs is determined not only by the chemical structure of the 
metabolites, but also by the nature of the adduct itself and the characteristics of its 
uptake, processing, and presentation by APCs [86]. Therefore, studies have been 
performed to analyze binding of BLs to carrier molecules, as well as the ability of the 
BL-carrier adducts to activate the immune system and the immunopathogenic 
relevance of them [17, 63]. It is still not fully known how haptenation occurs in vivo, 
nor do we fully understand the amplification mechanisms that cause an allergic 
reaction quickly after the drug administration and develop severe clinical 
manifestations. One of the main limitations of these studies is the difficulty involved in 
detecting the BL adducts produced after treatment. These studies have succeeded 
with penicillins due to their straightforward chemistry with proteins and the high 
stability of the resulting PO anchored structures [5]. However, it has been more 
difficult to perform when the BL involved in the haptenation process has a more 
complex chemical behaviour. First studies were performed to characterize the carrier 
proteins modified in vitro by BP, experiments that were performed in alkaline pH 
aqueous media to enhance the modification of proteins with BP [87], facilitating the 
detection and characterization of the adducts. New studies have been carried out 
recently using different conditions and experimental design for characterization of the 
adducts involved in allergic response to BLs [53, 88, 89]. Ariza et al. studied the 
formation of covalent adducts of low AX concentrations with human serum albumin 
(HSA) and potentially with other serum proteins in alkaline pH aqueous media [88]. 
Garzon et al. addressed the detection and characterization of the modification of HSA 
by AX in ex vivo samples [89]. Meng et al. explored the molecular basis of AX and CLV 
binding to HSA in vitro in neutral pH aqueous media and determined whether similar 
adducts could be detected in patients [53]. 
5.5. Candidate Carrier proteins for BLs 
- Human serum albumin as main carrier protein 
HSA is the major protein component of blood plasma. It plays an important role in the 
regulation of colloidal osmotic pressure and acts as a reservoir and transport protein for 
endogenous (e.g. fatty acids or bilirubin) and exogenous compounds (e.i. drugs or 
nutrients) in the blood [90-92]. As far as drugs are concerned, HSA accounts for the 
majority of binding in serum together with α1-acid-glycoprotein (α-AGP). HSA is a single-
chain, non-glycosylated polypeptide that contains 585 amino acids [90, 91] with a 
molecular weight of 66,500 Da [90, 93]. Most abundant amino acids in albumin are 
alanine, glutamic acid, leucin and lysine. The high percentage of ionic amino acids 
(glutamic acid and lysine) confers a relatively high solubility to the protein. Acidic 
residues are more abundant than basic residues, being -15 the net charge per molecule 
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at pH 7.0. As far as secondary structure is concerned, HSA is a highly helical molecule. 
The α-helix content is 67%, while 23% is extended chain and 10% β-turn, as determined 
by X-ray analysis [91]. HSA contains 35 cysteine (Cys) residues and all of them, except 
Cys34 that plays a key role in the antioxidant function of HSA, are involved in disulfide 
bond formation that serves to stabilize HSA [90, 91, 93]. The tertiary structure is a heart-
shaped molecule with approximate dimensions of 80 × 80 × 30 Å [90, 91]. 
Crystallographic data show that HSA contains three structurally similar α-helical 
domains: I, II and III [90-94], formed by 10 α-helix each, which can be further divided 
into subdomains A and B, formed by 6 and 4 α-helix respectively [90, 92-94] (Figure 14). 
Drugs that bind to HSA with high affinities usually interact with one or two specific sites 
(site I and II) on the protein. X-ray crystallographic data clearly demonstrated the 
location of sites I and II in subdomains IIA and IIIA, respectively [90, 92, 94]. Both sites 
are composed of all six helices of subdomains IIA or IIIA and are therefore topologically 
similar, however, there are significant differences between the two drug pockets [92]. 
The entrance to site I in subdomain IIA faces subdomain IIIA and this site has an 
extended binding region owing to the residues from subdomain IIB and IIIA. In contrast, 
the involvement of other subdomains in the drug binding capacity of site II is relatively 
modest [90].  
Figure 14. HSA structure showing the organization of the protein in domains and subdomains. Top: 
Sequence of HSA structure showing the three domains. Bottom: Crystal structure of HSA showing 
domains (I-III) and subdomains (A and B) as well as the approximate locations of site I and site II. 
Adapted from Yamasaki et al. [90]. 
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HSA structure is affected by variations in the pH conditions due to the high number of 
acidic and basic residues in its sequence. HSA can suffer some chemical modifications 
within its lifetime which can affect its antioxidant properties and ligand binding capacity, 
and furthermore, may confer antigenic properties [95-97]. Some possible modifications 
are acetylation, cysteinylation, homocysteinylation, nitrosilation, nitration, oxydation, 
phosphorilation, glutathionylation and glycation. 
Based on its extraordinary ligand-binding capacity, HSA has been traditionally 
considered the main target protein in the haptenation process for penicillins, and most 
studies have focused on characterization of the PO-HSA adducts. In an early study by 
Lafaye et al. [98], the number of penicillin molecules, which are covalently bound to 
HSA, was directly proportional to the drug concentration. In fact, the detection of PO 
groups decreased exponentially over time after interruption of drug treatment, and the 
half-life of penicilloylated HSA proved to be shorter than or equal to that of non-
modified HSA [98]. Some studies have explored the detection and identification of HSA 
residues modified by BL antibiotics. Early studies by Yvon et al. [99, 100] revealed BPO-
HSA adducts in serum samples from patients treated with BP or samples generated in 
vitro and in which binding of BPO was observed in 6 of the 59 Lys of HSA (Lys 190, 195, 
199, 432, 541, and 545) using separation of trypsinized peptides based on high-
performance liquid chromatography (LC) and peptide sequencing by Edman 
degradation. More recently, the modification of HSA by flucloxacillin [101], piperacillin 
[102], BP [103, 104], AX [53, 89] and CLV [53] has been characterized using tandem mass 
spectrometry (MS) coupled to a LC system performed with serum from patients treated 
with drugs or samples modified in vitro. In addition, the degree of HSA modification is 
dependent on the drug concentration and the incubation time used for the in vitro 
modification [53, 102-104], with BLs showing a binding preference for some HSA-specific 
residues (Figure 15 and Table 2). Lys residues are the most commonly modified, 
however, a couple of His residues were found to be modified by CLV [53].  
Figure 15. HSA model with the Lys modified by AX, BP, flucloxacillin, and piperacillin identified by MS in 
several of the studies referenced in the text. Image taken from Ariza et al. [17]. 
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Table 2. Identified HSA residues modified by AX, BP, flucloxacillin, piperacillin and CLV. 
AX BP Flucoxacillin Piperacillin CLV 
[106] [89] [53] [99, 
100] 
[103] [104] [101] [102] [107] [53] [53] 
Lys4 + a + b +a 
Lys12 + a + a + b 
Lys20 + a,b 
Lys73 + a 
Lys 137 + a,b + a,b + a +a + b +a 
Lys159 + a,b + a +a 
Lys162 + a + a,b + b 
Lys190 ++a ++b + a,b + a + a,b + a ++ a,b + a,b +a +b + a,b 
Lys195 + a + a,b + a + a,b + a,b + a +b +a 
Lys199 ++ a + a,b + a ++ a,b + a + a,b + b + a + a,b 
Lys212 + a + a,b + a ++ a,b + b +a 
Lys351 + a + a,b + a,b + a + a,b + b +a 
Lys359 + a 
Lys372 + a 
Lys414 + a +a 
Lys432 + a + a,b + a + a,b + a + a,b + a,b + a +b +a 
Lys436 + a + a + a 
Lys444 + a 
Lys475 + a 
Lys525 + a,b + a,b + a + b + b +a,b 
Lys541 ++ a + a,b + a + a,b + a,b + a,b + a +b +a 
Lys545 + a + a + a,b + b + b 
Lys560 + a 
His146 +a 
His338 +a 
The most reactive residues, which were identified in the shortest times of incubation or with the lowest 
concentrations of drugs, are shown as ++. aResidues identified in HSA-drug adducts generated in vitro.
bResidues identified in HSA purified from serum of patients with drug treatment. His: Histidine residues. 
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Interestingly, Lys modified residues seem to vary widely between patients in in vivo 
assays, although in the case of flucloxacillin, Lys 190 and Lys 212 appear in 8/8 patients 
along with other residues that vary from one individual to another [101], and in the case 
of AX, piperacillin and CLV, Lys 190 is a common modified residue in 4/4 patients studied 
[53] (Table 2). Furthermore, adducts formed by an AX dimer were seen in the same 
patients, which is an important observation since AX polymers could possess strong 
antigenic properties [53]. Lys 190, Lys 195 and Lys 199 are the most frequently modified 
HSA residues for the various antibiotic studied, being the differences observed in the 
patterns of in vitro modification probably due to structural differences between the BLs 
or the incubation conditions employed, while the differences observed in samples from 
patients likely arise from variations in the therapeutic conditions, including dosage and 
administration route or from the presence of concomitant treatments or pathological 
conditions [105]. Although the factors that determine which amino acids are modified 
by BLs are not known, it has been suggested that binding to Lys may be favored by the 
presence of a serine close to the polypeptide chain or the tertiary configuration of the 
protein [99, 100]. Molecular modeling studies have suggested in general that the 
reactivity of Lys is modulated not only by the residue accessibility, but also by the 
microenvironment around the lysine, which can enhance its intrinsic reactivity and 
contribute to the binding of AX through a recognition process which can stably constrain 
AX in a position leading to adduct formation [88].  
- Other seric and cellular carrier proteins: 
Besides HSA, other serum proteins could be involved in the haptenation process and in 
the induction of an immune response, however, very little is known about their nature 
or their role in the development of DHRs. In a study by Lafaye and Lapresle [98] based 
on blood samples from patients treated with BP, BPO groups were detected in a fraction 
of serum proteins where HSA had been removed, but the modified proteins detected 
were not identified. In a later study, HSA and transferrin were identified as target 
proteins for AMP using 2-dimensional electrophoresis and immunological detection 
with plasma from patients treated with this drug [108]. In a study by our group based 
on immunological and proteomic methods, we identified serum proteins modified in 
vitro by AX. We observed that transferrin and Ig (light and heavy chains), were modified 
by AX along with HSA [88, 89]. The fact that other relatively abundant serum proteins 
did not form detectable adducts under the experimental conditions used, suggests that 
factors other than plasma protein concentration could determine which serum proteins 
were targets for BLs. 
Most of the attention regarding adduct formation by BLs has been directed towards the 
characterization of serum proteins, mainly HSA, as a carrier protein for these drugs. 
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Nevertheless, other possibilities can be considered. Cell surface or intracellular proteins 
could also play a role in the activation of the immune system [105]. 
The formation of ADs with cellular proteins has been previously reported by several 
studies. BP derivatives have the ability to bind to the cellular membranes of 
macrophages [109, 110] and monocytes [111, 112], and it has been described that the 
formation of these ADs is slower with cellular proteins than with serum proteins [44]. 
Moreover, in a study performed in our group, it was showed that confocal fluorescence 
microscopy with a biotinylated AX analog (AX-B) revealed the presence of intracellular 
protein adducts and modified proteins in extracts from AX-B treated cell lines 
(monocytes, B-lymphoma cells, and macrophages) with different patterns, showing that 
the haptenation process may be cell type-dependent [45]. 
In a recent study, Sanchez-Gomez et al. [113] used a B-lymphocyte cell line to detect, 
identify and follow the fate of intracellular AX-protein adducts. They observed that in 
addition to classical pathways in which haptenated serum proteins can be taken up and 
processed by cells, proteins can be haptenated intracellularly and be secreted either as 
soluble proteins or in extracellular vesicles. These vesicles can be taken up by other cells 
and therefore can constitute an additional vehicle for haptenated proteins. They also 
observed that AX can bind to isolated exosomes. These results expand the array of 
structures potentially involved in allergic reactions. 
6. Clinical Symptoms and Diagnosis of Immediate Allergic Reactions to BLs
Symptoms of immediate allergic reactions may be located in the skin, being the organ 
most frequently involved (maculopapular, morbilliform, and urticarial rashes) [6], in the 
respiratory tract (rhinitis, bronchial asthma) or in the digestive tract (vomits, abdominal 
pain and diarrhea). There also may be generalized or systemic symptoms [6] such as 
anaphylactic shock (itching, urticaria, hypotension, angioedema and bronchospasm), 
being even possible patient death.  
The allergological work-up often comprises the performance of both a reliable clinical 
history and different diagnostic tests: in vivo methods such as ST and drug provocation 
test (DPT); and in vitro techniques such as immunoassays and celular assays (Figure 16). 
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Figure 16. Diagnostic algorithm for evaluation of immediate DHRs to BLs. BP-OL: BPO-octa-L-lysine. MD: 
Minor determinant (MD): benzylpenilloic acid. 
A detailed history is the first and most essential step toward an accurate diagnosis of 
DHRs. In addition to the clinical history, a careful physical examination can help better 
classify possible mechanisms underlying the reaction and guide further investigation 
[114]. Next step for stablishing clinical diagnostics is the testing of tissue mast cells 
activation by ST, detection and quantification of serum sIgE using different 
immunoassay methods, use of celular tests for analysis of the percentage of activated 
basophils after the stimulation with the interest drug [115] and diagnosis confirmation 
by DPT (Figure 17).  
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Figure 17. Diagnostic methods for evaluation of DHRs to BLs. 
6.1. In vivo tests 
-Skin test 
ST is considered the best validated in vivo method for diagnosing IR to BLs. In IRs, STs 
are usually performed using the skin prick test (SPT), by pricking the skin with an 
appropriate needle through an allergen solution. If this does not cause a reaction, an 
intradermal test (IDT) can then be carried out, by the injection of 0.02–0.05 mL of the 
drug solution, raising a small bleb that is marked initially. Both are usually performed on 
the volar forearm, although other skin areas can be used [116]. 
Due to the fact that for many years BP was the most relevant BL involved in immediate 
allergic reactions [117], classically, the diagnosis has been focused on the use of major 
and minor determinants of BP [118-122]. The major determinant, the PO-polylysine 
(PPL), is formed by the conjugation of BP to poly-L-lysine (PLL) [40] (Figure 20). The 
classic BP reagents used for ST have been penicilloyl-polylysine (PPL) and minor 
determinant mixture (MDM), originally consisting of BP, benzylpenilloic acid, and 
benzylpenicilloic acid, although current commercial reagents only include BPO-octa-L-
lysine (BP-OL) as major determinant and benzylpenilloic acid as MD [123].  
sIgE soluble in plasma
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BENZYLPENILLOIC ACID 
Figure 18. Described major (top) and minor (bottom) determinants for BP used for in vivo tests. 
The appearance of semisynthetic penicillins with different side chains required the use 
of other determinants, such as AX, AMP, and various cephalosporins and in the 1990s, 
the percentage of positive STs with AX or AMP in patients with penicillin allergy ranged 
from 26% to 47% [116]. In 2001, Torres et al. [124] confirmed that BPO was no longer 
the most relevant hapten in IRs to penicillins and demonstrated that including AX could 
increase ST positivity to 70%. Inclusion of its minor determinants (diketopiperazine and 
amoxicilloic acid) did not improve the diagnostic capacity [125]. Following these 
observations, the European Network on Drug Allergy (ENDA) recomended ST with PPL, 
MDM and AX [126-128] and in those cases negative to PPL and MDM, BP must be also 
included. After penicillins, cephalosporins are the BLs that most often induce IgE-
mediated reactions and for ST, the culprit cephalosporin diluted in 0.9% NaCl is used 
[129, 130]. Since the prescription of AX is recently combined with CLV, the description 
of selective reactions to CLV raised the need to include this drug as a potential culprit in 
the diagnostic evaluation. Initially, the suspicion of CLV allergy in patients with IR after 
AX–CLV administration had been classically based on the presence of negative results in 
both ST and sIgE determination to AX and a positive ST to AX-CLV [131]. However, using 
AX–CLV, only 18% of CLV IRs could be correctly diagnosed, being this low sensitivity due 
to the lower concentration of CLV compared to AX in the AX-CLV combination [80]. 
Attempts to improve the sensitivity of CLV allergy diagnosis by increasing the AX-CLV 
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concentration produced false-positive results, due to the high concentration of AX [80]. 
The recent commercialization of CLV for ST has allowed it to be used on its own in the 
diagnostic work-up [80, 132]. Through its usage, it has been shown that more than 30% 
of patients with AX–CLV IRs are selective to CLV [80, 132]. 
-Drug provocation tests  
DPT is usually performed in a single-blind procedure in the cases of patients with 
negative ST and in vitro tests in which confirmation of diagnosis is essential [133] and is 
performed under strict hospital suveillance with access to an emergency room [121, 
134]. DPTs consist of the controlled administration of increasing doses of the drug to a 
patient with a history suggestive of drug allergy. This can be either the suspected culprit, 
or an alternative structurally or pharmacologically related drug. This procedure is not 
recommended in patients with a history of life-threatening reactions [114, 116]. 
However, in those cases in which the drug is considered as potentially useful or 
mandatory, DPT can be evaluated. Moreover, this diagnostic tool can be used to find 
alternatives to an implicated drug and assessing tolerance to potentially cross-reactive 
drugs [116]. DPT is still the gold-standard method for diagnosing IRs to BLs since recent 
studies showed that more than 30% of patients could be diagnosed accurately only by 
means of DPT [133]. 
6.2. In vitro tests 
The most common in vitro tests are based on the detection of sIgE, either in serum 
(immunoassays) or bound to receptors on the surface of effector cells (basophil 
activation test, BAT). A detailed review of in vitro tests for drug allergic reactions has 
been done by ENDA/ European Academy of Allergy and Clinical Immunology (EAACI) 
Drug Allergy Interest Group [28].  
-Immunoassays 
Immunoassays are the methods employed for sIgE quantification in allergic diseases to 
BLs. In these assays, quantification relies on the sIgE recognition of a drug(hapten)-
carrier complex coupled to a solid phase. For this, the solid phase decorated with the 
hapten-carrier conjugate is incubated with the patient serum, and then, bound sIgE is 
detected using α-IgE antibodies labeled with either a radioisotope (radioimmunoassay, 
RIA), a fluorescent enzyme (fluorescence enzyme immunoassay, FEIA), or a 
colorimetric enzyme (enzyme-linked immunosorbent assay, ELISA) [28, 56, 114, 
134-137], being rarely used. 
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ImmunoCAP (Thermo-Fisher, Uppsala, Sweden) is the fluoroimmunoassay commercial 
method most widely used for diagnosing BL allergy [28, 114, 116], which uses a 
hydrophilic cellulose polymer configured into a small capsule to which the drug-PLL 
conjugates are covalently bound [114] (Figure 19, right). Fluorescence is induced by an 
enzimatically labeled α-IgE antibody and proportional to IgE amount in patient´s 
serum. Detection limits of these methods are 0,01-100 kUA/L (being A sIgE against the 
drug) with 0,35 KUA/L as cutoff. Values over 0,10 kUA/L are indicative of sensitization.  
Figure 19. Comparison of RAST (left) and ImmunoCap (right) assays. Adapted from [114]. 
Radioallergosorbent test (RAST) is a non-commercial RIA used in some laboratories for 
the detection of allergen-specific antibodies. The solid phase employed for RAST to BLs 
is cellulose paper disc activated with cyanogen bromide. A carrier molecule haptenized 
with the drug of interest is covalently coupled to the activated discs. Then, patient sera 
is incubated with the discs and allergen-specific antibodies recognizing the allergen 
fixed  to  the  solid  phase, and  finally,  sIgE detection is performed with a secondary α-
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human IgE antibody labeled with a radioisotope (125I) Figure 19, left). Advances 
achieved in these in-house immunoassay designs during last years are very promising 
[138, 139]. Thus, they have become more quantitative and sensitive although there is a 
lack of automation. 
-Basophil activation test 
BAT is based on flow cytometry with different strategies to identify basophils (using α-
IgE, CCR3, CRTH2 and/or CD203c) and quantify different activation markers on the 
basophil surface after the stimulation with the culprit drug or their metabolites [28, 114] 
(Figure 20). Once basophils have been selected, CD63 and CD203c are the most 
commonly used activation markers. CD63 is expressed in the membrane of histamine 
containing vesicles on basophils, mast cells, macrophages, and platelets and is highly 
displayed on the basophil surface after degranulation. However, CD203c, also 
upregulated after basophil activation, permits a more specific selection of basophils 
since it is constitutively expressed exclusively in basophils and mast cells. 
BAT sensitivity and specificity values for BLs are 50%-78% and 89%-97%, respectively 
[114]. It had been observed that BAT sensitivity is higher with haptens which have not 
been conjugated previously to a carrier molecule [140]. Conversely, in a recent study it 
has been observed that Poly(amidoamine) (PAMAM) dendrimers conjugated with 
penicillins are able to induce basophils activation [141]. 
BAT has received increasing attention for the diagnosis of drug allergy [114, 116] and is 
recommended for diagnosing BLs as complementary method to other in vitro tests. Also, 
when available, BAT should be performed before in vivo tests, including ST, in life-
threatening reactions or in high-risk patients [28, 114]. Over the last years, BAT has been 
included in the allergological workup for AX and CLV selective patients. Torres et al. 
demonstrated that around 30% of reactions in patients taking AX-CLV were CLV selective 
[80]. In a more recent study, it was observed that BAT sensitivity in the evaluation of 
CLV-selective patients was 62%, and combining these results with that from ST, the 
sensitivity increased to 91% [142], which is important because this is the only available 
in vitro test to diagnose CLV-selective patients. 
General Introduction 
70 
Figure 20. Schematic representation of BAT assays. 
6.3. In vivo versus in vitro tests 
Although the most consensual approach to diagnose BL allergy consists of in vivo test 
since they show higher sensitivity, they can be risky, especially in severe and life-
threatening reactions. In vitro tests nowadays have shown to be helpful and 
complementary to in vivo tests. They have greatly evolved in recent decades offering 
numerous advantages in drug allergy diagnosis, such as precise quantitation, absolute 
safety, controlled  conditions, and, for serologic tests, long-term storage of specimens 
[116].  
6.4. Limitations and future of in vitro tests 
In spite of the above mentioned advantages of in vitro tests, their main disadvantage is 
that they can show low sensitivity due mainly to the low concentration of sIgE in the 
blood, which is approximately 0.2% of total IgE for BLs allergy [139]. Additionally, in 
immunoassays other factors such as the drug binding to the solid phase, the carrier 
forming part of the AD, or the density of haptens in the conjugate can influence in the 
results [114].   
The use of ELISA has been reported for some cephalosporins [143-145] and pyrazolone 
[146] but optimization of this technique is time consuming since there are a lot of 
parameters to optimize (conjugate for plates coating and concentration…) for obtaining 
a suitable sensitivity and specificity, which are difficult to obtain. In case of BLs, 
ImmunoCAP is only available for several penicillins (BP, penicillin V, AX, and AMP) and 
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for a cephalosporin (cefaclor). Its sensitivity depends on the BL involved, but is rather 
low and variable (0%-50%), although specificity is high (83%-100%), and false positives 
have been described for cases where the hapten is penicillin V (26%) and in patients with 
high total IgE levels. [114]. Some RIAs have shown higher sensitivity than ImmunoCAP, 
for example, in-house RAST has shown sensitivity ranging from 43% to 75% and 
specificity from 68% to 83% for both penicillins and cephalosporins [114]. However, RIA 
presents the inconvenience of needing specific facilities and trained personnel to 
manipulate radioactive materials. Thus, other techniques avoiding radioactivity are 
preferred by many research groups. Moreover, other important drug allergies, such as 
CLV allergy cannot be diagnosed with this in-house assay, since no successful method 
has been reported. Several studies have also been carried out to analyze the 
performance of BAT for BLs allergy, with sensitivity ranging from 50% to 78% and 
specificity from 89% to 97% [114]. However, although commercially available tests exist, 
BAT protocols are not standardized between different laboratories in terms of markers, 
procedures and drug concentrations [28] and its sensitivity should be improved.  
Although many in vitro tests are available, there is currently no consensus on their 
diagnostic value in routine clinical care [28]. By one hand, there is a lack of well-
controlled studies, most information comes from small studies with few subjects and 
results are not always confirmed in later studies [28]. On the other hand, they present 
some disadvantages or technical limitations such as its lower sensitivity (and sometimes 
specificity) compared with ST. Finally, they are expensive and, in most cases, not 
refunded by medical insurances; and they require equipment that is not available in all 
laboratories [116].  
As a consequence, it is necessary to validate the currently available in vitro tests in a 
large series of well-characterized patients with DHR and to develop new tests for 
diagnosis [28]. 
Regarding future trends, the inclusion of different drug derivatives conjugates at a time 
in the assessment of sIgE would improve diagnosis accuracy. The variety of antibiotics 
and their AD structures plus the number of candidate carrier proteins result in a high 
quantity of potential conjugate combinations. Unfortunately, their inclusion is not 
possible for current in vivo tests and unmanageable for current in vitro tests. The only 
alternative is a microarray platform, which can include many determinants and carriers 
in the same substrate. The inclusion of a wide library of drug-carrier conjugates on a 
high-throughput platform together with enhanced and amplified detection methods will 
greatly improve existing in vitro diagnostic tests and could potentially offer the first 
available in vitro diagnostic assays for evaluating BLs allergy. This technology will allow 
the clinicians to evaluate a wide range of patients with allergy to antibiotics who present 
different patterns of recognition, and would guarantee a correct diagnosis. 
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Unfortunately, nowadays there are no microarray platforms for allergy diagnosis and 
the main reason is the lack of a fluorescent secondary antibody sensitive enough to 
allow detection of such a low sIgE concentration for these kind of allergies. 
6.5. Nanotechnology for improving in vitro tests 
In contrast with the limited changes in in vivo methods, only based on the inclusion of 
new haptens, major progress has been achieved in last years for in vitro tests with more 
sophisticated assays developed. Current efforts are focused on their sensitivity 
enhancement to advance in this field.  
By one hand, it is necessary to obtain more insight into the chemical structure of the 
ADs, the nature of the carrier protein, and how they bind [63, 116]. The use of structures 
similar to that formed in vivo may help to mimic in vitro the molecular recognition 
process that actually occurs [5, 43, 116]. Major progress has been made employing 
materials chemistry and nanotechnology. During last years, the suitability of different 
nanostructures for improving in vitro tests directed to IgE quantification in allergic 
reactions to drugs has been evaluated [116, 138, 139]. Regarding solid phases, besides 
the cellulose paper activated with cyanogen bromide, other materials have been 
investigated such as sepharose beads [130], zeolites [147], and silica particles [148], as 
well as other activation methods that increase hapten fixation or introduce spacers as 
linkers, increasing hydrophilicity, flexibility and distance between ADs and surfaces 
[147]. The high surface area/weight ratio of silica nanoparticles, which permits efficient 
functionalization and sIgE interaction, makes them the most promising material [116]. 
For these in vitro tests applications, dendrimers are also promising structures [51, 141, 
148] that are described in depth in the next section. 
On the other hand, the enhancement of immunoassays detection signal, using efficient 
techniques for site-selective secondary antibodies labeling [149], is also a fine strategy 
to tackle the issue of low sensitivity in in vitro diagnostic of allergy to drugs. 
Nanostructures such as dendritic probes are of interest in this field due to their capacity 
of bearing different units of label or reporter molecule [150, 151], which may lead to 
enhanced signal [150], and a single functionality at focal point for conjugation. 
Therefore, much work is still necessary in order to identify the chemical structures 
involved in the generation of the specific immunogenic epitopes, including candidate 
protein carriers, and to study their immunogenicity, as well as to successfully enhance 
detection signal. This will permit us to improve the diagnostic methods currently 
available and ensure that patients are correctly diagnosed. 
Definitely, multidisciplinary studies in the fields of immunology, proteomics, 
nanotechnology, and chemistry will help to both further understand hypersensitivity 
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reactions to BLs and improve immunoassays detection signal, and these results would 
allow to advance in in vitro methods [105, 116].  
7. Dendrimeric Structures for Improving In Vitro Tests
In the previous nanotechnology related point, dendrimers were briefly mentioned as 
one of the rising nanostructures that have contributed to the advance of the in vitro 
diagnosis of allergy. In fact, major progress in this field using nanotechnology are due to 
the use of dendrimers as nanostructures able to mimic carrier proteins, with the 
advantages of simpler structural build-up and the exposure of a greater number of 
haptens at their surface than conventional carriers. In addition, they are envisioned as 
promising structures for detection signal amplification through biolabeling. Here, some 
generalities of dendritic structures that allow to understand the particular 
characteristics making them promising materials, as well as their usefulness for 
improving in vitro tests for allergy diagnosis are presented.  
7.1. Generalities of Dendritic Structures 
Definition 
Dendrons and dendrimers have been widely studied in recent decades for their potential 
application in a number of areas [152-155]. Their multivalent nature, narrow 
polydispersity, unique structural geometry and the possibility of further polymerize or 
modify their surface with desired functional peripheral groups bring a huge range of 
applications. 
Dendrimers are macromolecules with a highly branched tridimensional structure. The 
term dendrimer derives from the Greek dendri- (tree-like) and meros (part of) but they 
have been also referred as arborols or cascade molecules. Branches growing from the 
core of focal point (red dot in Figure 21) receive the name dendron (grey shaded in 
Figure 21) and consist of repetitive monomer units that possess new branching points. 
Each of these branching points allows the incorporation of new repetitive units, thus 
increasing the generation (G, dotted areas in Figure 21) once all of them have reacted.  
The first dendrimeric structure, polypropylenimine (PPI), was synthesized by Vogtle et 
al. in 1978 but due to difficulties in the synthetic approach used, it was only possible the 
formation of low generation compounds. Newkome et al. [156] and Tomalia were able 
to synthesize well-defined higher generation dendrimers in mids-80 and, since then, 
over 100 different dendrimer structures have been developed. The most commonly 
referenced dendrimers along with their inventors and commercial sources are gathered 
in Figure 22 [153, 157-159]. 
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Figure 21. Depiction of general dendrimeric structures: dendrimer (left) and dendron (right). 
Figure 22. Chemical structures of several commonly used, commercially available dendrimer structures. 
Adapted from [157]. 
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Synthesis 
There are two main methods of synthesizing dendrimers [157, 159, 160] (Figure 23). The 
first one is the divergent method, which consists of growing the dendron from the core 
by adding monomer units to branching points in successive steps or generations. The 
second one is the convergent method, which consists of building a single-branched tree 
or dendron and after synthesis of individual trees, they are linked to the core structure 
as single units. The latter method allows the combination of different dendritic starting 
materials (dendrons) within the same dendrimer structure, also, it is advantageous 
because only a limited number of active sites are present per reaction, reducing 
structural defects in the product. The main disadvantage is that its use is limited to small 
dendrimers due to the fact that steric hindrance avoids the reaction of big dendrons 
with the core. More recently, introduction of click chemistry in dendrimers synthesis 
[153, 161] allowed decent yields with little purification steps required. In addition to 
improving the yields of the divergent strategy using click chemistry techniques, 
accelerated synthetic strategies have been developed to reduce the number of steps 
[162]. In this strategy, two different monomer units, AB2 and CD2, that have 
complementary functionalities can react spontaneously without the use of protecting 
groups or activating agents [159, 163, 164]. Evolution of dendrimer synthesis strategies 
is shown in Table 3.  
Table 3. Evolution of dendrimer synthesis and contributors [158]. 
Method Invented or validated by Year 
Divergent synthesis 
Tomalia et al. 
Newkome et al. 
Meijer et al. 
Majoral et al. 
Hult et al. 
Simanek et al. 
Tomalia et al. 
1979-1984 
1985 
1993 
1994 
1993 
2006 
2005 
Convergent synthesis Frechet et al. 1989 
Self-assembling synthesis Zimmerman et al. 1996 
“Lego” chemistry Maraval et al. 2003 
Click chemistry 
Sharpless et al. 
Hult et al. 
Calmark et al. 
2004 
2009 
2009 
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Figure 23. Schematic representation of dendrimer synthetic strategies [159]. 
7.2. Dendrimers as Synthetic Carriers 
Dendrimers have been used as nanostructures able to mimic proteins, and so employed 
as carriers, enabling the production of conjugates with the advantages of simpler 
structure, multivalency and the chance to control the number of haptens at their surface 
compared with conventional carriers [116]. Therefore, they have been used as synthetic 
carriers, whose multivalence increase the sensitivity and the control structure improves 
the reproducibility of the assays. The use of dendrimers haptenized with penicillins has 
permitted the precise definition of the chemical structures recognized by sIgE [148, 165]. 
Also, their tuneable structures have allowed the inclusion of two different drugs, BP and 
AX, on the same molecule in a well controlled way leading to bihaptenic structures which 
enabled the detection of sIgE from selective and cross-reactive patients [51]. 
Dendrimerized gold nanodisks were employed as a solid phase in a nanoplasmonic 
sensor device for the evaluation of AX allergic patients, showing a good correlation with 
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ImmunoCAP. The main advantage of this method is the use of label-free α-IgE and the 
short analysis time and it represents a potential new assay for the diagnosis of BLs 
allergy [166]. More recently, AXO and BPO decorated dendrimeric antigens (DeAns) 
were demonstrated to be able to induce basophils activation in a selective and specific 
way. This study allowed, for the first time, the performance of BAT with molecules other 
than the free drug, which enhances the response by way of a better control of the 
method in terms of reproducibility regarding the immunogen size and density of 
epitopes. Moreover, potential application to diagnosis are foreseen, in terms of 
sensitivity of the test [141]. 
The development of new nanostructure-based immunoassays is envisaged to provide 
highly sensitive methods, able to detect low concentrations of sIgE. Moreover, they have 
the potential to enable the testing of a variety of BLs and metabolites in the same assay 
[116]. However, these methods are currently limited to those drugs whose AD structure 
is well-known, being necessary structure-activity relationship (SAR) and proteomic 
studies for those BLs, such as cephalosporins or CLV, whose more complex chemistry 
has not allowed yet the complete elucidation of the epitope involved in the immune 
response. 
7.3. Dendrimers as Fluorescent Probes for Detection Signal Amplification 
Over the last decade, fluorescent labeling of biomolecules has become a powerful tool 
for bioimaging and diagnostics. In contrast to radioisotopes, fluorescent dyes have the 
advantage of being of low cost, ease of disposal, and the versatility of multicolor 
labeling [167]. While promising, there is a major drawback accompanying fluorescent 
labeling such as inherently low sensitivity [150]. To overcome this issue and expand 
the applicability of fluorescent probes, it is apparent that dyes with strong 
fluorescence signal need to be identified, synthesized and conjugated to biomolecules 
without jeopardizing the biological activity of the final construct.  
As a mean to enhance the fluorescence signal, different approaches have been 
suggested including conjugation of multiple fluorescent dyes to the biomolecules. 
Unfortunately, an obvious disadvantage of this approach is the high number of 
involved functionalization sites that may affect the specificity of conjugated 
biomolecule [150, 168]. A natural strategy to circumvent such concern is the use of 
orthogonal linkers with the capacity to carry multiple copies of fluorescent dyes as well 
as a single selective reactive group for site-specific conjugation to the biomolecule. 
However, a limitation coupled to this approach relates to the high dye content per 
macromolecule that can reduce fluorescence signal due to various processes such as 
self-quenching of fluorescence [150, 168-171]. Interestingly, although rare, some 
studies have described a stronger fluorescence with the inclusion of multiple 
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fluorescent units [150]. Consequently, the development of a set of intrinsically similar 
structures, sharing the same functional group for specific conjugation to biomolecules 
and bearing different concentration of fluorescent units, would provide the 
appropriate conditions for accurate structure-to-property assessment with emphasis 
on site-specific labeling and improved fluorescence signals, and dendrimers are 
suitable for this purpose.  
8. Bioconjugation Reactions for Antibodies Labeling
The main goal of most bioconjugation techniques is to use the functional groups on 
biomolecules to label with another type of biomolecule or link to synthetic probes [160]. 
Chemoselective bioconjugation (Figure 24) refers to the coupling of two mutually and 
uniquely reactive functional groups in an aqueous environment, which will react only 
with each other even among a multitude of potentially reactive functional groups, 
without side reactions [172, 173]. 
Figure 24. Schematic overview of the vast complexity of functional groups in living systems [174]. 
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The basis of the chemoselective ligation concept is based on the mutually exclusive 
reactivity of functional groups pairs, which are orthogonal groups. There are quite a few 
reviews that gather an extent number of chemoselective pairs [160, 172-179], among 
which, we will focus on the most usual strategies that allow antibody labeling.  
The diagnostic relevance of antibodies comprises classical serology 
(immunoprecipitation, agglutination, complement binding, RIA, ELISA), 
immunocytochemistry and immunohistochemistry, immunofluorescence (microscopic 
and flow cytometric), cytotoxicity tests, immunoblots, immunospot assays and 
immunoabsorption (affinity chromatography) [180]. Ig labeling is the first step for many 
antibody applications and is mostly based on the following covalent interactions: 1) 
modification of the lysine amine group, 2) disulfide modifications of the cystein thiol 
group (Figure 25A), and 3) hydrazone or oxime crosslinking of carbohydrates (Figure 
25B).  
Regarding the first two above mentioned methods used for labeling antibodies, in spite 
of using reactives considered to be site specific in their reactions, they often present 
cross-reactivity with functional groups on biomolecules different than the target ones. 
For instance, N-hydroxysuccinimide (NHS) esters although highly amine-reactive, they 
also can react with other nucleophilic functional groups present in cysteine, serine, 
threonine, and tyrosine side chain [160]. Also, although proteins can be site-specifically 
labeled at their solvent accessible (highly nucleophilic) cysteine residues by thiol-
reactive alkylation reagents such as maleimides and iodoacetamides, excess maleimide-
based reagents or basic pH values lead to the modification of the amino groups at the 
side chains of histidine, lysine and terminal α-amino groups [160, 176].  
Most of commercially available labeling kits are based on Lys reaction, but this 
modification makes quantitative control and reproducibility difficult, and antibody 
specificity can be reduced due to chemical modification of the antigen-binding site. 
However, the modification of carbohydrate residues located in the antibodies Fc region 
is specifically oriented, with a well-defined stoichiometry and without affecting the 
antibody recognition site. 1,2-diols in sialic acids located at the antibody glycan terminus 
can be easily oxidized to aldehydes in mildly oxidative conditions [181] without losing 
antibody affinity or causing further oxidative damage, and they can be afterwards 
functionalized via hydrazone bound with a hydrazide functionalized molecule (Figure 
III.7B). The fact that immobilisation via an oxidised oligosaccharide moiety present in 
the Fc region of the antibody is a strategy commonly used for designing immunoassays 
without assay performance lost [182, 183] proves that antibody binding site is not 
affected when this kind of linkage is used.   
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Figure 25. Most common reactions for antibody labeling. 
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The pairing of a carbonyl group with a hydrazide, thiosemicarbazide or aminooxy moiety 
is perhaps the most versatile chemoselective ligation strategy in terms of their chemical 
or metabolic installation into co-reacting species and ability to readily ligate in aqueous 
media [149]. Over the last few years, bioorthogonal reactions between hydrazide 
functionalized probes and biomolecules has gained popularity. Examples of hydrazide-
functionalized molecules for biomedical and bioimaging applications are dendrons 
[149], peptide tags [184], and dyes [185, 186]. Conversely, to our knowledge, there are 
not many commercially available hydrazide or hydrazine based products for targeting 
biomolecules. One example is the heterobifunctional crosslinker for selectively labeling 
of antibodies with biotin through aldehyde residues in Fc sugar chains (EZ-Link Biocytin 
Hydrazide, from Thermo Fisher Scientific).  
Another bioorthogonal reaction that last decade has revolutionized the modification of 
proteins field is Copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC). It was reported 
independently by Sharpless [187] and Meldal in 2001 and became popular due to the 
high specificity of azide and alkyne groups towards each other remaining inert 
chemically to other molecules in live systems, and the stable and inert regioselective 
1,4-triazole product formed (Figure 26). Bertozzi´s group introduced in 2004 the strain-
promoted azide–alkyne cycloaddition reaction (SPAAC) [188], another strategy for the 
azide–alkyne cycloaddition without need of Cu-catalysis, in which the ring strain of 
various cyclooctyne derivatives boost the reaction (Figure III.9B). The number of 
applications of click chemistry for bioconjugation is growing [189], especially for 
bioimaging applications [190-195]. Staudinger ligation and the inverse electron demand 
Diels−Alder cycloaddition are another kind of click chemistry reactions that have also 
been proven powerful in the hands of chemical biologists, biochemists, and biomedical 
scientists [191]. 
Figure 26. Bioorthogonal (3+2) cycloadditions of azides and alkynes to form triazoles. (A) CuAAC. (B) 
SPAAC. 
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DHRs are currently a major public health problem affecting patient health and increasing 
healthcare costs. They account for 6-10% of all ADRs, and those induced by antibiotics 
are the most common and best studied. Many pitfalls are related to the adequate 
diagnosis probably because the immunological mechanism involved has not been fully 
elucidated. The diagnosis of antibiotic allergy is usually overestimated, and less than 
24% and 10% of initial cases are finally confirmed in adults [15] and children [196], 
respectively.  
DHRs are caused by interactions between a drug and the human immune system and 
result in symptoms ranging from urticaria or angioedema to those more serious such as 
anaphylaxis or anaphylactic shock, and BLs are the drugs most frequently involved [5, 
28]. They are classified according to their chemical structure as penicillins, 
cephalosporins, monobactams, carbapenems, and clavams. All BLs have a β-lactam ring 
that is fused to a 5-member or 6-member ring (except in monobactams) and has 1, 2 or 
3 side chains (except in clavams). Differences in chemical structure mean that a wide 
range of BLs are recognized by the immune system, and patients may experience clinical 
reactions to one BL while tolerating others [17]. 
The first steps in diagnosis involve a clinical history, which is often unreliable, ST and if 
negative, a DPT. These methods show major drawbacks depending on the drug, which 
leads to misdiagnosis. In general, in vivo tests are not exempt of risk for the patient, 
require experienced personnel, and are both time consuming and expensive for the 
health care systems, in addition ST often show a low sensitivity due to false positive 
results, and as a consequence, DPT is the only option available. Thus, in vitro tests should 
be the preferred method for diagnosis, however currently available commercial tests do 
not fulfill the requirements for a reliable diagnosis. The main approach for allergy 
diagnosis consists of immunoassays, which quantify drug sIgE. In general, immunoassays 
work through the binding of sIgE present in patient sera to drug-carrier molecule 
conjugates immobilized onto a solid support. However the sensitivity of these methods 
is low, false positive results (26%) have been described with some penicillin 
determinants  and in patients with high total IgE levels [197] and there are commercially 
available (ImmunoCAP-FEIA) for only a few BLs. This situation has led some research 
groups to produce their own custom-made immunoassays such as RAST, methods 
showing higher sensitivity (42.9-75%) than ImmunoCAP-FEIA, although still not optimal 
[114].  
The most commonly accepted mechanism for immunological activation by BLs is based 
on the hapten hypothesis [18]. BLs are low molecular weight substances that cannot 
cause an immune response on their own but can act as haptens after covalent binding 
through nucleophilic attack of amino groups in proteins on the β-lactam ring. Thus, the 
resulting hapten-carrier (drug-protein) conjugate can induce an immune response by 
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the production of IgE antibodies or T cells. An epitope, or AD, is the part of the drug-
protein antigen that is specifically recognized by the immune system, which may 
involve not only the drug derivative but also part of the carrier protein [17, 115].  
The low sensitivity of both skin and in vitro tests for BLs allergy diagnosis is probably due 
to the fact that they are based on drugs or drug conjugates (ADs) which are not 
optimally recognized by the immune system [17]. Understanding the way in which 
drugs are metabolized after protein conjugation as well as the nature of the carrier 
protein and its contribution to the AD is vital in order to make progresses in the 
diagnosis of clinical allergy [5, 17, 63]. To date, some advances in the identification of 
the chemical structures of ADs involved in IRs to BLs have been presented relating  
drug structure, chemical reactivity and immune recognition [5]. ADs have been 
described for most of BLs [43, 53, 125, 198], although BP is the most widely studied. 
Also, the influence of the carrier molecule on AX recognition has been recently 
demostrated [63]. Moreover, formation of BL-protein adducts is selective, as we 
recently demonstrated for AX, which mainly modifies HSA, transferrin, and Ig heavy 
and light chains in human serum [88].  
In spite of such advances in ADs elucidation, variations in BLs prescription patterns and 
the introduction of new compounds from this family have modified the ADs that induce 
the reactions, leading to changes in the patterns of sensitization. From the first 
description of patients with IRs, the number of cases has progressively increased. 
Nowadays, allergy to new cephalosporins are also being reported and reactions to CLV 
have emerged in the last few years and are progressively increasing since the 
combination AX-CLV is the most highly consumed BL containing medicine worldwide 
[114]. In fact, IR to CLV are more common than IR to BP in Spain [131]. AX-CLV cross-
reactivity has not been reported, probably due to differences in their chemical 
structures and degradation patterns, which poses a diagnostic challenge. This is an 
important issue because CLV selective patients can safely take other BLs, including AX 
[199], increasing therapeutic options and avoiding the use of inappropriate alternative 
treatments, which are often more expensive and have more potential adverse effects 
[131]. Unlikely for penicillins, whose haptenic structure is stable and has been isolated 
and characterized, ADs for cephalosporins and CLV have not been fully characterized 
yet, although few studies have given relevant information about the potential ADs for 
cephalosporins [43, 69, 200] and CLV [53]. This has hampered the development of 
diagnostic tests for these BLs, being immunoCAP-FEIA for cefaclor [114], with low 
sensitivity, the only in vitro test commercially available. For this reason, there is the need 
for studies focused on the complete elucidation and characterization of ADs for 
cephalosporins and CLV. 
On the other hand, the extremely low abundance of sIgE in serum associated with drug 
allergy (femtograms or less) also repesents another factor affecting in vitro tests 
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performance. The high sensitivity needed to detect such low IgE levels is difficult to 
achieve and this is one of the reasons that has avoided the development of microarray 
platforms for diagnosing drug allergy. In this sense, the use of dendrons as 
nanostructures for secondary antibody labeling may allow the increase of fluorescent 
units due to their multivalency. An accurate design of these structures would lead to 
signal amplification without increasing immunoassay unspecific interactions, reaching 
an optimal commitement between the number of fluorescent units and fluorescence 
emission.  
Untangling the mechanisms underlying allergy to -lactam antibiotics for optimization 
of diagnostic methods require multidisciplinary approaches. To this end, in Chapters I 
and II of this thesis we shed light on the process involved in allergic response to 
aminocephalosporins and CLV using synthetic, immunological, proteomic and 
computational strategies. By one hand, we designed and synthesized structures derived 
from two aminocephalosporins (cefaclor and cefadroxil) and CLV, and studied their 
structure-immunological recognition relationships. Also, using a proteomic approach, 
we identified the AD and the HSA binding sites for CLV from in vitro adducted HSA-CLV. 
Finally, we used a CLV biotinylated derivative as a tool for identifying serum proteins 
target of modification by CLV. Besides, detection by novel amplification fluorescent 
measurement approaches are required for addressing the low sensitivity problem of in 
vitro tests, as they are safe, effective and compatible with microarray laser scanners. 
Thus, chapter III is related to the use of dendrimer molecules for signal amplification in 
the IgE detection, with the aim of providing high sensitivity and high throughput in 
diagnosis. For this, secondary antibodies were labeled with fluorescent dendrimers in 
an innovative fashion. 
All results generated from this work could be translated to the improvement of 
diagnostic methods. This would have a direct impact on clinical practice since it would 
provide faster and safer diagnostic methods, reducing the cost to public health systems. 
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The general objective of this thesis is to carry out studies directed to improve current in 
vitro tests for diagnosing immediate allergic reactions to BLs. For this purpose, 
different approaches were proposed: (i) elucidation of the chemical structure involved 
in immune system activation and (ii) amplification of immunoassays detection signal.  
Cephalosporins and CLV were the BLs object of the studies since their consumption has 
notably increase during the last years and there is lack of information about their ADs. 
On the other hand, dendrimeric structures were employed to design new fluorescent 
probes for signal amplification, making the most of their multivalent architecture.  
More specific objectives are the following: 
1. Identification of epitopes for α-aminocephalosporins by a synthetic design of
hypothetical ADs and their immunological evaluation. 
1.1. Synthesis, purification and characterization of pirazinone-like (cyclized) 
structures for cefaclor and cefadroxil. 
1.2. SAR study: Recognition of synthesized structures by sIgE in patients allergic 
to BLs. 
2. Elucidation of ADs for CLV using both a synthetic strategy followed by structure-
immunological recognition evaluation or proteomic approaches. 
2.1.      Synthesis, purification and characterization of structures derived from CLV.   
2.3. Proteomic analysis of HSA-CLV conjugates generated in vitro for elucidation 
of the AD of CLV and identification of its binding sites in HSA. 
3. Use of a biotinylated derivative of CLV as a tool for identification of serum
proteins target of modification.
3.1. Synthesis, purification and characterization of a CLV biotinylated derivative.   
3.3. Assesment of in vitro haptenation capacity of the biotinylated derivative 
3.4. Isolation and identification of serum proteins target of in vitro modification 
3.5. Evaluation of the competition between CLV and its biotinylated derivative for 
protein haptenation in vitro. 
2.2.      SAR study:  Recognition of synthesized structures by sIgE in basophil surface             
from allergic patients selective to CLV.  
 3.2. Nuclear Magnetic Resonance (NMR) comparison of stability and reactivity 
towards nucleophiles between native CLV and its biotinylated derivative.
using HSA as model. 
 
by the CLV derivative.  
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4.1. Synthesis, purification and characterization of a set of dendrons with 
hydazine functionality at focal point and different units of fluorescent 
moieties at periphery.  
4.2. Proof-of-concept site-specific labeling of a model secondary antibody using 
synthesized fluorescent dendrons as probes and spectroscopic 
characterization.  
4. Generation of a series of fluorescent secondary antibodies for amplification of
immunoassays detection signal. 
RESULTS AND DISCUSSION 
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I. Study of antigenic 
determinant structures for 
amino-cephalosporins 
Cephalosporins are BLs that are widely used for infectious illnesses treatment and 
prophylaxis, and they constitute, after penicillins, the most common cause of ADRs 
mediated by specific immunological mechanisms [42]. The characterization of their drug 
determinants [63], the identification of the carrier proteins [63, 201-203] as well as the 
IgE recognition of the conjugate [204] are crucial for understanding the mechanisms of 
allergy as well as to implement diagnostic assays.  
Although the epitopes for cephalosporins have not been fully elucidated, there is 
clinical and immunochemical evidence of R1 side chain contribution to sIgE recognition. 
Some patients are selective to the culprit cephalosporin, whilst others react to 
cephalosporins with identical or similar R1 side chains [9-11], and a third group of 
patients are cross-reactive to other BLs, especially penicillins, with identical or similar 
R1 side chains [10, 12-14]. Structural studies for the identification of the drug epitope 
linked to the protein for cephalosporins are difficult to perform. It seems that SAR 
studies have been the only successful approach for investigating the AD of these group 
of BL antibiotics [42, 43, 69, 70, 205].  
Antunez et al. [70] prepared a series of monomeric cephalosporin-butylamine 
conjugates and evaluated their molecular recognition by IgE in patients allergic to 
different cephalosporins. Although the mixture of different structures formed as result 
of cephalosporins conjugation to butylamine was difficult to characterize, the presence 
of the R1 side chain in most of the formed conjugates is assumed (NMR evidence) [69]. 
In patients allergic to cephalosporins, selective recognition of R1 side chain was proved 
in 67% of cases, with some degree of cross reactivity among cephalosporins with 
identical or similar R1 side chain. This study was quite useful to confirm the importance 
of the side chain in recognition by cephalosporins sIgE, however, it did not provide more 
information about the epitope or AD specific structure.  
Other studies have performed more precise epitope structure elucidation by means of 
the synthesis and immunological evaluation of well-defined structures as proposed AD 
for cephalosporins [43, 69, 205] derived from the CPO conjugate. Thus, a series of 
proposed epitopes were designed (Figure I.1) consisting of the R1 acyl side chain 
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condensed to the β-lactam fragment opened by butylamine, chosen as a nucleophile to 
emulate the ε-amino groups of Lys, and bearing different functionalities or oxidation 
states at the C-6 of the original cephalosporin (methyl, hydroxymethyl, mercaptomethyl 
and acetal). Those with hydroxyl or aldehyde functionality showed the strongest 
immunological recognition [43, 69]. A different pattern, with less recognition of these 
structures was observed for patients allergic to α-aminocephalosporins, which 
suggested the existence of other ADs.  
Figure I.1. Top: general degradation hypothesis for cephalosporins. Bottom: structures derived from 
cephalosporins synthesized and evaluated by Sánchez-Sancho et al. [69] and Montañez et al. [43]. 
The nucleophilic group present in R1 side chain of α-aminocephalosporins allows an 
additional reactivity. By one hand, autoaminolysis reactions would lead to β-lactam ring 
intramolecular opening with good leaving group R2 elimination/leaving to afford 
diketopyperazine structures similar to the observed for AX [206] (Figure I.2A). The 
instability of the dihydrothiazine ring compared to the thiazolidine is likely to result in 
different degradation structures. However, these structures are not conjugated to 
proteins and, according to hapten hypothesis, would not be involved in allergic reactions 
[18, 125]. On the other hand, after the protein binding through the nucleophilic attack 
of lysine amino groups to the β-lactam carbonyl of α-aminocephaloporins, a subsequent 
intramolecular cyclization would be possible by nucleofilic attack of the amino group in 
R1 towards the carbonyl group in the aldehyde proposed to be formed in carbon 6 of 
FG= H Ala (Sánchez-Sancho et al.) 
FG= OH Ser (Montañez et al.) 
FG=  SH Cys (Montañez et al.)
α-aminocephalosporins
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intermediate product [43, 205, 207] to yield, after aromatization, pyrazinone-like 
degradation products [205, 207, 208] (Figure I.2B).  
Figure I.2. Additional reactivity for α-aminocephalosporins due to the presence of an amino group in R1 
side chain. A) Autoaminolysis and B) intramolecular cyclization after protein binding. 
Venemalm et al. [205] isolated this pyrazinone derivatives for cefaclor and cephalexin, 
although in very low yields, which hampered their immunological evaluation. 
Consequently, a pyrazinone analog was synthetized and showed specific recognition in 
cefaclor allergic patients. However, this analog is different to the isolated structure: the 
carbonyl group of amide linkage with carrier nucleophile, instead of being directly bound 
to the C-6 of the pyrazine ring (Figure I.3), it is separated by a methylene from the 
pyrazinone moiety.  
Figure I.3. Left. Synthetic structure for conjugation with carrier molecules and further immunological 
evaluation.Right. Structure isolated after conjugation of cefaclor and cefalexin with propylamine, with 
27% and 10% yield, respectively. 
In this chapter, different approaches were carried out to study the chemical structures 
of the aminocephalosporin ADs formed after protein conjugation able to be recognized 
by the immune system. One consisted of the NMR monitoring of cefaclor and cefadroxil 
solutions in presence of a simple nucleophile, butylamine, as emulators of free amino 
groups from lysine in proteins. In order to better define the structural immunoreactivity 
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of α-aminocephalosporins, the other approach consisted of the design and synthesis of 
novel cyclized structures derived from cefaclor and cefadroxil as potential ADs for α-
aminocephalosporins. To evaluate the immunological recognition of the well-
characterized pyrazinone structures, immunoassays were to be performed with sera 
from patients allergic to BLs. PhD student carried out both the synthesis of the new 
ADs of α-aminocephalosporins and their immunological evaluation by RAST inhibition. 
I.1. Study of α-aminocephalosporins Reactivity Towards Simple 
Nucleophiles 
Lys amines, Cys thiols, His imidazoles and the amino terminal group are the main 
nucleophilic sites of HSA potentially able to covalently react with BLs [88, 209], being 
Lys residues the most reactives [88]. Taking this into account, butylamine and N-acetyl-
lysine were used as simple nucleophiles for in vitro reactions as a first approach for 
characterizing protein-BL adducts. NMR studies of this reaction could give valuable 
information about the structure derived from the remaining BL linked to the 
nucleophile molecule after conjugation via β-lactam acylation. This resulting structure 
might be identical or very similar to that formed when the nucleophile is an aminoacid 
of the protein. Thus, it would help in the structural elucidation of the AD. 
Reaction of cefaclor and cefadroxil in presence of butylamine was studied over time by 
1H-NMR while incubated at 37 ˚C. Solutions using nucleophile/BL 1:1 ratio, prepared in 
deuterated PBS 1X were analyzed.  
The following Figures (I.4-I.7) show stability and reactivity NMR studies for cefadroxil 
and cefaclor. Figure I.4 depicts stability studies for cefadroxil at neutral pH, to be used 
as control, and it was observed that after 16 hours incubation, β-lactam ring started 
opening and the dihydrothiazine ring started degrading but there was still starting 
product. After 40 hours incubation, original structure was degraded and only signals 
belonging to the side chain were still recognizable. Besides, the new signals appearing 
in the aromatic region could be related to some pyrazine degradation structures 
proposed for α-aminocephalosporins [205-207]. Slow β-lactam reactivity for cefadroxil 
could be attributed to the absence of a good leaving group R2.       
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Figure I.4. 1H-NMR spectra of cefadroxil registered in deuterated PBS 1X over time. Pointed with arrows 
changing signals over time. 
Results of cefadroxil reactivity studies with butylamine are presented in Figure I.5. The 
NMR shows again the opening of the β-lactam, the degradation of the dihydrotiazolidine 
ring, the presence of the aromatic ring in the side chain and the appearance of new 
aromatic signals after 14 days of reaction. Compared with control cefadroxil, new signals 
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appears when reacting with butylamine at 3.0-3.4 ppm but they can be clearly attributed 
to amide formation.  
Figure I.5. 1H-NMR study of cefadroxil reactivity with butylamine registered in deuterated PBS 1X. 
Pointed with arrows and circles changing signals over time. 
Stability studies for cefaclor at pH 7.4 were performed and Figure I.6 gathers the results 
obtained. After 16 hours of incubation, there was evidence of complete degradation of 
the starting product since signals belonging either to the β-lactam or to the 
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dihydrothiazine ring were completely gone and only aromatic signals were identifiable. 
Cefaclor has a chlorine atom, the high electronegative value of which facilitates the 
opening of the β-lactam ring by induction. 
Figure I.6. 1H-NMR spectra of cefaclor registered in deuterated PBS 1X within time. Pointed with arrows 
and circles changing signals over time. 
Reaction with butylamine took place since after 15 minutes incubation, when a signal 
belonging to amide formation appeared at 3.25 ppm (Figure I.7). The new signals that 
appeared in the aromatic region after 14 days reaction may be due to the aromatic 
degradation products for α-aminocephalosporins [205-207].    
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Figure I.7. 1H-NMR study of cefaclor reactivity with butylamine registered in deuterated PBS 1X. Pointed 
with arrows and circles changing signals over time. 
From these results, it was only possible the demonstration of the remaining aromatic 
side chain of cefaclor and cefadroxil after reaction with nucleophiles, as it was 
previously inferred [43, 69]. Thus, more sophisticated studies involving SAR evaluation 
are necessary to fully elucidate the structure of ADs for α-aminocephalosporins.  
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I.2. Synthesis of New Synthetic Antigenic Determinants for α-
aminocephalosporins 
IgE recognition evaluation of the exact pyrazinone-like degradation products identified 
for some α-aminocephalosporins had not been possible so far, due to the low yields in 
which they were isolated [205], as well as to the lack of a straightforward synthetic 
methodology that affords them in quantities that allow their evaluation. 
We addressed the synthesis of novel cefaclor and cefadroxil target pyrazinone-like 
derivatives according to the proposed cephalosporins degradation hypothesis, using 
butylamine as a model nucleophile emulating lysine.  
Figure I.8. Degradation hypothesis of cephalosporins (top) and aminocephalosporins (bottom) after β-
lactam ring opening by means of nucleophilic attack of amino groups in proteins and consequent AD 
formation. 
Two synthetic methodologies were tried (first approach) for ADs synthesis before we 
found the successful strategy (second approach, UDC strategy). 
First approach (Scheme I.1): 
In synthetic methodology I, synthesis was started with Boc-protected serine (N-Boc-Ser) 
and followed by amide coupling with butylamine (residue intended for emulating Lys in 
proteins) resulting in N-Boc-Ser-NHBu [43]. Then, alcohol group was to be activated in 
order to turn it into a good leaving group. In this step, tosylation did not work, but 
mesylation did affording N-Boc-Ser-NHBu-OMs. Nucleophilic substitution with 
phenylglycine (Phg) or phenylglycine methyl ester (Phg-COOMe), employing various 
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conditions such as different solvents or bases, was not successful. Thus, further amino 
deprotection and condensation could not be carried out to obtain the target structure.  
In synthetic methodology II, Boc-protected phenylglycine (N-Boc-Phg) was condensated 
via amide formation with Ser-NHBu to yield N-Boc-Phg- Ser-NHBu [43] which hydroxyl 
group was subsequently mesylated (N-Boc-Phg-Ser-NHBu-OMs). However, after 
deprotection of amino group (Phg-Ser-NHBu-OMs), further intramolecular 
condensation was not successful. The fact that both approaches failed in the SN2 
reaction, could be due to phenyl ring steric hindrance.    
Scheme I.1. First approach tried for aminocephalosporins derivatives synthesis. Details of synthetic 
designs (A and C) and synthetic methodology (B and D). Molecules in green were not prepared.  
D) Synthetic methodology II
A) Synthetic design I
B) Synthetic methodology I
C) Synthetic design II
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Second approach: 
The successful synthetic pathway for pyrazin-2(1H)-ones followed the 
Ugi/Deprotect/Cyclize strategy (UDC) [210] (Scheme I.2). First, required structures were 
assembled by following the one-pot Ugi four-component reaction (U-4CR) in which an 
isocyanide, an amine, an aldehyde or ketone and a carboxilic acid yielded the Ugi adduct, 
a bis-amide. More specifically, we selected as starting materials butyl isocyanide, a 
protected primary amine (2,4-dimethoxybenzylamine) as ammonia substitute, a glyoxal 
derivative (2,2-dimethoxyacetaldehyde) and a N-Boc protected aminoacid 
(phenylglycine or hydroxyphenylglycine) to produce the Ugi adduct. The subsequent 
acid-mediated-cleavage of the dimethoxyacetal, 2,4-dimethoxybenzylamine and Boc 
may result in the amino-functionalized aldehyde intermediate that, after cyclization 
through intramolecular imine formation and aromatization, directly afforded target 
pyrazinone V, after chromatographic purification, with yields ranging from 25 to 99%. 
The chemical structures were confirmed by means of 1D and 2D NMR as well as by MS. 
This UDC methodology, which finally enabled the versatile synthesis of our target 
molecules, was  based on a convergent strategy previously described for obtaining 
pyrazin-2-(1H)-ones bearing alkyl substituents at positions 3 and 5 of the pyrazine. We 
adapted the method to prevent substitution at position 5 by using a mono-protected 
dialdehyde, dimethoxyacetaldehyde, instead of glyoxal derivatives. The diversity at 
position 3 of the pyrazine is determined by the choice of the starting amino acid, 
corresponding to the different side chains of α-aminocephalosporins, which means 
that the corresponding target pyrazinones for both α-aminocephalosporins with 
different R1 were obtained by employing the suitable aminoacids. In addition, the 
method is relatively simple as well as time- and cost-effective since it consists of two 
synthetic and only one purification steps, compared to other synthetic alternatives 
involving multi-step chemical procedures [210] and unsuccessful intramolecular 
cyclization through SN2. The synthesized structures are of interest as potential ADs of 
α-aminocephalosporins. 
Scheme I.2. Synthesis of pyrazin-2(1H)-ones as ADs for α-aminocephalosporins, by means of UDC 
strategy. 
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I.3. Immunological Evaluation of Pyrazinone-Like Antigenic Determinants 
I.3.1. Patient´s selection 
After clinical evaluation, sera were assayed by RAST using cefaclor, cefadroxil and AX 
conjugated to PLL in the cellulose solid phase. In order to make sure an accurate 
evaluation of the synthesized structures, those sera with higher levels of sIgE for the 
culprit drug (higher than 6.7%) were chosen: eight from patients allergic to cefaclor and 
nine from patients allergic to AX. Data from the patients included in the study and in 
vitro evaluation of sIgE levels using direct RAST are given in Table I.1. 
Table I.1. Classification and clinical characteristics of patients diagnosed with an immediate allergic 
reaction to cefaclor or AX included in the study. F: female; M: male; AE: angioedema; INT: time interval 
between reaction and study; (+): positive; (-): negative; ND: non determined; NK: not known. aBold faced 
values indicate positive RAST results. 
Case Age Sex Reaction 
Drug 
involved 
in the 
reaction 
INT 
(days) 
ST % RAST 
AX
 
Ce
fa
cl
or
 
Ce
fa
dr
ox
ilo
 
AX
-P
LL
 
Ce
fa
cl
or
-P
LL
 
Ce
fa
dr
ox
il-
PL
L 
1 38 M Immediate urticaria Cefaclor 7 + + ND ND 33.37 ND 
2 43 F Immediate urticaria and AE Cefaclor NK + + ND ND 15.36 ND 
3 37 F Anaphylactic shock Cefaclor 240 - ND ND ND 20.55 ND 
4 56 F Anaphylaxis Cefaclor 120 + + - ND 19.44 ND 
5 13 F Anaphylactic shock Cefaclor 450 + + ND ND 11.17 ND 
6 5 F Erythema Cefaclor 30 - + ND ND 34.56 ND 
7 17 F Anaphylaixs Cefaclor 30 - + - ND 7.69 ND 
8 27 F Urticaria and AE Cefaclor 210 - + - ND 11.67 ND 
9 57 M Anaphylaxis AX-CLV 30 + ND + 47.33 ND 5.12 
10 26 M Anaphylaxis AX 10 + ND + 22.54 ND 1.90 
11 38 F NK NK NK + ND + 21.52 ND 3.85 
12 60 M Anaphylactic shock AX-CLV NK + ND ND 26.09 ND 3.42 
13 69 M Anaphylaxis AX-CLV 28 + ND + 21.80 ND 0 
14 59 M Anaphylaxis AX-CLV NK + ND ND 14.68 ND 4.83 
15 61 F Immediate urticaria and AE AX-CLV 150 - ND ND 7.93 ND 5.40 
16 62 M Immediate urticaria AX-CLV NK ND ND ND 6.77 ND 5.15 
17 53 M Anaphylaxis AX-CLV 120 + ND ND 6.84 ND 2.28 
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I.3.2. In Vitro Evaluation of Specific IgE Molecular Recognition by RAST 
Inhibition 
Immunochemical recognition of the new pyrazinone-like structures was evaluated by 
competitive RAST inhibition. This assay consists of competitive IgE recognition between 
the solid phase (drug-PLL conjugate attached to cellulose) and the inhibitors (Cef1, Cef2, 
Cef3, Cef4 and butylamine monomers for cefaclor and cefadroxil, depicted in Table I.2, 
at different concentrations in the fluid phase. 
Table I.2. Depiction of structures used as inhibitors for RAST inhibition studies. 
Related α-aminocephalosporin 
Cefaclor Cefadroxil 
Type of 
structure 
New pyrazinone-
like structures 
Cef1 Cef2 
Previous synthetic 
determinats 
Cef3 Cef4 
Butylamine 
conjugates 
Cef5 Cef6 
In the previous study of Montañez et al. [43] no recognition was obtained for 
structures Cef3 and Cef4, or related ones includying the same R1 side chain, no matter 
the functional group present at C-6, due to the fact that immunological evaluation was 
performed with sera from patients allergic to cephalosporins bearing a very different R1 
side chain: ceftazidime, cefotaxime or cefuroxime (Figure I.9). However, in our study, 
immunological evaluation was performed with sera from patients in which the culprit 
drug (cefaclor or AX) has the same R1 side chain as the evaluated structures (Cef1 and 
Cef3 or Cef2 and Cef4, respectively).  
In spite of being IgE recognition comparison between the two well-defined synthetic 
structures (Cef1 vs. Cef3 and Cef2 vs. Cef4) the main objective, monomeric conjugates 
of cefaclor and cefadroxil were also included in the study as inhibitors.  
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Figure I.9. R1 side chain for some cephalosporins. 
The two structures derived from cefaclor (Cef1 and Cef3) and cefaclor-butylamine 
conjugate were evaluated in sera from eight patients with allergic reaction to cefaclor 
(Figure I.10A). In most cases, at the maximum concentration (100 mM) of determinants, 
a higher percentage of inhibition was obtained for the pyrazinone Cef1 than for the 
synthetic determinant Cef3, indicating a better recognition of the cyclized structure. In 
general, inhibition dropped at the minimum concentration (10 mM) of inhibitor. In vitro 
IgE recognition is generally considered positive when the inhibition percentage is higher 
than 50%. Important differences in the positivity was obtained, since 63% of patients 
allergic to cefaclor significantly recognized the pyrazinone Cef1 and 12% of cases 
recognized the determinant Cef3, at the maximum concentration (Figure I.10B). 
Regarding results obtained for cefaclor-butylamine, IgE recognition is higher than for 
synthetic structures Cef1 and Cef3 only for two cases (5 and 8). This indicates that the 
sensitivity using the well-defined synthetic structures is higher than using the 
monomeric conjugates, since the latter may contain many kind of degradation 
structures possible but in a low concentration each.  
Results and Discussion     I. Study of antigenic determinant structures for amino-cephalosporins
109 
Figure I.10.  Immunological evaluation results with cefaclor derivatives. A) RAST inhibition assays 
performed with sera from 8 patients allergic to cefaclor, using compounds Cef1, Cef3 and cefaclor-
butylamine as inhibitors and cellulose discs modified with cefaclor-PLL as the solid phase; B) Comparison 
of positivity (%RAST inhibition >50%) between Cef1, Cef3 and Cef5 inhibitors at 100 mM concentration. 
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Since both AX and cefadroxil contain the same R1 side chain (Figure I.11), the recognition 
of cefadroxil proposed epitopes (Cef2 and Cef4) was evaluated in nine patients allergic 
to AX (Figure I.12) in order to study cross-immunoreactivity with penicillins.  
Figure I.11. Comparison of R1 side chain for aminocephalosporins (cefaclor and cefadroxil) and AX. 
Most sera showed similar IgE recognition with both molecules Cef2 and Cef4 (Figure 
I.12A). In fact, similar positive results (% RAST inhibition >50%) between synthetic 
determinants of cefadroxil (in vitro cross-reactivity) was observed in 44% of patients 
allergic to AX (cases 10, 12, 13 and 17). Also, same values of positivity were obtained 
with both molecules Cef2 and Cef4 (Figure I.12B), with 56% of patients allergic to AX 
recognizing each synthetic determinant of cefadroxil. Bearing in mind that the culprit is 
AX, these results can be helpful to get insight into the structure responsible for cefadroxil 
allergies and study cross-reactivities between penicillins and cephalosporins.  
Inhibition results obtained with synthetic structures were in agreement with in vivo test 
results (Table I.1) since there was in vitro recognition in all cases of cefadroxil positive 
ST (cases 9, 10, 11 and 13), either for one of the structures (Cef2 showed inhibition in 
case 9 and Cef4 in case 11) or for both structures Cef2 and Cef4 (cases 10 and 13). 
Furthermore, it is worth to highlight that three out of these four cases presented 
negative direct RAST results for cefadroxil using cefadroxil-PLL in the solid phase (cases 
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10, 11 and 13). However the inhibition showed with synthetic determinants, suggests 
that the cefadroxil-PLL conjugates, anchored to the solid phases for the direct RAST, 
include other structures different to the ones investigated here. This indicates that 
structures Cef2 and Cef4 would be valuable for improving sensitivity of in vitro tests for 
diagnosing AX/cefadroxil cross-reactivity. 
The conjugate cefadroxil-butylamine was better recognized than synthetic structures 
Cef2 and Cef4 for most of cases. As a variety of conjugates may be formed when 
incubating cefadroxil and butylamine, this is in agreement with the fact that other ADs 
different from those included in this study could be as well involved in the allergic 
response.  
Previous structure-immunological recognition relationships studies confirmed that 
besides R1 side chain structure, the rest of the nuclear structure of cephalosporin is also 
relevant for optimal molecular recognition, especially for patients with cross-reactivity 
[43, 69]. The trend observed for patients allergic to cephalosporins that recognized the 
proposed synthetic epitopes (I, II and III, Figure I.13A) was only found for a minority of 
patients allergic to aminocephalosporins, indicating a different immunoreactivity 
pattern, likely due to amino functionality. Our results showed that specificity of IgE 
antibodies from patients allergic to cefaclor is higher for pyrazinone Cef1 than for 
structure Cef3, indicating that the cyclized structures better mimic the real AD. Although 
the enhanced IgE molecular recognition takes place only with those corresponding to 
the pyrazinone V (Figure I.13B), we believe that after conjugation with protein, and 
subsequent cephalosporyl intermediate formation, molecules with structures II and III 
can also be generated.  
These findings provide insight into the structure responsible for cefaclor and cefadroxil 
allergies and cross-reactivity between penicillins and cephalosporins, and these new 
synthesized structures would be applicable for the diagnosis of allergy to those 
cephalosporins sharing the same R1 structure, such as cefprozil (same R1 than cefadroxil) 
or cephalexin and cefaloglycin (same R1 than cefaclor). Further studies involving the 
attachment of structures Cef1 and Cef2 to a solid phase could increase sensitivity by 
direct immunoassays.  
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Figure I.12. Immunological evaluation results for cefadroxil derivatives. RAST inhibition assays 
performed with sera from 9 patients allergic to AX using compounds Cef2, Cef4 and cefadroxil-
butylamine as inhibitors and cellulose discs modified with AX-PLL as the solid phase: A) Group of 
patients cross-reactive with BP; B) Comparison of positivity (%RAST inhibition >50%) between Cef2, Cef4 
and Cef6 inhibitors at 100 mM concentration. 
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Figure I.13. Structure of A) previously synthesized [43, 69] and B) new proposed pyrazinone-like 
synthetic ADs of α-aminocephalosporins. 
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II. Elucidation of antigenic
determinant structures for 
CLV 
Immunoassays employed for in vitro diagnosis of allergic diseases rely on the sIgE 
recognition of a drug(hapten)-carrier complex attached to a solid phase. The attachment 
of the exact AD that induces immune response in vivo would assure the immunoassay 
accuracy for diagnosis and, for this reason, elucidation of the AD involved in the allergic 
reaction should be the first step to design or implement an in vitro test.  
As explained in the previous chapter, one approach for ADs elucidation is the synthesis 
of BL derivatives according to a reactivity or degradation hypothesis, using butylamine 
as emulator of Lys in proteins, and then evaluate their sIgE recognition by means of RAST 
inhibition [43, 69]. However, an approach that provides information about the exact 
structure of the AD, the protein(s) target of modification as well as about binding sites 
would be more convenient.  
Attempts to identify protein targets of reactive electrophilic metabolites have been 
complicated because of the diversity of structures, the low extent of modification or the 
unavailability or prohibitively prices of chemicals or antibodies with high specific activity 
[209]. Thus, identification of novel drug-protein adducts, characterization of their 
precise chemical nature or identification of specific reactive chemical/metabolite-
mediated modification sites within proteins has been extremely challenging. However, 
recent developments in proteomic and MS ionization methods and instrumentation 
now make possible the rapid, high-throughput, and sensitive analysis of proteins, which 
is yielding a great wealth of  information on protein adduction by endogenous and 
exogenous reactive compounds [105, 209, 211-213] integrating work in model systems 
and in patients [212, 213].  
The first step necessary to successfully identify drug−protein adducts is their isolation 
from complex biological samples or the removal of unbound drug [213]. Isolating 
individual protein adducts for MS analysis can be achieved using different methods 
such as affinity chromatography, acrylamide gel electrophoresis (1D or 2D), dialysis or 
precipitation [213]. Often, it is also necessary sample quantification using, for example, 
protein  spectroscopic  assays  [213]  such  as  Bradford. Next step is adducts detection, 
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which can be a complex and challenging issue, especially when they are present in 
very low concentration.  
Radiometric analysis in combination with SDS−PAGE has been the most widely used 
method for the detection of drug−protein adducts in complex systems. However, the 
cost and storage/disposal of radioactive material restricts its use in most of the research 
facilities [213]. Specific antibodies can be used through ELISA and immunoblotting for 
the detection of drug-protein adducts, and the latter combined with separation 
methods, such as 1D and 2D sodium dodecyl sulfate-polyacrilamide gel electrophoresis 
(SDS-PAGE), are quite useful for complex samples as well as highly qualitative and the 
best methods used that visually display the adducts. However, the lack of specific 
antibodies for some epitopes and the lack of sensitivity for the detection of drug-protein 
adducts with a low abundance or with a low level of modification is the major drawback 
of these techniques [213]. From this follows that sophisticated tools are required to fully 
characterize drug−protein adducts.  
MS is an exceptionally powerful tool used to elucidate structures of both known and 
unknown adducts [213]. In top-down MS analysis, whole proteins are analyzed into the 
mass spectrometer where the molecular weight of an intact protein is first identified 
[213]. On analysis, drug-protein adducts will gain a mass addition, depending on the 
level of modification, resulting in a mass-shift that would be identifiable on the mass 
spectra produced. Further fragmentation by tandem MS allows identification of proteins 
with full sequence coverage (Figure II.1). This strategy is extremely useful for mapping 
labile drug-protein adducts that may be lost during digestion or cleaved off in MS 
analysis. High-resolution instruments, such as Quadrupole Time of Flight (QTOF), are 
needed because of the need to resolve the high molecular weight of intact protein. 
Matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) MS, “soft” 
ionization technique, is however a better option for fragile samples that can fragment 
during initial ionization. The incorporation of novel MS fragmentation techniques such 
as electron capture dissociation (ECD), has also allowed the identification of 
modification sites in post translational or chemical modifications. On the other hand, 
bottom-up MS analysis consists of the injection of peptides from proteins into a mass 
spectrometer. In this kind of analysis, after sample preparation, proteins are digested 
using proteolytic enzymes, then, peptides are separated by high performace liquid 
chromatography (HPLC) and finally analized by MS [213] (Figure II.1).  
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Figure II.1. Representation of drug-protein conjugate analysis. After conjugation, sample of interest 
must be isolated and detected previous to analysis by MS methods. 
Together with proteomic and MS techniques, as well as immunological detection 
methods, access to the synthetic or purified drug metabolites or labeled derivatives and 
in vitro generation of the drug-protein or metabolite-protein adduct can provide 
valuable information about the immunogenic structures [45, 214] since, in some cases 
the adducts formed are not stable and can suffer transformations difficult to predict, 
giving rise to structures that may be responsible for the hypersensitivity reaction. 
Therefore, the contributions of chemical synthesis and analytical chemistry to this field 
are critical. Multiple disciplines should contribute to untangle the complex mechanisms 
for drug hypersensitivity which are subjected to individual and context factors as well as 
to factors depending on each drug. Obtained findings may also be useful in the 
prevention, diagnosis and/or treatment of allergy to drugs. 
In this chapter, we used different approaches for identifying CLV derivative structures 
responsible for immunological recognition by the immune system. First, NMR 
monitoring of CLV solutions in presence of butylamine as simple nucleophile and 
emulators of free amino groups from lysine in proteins was performed, in order to 
study BL conjugation and formed structures. Taking into account that SAR analysis is a 
strategy successfully employed before for studying the involvement of drug metabolites 
or derived structures in IgE molecular recognition [215, 216], this was the second 
approach used. Different structures derived from two possible ADs for CLV, AD-I and 
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AD-II, were synthesized, characterized and their immunological evaluation performed, 
both anchored to a solid phase (by RAST) and in free form (by BAT), using samples 
from allergic patients selective to CLV. Moreover, proteomic and MS were employed 
as third approach. We investigated whether the specifically recognized AD corresponds 
to the resulting structure of the CLV that remains linked to the protein. Also, we 
envisaged a strategy that allowed to be a step closer to the identification of serum 
proteins target of modification by CLV. A biotinylated derivative of CLV was 
synthesized, and its reactivity with simple nucleophiles as well as its haptenation 
capacity using HSA as model protein investigated. The use of this biotinylated 
derivative was demonstrated to be a straightforward tool for identification of serum 
proteins target of modification. Finally, taking advantage of biotinylation benefits and, 
in order to gain insight into proteins haptenation by CLV, we prepared and 
characterized biotinylated derivatives of this BL (CLV-B and CLV-TEG-B) and evaluated 
their usefulness for identification of serum proteins target of modification by CLV.  
II.1. Elucidation of the Chemical Structure of Antigenic Determinants for 
CLV 
New prescription habits are changing specificity allergic patterns due to the apparition 
of new ADs [6, 15, 116, 131], fenomena that is nowadays happening in many countries 
with AX-CLV combination [116]. The ignorance of AD exact structure for CLV leads to an 
uncomplete diagnosis when this combination is involved in allergic reactions [131].  
CLV has increased chemical reactivity and more complex chemistry than AX [81-84] in 
terms of its conjugation process. Also, a very low intrinsic immunogenicity of CLV, with 
the formation of small determinants together with other degradation products was 
described in initial studies [74]. For these reasons, the advance in the elucidation of ADs 
for CLV and, as consequence, the development of in vitro tests for evaluation of allergy 
to CLV, have been hampered so far. 
Protein haptenation by CLV is supposed to occur similarly to other BLs [74, 204]. The 
reaction of Lys with CLV (Figure II.2) opens the strained β-lactam ring, leading to the 
formation of acylprotein 1. However, due to its high instability, the resulting structure 
rapidly degrades, leading to the formation of multiple fragments: Acylprotein 1 
undergoes the subsequent opening of the five-member oxazolidine ring, forming the 
linear imine 2. This intermediate 2 may follow different reactivity pathways: a) 
decarboxylation giving rise to derivative 3, which like molecule 2, can break down via 
the imine bond to yield the protein conjugated to the derived aldehyde [74, 217, 218], 
which we hypothesize as a possible AD (AD-I), and the aminoketone 6 and 7, 
respectively, being possible the reaction of 7 with protein amino groups via the ketone  
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functional group or self-condensation to derive 8, whose aromatization leads to the 
pyrazine 9; b) isomerization of both intermediates 2 and 3 to the imine 5, which would 
be hydrolyzed under biological conditions leading to the formation of the protein 
conjugated to the 3-aminopropanamide, second possible determinant (AD-II); and c) 
isomerization to the corresponding enamine 4, which apart from decarboxylation, in 
principle, should not experience further fragmentation. 
Figure II.2. Proposed reaction mechanism for covalent binding of CLV with protein and different 
fragmentation pathways leading to different possible ADs. 
We proposed two main ADs of CLV, AD-I and AD-II, which consist of very low molecular 
weight structures formed by only 3 carbon atoms. Whereas AD-I (1,3-dicarbonylic 
compound) may be fairly reactive towards the nucleophilic attack of amino groups of 
proteins through its terminal aldehyde functional group, reactivity of AD-II appears 
quite limited. It should be pointed out that the rest of the described intermediates 
(molecules 1 to 5 of Figure II.2 could also be possible ADs involved in IgE recognition. It 
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is assumed that different chemical functional groups would influence the molecular 
recognition and immunogenicity of compounds. However, in-depth studies using 
defined structures derived from CLV are still needed to elucidate their ADs [131]. This 
would allow the development of in vitro diagnostic tests for allergy to CLV, currently 
unavailable. 
II.1.1. Nuclear Magnetic Resonance Studies of CLV reactivity
Since Lys residues are the most reactive in proteins, butylamine was used as simple 
nucleophile for in vitro reactions as a first approach for studying simple conjugation and 
optimizing haptenation, that would be further extrapolated to protein adduct 
formation. 
Reaction of CLV in presence of butylamine was studied within time by 1H-NMR while 
incubated at 37 ˚ C. Solutions nucleophile/BL 1:1 prepared in deuterated PBS 1X for 
study. 
Stability studies for CLV revealed that this clavam rapid degrades at basic pH whereas 
it is quite stable at neutral pH (Figure II.3). Proton signals from β-lactam ring, labeled 
as H5 and H6, were used for monitoring the reactivity. They seemed to remain intact 
after 16 hours incubation, time typically employed for conjugates preparation. 
However, the broad singlet that appears around 3.8 ppm could be due to degradation. 
After 40 hours incubation, β-lactam ring remains closed but oxazolidine degradation 
seems to be more evident (pointed by arrows). CLV stability after almost 5 days is 
represented in bottom spectrum of Figure II.3.  Although degradation of CLV (signals 
between 3.8-4.0 ppm) seems to be more evident over time, there is still presence of 
the original drug, which denotes the low kinetic of degradation at neutral pH. Signals 
at 8.5 and 9.5 ppm could be compatible with pyrazine degradation products reported 
by Meng et al. [53]. 
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Figure II.3. 1H-NMR spectra of CLV registered in deuterated PBS 1X over time. Pointed with arrows or 
circle signals changing over time. 
The results of CLV reactivity in presence of butylamine (Figure II.4) showed evidence of 
β-lactam opening, since signals H5 and H6 decreased with time, while a new signal 
appears at around 3.25 ppm, consistent with an amide bond formation. In addition, 
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oxazolidine ring also degrades quickly. After 16 hours incubation there is no starting CLV 
left. 
Figure II.4. 1H-NMR study of CLV reactivity with butylamine registered in deuterated PBS 1X. Pointed 
with arrows or circle signals changing over time. 
Here we presented a selection of the most relevant results obtained using physiological 
conditions or butylamine to study β-lactam ring opening in CLV. From these studies 
could be deduced that CLV is highly unstable in basic media because of the opening of 
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the β-lactam. In spite of the fact that these studies did not allow the elucidation of the 
chemical structure result of CLV reaction with nitrogenous kind nucleophiles, there is 
clinical evidence of the course of this reaction when the nitrogenous nucleophile is 
supported in a macromolecule. Then, haptenization of the macromolecule takes place 
and, as a result, there is conjugation between CLV and the carrier. Obviously, the 
uncertainty of what is the structure that corresponds to this epitope, and what part of 
the molecule comprises it still remains. 
II.1.2. Structure-Activity Relationship of Synthetic Determinant Structures
II.1.2.1. Cellulose Discs and Nanoparticles Functionalized with CLV Derivatives
The first approach used to evaluate the IgE recognition of AD-I and AD-II like structures 
was the use of RAST as immunoassay. For this purpose, it was necessary the coupling to 
solid surfaces of well defined structures derived from the two ADs proposed as well as 
CLV complete molecule, using a protein as carrier. These structures were prepared by 
Dr. Nekane Barbero from Dr. Ezequiel Pérez-Inestrosa research group. Cellulose discs or 
silica nanoparticles were decorated either with the CLV derivate structures or with 
whole CLV molecule, with or without spacer between carrier molecule and the -lactam. 
Immunological evaluation was performed by RAST by the PhD student in our 
laboratories using sera from patients selective to CLV and control subjects non-allergic 
to BLs. All evaluated solid surfaces and results obtained are depicted in (Figures II.5-II.7). 
In Figure II.5B and II.5C, it is observed that structures derived from AD-I (depicted in 
purple and blue) were better recognized than discs functionalized with the whole 
molecule of CLV, and structure derived from AD-II (depicted in orange) was the worst 
recognized. Among AD-I derivatives, the structure with deprotected aldehyde was the 
best recognized. However, there was no difference between patients and controls, 
obtaining a very similar pattern of recognition in both cases. Therefore, an unspecific IgE 
recognition was observed with these structures.  
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Figure II.5. Evaluation of IgE recognition of structures derived from CLV (AD-I and AD-II). (A) Structures 
used for evaluation (AD-I and AD-II) coupled to transferrin (TRF) and anchored to cellulose discs. (B) 
RAST results using sera from patients selective to CLV. (C) RAST results using sera from control subjects 
(non-allergic to BLs). 
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In previous studies, it was found that the introduction of a spacer molecule improved 
recognition [147] maybe because of the better flexibility and availability of the potential 
AD towards IgE. In order to assay the effect of the introduction of a spacer in IgE 
recognition, we evaluated discs bearing the whole CLV molecule distanced from carrier 
molecule with a tetraethyleneglycol (TEG) spacer (Figure II.6). This evaluation resulted 
again in a similar pattern of recognition between patients and controls, although only 
an isolated patient seemed to recognize selectively both structures. Therefore, an 
unspecific IgE recognition was observed for these structures as well. 
Figure II.6. Evaluation of IgE recognition of CLV. (A) Structures used for evaluation (CLV closed and CLV 
open) coupled to transferrin (TRF) and anchored to cellulose discs. (B) RAST results using sera from 
patients selective to CLV. (C) RAST results using sera from control subjects (non-allergic to BLs). 
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Due to the unsuccessful results obtained after cellulose disc evaluation, we decided to 
assay CLV derived structures anchored to another kind of solid phase. Silica 
nanoparticles (NpSiO2) had been used before as solid phase to evaluate ADs of AX [148] 
so we decided to use them as an alternative solid support for assaying our potential ADs. 
Results (Figure II.7) showed that IgE recognition of proposed CLV ADs linked to NpSiO2 
had a similar pattern of recognition for patients and controls, as observed for cellulose 
discs. AD derived from AD-II seemed to be better recognized than AD-I derivative or the 
whole CLV molecule, however, this recognition would be unspecific.  
Figure II.7. Evaluation of IgE recognition of structures derived from CLV (AD-I and AD-II). (A) Structures 
used for evaluation (AD-I and AD-II) coupled to G2 PAMAM dendrimer and anchored to silica 
nanoparticles. (B) RAST results using sera from patients selective to CLV. (C) RAST results using sera 
from control subjects (non-allergic to BLs). * represent controls, and the rest of sera were from patients. 
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To sum up, synthetic structures derived from CLV AD-I and AD-II and the whole CLV 
molecule (with or without spacer), were anchored to cellulose discs or NpSiO2 and their 
sIgE recognition evaluated by RAST. The fact that there was no specific recognition for 
any of the structures, no matter the solid phase to which they were supported, is an 
evidence of the difficulty of the evaluation of CLV immunogenicity using immunoassays. 
II.1.2.2. CLV Derivatives in Free Form
As second approach, six synthetic analogs, whose structure is depicted in Figure II.8, 
were synthesized for further IgE recognition evaluation by BAT, in order to identify the 
CLV ADs better recognized by the immune system and gain insight into the exact 
structure involved in allergic reactions to CLV.   
Figure II.8. Synthetic determinants corresponding to AD-I (Clav1-Clav3) and AD-II (Clav4-Clav6). 
Synthesis of Antigenic Determinants for CLV 
The synthesis was carried out in collaboration with Dr. Nekane Barbero from Dr. Ezequiel 
Pérez-Inestrosa research group. Three of the proposed ADs, Clav1, Clav2 and Clav3 were 
prepared to emulate the AD-I structure (N-protein, 3-oxopropanamide). In Clav1, both 
carbonyl groups of the molecule are protected, one as an amide and the other as an 
acetal group, so the expected reactivity is low. However, the carbonyl groups of both 
Clav2 and Clav3 were activated, modified chemically to form the anhydride, to enhance 
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significant differences (p=0.049). Individual results of BAT expressed as stimulation 
index (SI), defined as the percentage of activated basophils after allergen stimulation 
per negative control stimulation, are shown in Table II.2. Concentrations higher than 8 
mM were also tested, but they were discarded due to their high cytotoxicity (data not 
shown). Only the structures that induced basophil activation in patients (CLV, Clav2 and 
Clav3), at the concentration of 8 mM, were used for further study. 
Table II.1. Clinical data and results of in vivo test for each allergic patient to CLV. Pat: patient; React: 
reaction; IDT: intradermal test; MD: minor determinant; DPT: drug provocation test; PV: penicillin V; ND: 
non-determined. 
Pat Gender Age(years) 
Time 
drug-
react 
(min) 
Time 
react-
study 
(days) 
ST 
DPT 
SPT IDT 
BP/MD AX CLV BP/DM AX CLV BP/PV AX AX-CLV 
P1 F 64 5 1825 - - - - - + ND ND ND 
P2 F 27 120 180 - - - - - + ND ND ND 
P3 F 72 15 2190 - - - - - + ND ND ND 
P4 M 63 15 1095 - - + - - ND ND - ND 
P5 F 39 30 180 - - - - - + ND - ND 
P6 F 49 15 1095 - - - - - + ND - ND 
P7 F 43 5 365 - - - - - - ND - + 
P8 M 28 30 365 ND - ND ND - ND ND - + 
P9 F 32 60 730 - - - - - + ND - ND 
P10 F 40 60 540 - - + - - ND - - ND 
P11 F 38 30 1095 - - + - - ND - - ND 
P12 F 50 5 60 - - - - - + ND - ND 
P13 M 41 15 1095 - - - - - - - - + 
P14 F 27 15 1460 - - - - - + ND - ND 
P15 M 38 15 1825 - - - - - - ND - + 
P16 M 51 30 730 - - - - - + ND - ND 
P17 M 74 2 40 - + + ND ND ND ND ND ND 
P18 M 39 5 210 - - - - - + ND + ND 
P19 M 43 30 730 - - + - - ND ND - ND 
P20 F 35 15 365 - - - - - + ND - ND 
P21 F 39 30 2536 - - + - - ND ND ND ND 
P22 F 43 15 730 - - + - - ND ND - ND 
P23 M 34 15 1460 - - - - - + ND ND ND 
P24 F 45 15 640 - - + - - ND ND - ND 
P25 F 52 UK UK - - - - - + ND ND ND 
P26 F 46 15 120 - - - - - + ND ND ND 
P27 F 40 30 2920 - - + - - ND ND ND ND 
P28 M 58 15 1825 - - + - - ND ND ND ND 
P29 M 63 30 240 - - - - - + ND ND ND 
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their reactivity towards nucleophiles. The main difference is that Clav3 has one of the 
carbonyl groups protected as an acetal, decreasing its ability to bind to proteins 
compared to Clav2. For Clav1 the amide binding with the protein is represented with a 
butyl amide emulating a side chain of Lys; for Clav2 and Clav3 binding is expected to 
occur with proteins during the cellular assay via the activated carbonyl group. The other 
three structures, Clav4, Clav5 and Clav6 were chosen as model analogs of AD-II (N-
protein, 3-aminopropanamide). Clav4 and Clav5 are less reactive than Clav6 because 
their carbonyl groups have not been activated. The resulting conjugate of Clav6 would 
present as an AD-II structure but with its amino group protected as an acyl group. For 
Clav4, amide binding with the protein is represented with a butyl amide emulating a 
side chain of Lys; for Clav5 and Clav6 this is expected to occur with proteins during 
cellular assay via the carboxylic group (Clav5) or activated carbonyl group (Clav6).  
In summary, AD-I and AD-II consist of small structures (71 Da or 72 Da, respectively) 
containing only 3 carbon atoms, considered too small to be immunogenic. Some of their 
corresponding analogs (Clav2, Clav3 and Clav6) were designed with greater ability to 
bind proteins during the cellular assay.  
Patient´s Selection 
The study involved 29 patients with immediate hypersensitivity reactions to CLV after 
the intake of AX-CLV. Diagnosis was confirmed by ST or DPT to penicillin, AX or CLV 
following the European Network for Drug Allergy (ENDA) guidelines [219]. Clinical data 
and individual results for the allergological work-up are shown in Table II.1. As control 
group, 25 cases with confirmed tolerance to AX-CLV were selected. 
Immunological Evaluation by Basophil Activation Test 
IgE recognition of the six different synthetic structures (Figure II.9) derived from AD-I 
and AD-II was evaluated by BAT in patients with selective reactions to CLV and tolerant 
subjects non-allergic to BLs. This evaluation was performed in our research group by 
Rubén Fernández.  
All synthetic analogs of CLV determinants and CLV itself were evaluated in patients and 
controls. The optimal concentration to study basophil activation with each structure was 
selected using dose-response curves (Figure II.10). Analyzing the expression of CD63 on 
basophil surface, the only concentration of CLV that showed significant differences 
between patients and controls was 8 mM (p=0.042). For the different synthetic analogs, 
only Clav2 and Clav3, both coming from the AD-I, showed significant differences 
between patients and controls. For Clav2 the best concentrations were 4 mM (p=0.022) 
and 8 mM (p=0.008), whereas for Clav3 only the highest concentration (8 mM) showed 
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Figure II.9. Detailed structure of the six synthetic ADs derived from CLV. 
Figure II.10. Dose-response curve for BAT using determinants (Clav1-Clav6) and CLV. 
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ROC curves for these structures were performed to select the cut-off to obtain the best 
sensitivity/specificity balance (Figure II.11A) and this was established at: SI >2 for CLV; 
and SI >4 for Clav2 and Clav3 (Figure II.11B). Based on the chosen cut-off, we observed 
a positive basophil activation with CLV in 41.4% of patients, with Clav2 in 58.6% and with 
Clav3 in 27.6%. In controls, basophil activation was positive in 12% of cases for all three 
structures (Figure II.11B). 
Finally, to prove that the observed basophil activation was IgE mediated, BAT was 
performed after incubating cells with wortmannin (WTM), a potent inhibitor of the IgE 
signaling pathway. In all cases, this treatment significantly reduced the percentage of 
CD63 expression compared with BAT performed in the absence of WTM (p<0.001 for 
CLV; p<0.001 for Clav2; p=0.007 for Clav3) (Figure II.12). Bars show the mean value + 
standard deviation (SD) of percentage of CD63 on basophil surface obtained for non-
inhibited and WTM inhibited basophils in BAT. Results are expressed as the mean + SD 
of CD63 % in patients (N = 29) and healthy controls (N = 25). Significant differences are 
indicated in the graph (* p<0.05 and ** p<0.01). 
Figure II.11. Determination of BAT cut-off for CLV, Clav2 and Clav3 at 8 mM concentration. A, ROC curve 
analysis of each structure. B, Dot plots graphs showing individual BAT results expressed as SI of each 
structure for patients and controls. Positive results for BAT (over cut-off) in allergic patients and controls 
are represented as percentages. 
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Table II.2. Results of BAT with CLV and the six synthetic structures at 8 mM, expressed as SI, for 
each allergic patient to CLV. Positive results are highlighted in bold. 
Patient CLV Clav1 Clav2 Clav3 Clav4 Clav5 Clav6 
P1 0.97 0.92 2.74 1.85 0.31 1.25 0.74 
P2 0.68 0.16 2.38 2.67 0.35 0.51 0.65 
P3 0.64 0.73 3.38 1.41 0.14 0.34 0.32 
P4 1.15 1.07 3.35 3.61 1.08 1.19 0.89 
P5 1.32 1.12 2.95 3.05 1.24 0.55 1.00 
P6 0.62 0.27 0.21 2.14 0.51 0.24 0.24 
P7 0.66 1.25 2.55 1.20 1.07 2.31 0.41 
P8 1.44 0.65 3.33 2.53 1.25 0.58 1.12 
P9 1.59 1.74 3.18 1.44 0.56 0.79 1.14 
P10 2.98 0.65 3.39 3.15 0.69 1.27 0.67 
P11 2.11 0.97 2.44 3.12 1.30 1.20 0.65 
P12 5.52 1.03 3.70 3.25 0.39 1.08 0.94 
P13 1.11 0.59 5.00 2.45 0.65 2.51 1.25 
P14 0.72 0.51 5.07 3.27 0.28 0.63 0.56 
P15 0.64 1.87 4.22 1.74 0.50 0.37 0.25 
P16 1.23 0.43 8.98 3.05 0.61 1.00 1.13 
P17 2.02 1.25 5.10 2.68 0.36 1.68 2.22 
P18 2.46 0.43 4.88 3.00 1.25 0.98 1.26 
P19 2.36 0.98 5.93 3.34 0.87 0.54 0.61 
P20 4.35 0.84 4.41 2.72 0.54 0.67 0.92 
P21 3.62 0.87 5.49 3.62 1.07 1.02 0.56 
P22 0.95 0.37 8.22 4.43 0.18 0.53 1.48 
P23 0.96 0.56 4.12 4.05 0.63 1.10 0.99 
P24 1.65 1.37 5.58 4.20 0.77 0.78 1.65 
P25 1.30 0.94 4.16 4.09 0.26 0.56 1.87 
P26 4.67 1.23 5.38 4.20 0.25 0.79 1.17 
P27 5.10 1.25 6.93 4.08 0.39 1.89 2.14 
P28 2.21 0.73 5.45 4.06 0.70 0.53 1.23 
P29 6.06 0.65 6.51 8.18 0.98 0.36 0.85 
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Figure II.12. Results of inhibition of BAT with WTM prior to stimulation with CLV, Clav2 and Clav3 or 
positive control (α-IgE) after optimization of experimental procedures in which it was observed that 
only IgE mediated pathway was inhibited. 
We observed that from those patients with positive BAT to CLV, 75% were also positive 
to Clav2 and 33.3% to Clav3. More interestingly, from cases with negative BAT to CLV, 
47.1% showed positive results with Clav2 and 23.5% to Clav3 (Figure II.13A). The 
percentage of patients showing basophil activation increased significantly to 69.0% 
when results obtained with CLV and Clav2 were combined compared with CLV alone 
(p=0.002), however no improvement was observed when Clav3 was added (Figure II.13B 
and Table II.2).  
Figure II.13. Positive BAT results in allergic patients. A, Comparison of the percentage of positive results 
of BAT for Clav2 and Clav3 in cases with positive or negative BAT to CLV. B, Comparison of the 
percentage of positivity of BAT combining the results with CLV, Clav2 or Clav3. Significant differences 
are indicated in the graph (* p<0.01). 
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Herein, the ability to stimulate basophils of synthetic structures designed according our 
CLV degradation hypothesis was evaluated, finding that only two of them (Clav2 and 
Clav3) were able to induce activation in allergic patients. Interestingly, both molecules 
correspond to AD-I, suggesting that these synthetic analogs, containing aldehyde 
functionality, are the ones recognized by IgE bound on the basophil surface.  
Clav2 is an analog of AD-I modified chemically to form the anhydride of its carboxylic 
group, to enhance their reactivity towards nucleophiles. In this way, Clav2 binding is 
expected to occur with proteins during the cellular assay via the activated carbonyl 
group. Moreover, the aldehyde group of AD-I is represented in Clav2 as a carboxylic 
group which may be formed through hydrolysis of the second carboxylic anhydride in 
the aqueous media, which would lead to a molecule that is more similar to AD-I than 
Clav3. Although the oxidation state of Clav3 is equal to the proposed structure AD-I, in 
contrast to a higher oxidation presented in Clav2, Clav3 may involve a higher steric 
hindrance through the diethoxyacetal compared to the carboxylic acid group that may 
be formed in Clav2. Thus, in terms of 3D structure, in comparison to Clav3, Clav2 forms 
a structure more similar to AD-I. It is important to highlight that these facts are in 
agreement with the degree of recognition found (Clav2 > Clav3). 
Basophil activation requires the crosslinking of two adjacent IgEs at the cell surface, and 
this is only possible with the recognition of a structure with a size ranging from 40-100 
Å [220]. This explains the fact that in our study only the analogs able to bind proteins 
can stimulate the basophil. This is in agreement with the hapten hypothesis, which is 
currently accepted as the mechanism of action for other BLs, such as penicillins [63, 
204]. Although Clav6 can also bind to proteins, their conjugates are not recognized by 
IgE from CLV allergic patients. This suggests that small differences in the structure can 
highly influence the immunological recognition. The IgE-mediated mechanism was 
confirmed by inhibition of the basophil activation with WTM, an inhibitor of 
phosphoinositide 3-kinase enzymes, which are part of the IgE signaling pathway [221] 
and have been shown to be a key set of kinases activated by FceRI receptor cross-linking 
[222]. 
We evaluated whether the inclusion of these synthetic analogs can improve the 
potential of BAT for diagnosing CLV allergic patients. Using the complete molecule of 
CLV, 41.4% of patients showed a positive BAT, whereas using Clav2, this increased to 
58.6%. Interestingly, the combination of results obtained with CLV and Clav2 
significantly increased the percentage of patients showing basophil activation to 69.0%, 
due to a proportion of patients that were activated by only one of the molecules. When 
CLV is used for the assay, the resulting conjugates can contain different and 
heterogeneous determinants, including the ones we proposed as main determinants 
(AD-I and AD-II) and others (Figure II.2). Thus, the concentration of AD-I would be lower 
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than the one that we used in vitro when we included the synthetic analog Clav2. This 
lower density of AD-I would affect the recognition in BAT and could explain why some 
patients that respond to Clav2 do not respond to CLV. A similar pattern has been 
observed with metamizole in BAT studies: some patients showing IgE recognition to 
some of its metabolites did not recognize the parent drug [216]. BAT results showed an 
increase of positivity from 37% to 62% using metamizole plus metabolites as compared 
to metamizole alone, demonstrating that these metabolites have an important role in 
the allergic reaction. All patients that responded to metamizole also responded to any 
of its metabolites, however in the present study we have found some patients that 
respond to CLV and not to Clav2. These patients may be sensitized to other 
determinants formed during CLV conjugate fragmentation, which have not been 
considered in the present study. 
Assesment of the haptenation capacity of Clav2 and Clav3 
In order to prove the ability to bind proteins (Figure II.14) of the structures that 
presented BAT positive results (Clav2 and Clav3), we incubated these structures with 
HSA in PBS 1X for 16 hours at 37˚C using molar ratio HSA/structure 1:10 and, after 
purification by dialysis resulting conjugates were analyzed by MALDI-TOF MS. PhD 
student prepared and purified the conjugates, that were analized by at Central Service 
for Research Support, University of Málaga (SCAI, UMA), and analized the results. The 
fact that for both conjugates a mass increment was obtained with respect to the mass 
of control HSA, Δm= 112.3 for HSA-Clav2 and Δm= 64.5 for HSA-Clav3, confirms that 
both structures derived from CLV (AD-I) are able to bind proteins as expected.  
Figure II.14. Clav2 and Clav3 reactivity with proteins. 
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II.2. Characterization of CLV-Protein Adducts Generated In Vitro 
As mentioned before, the reactivity of BLs is well known and the formation of hapten-
protein conjugates is a key process in BL allergic reactions. The study of these resulting 
conjugates is really important in terms of understanding the mechanisms involved in 
the immunological recognition of the BL antibiotics and the fully characterization of 
these adducts would provide valuable information to improve the diagnosis of drug 
allergy.  
In the last decade, the combination of immunochemical studies with MS techniques 
have allowed to gain insight not only into the proteins involved [88] but also into the 
identification of protein binding sites [53, 89, 101-104, 107] and the determination of 
exact drug moieties forming part of the AD [53]. Among BLs, penicillins conjugation is 
the most studied: AX [53, 89, 106], BP [103, 104], flucoxacillin [101] and piperacillin 
[53, 102, 107].  
However, in the case of CLV as a hapten, neither the chemical structure of its AD nor the 
relevance of the proteins involved is known and, to our knowledge, there is only an study 
directed to study CLV conjugation. Meng et al. [53] investigated the haptenation of HSA 
by AX and CLV in drug-protein adducts generated in vitro and in serum samples from 
drug-induced liver injury (DILI) patients treated with the antibotics. Incubation of HSA 
with a range of molar ratios of CLV (1:1 to 50:1) was performed and LC-MS/MS analysis 
of the tryptic digests of HSA-CLV revealed seven types of adducts (Figure II.15), 
including direct binding of CLV to lysine (Δm=199), subsequent degradation products 
(Δm=155, 137 and 70), and pyrazine adducts (Δm=222), preferently formed at high 
concentration of CLV, on lysine and histidine residues.  
Figure II.15. Representation of CLV residues that were found after HSA incubation with CLV in vitro and 
their mass increments. 
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The fragment involving Δm=70 seemed to be the most stable. Also, HSA modified by AX-
CLV were detected in patients receiving AX-CLV combination. The profile of CLV-
modified peptides in patients was less complicated than in vitro. Only the Δm=70 
adducts were detected, with Lys190 adducts being found in all patients. 
With the aim to contribute to the study of CLV haptenation, we propose the use of HSA 
as a model protein to gain insight into the nature of the relevant determinants formed 
by CLV. For this, HSA-CLV conjugates were prepared in vitro and their detailed 
characterization performed. To start with, dependence of modification with drug 
concentration was studied. Besides, studies for identification both HSA nucleophilic 
residues modified and the exact structure derived from CLV that remains linked to the 
protein after conjugation were carried out. Results would confirm the structures derived 
from AD-I with positive BAT as the AD involved in allergic reactions to CLV. 
II.2.1. Mass Spectrometry Characterization
HSA was incubated with different concentrations of CLV from HSA/CLV molar ratio 1:10 
(close to physiological conditions) to a high excess of the drug (1:600). In Figure II.16, 
each MALDI-TOF MS spectrum shows a peak belonging to monocharged HSA (66846 Da 
for control HSA) as well as a peak belonging to double charged HSA (33372 Da for control 
HSA). Conjugates were prepared by the PhD student and analyzed at SCAI, UMA.  
Figure II.16. MALDI-TOF results for different HSA-CLV conjugates. 
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MALDI-TOF MS results showed that incubation of HSA with increasing concentrations of 
CLV induced a concentration-dependent increase in the mass of the protein (Figure 
II.16), from 1:10 up to a 1:320 molar ratio. Saturation of CLV binding to HSA occurs at a
1:320 molar ratio, since conjugates derived from a 1:600 molar ratio showed the same 
mass increment. 
II.2.2. Identification of HSA Binding Sites
a) Characterization of HSA-CLV conjugates by linear trap quadrupole (LTQ)
Orbitrap XL 
Since HSA modification was observed even in the conjugate derived from a 1:10 molar 
ratio incubation, we used this for further characterization studies, since it is the closest 
to therapeutic conditions. Residues modified by CLV were identified by arginine C 
digestion of native and modified HSA prepared at neutral pH, followed by LC-MS/MS 
analysis of the resulting peptides. These experiments were carried out in the Proteomic 
Laboratory at University Hospital Vall d´Hebron Research Institute. We observed that, in 
vitro, CLV binds covalently to the amino groups of Lys in HSA. The resulting conjugates, 
formed after β-lactam ring opening, show a mass increase of 70 Da, which is consistent 
with the addition of a fragment of the CLV molecule of 71 Da accompanied by the loss 
of a hydrogen atom (Figure II.17). This finding is compatible with the haptenation 
process proposed in Figure II.2. Interestingly, mass increments corresponding to the 
entire molecule of CLV were not found. 
When injecting 1µL of conjugate in the LC-MS/MS analyzer, we observed one peptide 
(473VTK*CCTESLVNR484, calculated mass: 1421.6625 Da) showing a mass increase of 70 
Da on Lys 475. The MS/MS fragmentation pathway was carried out from the [M+2]2+ as 
parent ion at m/z 711.8385 Da (Figure II.17A). In order to increase the coverage and 
find additional modified peptides, a higher amount of sample was injected (4µL). This 
led us to observe a new peptide (187DEGKASSAK*QR197, calculated mass: 1245.5949 
Da) covalently modified at Lys 195. Figure II.17B shows the MS/MS spectrum for a 
triply charged ion at m/z 416.2059, corresponding to the peptide HSA 187-197 with 
the 70 Da mass increment. The peptide sequences were confirmed by the b and y ion 
series determined by MS/MS. The same peptides were also observed without 
modification, demonstrating that not all the HSA is modified in those residues at 
therapeutic dose conditions. It should also be noted that the conditions at which the 
MS/MS experiments took place, performed in collision induced dissociation (CID) 
mode, could cause fragmentation due to the unstable nature of this modification, 
which could be lost during the collision.  
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Figure II.17. MS/MS spectra of CLV-HSA derived peptides identified in vitro with a mass increment of 70 
Da. A, Collision-induced dissociation (CID) based MS/MS spectra of the [M+2H]2+ precursor ion of the 
peptide 473VTK(+70)CCTESLVNR484 modified at Lys 475. Calculated mass of modified peptide: 1421.6643, 
experimental mass: 1421.6625 and observed parent ion at m/z: 711.8385. B, Collision-induced 
dissociation (CID) based MS/MS spectra of the [M+3H]3+ precursor ion of the peptide 
187DEGKASSAK(+70)QR197 modified at Lys 195. Calculated mass of modified peptide: 1245.5949, 
experimental mass: 1245.5960 and observed parent ion at m/z: 416.2059. Matched b- and y-ions are 
indicated in the spectra as well as the peptide sequence. 
Summing up, we observed that covalent binding of CLV to HSA takes place in vitro and 
that this modification is concentration-dependent, consistent with recent studies [217]. 
As expected, given the complexity of CLV reactivity, analysis of the CLV-protein 
conjugates did not allow the detection of mass increments corresponding to the 
addition of the complete CLV molecule, and only a 70 Da mass increase was observed, 
which corresponds to an adduct with AD-I structure. This result is in agreement with 
one fragment recently identified in cell culture media and in patients with DILI exposed 
to AX-CLV [217]. Moreover, these results are also consistent with mechanisms and 
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structures proposed in other publications out of the context of allergy, describing CLV 
binding to β-lactamases [82, 223, 224], although through a serine residue rather than a 
lysine [218].  
It is important to highlight that the fact that proteomic results confirmed that HSA was 
modified with a 70 Da residue is in agreement with the results obtained with BAT, and 
confirms that the specifically recognized AD derived from AD-I forms part of the 
resulting CLV-protein conjugate. 
b) Molecular modeling of HSA residues modified by CLV in vitro
In order to obtain further insights into the observed adducted Lys for HSA-CLV (Lys 195 
and Lys 475), molecular modeling studies were performed by Dr. Francisco Nájera, from 
Ezequiel Pérez-Inestrosa Research Group (UMA), exploring the regions surrounding the 
modified residues. Even though Lys 475 is more basic than Lys 195, the former is more 
exposed because it is located at the surface of HSA, enabling CLV to get close. Lys 195, 
although less accessible, is surrounded by other positively charge residues that 
contribute a reduced basicity [225]. 
Docking simulations were used to know how the region adjacent to the adducted Lys 
residues can stabilize an appropriate complex with CLV and contribute to adduct 
formation. Figure II.18 shows these complexes with the interactions stabilizing CLV in 
the proximity of Lys 195 or Lys 475. In both complexes, the CLV is visibly close and with 
the proper orientation to react with the adducted lysines. The nitrogen atom in the Lys 
reacts with the carbon atom of the carbonyl group of the β-lactam ring. In both cases, 
the carboxylate group of CLV is involved in a salt bridge (with Arg 218 for Lys 195 and 
Arg 472 for Lys 475) which plays a key role in the orientation of CLV. In the case of Lys 
195, an additional hydrogen bond between the hydroxyl of CLV and His 242 also 
contributes to stabilizing the complex. 
Figure II.18. Docking simulation of the environment of HSA residues adducted by CLV. 
Results and Discussion II. Elucidation of antigenic determinant structures for CLV
141 
Lys 195 has been previously reported to be linked in vitro to a bigger CLV-derived 
structure with a mass equivalent to three AD-I moieties [217]. This result can be 
attributed to the self-condensation of CLV degradation molecules (71 Da) at higher 
drug concentrations. The same residue has been shown to be modified by BLs, such as 
BP [226], flucoxacillin [227] and piperacillin [228]. Lys 475 has not been previously 
reported to be modified by CLV, although it has been identified as target for AX [217]. 
These modeling studies were able to explain the reactivity of these residues, which is 
determined by the surrounding environment and residue accessibility.  
II.3. Development of Approaches for Detection of Serum Proteins 
Modified by CLV 
As stated before, drug binding to proteins is known to play a key role in the development 
of drug allergy. Drugs or their metabolites can be labeled to facilitate the detection and 
enrichment of the adducts in complex samples [105]. The avidin-biotin interaction 
provides great affinity and sensitivity, and the possibility of coupling modification of 
proteins by biotinylated compounds with several methods for detection, purification 
and imaging [45] and that is why the incorporation of a biotin moiety is one of the most 
used procedures for non-isotopic labeling [229]. Recently, some studies employed biotin 
as probe for biochemical/pharmacological [230-232] or antigenicity studies [214]. Also, 
biotin labeling has been combined with proteomic techniques for the identification of 
potential protein targets for haptenation [45, 113, 233, 234] or modified protein 
residues [235]. Some of these studies have been performed in our group or with 
collaborators, using AX-B (Figure II.19) [45, 113]. It was demonstrated that AX and AX-B 
compete for their binding to proteins, suggesting that they may bind to common sites 
[45]. Furthermore, the use of AX-B  allowed the highly sensitive detection of haptoglobin 
haptenation although it had not been detected as target of haptenation by AX using 
immunological procedures [45]. Also, several novel targets for haptenation by AX have 
been identified in B lymphocytes through the use of AX-B [113].  
Figure II.19. Structure of AX-B used by Ariza et al. 
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The lack of existence of α-CLV monoclonal antibodies did not allow the immunological 
evaluation of protein-CLV adducts before and, as a consequence, there are no currently 
available methods for immunological evaluation of CLV adducts. This fact could make 
biotinylated derivatives of CLV a really valuable and straightforward tool for studying 
haptenization and developing methods to identify CLV target proteins. Nevertheless, it 
should be taken into account that the introduction of a biotin moiety into a parent 
molecule could result in steric hindrances of its interaction with certain targets, for 
which it is very important to confirm the results obtained with biotinylated molecules 
using the parent molecule [45, 105].  
II.3.1. Synthesis of Biotinylated Derivatives of CLV
To detect serum proteins that conjugate to CLV, a biotin derivative was chosen as probe, 
due to its extremely high affinity for streptavidin binding and no impact on the biological 
activity of its substrate. The synthesis of CLV derivatives was optimized by Dr. Nekane 
Barbero (Dr. Pérez-Inestrosa research group) and prepared by the PhD student when it 
was needed for performing the studies.  
The functionalization of CLV was carried out in optimal conditions that do not affect the 
β-lactam ring, its reactive site towards nucleophiles. CLV was successfully labeled with a 
biotin moiety to its carboxylic group through two different approaches (Schemes II.1 and 
II.2).
First approach consisted on the direct coupling between CLV and biotin iodide to 
synthesize CLV-B (Scheme II.1). Biotin esterification to form the methyl ester was the 
first step. Further reduction to alcohol and subsequent tosylation allowed to have a 
good leaving group which, after substitution by an iodine group, and final reaction with 
carboxyl in CLV allowed biotinylation of the drug.  
Scheme II.1. Synthesis of biotinylated derivative CLV-B 
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The product was isolated with 73% average yield. Assigned 1H-NMR spectra of pure 
CLV-B is depicted in Figure 20.  The resulting compound was not soluble in water and 
DMSO  was used to make it soluble in aqueous media for further protein incubation 
experiments. 
Figure II.20. 1H-NMR (DMSO)   of CLV-B 
Second approach employed an extending TEG linker between CLV and a biotin by 
means of a two-step synthetic process (Scheme II.2). First, tetraethylenglycol chain 
was ditosylated and both tosyl groups were substituted by iodine. Selective reaction of 
commercial biotine with the trioxygenated di-iodide afforded biotine iodide, which 
was then subjected to reaction with potassium clavulanate leading to the target 
molecule. These linkers increase the hydrophilicity of the compound, which provides 
solubility in aqueous media. In addition, the flexibility and length of the spacer make 
biotin moiety more available to interaction with streptavidin, which may lead to higher 
detection efficiency.  
NH NH 5 2 1´´ 12´
8´ 2´ 2´´
6
6 7´
13´
6´ 5´ 4´ 3´
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Scheme II.2. Synthesis of biotynilated derivative CLV-TEG-B. 
Figure II.21. 1H-NMR monitoring of synthetic steps for preparing CLV-TEG-B. 
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Reactions were monitored using 1H-NMR (Figure II.21). In Figure II.21B we can notice 
the disappearance of signals belonging to tosyl groups as well as the shift of the signals 
adjacent to tosyl groups in A or iodine groups in B. In Figure II.21C, one of the methylene 
groups near to iodine shifts from 3.25 ppm to 4.25 ppm, which confirms the coupling 
with biotin. In Figure II.21D, the shift of the methylene near to the iodine in C (2´´) to 
4.25 ppm along with the apparition of CLV signals proved the reaction success. The final 
product CLV-TEG-B was isolated with 62% average yield. 
Since this second derivative is water soluble and the biotinylated derivative of CLV is 
aimed to be used in experiments that need to be performed in aqueous media, we will 
focus on CLV-TEG-B further on. 
II.3.2. Reactivity of CLV-TEG-B towards simple nucleophiles
Stability studies for CLV-TEG-B (Figure II.22) revealed that after 1 hour of incubation 20% 
of the β-lactam ring was opened and kept on opening over time, with 50% of opened β-
lactam at 16 hours and 58% at 40 hours.  
The fact that after 16 hours incubation there was still remaining original biotinylated 
drug, with closed β-lactam ring, is compatible with the use of this time period for 
conjugates formation. Also after 1 hour, a peak at 2.25 ppm appeared and the 
oxazolidine ring started to degrade (signal 1´).     
The same as we did for cephalosporins in previous chapter and for CLV, the first attempt 
to understand the reactivity of the biotinylated derivative of CLV was NMR monitoring 
of its stability and reactivity towards butylamine as simple nucleophile. These studies 
would allow as well the comparison of chemical behavior between native CLV and its 
derivative.  
Results of CLV-TEG-B reactivity studies with butylamine as simple nucleophile are 
depicted in Figure II.23. After 15 minutes incubation with butylamine, there was no 
remaining methylene next to the amine in butylamine at 2.6 ppm and a the appearance 
of a triplet at 3.2 ppm can be due to amide formation. Evidence of β-lactam ring opening 
is observed as well from 15 minutes of incubation and it was completely consumed after 
16 hours (see changes in signals H5 and H6).      
From these NMR studies, it is inferred that the β-lactam reactivity toward nucleophiles 
remains in spite of the modification introduced in the structure of CLV with the 
incorporation of the biotin moiety. Also, this derivative is stable enough during at least 
16 hours (usual incubation time for studying conjugation) in physiological conditions and 
so, it could be used for further conjugation studies with proteins.  
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Figure II.22. 1H-NMR spectra of CLV-TEG-B registered in deuterated PBS 1X over time. 
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Figure II.23. 1H-NMR study of CLV-TEG-B reactivity with butylamine registered in deuterated PBS 1X. 
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II.3.3. Comparison of Reactivity between CLV and CLV-TEG-B
Figures II.24-II.26 show the comparison of reactivity between CLV and CLV-TEG-B. In 
Figure II.24, in which it can be observed that in physiological conditions, CLV is more 
stable than CLV-TEG-B since β-lactam opening did not take place for the former.  
Figure II.24. Stability comparison between CLV (top) and CLV-TEG-B (bottom) at the typical incubation 
time for preparing conjugates. Pointed with arrows changing signals for comparison. 
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However, in presence of butylamine (Figures II.25 and II.26), CLV degrades quickly with 
no evidence of amide formation while a signal around 3.2 ppm is evidence of amide 
formation for CLV-TEG-B after 15 min of incubation with butylamine.  
Figure II.25. Reactivity comparison of CLV (top) and CLV-TEG-B (bottom) with butylamine after 15 min 
incubation. Pointed with arrows and circle changing signals for comparison. 
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Figure II.26. Evidence of amide formation by nucleophilic attack of butylamine towards the β-lactam 
ring of CLV. Pointed with arrows and circle changing signals for comparison. 
II.3.4. Study of CLV Biotynilated Derivatives Proteins Haptenation Capacity
The chance of using biotinylated derivatives of CLV for the identification of modified 
serum proteins was studied since biotinylated CLV could be detected by Western blot 
with a high sensibility using steptavidin conjugated with peroxidase, or by fluorescence 
microscopy using streptavidin conjugated with a fluorochrome. Furthermore, these CLV 
derivatives could be useful for complex systems study, such as serum and cellular lysates 
since modified proteins could be purified with streptavidin columns. However, due to 
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the modification of the molecule as consequence of the incorporation of the biotin 
moiety, there is first the need of studying structure-function relationship. For this 
purpose, conjugation of CLV derivatives with HSA were studied by SDS-PAGE and MALDI-
TOF MS. HSA was the protein used as model since in literature it has been inferred that, 
among serum proteins, it is the main target for protein haptenation [45]. All SDS-PAGE 
experiments, transferences and detection with enhanced chemiluminiscence (ECL) were 
carried out by the PhD student and MALDI-TOF MS analysis at SCAI, UMA. 
SDS-PAGE Analysis and Detection of HSA-biotynilated CLV Conjugates 
a) Study of ability of haptenization of biotinylated derivatives of CLV
After synthesis of the biotynilated derivatives of CLV, the first thing to do was to assay 
their ability to bind covalently to proteins. HSA prepared in PBS 1X (pH 7.4) was 
incubated for 16 hours at 37˚C in presence of any of both biotinylated derivatives of CLV 
prepared in PBS 1X (pH 7.4) at protein/biotinylated CLV ratios from 1:3.07·10-4 to 1:600 
(final concentration of HSA 0.15 mM and biotinylated CLV from 4,61·10-5 to 90 mM). As 
proof-of-concept, 2 µg aliquots of some of the resulting adducts were subjected to 
SDS-PAGE electrophoresis, transferred to a polyvinylidene fluoride (PVDF) membrane 
and detected with streptavidin-horseradish peroxidase (HRP) and ECL (Figure II.27).  
Figure II.27. Detection of HSA modified in presence of different ratios HSA/biotinylated derivatives of 
CLV.  
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Results showed that both biotinylated derivatives of CLV bind covalently to HSA and 
that protein modification was concentration dependent for both cases (using CLV-B or 
CLV-TEG-B). Signal obtained after detection is selectively due to HSA conjugation to 
biotinylated derivatives of CLV, since no signal was detected for control HSA and it was 
detected even at very low protein/biotinylated ratio (1:0.00768), which confirms the 
high sensitivity of the method. Also, these results demonstrate that biotin moiety 
remain linked to CLV after conjugation for both derivatives. 
A similar haptenization pattern was obtained for both biotinylated derivatives, so we 
decided to use CLV-TEG-B for further studies since it is completely water soluble and 
there is no need to use any organic solvent to dissolve it (it was necessary to dissolve 
CLV-B first in DMSO before preparing dilutions using PBS 1X).  
b) Dose-response
In order to carry out this assay, 2 µg aliquots of the HSA adducts obtained in vitro with 
protein/CLV-TEG-B molar ratios ranging from 1:0.0003072 to 1:24 were subjected to 
SDS-PAGE electrophoresis, transferred to a PVDF membrane and detected with 
streptavidin-HRP and following ECL. Higher protein/CLV-TEG-B molar ratios (1:600 and 
1:120) were not loaded in the gel since for 1:120 conjugates signal reached saturation 
(Figure II.28).   
Figure II.28. Detection of HSA modified in presence of different ratios HSA:CLV-TEG-B. 
These results confirm the usefulness of CLV-TEG-B in the detection of HSA adducts with 
high sensitivity, being detected even the conjugate modified with 1:0.0003072 HSA/CLV-
TEG-B molar ratio. These properties can be exploited to obtain novel information on the 
mechanisms of the allergic reactions towards CLV. 
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c) Degree of biotinylation
Once studied HSA modification dependence with the amount of biotinilated CLV, the 
extent of incorporation was estimated by comparison with a biotinyated BSA standard 
(10 mol biotin/mol) [236, 237]. Aliquots of 2 pmol (0.13 µg) of HSA adducts, prepared 
using different protein/CLV-TEG-B molar ratios during incubation (1:1, 1:10 and 1:100) 
were loaded in a polyacrylamide gel along with different amounts of BSA-B ranging from 
0.006 pmol to 0.377 pmol. Proteins were transferred to a PVDF membrane and we 
confirmed the amount of HSA conjugates transferred by Western blot using an α-
human HSA antibody followed by incubation with HRP-conjugated secondary antibody 
and ECL detection (Figure II.29 top). After, membrane stripping was performed with 
guanidine hydrochloride to remove previous antibodies used, and the presence of 
biotinylated  species  was  detected  with s treptavidin-HRP  and  ECL  detection  (Figure 
II.29 bottom). The dose-dependent modification of HSA by CLV-TEG-B previously
observed was confirmed analyzing 1:1, 1:10 and 1:100 HSA/CLV-TEG-B conjugates.  
Images obtained after detection with streptavidin-HRP for three replicates were 
analyzed with ImageJ software. The equation obtained after representation of intensity 
versus pmol of BSA-B was used to calculate the amount of biotin in each conjugate taking 
into account the intensity obtained for each conjugate. Results expressed as pmol 
biotin/pmol HSA are representative of three assays and resulted to be 0.0935, 0.013, 
0.00055 pmol biotin/pmol HSA for HSA-CLV-B 1:100, 1:10 and 1:1, respectively. 
Figure II.29. Detection of HSA (top) and biotin (bottom) by Western blot. Aliquots of HSA-CLV-TEG-B (2 
pm) (left) and BSA-B standards  (right) were analyzed by SAS-PAGE followed by Western bot with α-
human-HSA antibody and HRP-conjugated secondary antibody or with streptavidin-HRP followed by ECL 
detection. 
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d) Enrichment of HSA-CLV-TEG-B biotinylated fraction by avidin affinity
chromatography 
It is known that the extent of protein modification is not 100 % and that non-adducted 
protein can interfere in further analysis of the conjugated protein. Separation of the 
modified proteins from that which remain unmodified after incubation would improve 
the chance to characterize the resulting adducts. Thus, the resulting sample of the 
incubation of HSA with CLV-TEG-B at 1:10 protein/ CLV-TEG-B was filtered off to remove 
any excess of unbound CLV-TEG-B and then subjected to purification using agarose 
beads coated with Neutravidin. This purification procedure was learned during a stay of 
the PhD student in the group of Dr. Dolores Pérez-Sala at CIB, CSIC (Madrid) and 
replicated by her in our home laboratory. First, the sample was incubated with the beads 
for two hours at room temperature, time in which biotinylated protein would bind to 
the beads. Supernatant containing not bound protein was kept. Then, resin was whased 
with a strong buffer for elimination of unespecifically bound protein and the last 
washing volume kept for analysis. Finally, biotinylated fraction was released from the 
resine using a buffer containing SDS and β-mercaptoethanol and denaturalized for 
analysis. In parallel, control HSA was subjected to affinity purification as well to assay 
the possibility of unspecific interaction of the protein to the resin. Purification fractions 
were analyzed by SDS-PAGE, transferred into a PVDF membrane that was incubated with 
streptavidin-HRP for ECL detection and, after stripping with guanidine chloride, with 
Ponceau Red (Figure II.30).  
As it can be seen in Figure II.30 top, comparing signal obtained for input fraction and 
eluted fraction from HSA- CLV-TEG-B after incubation with streptavidin-HRP, the later 
showed an enrichment of biotin signal, which means a successful purification of 
modified protein. Also, for not bound fraction signal is detectable with Ponceau but it is 
barely detectable with streptavidin-HRP, which confirms that the remaining unmodified 
protein after incubation was removed from the biotinylated adduct.  
The lack of signal for purification carried out with control HSA after incubation with 
streptavidin-HRP proves that the signal obtained for HSA-CLV-TEG-B experiment is due 
selectively to biotin presence. Besides, the fact that after detection with Ponceau there 
is signal only for input and not bound fractions means that there is not unspecific binding 
of HSA to the resin (Figure II.30 bottom). The scale-up of this optimized purification 
method for purifying HSA-CLV-TEG-B would alow the enrichment of modified proteins 
in a complex mixture, increasing the chances of detection and identification of binding 
sites.  
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Figure II.30. SDS-PAGE analysis of the fractions obtained by affinity purification with neutravidin beads. 
Dotted line separates fractions obtained for control HSA on the left or HSA-CLV-TEG-B on the right. Top 
image shows results obtained after membrane incubation with streptavidin-HRP and ECL detection. 
Bottom image depicts results obtained after membrane incubation with Ponceau for detecting total 
proteins. 
e) CLV-CLV-B competition for protein binding sites
Once probed the capability of CLV-TEG-B for HSA haptenization and that the degree of 
haptenation is dose-dependent, another experiment was designed for studying whether 
a similar haptenation mechanism is involved with CLV and CLV-TEG-B.  
In order to compare the binding capacity, competition assays between both drugs 
were performed. HSA was incubated for 2 h with 80 mM CLV-TEG-B, after 16 h 
preincubation with the indicated concentrations of CLV (Table II.3).  
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Table II.3. Conjugates prepared for comparison of CLV and CLV-B haptenation ability 
 
 
 
 
 
 
 
 
 
 
[HSA]0 [HSA]f [CLV]0 [CLV]f [CLV-TEG-B]f Vf 
CLV 0 20 mg/mL 
0,3 mM 
10 
mg/mL 
0,15 mM 
0 mg/mL 
0 M 
0 mg/mL 
0 M 
80 M 200 
L 
CLV 1X 3,80·10-2 mg/mL 
160 M 
1,90·10-2 mg/mL 
80 M 
CLV 10X 3,80·10-1 mg/mL 
1600 M 
1,90·10-1 mg/mL 
800 M 
CLV 100X 3,80 mg/mL 
16000 M 
1,90 mg/mL 
8000 M 
Figure II.31. Competition assay between CLV and CLV-TEG-B. Samples were generated by means of 
preincubation with increasing amounts of CLV and then, the incubation with the same amount of CLV-
TEG-B. The incorporation to HSA of CLV-TEG-B was detected using streptavidin-HRP, while Coomassie 
staining shows protein load. 
Interestingly, preincubation of HSA in the presence of an excess of CLV reduced the 
formation of adducts containing CLV-TEG-B, which means that both compounds 
compete for their binding to proteins, suggesting that they may bind to common sites. 
In order to study incorporation of CLV-TEG-B in HSA after the preincubation with CLV, 
aliquots of resulting conjugates were subjected to SDS-PAGE in duplicate. One of the 
gels was stained with Coomassie in order to check the amount of protein loaded. The 
second gel was transferred to a PVDF membrane, and assessed by detection with HRP-
streptavidin, which allowed to detect the incorporation of CLV-TEG-B. Results shown 
(Figure II.31) are representative of three independent assays with similar results. 
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II.3.5 Mass Spectrometry Characterization of HSA-CLV-B Conjugates
HSA was incubated with 1:1, 1:10 and 1:100 protein/ CLV-TEG-B molar ratios. Those 
concentrations were chosen since we intended to study 1:10 conjugate, close to 
physiological conditions and also analyzed for HSA-CLV, as well as a lower and a higher 
concentration of biotinylated derivative. Mass increments obtained after MALDI-TOF 
MS of conjugates were 35.4, 163.7 and 1658.9 for 1:1, 1:10 and 1:100 conjugates, 
respectively. With this analysis, we confirmed that HSA haptenization with CLV-TEG-B is 
dependent of the concentration of drug, the same as for haptenation with CLV. This 
results are in agreement with the SDS-PAGE analysis of these conjugates, in which it was 
demonstrated as well that the more concentration of CLV-TEG-B used during incubation, 
the more was the extent of biotinylation.  
Peptides are more simple systems than a whole protein for studying drug-protein 
interactions since they have limited nucleophilic sites to react with BLs, so we decided 
to use an HSA peptide as second approach for studying the interaction between CLV-
TEG-B and Lys in proteins. 182-195HSA peptide (LDELRDEGKASSAK), containing both Lys 
190 and Lys 195, was chosen since these residues have been found to be target of 
modification by some drugs such as abcavir or flucoxacillin (Lys 190) [105], diclofenac 
(Lys 195) [105] as well as for BLs such as AX and piperacillin [105] or BP and 
flucoxacillin [17] (both Lys 190 and 195). Taking into account that for peptides 
modification conformational factor of HSA is lost, we employed more forced 
conditions for conjugation: peptide/CLV-TEG-B molar ratio 1:90, 24 hours incubation at 
37 ˚C. After elimination of the excess of drug by size exclusion chromatography, sample 
was analyzed by MALDI-TOF-MS. MALDI-TOF spectra (Figure II.41X top) shows a peak 
belonging to the unmodified peptide 1518.686 Da) and a low peak at 2118.898 Da 
corresponding to the conjugated peptide. Mass increment found was Δm=600.2 Da.  
These results suggest that the extent of conjugation is low since the peak belonging to 
the adduct formed after conjugation is really low compared with the amount of 
remaining native peptide. Also, we observed that only one of the two lysines were 
modified in the conditions used for peptide incubation and mass increment obtained 
could be a valuable information for further study the modification of the whole HSA with 
CLV-TEG-B.   
Taking into account that the relative abundance of the adducts can be considered as a 
good index of the chemical reactivity of the peptide towards the β-lactam [88], since the 
amount of unmodified peptide after incubation is high, it can be said that CLV-TEG-B is 
not very reactive towards the peptide. This fact would be in agreement with the 
difficulty of the identification of the binding residues by CLV-TEG-B. 
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Figure II.32. MALDI-TOF MS spectra of 182-195HSA after conjugation with CLV-TEG-B (top) and without 
conjugation (bottom). 
II.3.6. Characterization of HSA-CLV-TEG-B Conjugates by LC-MS/MS
In order to compare if HSA residues modified by CLV-TEG-B are the same as the 
modified by CLV, HSA-CLV-TEG-B 1:10 conjugate was analyzed by LTQ Orbitrap XL at 
University Hospital Vall d´Hebron Research Institute Proteomic Laboratory. The 
analysis was performed for either the conjugate by dialysis filtration after conjugation 
or for the biotinylated fraction enriched by passing the conjugate through a column 
packed with Soft Link release Avidin. However, the identification of modified residues 
was not possible in none of the cases. It could be due to a higher stability of CLV-TEG-B 
compared to CLV, which would difficult ionization in the former case or due to a low 
degree of modification. Other possibility is that the collision-induced dissociation (CID) 
method used for fragmentation is too aggressive and fragmentates the expected 
bound residue preventing the identification of the modified residues because of the 
search for a wrong mass increment.  
We decided to perform the analysis of the conjugate using electron transfer dissociation 
(ETD) fragmentation mode, which is less aggressive and therefore more suitable for 
posttranslational modifications identification, either from biological source or 
chemically induced as in this case, since the structure responsible for the modification 
is  supposed to  be preserved.  These experiments  were carried out at Centro Nacional 
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de Biotecnología (CNB), Madrid, using a Bruker AmaZon Speed ionic trap for mass 
fragmentation after sample digestion with trypsin, chemotrypsin and LysC. Both HSA-
CLV-TEG-B cleaned by dialysis and the conjugate cleaned and further enriched the 
biotinylated fraction by using an avidin resin were analyzed. Only for the enriched 
conjugate digested with chemotrypsin, a peptide modified with a mass of 600.22 was 
found: 404-430HSA with the following aminoacid sequence 
QNALLVRYTKKVPQVSTPTLVEVSRNL. 
Table II.4. Information obtained about the modified peptide. 
 
 
 
 
 
 
 
 
 
 
 
 
Accession 
number 
Protein name Score 
Molecular 
weight (Da) 
Peptides 
matched 
P02768 HSA 36 3652.96 9 
II.4. Detection and Identification of Serum Proteins Target of Modification 
by CLV-TEG-B 
Despite the fact that label-dependent techniques cannot be used to study adduct 
formation in patients and usually do not provide information on the site of modification 
and/or structure of the adducts, they are quite useful to visualize adducts and to identify 
the modified proteins, for instance by peptide mass fingerprinting [105]. This is a big 
step to gain insight into adducts formation in that cases in which there are no specific 
antibodies against the drug moiety available (for example CLV) or the adduction takes 
place in such a low extention that difficults detection using label-free approaches. 
Furthermore, requirements for adduct detection by label-dependent approaches can be 
met by most biochemistry laboratories without the need of high specialized equipment 
and protocols. 
Some studies of protein haptenation by BLs were carried out previously in our research 
group. By assaying serum protein  adducts with AX or AX-B by 1D and 2D-
electrophoresis and following Western B lot using α-AX antibodies for the AX detection 
or streptavidin for the biotin detection, it was observed that both compounds bind to 
the same serum targets (HSA, transferrin and Igs light and heavy chains), with the only 
difference of a weak binding to haptoglobin, which is undetectable using 
immunological AX detection, but is visible with AX-B due to the higher sensitivity of 
this method [45]. Following a similar approach, studies directed to identify serum 
proteins target of modification by CLV-TEG-B were performed. Results would be of 
great interest since, for the first time, serum proteins that may act as carrier in allergic 
reactions to CLV would be identified.    
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II.4.1. Conjugation of CLV-TEG-B with Human Serum Proteins and Detection of
Modification 
In order to study serum protein haptenation by CLV-TEG-B, human sera were incubated 
in PBS 1X (pH 7.4) with two concentrations of the biotinylated compound. Then, 4 µg 
aliquots of incubated sera were subjected to SDS-PAGE along with a control serum 
incubated with PBS 1X, transferred and detected with streptavidin-HRP and ECL (Figure 
II.33). Some bands were observed for the serum incubated with the highest amount of
CLV-TEG-B and one band for the serum incubated with a lower concentration. No band 
was observed in the lane corresponding to the control sera, indicating that signal was 
specifically detected for biotinylation. Comparison with Coomassie staining revealed 
that the amount of protein loaded in each lane was the same and thus, intensity change 
observed for detection with streptavidin-HRP is only due to the modification of samples 
by CLV-TEG-B.  
Also, with this experiment, we proved that biotinylated CLV was covalently attached to 
its target proteins.   
Figure II.33. Detection of biotinylated serum proteins (top) and total protein pattern with Coomassie 
staining (bottom). 
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II.4.2. Identification of Serum Proteins Target of Modification by Peptidic
Fingerprint 
Monodimensional SDS-PAGE allowed us to confirm that besides HSA, other serum 
proteins were target of haptenation by CLV-TEG-B but further studies were necessary 
for identification of these proteins. 2D-electrophoresis gives more information about 
samples in which several proteins are present since separation is based in both 
isoelectric point (first dimension) and molecular weight (second dimension). Thus, sera 
samples incubated with CLV-TEG-B at 1:0.192 total protein/ CLV-TEG-B ratio and control 
serum were analyzed by 2D-electrophoresis, running two gels in parallel. 2D-
electrophoresis experiments were performed during the PhD student stay in the group 
of Dr. Dolores Pérez-Sala in Madrid. One of the gels was transferred and biotinylated 
proteins detected with streptavidin-HRP. The second gel was used for total proteins 
detection by Coomassie staining (Figure II.34) and “spots” of interest were excised, 
digested with trypsin and identified by peptidic fingerprint using MALDI-TOF-TOF MS 
(Table II.5). This proteomic analysis was performed in the Proteomics Unit of 
Complutense University of Madrid.  
Figure II.34. Detection of adducts of CLV-TEG-B and serum proteins and identification of targets. 
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Serum proteins modified by CLV-TEG-B identified in this assay were HSA, haptoglobin 
and heavy and light chains of inmunoglobulins (Table II.5). The lack of monoclonal 
antibodies against CLV prevents the immunological evaluation of protein-CLV adducts 
and, therefore, we could not compare whether the proteins haptenated by CLV are the 
same as the modified by its biotinylated derivative as Ariza et al. did [45, 88]. One of the 
aspect that should be taken into account is that the presence of the biotin moiety may 
impose steric impediments for binding to some targets or it may shield part of the 
molecule [45]. However, we have set up a model that may shed light into the process of 
protein haptenation by CLV through the use of highly sensitive approaches, such as 
labeling with biotinylated analogs, which allow the detection of its target serum 
proteins.  
Further structural information on the binding sites on various targets would provide 
potential ADs to be used in diagnostic procedures and in studies on the mechanisms of 
CLV induced allergy. 
Table II.5. Identification of serum proteins modified by CLV-TEG-B by peptidic fingerprint by tryptic 
digestion and MALDI-TOF MS. 
Spot Accession 
Number Protein name 
Total 
score 
Limit 
score 
Molecular 
weight (Da) pI 
Peptides 
matched 
Coverage 
(%) 
1 P02768 HSA 470 56 71317 5.92 43 69 
2 P01857 Ig gamma-1 chain C region human 119 56 36596 
8.46 13 52 
3 P01857 Ig gamma-1 chain C region human 197 56 36596 
8.46 18 66 
4 P00738 Haptoglobin human 128 56 45861 6.13 18 35 
5 P00738 Haptoglobin human 102 56 45861 6.13 16 33 
6 P01834 Ig kappa chain C region human 86 56 11773 5.58 7 76 
7 P01834 Ig kappa chain C region human 66 56 11773 5.58 6 76 
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III. Antibody labeling for
detecting sIgE in drug allergy 
The term “immunoassay” refers to the use of antibodies raised against an analyte of 
interest with the purpose of detecting the presence of that analyte in a sample. Two 
important parameters of a reliable immunoassay are specificity and sensitivity, that is 
to say, the analyte should be selectively detected even in presence of big amount of 
interfering substances and detectable at the low concentrations required for most 
applications. Specificity is provided by antibodies raised against the analyte of interest, 
whereas sensitivity relies on coupling of analyte-antibody binding with a detectable and 
quantifiable signal [238] (radioactivity, luminescence or enzymatic process).  
Sensitive and specific detection of analytes of interest in biological samples is crucial for 
in vitro diagnosis. Biological samples are really complex, containing a huge number of 
different proteins which makes detection of a specific molecule a special challenge. Also, 
some proteins, as is the case of sIgE to drugs, are in an extremely low concentration 
making it difficult to obtain good sensitivity using simple fluorophores [238]. 
The use of antibodies as detection method requires some way of labeling of the antibody 
with an easily detectable reporter molecule such as radioisotopes, luminophores or 
enzymes. First immunoassays used antibodies labeled with radioisotopes and detection 
using scintillation counters. Although they are high sensitive, problem related with 
stability and safe disposal of radioisotopes leaded to the development of alternative 
detection strategies, being the most important enzyme conjugated antibodies, in which 
an enzymatic reaction leads to a colored product that can be measured by colorimetry. 
Amplification is the best advantage of these kind of assays but linear range of colorimetic 
detection is limited and color development requires additional time, steps and reagents. 
Fluorophore labeled antibodies allow direct measure of immunocomplex on the surface 
or in solution but conversely, no amplification occurs, requiring very bright 
luminescence from the fluorophore or high degrees of labeling [238].   
This chapter is dedicated to develop antibody labeling methods for signal detection in in 
vitro tests for drug allergy diagnosis. By one hand, we optimized the radiolabeling of a 
highly specific α-human IgE for our in-house RAST assays. On the other hand, we 
designed, synthesized and characterized a series of fluorescent dendron structures 
bearing multiple fluorescent units and proved their suitability for antibody labeling and 
fluorescent signal amplification for future use in microarray platforms.  
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III.1. Radiolabeling of a High Specific α-human IgG 
Many of the studies performed in our research group which are focused on drug allergy, 
rely on the use of in-house RAST immunoassays. This practice has been prevented for 
the last years due to the withdrawal from the market of α-IgE antibodies radiolabeled 
with 125I, commercialized by Phadia. Other radiolabeled antibodies from different 
providers were useful for performing RAST assays to allergens but not to drugs, whose 
outcome was inespecific results with not enough sensitivity. This is likely due to the 
low concentration of sIgE associated to drug allergy. We got the α-IgE previously 
provided by Phadia, a mix of two α-IgE monoclonal antibodies, but unlabeled. That is 
why we arise the optimization of a method for radiolabeling this mix of specific 
secondary antibodies, which would be evaluated with different samples for validation 
and making sure that its use is reliable and reproducible for sIgE detection in drug 
allergy.  
Figure III.1. Oxidation reaction of Iodogen. 
Nowadays there are several commercial reagents for general protein radioiodination. 
We have selected Iodogen, 1, 3, 4, 6- tetrachloro-3α, 6α-diphenylglycouril, an effective 
and mild oxidizing agent. The advantages of Iodogen over other alternative reagents 
previously used for radiolabeling such as chloramine T, lactoperoxidase/hydrogen 
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peroxide and 125I-labeled Bolton-Hunter reagent are that the reaction is rapid, 
technically simple to perform, and gives reproducibly high levels of incorporations of 
radioactivity [239] with minimal oxidative damage to the protein [239, 240]. Iodogen is 
insoluble in aqueous phase so a solution in dichloromethane or chloroform is used to 
prepare a thin film of material on the walls of the reaction vessel. The reaction of 
Iodogen with aqueous solution of Na+/125I- results in oxidation with generation of the 
reactive intermediate (I+/I3+), in form of mixed halogen species, that participates in 
electrophilic attack primarily at tyrosine but also at histidine residues in the protein with 
minimal oxidative damage to the protein [239]. Oxidative side reactions such as damage 
to sensitive residues (particularly methionine and tryptophan) is much less using 
Iodogen [239, 240]. Oxidation reaction of Iodogen is depicted in Figure III.1. 
III.1.1. Labeling optimization 
Labeling procedures were carried out by the PhD student at SCAI, UMA. In order to 
optimize the protocol, pre-coated iodination tubes (with Iodogen) were employed to 
label a commercial α-IgE antibody in aqueous solution. Two different concentrations of 
125NaI were used to evaluate the efficacy of the method. After labeling, the protein 
fractions were purified by size exclusion chromatography, collecting 0.5 mL fractions 
(Figure III.2).  
Figure III.2. Elution profile obtained in labeled IgG purification. 
Elution profiles allowed to identify fractions 2 and 3 as the ones containing the 
radiolabeled IgG. Fraction 4 and followings correspond to unreacted NaI125. 
Results obtained with different concentration of NaI125 are compared in Table III.1, and 
we can conclude that the more efficient iodination conditions for IgG labeling involved 
the use of the higher concentration of NaI125 (250 µCi). 
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Table III.1. Labeling results for Experiment 1 and Experiment 2. 
 
 
 
75 µCi 250 µCi 
Iodination yield (%) 43.6 54.0 
Incorporated activity (µCi) 32.7 135 
Specific activity (µCi/µg) 2.18 9.0 
III.1.2. Labeling of α-human IgE monoclonal antibody with 125I 
Once optimized labeling protocol, the antibody that was to be used in immunoassays 
was labeled. After size exclusion chromatography, the purification elution profile (Figure 
III.3) was obtained, indicating that fractions 2 and 3 contained the labeled antibody.  
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Figure III.3. Elution profile obtained in labeled IgG purification. 
After pertinent calculations, we obtained 58.2 % iodination yield, 145.6 µCi incorporated 
activity and 9.7 µCi/µg specific activity. Both fractions containing labeled antibodies 
were combined and dissolved in similar buffer conditions to that of previously 
commercialized by Phadia (1.5% (w/v) BSA in PBS 1X pH 7,4-Tween 0,1%).  
Final antibody concentration was 0.15 µg/mL and activity per volume was 1.57 Ci/mL, 
even higher than the activity per volume of the labeled antibody previously 
commercialized by Phadia (1.06 Ci/mL).  
III.1.3. Labeled IgG sensitivity evaluation by Radio Allergo Sorbent Test (RAST) 
PhD student evaluated these labeled antibodies by RAST using sera from well-
phenotyped patients and compared the results with other α-IgE antibodies or isotopic 
labeling procedures. 
First, sera from six patients allergic to AX and six tolerant controls (non-allergic to BLs) 
were included in the study, and RAST results using the same antibody but with different 
label procedures were compared: the former commercial Phadia antibody, the one 
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labeled by a company (Chelatec) and the one labeled using our optimized protocol 
(Figure III.4).  
Figure III.4. % RAST results comparison. 
Results obtained with the antibody labeled using our optimized procedure show clear 
positive % of RAST results for all patients allergic to AX, having in mind that % of RAST > 
4.8 (the mean +2SD of a negative control group) were considered positive. Moreover, 
the values of RAST obtained in all AX positive cases with this antibody were higher than 
those obtained with the other commercial batches (Phadia and Chelatec labeling). From 
this follows that we got a sensitivity improvement with our labeling conditions. 
Additionally, RAST results for control individuals were lower than 4.8 % in all cases, 
indicating that specificity is not affected.  
In order to further assay the sensitivity of the labeled antibody, sera from 40 patients 
allergic to cefaclor were evaluated. These sera had already been assayed by RAST using 
another batches of Phadia antibody or even using a commercial radiolabeled antibody 
kindly provided by ALK-Abelló. Results obtained are compared in Figure III.5.  
Again, % of RAST results obtained with our antibody labeling are higher than for the rest 
of batches for most of cases, confirming that the developed procedure is appropriate 
for the isotopic labeling of antibodies for further detection in immunoassays.   
It should be noted that those cases with negative RAST results can be due to other 
factors intrinsic to the sensitivity of the technique.  
As a result, high specific α-human IgE monoclonal antibody labeling with I125 was 
optimized for in-house RAST assays, allowing the performance of immunoassay with a 
high specificity and improved sensitivity. 
Ca
se
 1
Ca
se
 2
Ca
se
 3
Ca
se
 4
Ca
se
 5
Ca
se
 6
Co
ntr
ol 
1
Co
ntr
ol 
2
Co
ntr
ol 
3
Co
ntr
ol 
4
Co
ntr
ol 
5
Co
ntr
ol 
6
0
20
40
60
80
100
Phadia
Chelatec labeling
Our labeling protocol
%
 R
AS
T
Results and Discussion III. Antibody labeling for detecting sIgE in drug allergy
168 
Figure III.5. % RAST results comparison. 
III.2. Multivalent fluorescent dendritic probes for immunoassays signal 
amplification 
Dendrons, as highly branched and monodisperse wedge-shaped scaffolds with multiple 
peripherial end-groups and a single reactive functionality at the focal point, bring the 
option of orthogonal reactions [151, 241] suited for site-specific labeling of biomolecules 
[149, 150]. For instance, Wängler et al. [150] synthesized a library of PAMAM dendrons 
being peripherally decorated with various fluorescent dyes and encompassing a single 
thiol functionality at the focal point. In their work and for most of fluorescently labeled 
dendrons, the fluorescence signal decreased with increased number of dye units, and 
only dansylated dendrons met the requirements of enhanced fluorescence signals.  
Independent on conjugation chemistry or orthogonal linkers, cyanine-based dyes are 
one of the most promising Near Infrared (NIR) dyes, ideal for in vivo and in vitro optical 
imaging [242]. Among them, Cy5 has been identified as the champion as it can be excited 
at wavelength above 600 nm i.e. where the auto-fluorescence background of live cells 
is lower by orders of magnitude as compared with the excitation range of TMR 
(tetramethylrhodamine), Cy3, and Cy3.5 [169]. Moreover, scanners in microarray 
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systems have the capacity for signal detection of Cy5. Most examples in literature detail 
the monovalent conjugation of Cy5 probes using simple bifunctional linkers [194, 195, 
243-247]. Dendrimers functionalized with Cy5 substituents, either at periphery [192, 
248, 249] or at focal point [241, 249, 250], have also been reported on as monodisperse 
scaffolds,  including popular PAMAM [248] or 2,2-bis(methylol)propionic acid (bis-MPA) 
[250] architecture among others. The bioconjugation of Cy5 via covalent linkages to the 
target molecule often involves click chemistries [192, 194, 195, 246] although 1, 2-
addition reaction [243], or reaction with amines through NHS chemistry [247] have also 
been described. Of note is the use of hydrazide [244] or hydrazine [245] monovalent Cy5 
probes, since they react selectively with carbohydrate on the Fc region of antibodies, 
with a well-defined stoichiometry of conjugation, without affecting the binding site of 
the biomolecule.  
III.2.1. Design of Fluorescent Dendrons for Site Specific Antibody Labeling with 
Application in Microarray Systems 
From the great number of dendritic scaffolds available, orthogonally functionalized 
dendrons based on bis-MPA belong to the most desirable scaffolds for biomedical 
applications. This is mainly due to their biodegradable and biocompatible profile, facile 
synthesis, proven flawless nature as well as the large and exact number of functional 
groups with orthogonal features [251].  
Herein, we propose the synthesis of a set of novel probes displaying mono or multivalent 
hydrazine/dye functionalities. The multivalent features capitalizes on dendrons based 
on bis-MPA as sophisticated orthogonal linkers with amplifying capacity, Figure III.6.  
To explore bis-MPA based frameworks as versatile fluorescent amplifiers for enhanced 
detection of biomolecules we sought out a novel synthetic scheme. The dendrons 
targeted should display (i) a single hydrazine functionality in the focal point, for 
chemoselective reaction with carbonyl from aldehydes present on the biomolecules; 
(ii) TEG extender that provides spacious distance between the hydrazine group and the 
main dendritic skeleton to avoid steric hindrance during bioconjugation and promote 
solubility in aqueous media; and (iii) multiple fluorescent Cy5 moieties at the 
periphery, for signal amplification.  
For the introduction of fluorescence to the orthogonally functionalized probes, Sulfo-
Cyanine 5 azide (sulfo-Cy5-azide) was chosen. This due to its (i) excitation maximum at 
646 nm, which makes it suitable for microarray scanner systems; (ii) azide functionality 
that allows for coupling to alkyne decorated dendrons via CuAAC and (iii) additional 
sulfo-groups that facilitate water solubility and decrease aggregation of dye molecules 
in heavily labeled conjugates [252]. 
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Figure III.6. Mono and multivalent hydrazine/dyes probes consisting of hydrazine functionalization as 
linking group, a hydrophilic TEG spacer and one or multiple units of fluorescent. 
III.2.2. Synthesis of Fluorescent Dendrons 
A set of fluorescent dendrons (G0-Cy5, G1-Cy5 and G3-Cy5) were synthesized prior to 
their bioconjugation to Ig as a model biomolecule (Figure III.6). The synthesis as well as 
NMR and MALDI characterization of fluorescent dendrons were carried out by the PhD 
student during a stay at Royal Institute of Technology (KTH) in Stockholm, Sweden, 
funded by a FEBS Summer Fellowship. 
Initially, the precursors were constructed to exhibit the appropriate orthogonal 
functionalities: protected hydrazine in the focal point and alkyne groups in the 
periphery, for further dye functionalization via click chemistry. A more in-depth 
description of the synthetic strategy is shown in Scheme III.1.  
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Scheme III.1. Synthesis of fluorescent dendrimers. A) Spacer synthesis based on derivatization of a TEG 
chain with a diboc-protected hydrazine containing molecule. B) Synthesis of G0-Cy5 bearing one 
fluorescent moiety. C) Synthesis of dendron G1-Cy5 bearing two fluorescent moieties. D) Synthesis of 
dendron G3-Cy5 bearing eight fluorescent moieties. 
First, Boc- hydrazine-TEG-OH Dend4 was synthesized in four consecutive reaction steps 
(Scheme III.1A). The synthesis was initiated by the derivatization of TEG as benzyl 
protected TEG (Dend1) [151]. Then after, a succinic moiety was incorporated to yield 
the carboxylic acid functional Dend2 that facilitated covalent coupling of amino-
protected diboc-2-hydroxyethylhydrazine, via fluoride promoted esterification (FPE) 
chemistry [253] resulting in Dend3. The benzyl group was deprotected using catalytic 
hydrogenation resulting in the Boc-hydrazine-TEG-OH Dend4 with an average yield of 
85%.  
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Figure III.7 shows 1H-NMR evidence of the condensation of diboc-hydrazine and 
Dend2, since the methylene next to the hydroxyl group in diboc-hydrazine was 
displaced from 3.63 ppm to 4.30-4.21 ppm in Dend3 due to the esterification that took 
place. Also, aromatic signals at 7.35-7.32 in Dend3 disappeared in benzyl deprotection 
product (Dend4). Figure III.8 shows MALDI-TOF characterization.  
Figure III.7. 1H-NMR monitoring of reactions necessary for obtaining the TEG derived spacer Dend4. 
Figure III.8. MALDI-TOF characterization of Dend2- Dend4. 
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To generate the mono and multivalent hydrazine/dye probes, Dend4 was used as a 
precursor. In one end, the 4-pentynoic acid was covalently attached via FPE chemistry 
which yielded Dend5 in a quantitative yield. This represents the G0 dendron with 
protected hydrazine and bearing one alkyne group, ready for click functionalization 
(Scheme III.1B).  
1H-NMR spectra in Figure III.9, provide evidence of the condensation of Dend4 and 4-
pentinoic acid, since the methylene next to the hydroxyl group in Dend4 is displaced 
from 3.57-3.52 ppm to 4.26-4.18 ppm in Dend5 due to esterification and 4-pentinoic 
acid methylene signals appeared at 2.56-2.52 and 2.50-2.44 ppm and methyne triplet at 
1.95 ppm. Figure III.10 shows MALDI-TOF characterization. 
Figure III.9. 1H-NMR monitoring of reaction to obtain Dend5 starting from Dend4. 
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Figure III.10. MALDI-TOF characterization of Dend4- Dend5. 
In the other end, the use of growth/activation divergent growth approach resulted in 
dendron G1 (Dend9), displaying two peripheral alkyne groups (Scheme III.1C). In 
contrast to the G1 (Dend9), the G3 (Dend15), with eight peripheral alkyne groups, was 
synthesized as previously reported [151] prior to the deprotection by palladium-
catalyzed hydrogenation, introduction of succinic modified diboc-2-
hydroxyethylhydrazine and finally the functionalization with peripheral alkynes (Scheme 
III.1D). In both cases, the dendritic frameworks were isolated in an average yield of 80% 
(Scheme III.1C-D). The synthesis of the three alkyne decorated molecules (Dend5, 
Dend9 and Dend15) and their intermediates were monitored by 1H-NMR (Figures III.9, 
III.11 and III.13) and 13C-NMR as well as by MALDI-TOF MS (Figures III.10, III.12 and
III.15).
1H-NMR spectra in Figure III.11 provide evidence of the condensation of Dend4 and 
acetonide protected bis-MPA, since the methylene next to the hydroxyl group in Dend4 
is displaced from 3.57-3.52 ppm to 4.32-4.16 ppm in Dend7 due to esterification, and 
also, we can see a doublet at 4.22 ppm and a singlet at 1.22 ppm belonging to methylene 
and methyl groups in bis-MPA, respectively, and two singlet at 1.43 and 1.39 ppm 
belonging to methyl groups in acetonide protection. We can see in Dend8 the 
disappearance of singlets belonging to acetonide methyl groups as the clearest evidence 
of deprotection and also, methylenes in bis-MPA moiety move to 3.78 ppm. Finally, in 
compound Dend9, due to esterification with 4-pentinoic acid, bis-MPA methylenes 
move to 4.34-4.22 ppm and alkyne methylene signals appear at 2.58-2.58 and 
2.52-2.46 ppm and methyne triplet at 1.98 ppm. Figure III.12. gathers MALDI-TOF 
characterization of Dend4, Dend7- Dend9. 
576.183 = M + Na+
658.142 = M + Na+
400 600 800 1000 1200 1400 1600 1800
m/z
Results and Discussion III. Antibody labeling for detecting sIgE in drug allergy
175 
Figure III.11. 1H-NMR monitoring of synthesis of the divalent alkyne decorated dendron Dend9 from 
the TEG derived spacer Dend4. 
Figure III.12. MALDI-TOF characterization of Dend4, Dend7- Dend9. 
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In Figure III.13, the incorporation of diboc-hydrazine-succinic moiety to the dendron 
Dend12 to afford Dend13 is proved. The shift of methylene next to the hydroxyl in TEG 
chain from 3.74-3.18 ppm to 4.36-4.23 ppm multiplet due to esterification is observed. 
Also, there is evidence of acetonide deprotection in Dend14 since singlets at 1.37 and 
1.31 ppm belonging to methyl groups in acetonide moiety in Dend13 disappear. Also, 
esterification of Dend14 with 4-pentinoic acid to afford Dend15 can be confirmed by 
displacement of signals belonging to methylenes next to the peripheral hydroxyls from 
3.79-3.54 ppm to 4.37-4.10 and appearance of new signals from alkyne incorporation as 
methylenes at 2.58-2.51 and 2.50-2.43 ppm and methyne at 2.00 ppm. 
Characterization of these molecules was completed with MALDI-TOF (Figures III.14 and 
III.15).
Figure III.13. 1H-NMR monitoring of synthesis of the octavalent alkyne decorated dendron Dend15. 
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Figure III.14. From left to right, MALDI-TOF MS spectra comparison of Dend11 and Dend12, resulting a 
mass of 90 Da due to the benzyl deprotection. 
Figure III.15. MALDI-TOF MS characterization of Dend12- Dend15. 
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For the introduction of fluorescent Cy5, the click reaction was optimized for the 
monovalent molecule Dend5 (Scheme III.1B). Traditional CuAAC using CuSO4/sodium 
ascorbate in THF/H2O (1:1) at 50˚C was first performed. The reaction was monitored by 
MALDI-TOF MS until completion and the di-Boc-hydrazine monovalent sulfo-Cy5 Dend6 
was isolated in quantitive yields by preparative TLC using EtOAc/MeOH (1:1). 
Interestingly, the click reaction was found to proceed at much higher rate when 
performed in DMSO using CuBr/PMDTA as catalyst pair, at room temperature and under 
argon as inert atmosphere. This is reasoned to be an effect of solubility in which the 
starting materials were soluble in DMSO in contrast to THF/H2O mixture. Utilizing the 
CuAAC with CuBr/PMDTA as catalyst pair and DMSO as solvent were chosen for the 
synthesis of Dend10, a di-Boc-hydrazine TEG core decorated with two sulfo-Cy5 groups 
(Scheme III.1C). The reaction was complete after overnight stirring and dialyzed against 
water to obtain Dend10 as a pure compound with a yield of 88%. For the G3-Cy5 Dend16 
with eight peripheral copies of sulfo-Cy5 (Scheme III.1D), CuAAC in THF/H2O (1:1) were 
reaction conditions. To reach completion, the reaction required 48 hours of stirring at 
elevated temperature (50˚C). After solvents elimination, the crude mixture was 
dissolved in water and purified by means of sephadex G-25 to exclude excess of dye, 
affording dendron Dend16 with 57% yield.  
For all probes decorated with sulfo-Cy5, the reactions were considered completed upon 
the disappearance of alkyne-derived molecules (Dend5, Dend9 and Dend15, 
respectively) in the MALDI-TOF MS and their purity corroborated by NMR (Figures 
III.16, III.20 and III.21).  
For example, Figure III.16 details spectra of Dend6, which support the complete 
consumption of the alkyne group (absence of the signal at 2.25 ppm in sulfo-Cy5 azide, 
see Figure III.17) along with the formation of triazol ring with specific signal allocated 
at 7.84 ppm. The click reaction is also exemplified by the shift of signals belonging to 
methylene groups next to the azide in sulfo-Cy5-azide from 1.44 and 1.79 ppm to 4.39 
and 2.75 ppm in Dend6, and signal displacement of methylene group directly bounded 
to alkyne from 2.47 ppm in Dend5, to 3.02 ppm in Dend6 (Figures III.16 and III.18). 
MALDI-TOF spectra also confirmed the structure of Dend6 (Figure III.19).    
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Figure III.16. 1H-RMN spectra of Dend6. 
Figure III.17. 1H-RMN spectra of sulfo-Cy5-azide. 
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Figure III.18. Monitoring of fluorescent functionalization of the monovalent alkyne decorated molecule 
Dend5 to form Dend6 and following deprotection to yield G0-Cy5. 
Figure III.19. MALDI-TOF spectra of monovalent Cy5 decorated dendron Dend6. Top spectrum was 
registered using (top) α-cyano-4-hydroxycinamic acid (CHCA) or (bottom) sinapinic acid (SPA) as 
matrix. 
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In Figure III.20, 1H-NMR evidence of triazol ring formation in Dend10 can be observed 
by displacement of methylene groups close to the azide in free dye, as described for 
compound Dend6. Also, methylene group next to the alkynes in compound Dend9 are 
displaced from 2.52-2.46 ppm to 3.02-2.92 ppm due to triazol ring formation. A signal 
belonging to the methyne in triazol ring appears at 7.80 ppm.  
Figure III.20. Monitoring of fluorescent functionalization of the diovalent alkyne decorated linker Dend9 
to form Dend10 and following deprotection to yield G1-Cy5. 
In Figure III.21, 1H-NMR evidence of triazol ring formation in Dend16 can be observed 
by displacement of methylene groups next to the azide in free dye, as described for 
Dend16 and Dend10, and appearance of the methyne in triazol ring at 7.99 ppm. Also, 
methylene group next to the alkyne in compound Dend15 is displaced from 2.50-2.43 
ppm to 3.16-3.05 ppm in compound Dend16 with disappeareareance of methyne signal. 
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Figure III.21. Monitoring of fluorescent functionalization of the octavalent alkyne decorated linker 
Dend15 to form Dend16 and following deprotection to yield G3-Cy5. 
The final activation of these probes included the deprotection of the hydrazine groups. 
For the monovalent sulfo-Cy5 Dend6 and divalent sulfo-Cy5 Dend10, the deprotection 
was accomplished using TFA/DCM (1:1) at room temperature, affording G0-Cy5 and 
G1-Cy5 in quantitative yields. As can be seen in Figure III.22, the MALDI-TOF MS for the 
G0-Cy5 revealed a molecular weight corresponding to expected ionized mass of 1178 
(M)+. The deprotection of the octavalent sulfo-Cy5 Dend16 was carried out in pure 
TFA. This is due to solubility issues in TFA/DCM (1:1) governed by the higher amount of 
water soluble dyes at the periphery. The G3-Cy5 was successfully isolated in a 
quantitative yield. In all cases, the deprotection of the Boc groups was confirmed by 
1H-NMR,  looking  at  the  disappearance  of  Boc signal at 1.40-1.50 ppm (Figures III.18, 
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III.20 and III.21) and resulted in fluorescently labeled probes G0-Cy5, G1-Cy5 and G3-
Cy5 bearing 1, 2 or 8 dye moieties and a single hydrazine ready for biomolecule 
labeling (Figure III.6). 
Figure III.22. MALDI-TOF spectra of deprotected monovalent Cy5 decorated dendron G0-Cy5 using 
CHCA (top) or SPA (bottom) as matrix. 
III.2.3. UV-Visible and Fluorescence Spectroscopy Characterization of Dendrons 
Satisfied with the successful synthetic machinery of the probes, their performance was 
evaluated by UV and fluorescence spectroscopic techniques. This characterization was 
carried out by José María Montenegro at SCAI, UMA. As shown in Figure III.23A, UV 
spectra revealed an increase in absorbance at 646 nm along with the number of dyes. 
The molar extinction coefficient, ε646, was 80342, 154050 and 600459 M-1·cm-1 for G0-
Cy5, G1-Cy5 and G3-Cy5, respectively. ε646 ratio obtained for each dendron resulted to 
be 1/1.9/7.5. These values are in close approximation to the number of fluorescent 
sulfo-Cy5 units available on each dendron, 1:2:8, confirming the peripheral valence as 
well as the success of fluorescent decoration. However, besides the band at 646 nm, the 
presence of a little band at shorter wavelength (600 nm) was observed for G3-Cy5, 
feature that is quite commonly attributed to the presence of aggregates and often 
results in a decrease in fluorescence. 
G0-Cy5
[M]+[M-Na+H]
+
[M-Na+H]+ [M]+
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Concerning the fluorescence of the dendrons, results shown in Figure III.23B, increased 
number of fluorescent units yields higher fluorescence emission for the dendrons (G3-
Cy5 > G1-Cy5 > G0-Cy5). Quantum yields (φ) obtained for G0-Cy5, G1-Cy5 and G3-Cy5 
were noted to 0.33, 0.22 and 0.21, respectively. It should be noted that molecules with 
high quantum yield and extinction coefficient have the brightest features. To compare 
the brightness of different fluorophores, the relative brightness of fluorophore is taken 
by multiplying the extinction coefficient with the quantum yield (ε·φ) [254]. Brightness 
obtained for G0-Cy5, G1-Cy5 and G3-Cy5 were 26330, 34046 and 128374, respectively. 
High brightness is required to have a strong fluorescence signal. Although φ for G3-Cy5 
is the lowest, it shows the highest brightness. Therefore, the G1-Cy5 and G3-Cy5 
dendrons decorated with 2 and 8 dye molecules, respectively, met the prerequisites for 
enhance fluorescence signals compared with the monovalent G0-Cy5. These results 
demonstrate the targeted proof-of-concept, contrary to the reported decrease in 
fluorescence previously detailed for dendrimers decorated with high number of dyes 
[150, 170, 171].  
Figure III.23. A) UV-visible spectroscopy of dendrons G0-Cy5, G1-Cy5 and G3-Cy5. B) Fluorescence 
emission of dendrons G0-Cy5, G1-Cy5 and G3-Cy5. 
III.2.4. Chemoselective Conjugation of Dendrons to a Model Antibody 
As the main motivation for the construction of these probes is their applicability in 
macromolecules labeling for bioimaging or diagnostic, we further demonstrate the 
conjugation to α-Human IgG Fc as a structural model of antibody. The labeling was 
performed as well by the PhD student during her stay at KTH. The methodology used for 
labeling capitalized on site-directed conjugation to the aldehydes of antibody that are 
generated through the oxidation of 1,2-diols in sialic acids in glycan carbohydrate 
chains attached to the CH2 domain between the heavy chains in the Fc region [181]. 
These  aldehydes  carbonyls  were  envisaged to selectively react with hydrazine groups 
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to generate hydrazone linkages without compromising antibody activity, recognition or 
causing further oxidative damage. The protocol [160] utilized was based on  a mild 
oxidation of polysaccharide chains with NaIO4 and the subsequent conjugation with 
the set of fluorescent probes G0-Cy5, G1-Cy5 and G3-Cy5, Figure III.24. Upon labeling, 
a purification step using Sephadex-G-25 was necessary to exclude any unconjugated 
fluorescent probes. Dialysis filtration was also performed as an additional purification 
step to ensure the exclusion of any remaining dyes. As visualized in Figure III.24, for 
the purified antibodies a clear shift in blue color intensity can be observed, which 
reflects the amplification capacity the fluorescent dendrons provides to the final 
conjugates.  
Figure III.24. Antibody labeling scheme. Labeled antibody concentration in the picture was around 8 
mg/mL.  
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SDS-PAGE analysis was performed by the PhD student once back in her home 
laboratory to confirm covalent attachment of the probes to the antibody (Figure III.25). 
The use of Commassie staining as a detection technique enabled the semi-
quantification of the labeled antibody, by comparison to unlabeled counterparts, and 
confirmed a similar recovery for all three fluorescently conjugated biomolecules. The 
fluorescent detection revealed bands for labeled antibodies while the controls were 
undetectable. This corroborates on successful covalent attachment of the fluorescent 
probes to the antibody via hydrazone linkages (Figure III.25).  
Figure III.25. SDS-PAGE characterization of labeled antibody. A molecular weight marker (lane 1), four 
decreasing amounts of unlabeled IgG as control (lanes 2-5) and conjugates IgG-G0-Cy5, IgG-G1-Cy5, IgG-
G3-Cy5 (lanes 6-8) were loaded. Commassie (left) and fluorescent detection (right). 
The absorbance for the labeled antibodies, measured by José María Montenegro at 
SCAI, UMA, registered a band at 646 nm, yielding higher intensity with increasing 
number of dye units present on the fluorescent probes. ε646 values were 49667, 274985 
and 2280894 M-1·cm-1 for IgG-G0-Cy5, IgG-G1-Cy5 and IgG-G3-Cy5, respectively (Figure 
III.26 top). Interestingly, the spectra for IgG-G3-Cy5 had a pronounced bimodal shape
with a maximum intensity at 600 nm. Such behavior has been previously observed by 
Gruber et al. [169] for IgG labeled with six Cy5 molecules. In their work, it was postulated 
to be an effect of H aggregates formation, so called H-dimers. This was explained by the 
tendency of cyanine dyes to aggregate in solution through plane-to-plane stacking 
(parallel aggregates) or through an end-to-end arrangement (head-to-tail). The 
transition to the upper state in parallel aggregates leads to a hypsochromic (red) shift 
and these groups of molecules are called H aggregates [249].  
As seen in Figure III.27, the fluorescence properties of labeled antibodies, measured as 
well at SCAI, UMA, noted the maximum emission for IgG-G1-Cy5 (φ= 0.25, ε·φ= 67891) 
followed by IgG-G0-Cy5 (φ= 0.41; ε·φ= 20473). The antibody labeled with G1-Cy5, 
compared to the conjugation with G0-Cy5, enhanced the fluorescence emission by one 
degree of magnitude. On the contrary, IgG-G3-Cy5 was barely fluorescent with an 
extremely low  φ  value of  0.02.  A plausible explanation is that most of the photon are
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absorbed and deactivated by means of non-radiative process. The drop in fluorescence 
of IgG-G3-Cy5 compared to the neat G3-Cy5 could be explained by the more restricted 
environment where the dendron is confined in the IgG, probably hydrophobic, leading 
to a more rigid conformation and thereof to a higher proximity among Cy5 units. H-
dimer formation was previously reported for Cy5, [249, 255] and other dyes [255, 256] 
as the cause of quenching for cases with a high degree of labeling. To investigate 
whether the scarce fluorescent properties of IgG-G3-Cy5 is due to this phenomena, 
absorbance and fluorescence values with and without Sodium dodecyl sulfate (SDS) 
were compared [169, 255, 256]. The addition of SDS to IgG-G3-Cy5 decreased the 
intensity of the band absorbance at 600 nm and increased that at 646 nm (Figure III.26 
bottom) as well as increased the intensity of the band in the fluorescence spectrum 
(Figure III.27 right). The large reversed anomalous effect could be explained by the 
partial unfolding of the antibody because of disruption of the tertiary structure due to 
SDS. In spite of the formation of Cy5 dimers, the quenching of Cy5 fluorescence in the 
highly Cy5-labeled biomolecule may be due to resonance energy transfer [169]. Similar 
argument can explain the observed fluorescent band for IgG-G3-Cy5 after SDS-PAGE, 
since SDS and -mercaptoethanol used in denaturalization step may affect protein 
conformation, being the dendritic structure surrounded by a less restricted 
environment, which would reduce quenching.  
Figure III.26. Absorbance spectra obtained for antibody labeled with the series of synthesized dendrons 
(IgG-G0-Cy5, IgG-G1-Cy5, IgG-G3-Cy5) (top left). Comparison of the different shape obtained for IgG-G3-
Cy5 (top right). Change in absorbance after 90 min of adding SDS (1%) to IgG-G3-Cy5 solution (bottom). 
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Figure III.27. Fluorescence emission results obtained for labeled IgG (IgG-G0-Cy5, IgG-G1-Cy5, IgG-G3-
Cy5) (left) and change in fluorescence 90 min after adding SDS (1%) (right). 
Among the three labeling studied, IgG-G1-Cy5, functionalized with dendrons bearing 
two dyes moieties, was found to be the most fluorescent. These findings are in good 
agreement with previous studies of the monovalent-Cy5/protein ratios in which 2 to 3 
Cy5 labels per antibody resulted in optimal fluorescence [169, 257]. However, these 
studies employed monovalent NHS-activated-dyes as a random-site bioconjugation to 
present lysines on the biomolecules. In this context, the orthogonality present in 
hydrazine/click frameworks provides water-soluble probes with site-directed 
conjugation and detection without jeopardizing the recognition site of the antibody.  
Due to the increasing use of fluorescent probes in biomedical applications, the 
development of novel fluorescent probes that allows for chemoselective labeling of 
biomolecules is highly desirable.  In this context, we herein described the synthetic 
design of dendritic scaffolds based bis-MPA as a monomer displaying a single protected 
hydrazine and multiple alkyne functionalities. These scaffolds (Dend5, Dend9 and 
Dend15), with orthogonal features were, for the first time, successfully decorated with 
the highly desirable bioimaging dye sulfo-Cy5, bearing one, two or eight fluorescent 
copies along with a single reactive hydrazine. The potential of the multivalent 
hydrazine/dyes probes, as a conjugation reagent to functionalize biomolecules, was 
demonstrated on α-Human IgG Fc. The most favorable signal amplification was obtained 
for Ig labeled with G1-Cy5 bearing 2 units of sulfo-Cy5. It was found to enhance the 
fluorescence by one order of magnitude when compared to the monovalent 
crosslinker G0-Cy5. This makes hydrazine functionalized G1-Cy5 dendron a valuable 
candidate for macromolecules labeling for applications such as immunoassays signal 
amplification. In contrast, strong fluorescence quenching was observed for α-Human 
IgG Fc labeled with G3-Cy5.   
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The results presented in section III.2. gave rise to the following publication in 
collaboration with the KTH, being first author the PhD student presenting this memory: 
Design of multivalent fluorescent dendritic probes for site-specific labeling of 
biomolecules, Journal of Polymer Science Part A: Polymer Chemistry. 56(15), 
1609-1616), reference [278]. 
While not favorable in this study, quenching phenomena observed for IgG-G3-Cy5 may 
be suppressed by the conjugation of the probe to biomolecules with less restricted 
environment. This could facilitate the exploitation of G3-Cy5 as a strong fluorescent 
enhancer for bioimaging and diagnostic applications. Finally, the chemistry is not limited 
to Cy5 and alternative dyes may lead to higher fluorescent emission for biomolecules 
labeled with dendron utilizing the presented synthetic strategy. 
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DHRs are a significant public health problem with important consequences on patient 
health and healthcare costs. It has been reported that only a low percentage of initial 
cases suspected of allergy to antibiotics are finally confirmed [15, 196], and BLs are the 
drugs most frequently involved [5, 28]. In vivo tests (ST and DPT) are often the first and 
only option for diagnosis, however they could be risky for patients. Thus, in vitro tests 
are a more convenient and safer alternative for diagnosis.  
Sensitive and specific detection of sIgE is crucial for in vitro allergy diagnosis, which is 
difficult to achieve due to the extremely low concentration present in patients serum 
[238]. Due to the low sensitivity and the report of some cases of false positives [197] for 
ImmunoCAP-FEIA, the only commercially available in vitro test for allergy diagnosis, 
currently, most of laboratories rely on the design and use of in-house immunoassays 
[138, 139], which have become more quantitative and sensitive. 
The sensitivity of in vitro tests for diagnosing allergy to BLs depends, among other 
factors, on: (i) the similarity between the structure used in the assay as emulator of the 
AD formed in vivo and the structure actually formed after BL intake, which is related to 
the mechanisms involved in the allergic process, and (ii) the intensity of the detection 
signal (radioactivity, enzimatic proccess or fluorescence) at low concentrations of sIgE 
to drugs. In the work presented, we did our bit to help to the improvement of in vitro 
tests for BLs allergy diagnosis by tackling the both previous mentioned points. 
Regarding the mechanism, it is known that the formation of hapten-protein conjugates 
takes place for BLs. Penicillins have been studied as model BLs [40, 46, 50] and their AD 
are well defined. Also, some studies allowed the identification of serum target proteins 
[45, 88, 89], binding sites [53, 89, 101-104] and the influence of the carrier molecule in 
recognition [63], allowing the advance in the design of in vitro tests for AX and BP using 
synthetic carriers or using novel solid surfaces [51, 148]. Nevertheless, ADs for 
cephalosporins and CLV are still to be characterized, and only a few studies have been 
published about the potential ADs for cephalosporins [43, 69, 200] and CLV [53]. It is 
important to highlight that the elucidation of the mechanism involved in allergy to 
cephalosporins and CLV has become of great interest, since cases of allergy to these BLs 
have increased in the last years due to the change in prescription patterns [15].  
In this study, we aimed to research, from a chemical approach, the structures recognized 
by sIgE for cephalosporins and CLV. We designed and synthesized structures derived 
from these BLs and performed their immunological evaluation using RAST or BAT. 
Degree of sIgE recognition of new synthetic structures were compared with previous 
reported structures or the native BL itself. Moreover, a biotinylated derivative of CLV 
was used as tool for identification of serum proteins target of modification.  
There are some works published in which SAR studies were employed for investigating 
the AD for cephalosporins [42, 43, 69, 70, 205], and it was the strategy we also used. 
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First, UDC methodology [210] was adapted to synthesize the target pyrazinone-like 
structures of interest (Cef1 and Cef2) as potential ADs of α-aminocephalosporins. 
Recognition of these molecules was evaluated by RAST inhibition and compared with 
the structures derived from cefaclor and cefadroxil reported previously by Montañez 
et al. [43], Cef3 and Cef4, respectively. Results after evaluation of Cef1 and Cef3 using 
sera from patients allergic to cefaclor showed that the pyrazinone Cef1 was better 
recognized (63% of patients) than Cef3 (12% of patients) and so, that the pyrazinone 
derivatives would be potential ADs for α-aminocephalosporins. Furthermore, 
evaluation of  Cef2 and Cef4 using sera from patients allergic to amoxicillin showed 
similar results for both structures, being these results helpful to get insight into the 
structure responsible for cefadroxil allergies and study cross-reactivities between 
penicillins and cephalosporins. 
Regarding CLV, the ignorance of its AD exact structure leads to an uncomplete diagnosis 
when allergic reactions are consequence of the administration of the AX-CLV 
combination [131]. Protein haptenation by CLV is supposed to occur similarly to other 
β-lactams [74, 204], but due to its high instability, the resulting structure rapidly 
degrades, leading to the formation of multiple fragments [74]. Thus, the formation of 
two main ADs of CLV, AD-I and AD-II, very low molecular weight structures formed by 
only 3 carbon atoms, was hypothesized and six structures derived from them 
synthesized. Basophil activation by these structures was evaluated and only Clav2 and 
Clav3, both coming from the AD-I, an 1,3-dicarbonylic compound, showed significant 
differences between patients and controls. The hydrolysis of the second carbonyl group 
of Clav2 after protein conjugation would lead to a molecule that is more similar to AD-I 
than Clav3, which is in agreement with the degree of recognition found (Clav2 > Clav3). 
The percentage of patients with BAT positive increased significantly to 69.0% when CLV 
and Clav2 were combined compared with native CLV, so the use of Clav 2 in BAT could 
be used to improve assay sensitivity.  
In order to study CLV conjugation with proteins, LC-MS/MS analysis of the tryptic digests 
of HSA-CLV were performed and only a 70 Da mass increment was observed. It is worth 
to highlight that this mass is compatible with that of AD-I, which is in agreement with 
BAT results and confirms that the specifically recognized Clav2 molecule is part of the 
resulting CLV-protein conjugate. Meng et al. previously investigated the haptenation of 
HSA by CLV and also found the 70 Da mass increment both in conjugates generated in 
vitro and in serum from patients taking AX-CLV [53].   
The study of the serum proteins target of modification by CLV could give important 
information about haptenation process but the lack of a monoclonal antibody makes 
difficult the identification of these adducts. In recent publications, biotin labeling has 
been combined with proteomic techniques to identify protein targets of haptenation 
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[45, 113, 233, 234] or modified protein residues [235]. In our group, it was demonstrated 
that AX and an biotinylated derivative of AX compete for their binding to proteins 
studies, which suggests that they may bind to common sites [45]. Using this same 
approach, we used CLV-TEG-B for identification of serum proteins target of 
modification by CLV and HSA, haptoglobin and heavy and light chains of 
inmunoglobulins were the proteins isolated.  
About immunoassays detection signal, radioactivity is the label for secondary antibodies 
presenting the highest sensitivity in immunoassays for allergy diagnosis (RAST). 
However, fluorescent labeling is a desirable alternative that would finish with the special 
requirements intrinsic to radioactivity handling. The focus of this study was to design 
fluorescent dendrimers as probes that allow fluorescent signal amplification, without 
affecting secondary antibody specificity, with the objective of reaching the sensitivity 
needed for detecting the low levels of IgE associated with allergy to drugs.  
Some studies have reported the coupling of fluorescent moieties to different kind of 
dendrons, such as PAMAM [248] or bis-MPA [250]. However, only in a few cases 
fluorescent signal increased with dendron generation, that is to say, with the number 
of fluorescent units. For instance, Wängler et al. [150] synthesized a library of 
increasing generations of PAMAM dendrons decorated in the periphery with different 
dansyl   chloride,   7-nitro-2,1,3-benzoxadiazol-4-yl chloride,   coumarin-343,  5(6)-carb- 
oxyfluorescein pentafluorophenyl ester and sulforhodamine B2 acid fluoride and a 
single thiol functionality at the focal point. Fluorescent evaluation of the set of dendrons 
resulted in enhanced fluorescence signal with dye units only for dansylated dendrons. 
However, dansyl moieties would prevent solubility in water, and bioconjugation through 
amine groups in the antibody could affect binding site and so, specificity.  
We designed and synthesized bis-MPA dendrimers (G0-Cy5, G1-Cy5 and G3-Cy5) 
bearing hydrazine functionality at focal point for site-specific conjugation to 
biomolecules, a TEG spacer to make sure their solubility in water, and decorated with 
sulfo-Cy5 fluorescent units [278], molecule also water soluble and compatible with 
microarray scanners. Their spectroscopic characterization showed an increment of 
fluorescence with the number of fluorescent units, and they were proved to be suitable 
for antibody labeling. IgG-G1-Cy5, with two fluorescent moieties, showed the highest 
fluorescence, being an order of magnitude higher than for the antibody labeled with an 
only fluorescent moiety IgG-G0-Cy5. However, IgG-G3-Cy5, with eight fluorescent units, 
was barely fluorescent, effect that has already been described for high degrees of Cy5 
labeling [169]. 
To sum up, results presented in this memory shed light into the mechanism involved in 
allergy  to  α-aminocephalosporins  and  CLV,  as  well as the possible proteins target of  
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modification by CLV, and shows the potential of dendrons as fluorescent labels 
allowing signal amplification. As future applications, the attachment to solid phases of 
the new pyrazinone-like structures for cefaclor and cefadroxil could improve sensitivity 
of in vitro tests directed to cephalosporins allergy. Furthermore, the elucidation of AD 
and carrier proteins for CLV, besides to give information about the mechanism 
involved in allergy and contribute to in vitro tests sensitivity, could help to the 
development of a monoclonal antibody which would allow to provide further 
information about CLV conjugation with serum proteins. Finally, synthesized 
fluorescent dendrons with hydrazine functionality could be used not only for labeling 
antibodies but for labeling other biomolecules bearing oxidizable carbonyl 
functionality, and they could be functionalized with dyes different from Cy5 for 
different applications. Added to that, the use of elucidated ADs in in vitro tests 
combined with the use of an antibody labeled with our fluorescent dendrons would be 
an important breakthrought in drug allergy diagnosis.  
CONCLUSIONS 

Conclusions
199 
1. From SAR studies of α-aminocephalosporin determinants, through the synthesis of
pyrazinone-like structures V (Cef1 and Cef2), derived from cefaclor and cefadroxil
respectively, and their immunological recognition, it is deduced that these cyclized
structures are specifically recognised by sIgE from patients allergic to the
corresponding cephalosporin or to penicillins containing the same R1 side chain.
Structure Cef1 (pyrazinone) seems to improve sIgE recognition to cefaclor
compared with previous synthetic determinant Cef3.
New structure Cef2 (pyrazinone) in combination with previous synthetic determinant
Cef4 resulted to be useful for studying cross-reactive recognition between α-
aminocephalosporins and α-aminopenicillins.
2. From the synthesis of well-defined structures derived from CLV, it was concluded that
the ability of synthetic determinants of CLV to activate basophils from patients with
immediate reactions to this drug is influenced by the chemical structure and their
reactivity to proteins. The AD analog of AD-I (N-protein, 3-oxopropanamide
derivative), Clav2, can activate basophils in a higher proportion of patients
compared to the native drug, CLV, and thus represents a promising structure to
improve the sensitivity of in vitro diagnosis.
The identified fragment of the CLV structure (of 70 Da mass) that remains linked to
the protein (modifying Lys 195 and Lys 475 of HSA), AD-I, is in agreement with that
synthetic determinant able to activate basophils, confirming SAR results.
3. A water soluble biotinylated derivative of CLV (CLV-TEG-B) was designed and 
synthesized, and showed in vitro protein haptenation capacity, which is 
concentration-dependent.
From the study of serum proteins haptenation by the biotinylated derivative of CLV 
it is deduced that CLV-TEG-B is an useful tool for target proteins identification. In fact, 
HSA, haptoglobin and heavy and light chains of immunoglobulins were identified as 
potential serum proteins target of modification by CLV.
4. Three scaffolds (Dend5, Dend9, and Dend15), with orthogonal features, were
successfully decorated with the dye sulfo-Cy5, bearing one, two, or eight fluorescent
copies along with a single reactive hydrazine (G0-Cy5, G1-Cy5 y G3-Cy5). From
spectroscopical studies, it is deduced that absorbance and fluorescence values
increase with fluorescent units.
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From the proof-of-concept consisting of the use of the dendrons G0-Cy5, G1-Cy5 
and G3-Cy5 as fluorescent probes for antibody labeling is deduced that they can be 
used for site-specific labeling. The potential of the multivalent hydrazine/dyes 
probes, as a conjugation reagent to functionalize biomolecules, was demonstrated 
on α-Human IgG Fc.  
The most favorable signal amplification was obtained for IgG labeled with G1-Cy5, 
bearing 2 units of sulfo-Cy5. It was found to enhance the fluorescence by one order 
of magnitude when compared to the monovalent probe G0-Cy5. This makes 
hydrazine functionalized G1-Cy5 dendron a valuable candidate for macromolecules 
labeling for applications such as immunoassays signal amplification.  
In contrast, strong fluorescence quenching was observed for α-Human IgG Fc labeled 
with G3-Cy5. 
EXPERIMENTAL
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1. Identification of β-lactam Antibiotics Antigenic Determinants
Recognized by Specific IgE 
Two studies were carried out for evaluating recognition of new syntetic ADs by sIgE from 
patients who had suffered from an immediate hypersensitivity reaction due to that BLs: 
A. Immunological evaluation of pyrazinone-like potential ADs for 
aminocephalosporins: cefaclor and cefadroxil.  
B. Immunological evaluation of structures derived from CLV. 
The studies were conducted according to the Declaration of Helsinki principles and were 
approved by the Provincial Ethics Committee of Malaga. All subjects included in the 
study were informed orally and signed the corresponding informed consent. 
1.1. Scope of the Study 
Experimental work was carried out at Regional University Hospital of Malaga research 
laboratory, belonging to IBIMA and except for chemical synthesis and molecules 
characterization, which were performed at BIONAND. Evaluation and selection of 
patients was performed at Regional University Hospital of Malaga Allergy Unit. Regional 
University Hospital of Malaga is a third level hospital, the one reference centre for 
allergy diseases in Malaga province, Melilla and Gibraltar. 
1.2. Study of CLV or α-aminocephalosporins Reactivity towards Nucleophilic 
Species  
Stability of different β-lactam was studied in the presence of butylamine. Solutions 
nucleophile/BL 1:1, at 10 mM concentration for each specie, were prepared. For CLV 
or derivatives the solvent used was deuterated PBS1X and for the rest of BLs 
deuterated PBS1X and deuterated CO32-/HCO3- 1:1 mixture (Table E.1). 1H-RMN was 
registered after 15 minutes, 1 hour, 16 hours and 40 hours while incubated at 37  ˚C.  
Table E.1. Solutions used for NMR monitoring of cefaclor, cefadroxil and CLV reaction towards 
butylamine. 
Nucleophile BL VF CF 
Cefaclor control --- 1.90 mg 0.5 mL 10 mM 
Cefadroxil control --- 1.90 mg 0.5 mL 10 mM 
CLV control --- 1.26 mg 0.5 mL 10 mM 
Butylamine-cefaclor 0.5 µL 1.86 mg 0.5 mL 10 mM 
Butylamine-cefadroxil 0.5 µL 1.84 mg 0.5 mL 10 mM 
Butylamine-CLV 0.831 µL 2.00 mg 0.5 mL 17 mM 
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1.3. Synthesis of structures derived from aminocephalosporins 
General procedure for pyrazinone synthesis. Ugi/Desprotect/Cyclize (UDC) strategy 
was employed for synthesizing the desired products [279]. Equimolar amounts of each 
substrate (butyl isocyanide, 2,5-dimethoxybenzylamine, 2,2-dimethoxyacetaldehyde 
solution 60% in H2O and Boc-protected corresponding aminoacid) were left to react in 
methanol (MeOH) at room temperature until Ugi adduct formation was completed. In 
order to remove a possible rest of isocyanide, CH2Cl2 and pol ys t yr ene s uppor t ed p-
toluenesulfonic acid (PS-p-TsOH) were added and submitted to orbital stirring at room 
temperature for approximately 1,5h. The PS-p-TsOH was filtered off and successively 
washed with MeOH, AcOEt and CH2Cl2 (3 times with 5 mL of each solvent). For 
deprotection and cyclization, the residue (Ugi adduct) obtained after solvents 
evaporation was treated with 30% TFA in DCE and heated to 80C˚ for 2h. The solution 
was then treated with saturated solution of NaHCO3 until pH 8 and extracted with 
EtOAc. Organic phase was dried over MgSO4 and evaporated under reduced pressure 
to afford a yellow oily residue that was purified by chromatographic methods on silica 
gel using DCM/MeOH mixtures. 
Cefaclor pyrazinone. N-butyl-6-oxo-5-phenyl-1,6-dihydropyrazine-2-carboxamide 
(Cef1). Synthetized following the general procedure. Corresponding aminoacid is N-Boc-
phenylglycine. The time needed for Ugi aduct formation was 7 days. For purification, 2% 
NH3 had to be added to DCM/MeOH mixtures to allow a good yield. Fair yellow solid, 
99% yield. 1H-NMR (400 MHz, MeOD): δ (ppm) 8.52 (s, 1H; N-CH=CCO), 8.19 (m, 2H; Ar-
ortho), 7.45 (m, 3H; Ar-meta+para), 3.41 (t, 3J(H,H) = 7.2 Hz, 2H; -CONH-CH2-), 1.62 (m, 
2H; -CH2-CH2-CH2-), 1.43 (m, 2H; -CH2-CH2-CH3), 0.98 (t, 3J(H,H) = 7.6 Hz, 3H; -CH2-CH3). 
13C-NMR (100 MHz, MeOD): δ (ppm) 164.3, 157.7, 149.8, 136.9, 133.5, 131.0, 130.29, 
129.1(x2), 40.41, 32.61, 21.14, 14.08. ESI MS calculated for C15H17N3O2 (M + H)+ 
272.1399, found: 272.1393.  
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Cefadroxil pyrazinone. N-butyl-5-(4-hydroxyphenyl)-6-oxo-1,6-dihydropyrazine-2-
carboxamide (Cef2). Synthetized following the general procedure. Corresponding 
aminoacid is N-Boc-hydroxyphenylglycine. The time need for Ugi aduct formation was 
48 hours. Bright(dark) yellow solid, 25% yield. After extraction with EtOAc as stated in 
the general procedure, the aqueous phase was treated with saturated solution of 
NaHCO3 until pH 7 and extracted again with EtOAc. Organic phases were combined. 1H-
NMR (400 MHz, MeOD): δ (ppm) 8.39 (s, 1H; N-CH=CCO), 8.17 (d, 3J(H,H) = 9.5 Hz, 2H; 
Ar-ortho), 6.86 (d, 3J(H,H) = 9.5 Hz, 2H; Ar-meta), 3.39 (t, 2H; -CONH-CH2-), 1.60 (m, 2H; 
-CH2-CH2-CH2-), 1.40 (m, 2H; -CH2-CH2-CH3), 0.97 (t, 3J(H,H) = 7.6Hz, 3H; -CH2-CH3). 13C-
NMR (150 MHz, MeOD): δ (ppm) 164.1, 160.9, 157.1, 150.5, 135.6, 131.7, 130.4, 128.0, 
115.9, 40.4, 32.6, 21.1, 14.1. ESI MS calculated for C15H17N3O3 (M + H)+ 288.1348, found: 
288.1342. 
1.4. Synthesis of structures derived from CLV 
N-Butyl-3,3-dimethoxypropanamide (Clav1): In a Schlenk flask (oven dried and 
cooled under nitrogen), butylamine (3.5 mL, 35 mmol) and commercially available 
methyl 3,3-dimethoxypropanoate (0.7 mL, 5 mmol) were mixed and stirred at 60°C for 
four days. The reaction mixture was cooled, diluted with dichloromethane (10 mL) and 
washed with 10 mL of HCl 2M. The organic layer was dried over anhydrous MgSO4, 
filtered, and concentrated in vacuo to afford quantitatively the target pure compound 
as a yellow oil (1.05 g). 1H-NMR (400 MHz, CDCl3): δ  0.89 (3H, t, J = 7.3 Hz, CH3), 1.27-
1.36 (2H, m, CH2), 1.43-1.51 (2H, m, CH2), 2.55 (2H, d, J = 5.3 Hz, CH2CH), 3.17-3.26 (2H, 
m, CH2NH), 3.35 (6H, s, 2 x OMe), 4.67 (1H, t, J = 5.3 Hz, CHCH2), 6.08 (1H, bs, NH); 13C-
NMR (400 MHz, CDCl3): δ 13.8 (CH3), 20.1 (CH2), 31.6 (CH2), 39.2 (CH2), 41.0 (CH2), 54.2 
(2 x OCH3), 102.3 (CH), 169.1 (CO). HRMS (C9H19NO3 + Na, 212.1263), found: 212.1258.   
Bis(isobutylcarbonic) malonic anhydride (Clav2): Under nitrogen atmosphere, malonic 
acid (105 mg, 1.0 mmol) was dissolved in dry CH2Cl2 (3 mL) and cooled to 0°C. N-Methyl 
morpholine (0.44 mL, 4 mmol) and isobutylchloroformate (0.26 mL, 2 mmol) were added 
slowly and the reaction mixture was allowed to stir and reach room temperature for two 
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hours. The solution was then washed with HCl 1M (5 mL), 1M NaHCO3 aqueous solution 
(5 mL) and water (5 mL). The organic layer was dried over anhydrous MgSO4, filtered, 
and concentrated in vacuo to afford the target pure compound as a brownish oil (250 
mg, 82%). 1H-NMR (400 MHz, CDCl3): δ  0.92 (12H, d, J = 6.7 Hz, 4 x CH3), 1.89-1.99 (2H, 
m, 2 x CH), 3.38 (2H, s, COCH2CO), 3.92 (4H, d, J = 6.7 Hz, CH2). 13C-NMR (400 MHz, 
CDCl3): δ 19.0 (4 x CH3), 27.7 (2 x CHCH2), 41.7 (COCH2CO), 71.6 (2 x CH2CH), 166.7 (4 x 
CO).   
3,3-Diethoxypropanoic anhydride (Clav3): Under nitrogen atmosphere, 3,3-
diethoxypropanoic acid (300 mg, 1.85 mmol) was dissolved in dry CH2Cl2 (5 mL) and 
cooled to 0˚C. EDCI (177 mg, 0.92 mmol) was added slowly and the reaction mixture was 
allowed to stir and reach room temperature overnight. The solution was then washed 
with water (2 x 5 mL) and the organic layer was dried over anhydrous MgSO4, filtered, 
and concentrated in vacuo to afford the target pure compound as a brownish oil (198 
mg, 71%). 1H-NMR (400 MHz, CDCl3): δ  1.23 (12H, t, J = 7.0 Hz, 4 x CH3), 2.82 (4H, d, J 
=5.8 Hz, 2 x CH2CO), 3.59 (4H, m, 2 x CH2), 3.70 (4H, m, 2 x CH2), 4.97 (2H, t, J = 5.8 Hz, 2 
x CH); 13C-NMR (400 MHz, CDCl3): δ 15.3 (4 x CH3), 41.0 (2 x CH2CO), 62.5 (4 x CH2CH3), 
99.0 (2 x CH), 165.3 (2 x CO);  HRMS (C14H26O7 + Na, 329.1576), found: 329.1571.   
3-Amino-N-butylpropanamide (Clav4): Previously prepared N-butyl-3-(1,3-
dioxoisoindolin-2-yl)propanamide (147 mg, 0.53 mmol) and hydrazine hydrate (4 mL) 
in EtOH (5 mL) were heated at 100˚C for three hours. The solution was then extracted 
with CH2Cl2 (3 x 10 mL), dried over anhydrous MgSO4, filtered, and concentrated in vacuo 
to afford the target pure compound as a white solid (50 mg, 65%). 1H-NMR (400 MHz, 
MeOD): δ  0.94 (3H, t, J = 7.3 Hz, CH3), 1.33-1.40 (2H, m), 1.45-1.52 (2H, m), 2.39 (2H, t, 
J = 6.6 Hz), 2.94 (2H, t, J = 6.6 Hz), 3.18 (2H, t, J = 7.0 Hz); 13C-NMR (400 MHz, MeOD): δ 
14.1 (CH3), 21.1 (CH2), 32.5 (CH2), 37.9 (CH2), 38.6 (CH2), 40.0 (CH2), 173.7 (CO). HRMS 
(C7H16N2O+H, 145.1335), found: 145.1335.  
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1,3-Dihydro-1,3-dioxo-2H-isoindole-2-propanoic acid: A vigorously stirred solution of 
β-alanine (1.0 g, 11.23 mmol) and phthalic anhydride (1.0 g, 6.75 mmol) in glacial acetic 
acid (5 mL) was heated at 120°C overnight. The solution was cooled, diluted with CH2Cl2 
(10 mL) and washed with water (2 x 15 mL). The organic layer was dried over anhydrous 
MgSO4, filtered, and concentrated in vacuo to afford the target pure compound as a 
white solid (1.16 g, 78%). Spectral data are in agreement with those reported in the 
literature [258]. 
N-Butyl-1,3-dihydro-1,3-dioxo-2H-isoindole-2-propanamide: Under nitrogen 
atmosphere, previously prepared 1,3-Dihydro-1,3-dioxo-2H-isoindole-2-propanoic acid 
(250 mg, 1.14 mmol) was dissolved in dry CH2Cl2 (2 mL) and cooled to 0°C. Then, HOBt 
(170.1 mg, 1.25 mmol) dissolved in CH2Cl2/DMF (2 mL / 1 mL) and EDCI (235 mg, 1.4 
mmol) dissolved in CH2Cl2 (2 mL) were added. The reaction mixture was allowed to stir 
and reach room temperature for 2 hours. Then, butylamine (0.1 mL, 1.02 mmol) was 
added and the reaction mixture was stirred at room temperature overnight. The 
solution was washed with HCl 1M (10 mL), 1M NaHCO3 aqueous solution (10 mL) and 
water (10 mL). The organic layer was dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo to afford the target pure compound as a white solid (270 mg, 
86%). Spectral data are in agreement with those reported by the commercial firm. 
Succinimidyl 3-acetamidopropanoate (Clav 6) [259]: Under nitrogen 
atmosphere, 3-acetamidopropanoic acid (201 mg, 1.5 mmol) was dissolved in dry CH2Cl2 
(5 mL) and cooled to 0°C. EDCI (352 mg, 1.8 mmol) and N-hydroxysuccinimide (211 mg, 
1.8 mmol) were added slowly and the reaction mixture was allowed to stir and reach 
room temperature overnight. The solution was then washed with water (2 x 5 mL) and 
the organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo 
to afford the target pure compound as a colorless oil (175 mg, 50%). 1H-NMR (400 MHz, 
CDCl3): δ 1.99 (3H, s, CH3), 2.81-2.88 (6H, m, 3 x CH2), 3.63-3.68 (2H, m, CH2NH), 6.26 
(1H, s, NH). 13C-NMR (400 MHz, CDCl3): δ 22.8 (CH3), 25.5 (2 x CH2), 31.4 (CH2), 34.8 (CH2), 
167.3 (CO), 169.3 (2 x CO), 170.7 (CO). HRMS (C9H12N2O5+H, 229.0824), found: 229.0812. 
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1.5. Patients and controls selection 
Selection and evaluation of patients was carried out by medical doctors belonging to 
Allergy Unit at IBIMA-Regional University Hospital of Malaga.  
Samples from patients were processed following current procedures and frozen 
immediately after their reception by the Málaga Regional Hospital Biobank, Andalusian 
Public Health System Biobank. The studies were conducted according to the Declaration 
of Helsinki principles and were approved by the Provincial Ethics Committee of Malaga. 
All subjects included in the studies were informed orally and signed the corresponding 
informed consent. 
A. Immunological evaluation of synthetic ADs of aminocephalosporins. 
Patients with a clinical history of immediate allergy to BLs, with a positive in vivo test 
(ST or drug provocation test) and/or in vitro detection of sIgE antibodies, following 
European Network of Drug Allergy (ENDA) guidelines [219] were diagnosed as allergic 
to BLs. Those with severe reactions, for which drug provocation tests are not 
recommended, were diagnosed based on positive RAST results and/or the suggestive 
clinical history. Depending on their response to drugs, patients were further classified 
into three groups: cefaclor reactors, which included patients with a positive ST for 
cefaclor; selective AX reactors, which included patients with a positive ST for AX, a 
negative ST for determinants of BP ( (BP-OL or MD) and tolerance to BP in a drug 
provocation test; and cross-reactors, which included patients with a positive ST for both 
determinants of BP (BP-OL or MD) and AX. 
Of the patients with a confirmed diagnosis of an immediate reaction to cefaclor, we 
selected eight cases that showed high levels (greater than 7%) of sIgE antibodies to the 
cephalosporin involved in the reaction measured by direct RAST.  
Of the patients with a confirmed diagnosis of an immediate reaction to AX, we selected 
those that showed high levels (greater than 6.7%) of sIgE antibodies to the AX.  
B. Immunological evaluation of synthetic ADs of CLV. 
Patients selective to CLV were chosen for the study by following the evaluation workup 
represented in Figure E.1 [142]. Diagnosis was confirmed by ST or drug provocation test 
(DPT) to penicillin, AX or CLV following the European Network for Drug Allergy (ENDA) 
guidelines [219]. As control group, cases with confirmed tolerance to AX-CLV and 
negative ST to major (BP-OL) and MD of BP, and to AX and CLV were chosen. 
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Figure E.1. Flow chart of the allergologic workup for patients classification. 
1.6. Conjugation of -lactam antibiotics with different carrier molecules for in 
vitro studies  
Monomeric conjugates of cephalosporins with butylamine for RAST inhibition assays 
Monomeric conjugates for cefaclor and cefadroxil with butylamine were prepared 
dissolving the corresponding cephalosporin in an excess of butylamine and then adding 
milliQ water. The mixture was left to react at room temperature for 48 hours and was 
kept in a desiccator until the conjugate was completely dry. 
General procedure for preparation of -lactam conjugates with different carrier 
molecules 
Conjugates were prepared dissolving the carrier protein at 20 mg/mL in PBS 1X (pH 7.4) 
and incubating it with an equivalent volume of the corresponding -lactam dissolved in 
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CO32-/HCO3- 50 mM (pH 10.2), except for CLV, that was dissolved in PBS 1X (pH 7.4), in 
order to have the desired protein/BL molar ratio. Resulting solution was incubated at 
37 ˚ C for 16-18 hours. BL amount not bound to the protein after conjugation was 
removed by dialysis filtration using Amicon filters (Merck-Millipore). Several washing 
steps were performed with milliQ water and resulting filtrates were freeze dried, 
dissolved in D2O and analyzed by 1H-NMR. Conjugates were considered completely 
clean when NMR revealed the absence of drug in the filtrate. Once clean, conjugates 
were freeze dried and kept at -20 ˚ C until use. An aliquote of each conjugate was 
analyzed by MALDI-TOF MS to confirm conjugation.  
Conjugates with synthetic structures derived from CLV 
HSA conjugates with Clav2 or Clav3 were prepared following the general procedure. 
Protein/CLV-derivated-structure molar ratio employed was 1:10.  
1.7. In vivo tests 
Skin test 
ST was performed by prick, and if negative followed by IDT as recommended [219]. For 
ST procedure, target hapten solutions were freshly prepared daily in saline and 
histamine (ALK Abelló) and saline solution (Serra Pamies) were used as positive and 
negative controls, respectively. For prick or intracutaneous test, a drop of hapten 
solution is deposited in the forearm and then, skin under is scratched with a lancet. If 
result is negative, intradermal test was performed, in which 20-50 µL of hapten 
solution is injected under the skin forming a papule whose initial diameter is 
measured. In those cases with a history of severe anaphylaxis test was performed with 
increasing concentrations until the maximum was reached, as described [219]. In the 
SPT, a wheal larger than 3 mm along with erythema and no whealing for the control 
saline after 30 minutes was considered positive [260]. In the IDT, the wheal area was 
measured initially and 20 min after testing and a diameter increase bigger than 3 mm 
was considered positive [260]. 
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Figure E.2. Representation of ST procedure. 
The ADs and maximum concentrations used for prick tests were as follows: BP-OL 0.04 
mg/mL (with a molar concentration of the BPO moiety of 8.64x105 mol), MD 0.5 mg/mL 
(with a molar concentration of sodium benzylpenilloate of 1.5x103 mol), AX 20 mg/ml 
and CLV 20 mg/ml (all from DIATER Laboratories, Madrid, Spain).  
Drug provocation test 
Single-blind placebo controlled DPT consists on administration of drug increasing doses 
at regular time intervals of 30-60 minutes until therapeutical dose is reached, under 
strict medical surveillance[219, 261] 
A. Immunological evaluation of pyrazinone-like potential ADs for 
aminocephalosporins. 
When in vitro tests and ST s for cephalosporins were negative, DPT is performed using a 
cephalosporin with different side chain to that in the culprit drug in case of serious 
reactions. In cases of mild reaction, DPT with the culprit cephalosorin was performed in 
two days course, reaching a quarter of the therapeutic dose the first day and the whole 
dose the second.    
B. Immunological evaluation of structures derived from CLV. 
To confirm selective reactions, a single-blind, placebo controlled DPT was performed 
using BP and AX. In brief, in subjects with negative ST to BP-OL and MD, DPT with BP 
was performed by parenteral route with increasing doses until reaching the cumulative 
dose (106 IU) and this was followed by a 2 days therapeutic course of PV of 500 mg/8-
hours. If  DPT with  BP and  PV was negative and  ST was negative to AX, a  DPT with AX
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was performed using incremental doses with 30-min time intervals until reaching a 500 
mg cumulative dose and this was followed by a 2-day therapeutic course of AX 500 
mg/8-hours. If good tolerance to AX was demonstrated and the ST result with CLV was 
negative, a DPT with AX-CLV was performed following the same procedure described 
earlier for DPT with AX. 
1.8. In vitro tests 
Sample collection 
Nursing staff of different hospitals Allergy Units (Malaga and Italia) extracted 10 mL of 
peripheral blood in gels filled with gel (Vacuette, Greiner bio-one) and of 10-20 mL in 
lytic heparin tubes (Vacuette, Greiner bio-one). Tubes with gel were used for serum 
extraction by 4000 rpm centrifugation for 5 minutes and serum obtained was kept at 
-20 ˚C until use. Blood extracted in lytic heparin tubes was used for cellular tests which 
were performed up to 24 hours after extraction at the latest. 
Radio Allergo Sorbent Test 
SIgE levels in patient´s serum were quantified by RAST  following the protocol previously 
described in our research group [262]. Cellulose discs (nº 54, Whatman International 
Ltd) were used as solid phase. They were activated by cyanogen bromide (Sigma-
Aldrich), reacted with PLL (Sigma-Aldrich) as carrier molecule and then, ethanolamine 
or BSA were used for blocking remaining activated groups in cellulose discs (Figure E.3). 
Finally, discs were conjugated with AX (Glaxo Smithkline), BP (Normon), cefaclor (Sigma-
Aldrich) or cefadroxil (Sigma-Aldrich) as previously described [56, 263]. Control discs 
containing PLL and blocked but without conjugation to drug were also prepared. Discs 
and silica nanoparticles (NPs) bearing different structures derived from CLV with 
transferrin or G2 PAMAM dendrimer as carrier molecules were prepared by Dr. 
Nekane Barbero. In this case, control discs or NPs beared carrier molecule in their 
surface without further conjugation with drug.  
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Figure E.3. Scheme of cellulose discs activation and conjugation with BLs. 
Protocol used for RAST (Figure E.4) assays was the previously described by Wide et al.
[264]. First, 30 µL of serum were incubated in duplicate with both drug conjugated and 
control discs for 3 hours at room temperature. After incubation, 3 washing steps with 
PBS1X-0.05% Tween 20 (v/v) were done and then, 25 µL of 125I labeled α-human IgE 
(labeled by Chalatec or using our optimized protocol) added and incubated with 
samples for 16 hours. After incubation, 3 washing steps with PBS1X-0.05% Tween 20 
(v/v) were done and counts per minute measured in a gamma counter (Cobra II Auto 
Gamma Counting System, Perkin-Elmer Packard). Counts per minute of 25 µL of I125 
labeled α-human IgE were measured in duplicate as a reference maximum value. For 
NPs, described protocol was adapted being the only change the need of using 
centrifugation in washing steps. 
Results were expressed as counts per minute obtained for drug conjugated discs minus 
counts per minute obtained for control discs, expressed as a counts per minute 
BL
BL
BL
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BL
BL
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percentage with respect to the maximum value (Equation E.1). Results were considered 
positive if calculated percentage was higher than mean + 2SD of results obtained for 
negative control sera group.  
Figure E.4. Representation of RAST procedure. 
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RAST inhibition 
RAST inhibition assays were performed following previously described procedures [56, 
262, 265]. Only sera with RAST % higher than 7% were inhibited and synthetic ADs and 
monomeric conjugates at two concentrations (10 and 100 mM) were used as inhibitors. 
First, 30 µL of serum were incubated in duplicate with 15 µL of inhibitor for 3 hours at 
room temperature. As control, each serum was as well incubated in duplicate without 
inhibitor, with 15 µL of PBS1X. Then, solid phase (cellulose discs conjugated with cefaclor 
or AX) was added to each tube and were incubated for 3 hours. This incubation was 
followed by three washing steps with PBS1X-0.05% Tween 20 (v/v), after which, 25 µL 
of 125I labeled α-human IgE were added and incubated for 16 hours. Again, incubation 
was followed by three washing steps with PBS1X-0.05% Tween 20 (v/v) and, finally, 
counts per minute were registered using a gamma counter (Figure E.5). Counts per 
minute of 25 µL of I125 labeled α-human IgE were also measured in duplicate as a 
reference maximum value. 
Results were expressed as inhibition percentage of counts per minute obtained with 
inhibitors with respect to the control sample incubated with PBS1X (Equation E.2). 
Inhibition capacity was compared among structures used as inhibitors taking into 
account whether their inhibition percentage was higher than 50% at 100 mM. 
Figure E.5. Representation of RAST inhibition procedure. 
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Basophil activation test 
BAT was carried out following a four-step protocol adapted from the previously 
described [140] with CLV (Sigma Aldrich, Saint Louis, USA) and different synthetized 
structures (Clav1 to Clav6) at different concentrations: 8, 4, 2 and 1 mM. Optimal 
concentrations for haptens were chosen on the basis of dose-response curves and 
cytotoxicity studies in order to avoid cytotoxic and non-sensitive concentrations. 
1.Degranulation. 100 µL of heparinized whole blood was aliquoted per tube and 20 µL
of stimulation buffer (0.78% NaCl, 0.037% KCl, 0.078% CaCl2, 0.033% MgCl2, 0.1% HSA, 
1 M HEPES and 10 µg/ml IL-3) and 1 µL CCR3-APC (Biolegend) were added and incubated 
for 10 min at 37˚C in a water bath. Then, 100 µL of the washing solution was added to 
the negative control tube, 100 µL of α-human IgE (Dako, Santa Clara, CA, USA) to the 
positive control tube and 100 µL of different concentrations of haptens to the different 
samples. The samples were incubated for 30 min at 37˚C swinging in a water bath. The 
degranulation was stopped by incubating the samples on ice for 5 min. 
2.Labeling.  Cells were stained with monoclonal antibodies.  1 µL  of  α-CD63-FITC and 1
µL of CD203c-PE (Biolegend) were added to each tube and incubated for 20 min at 4˚C 
in the dark.  
3.Lysis. Red blood cells were lysated and the rest of cells fixated by adding 2 mL of pre-
warmed lysing solution (BD FACS Lysing solution, BD Biosciences) was added and 
incubated for 5 min at room temperature. Then, samples were centrifuged for 5 min at 
1500 rpm and supernatant was discarded.  
4.Washing. Samples were washed with 3mL PBS1X-0.05% Tween 20 (v/v) and
centrifuged for 5 min at 1500 rpm, discarding the supernatant. 
Cells were analyzed in a flow cytometer FACSCalibur flow cytometer (Becton-Dickinson 
Bioscience, San Jose, CA) by acquiring at least 500-1000 basophils per sample, selected 
as CCR3+CD203c+ cells (Figure E.7) and results were analized with FlowJo® software (Tree 
Star, Inc. USA) Activation was expressed as SI, calculated as the ratio between the 
percentage of activated basophils (CD63+ cells) in samples stimulated with the different 
haptens and the negative control. Results were considered as positive when the SI) was 
≤2 to at least one of the cocentrations mentioned above. The percentage of 
spontaneously activated basophils was required to be equal to or greater than 5% to 
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calculate the SI, as previously described [266]. ROC curves for evaluated haptens were 
performed to select the cut-off to obtain the best sensitivity/specificity balance. 
Figura E.6. Representation of steps involved in basophils activation. 
Figure E.7. Analysis of fluorescent labeled basophils and following cytometry dot plots showing 
basophils selection strategy and a representative example of positives results for tree different haptens. 
BAT inhibition with Wortmannin 
WTM acts as a specific inhibitor of phosphatidylinositol 3-kinase (PI3-K), which has been 
shown to be one of the important kinases activated by FcεRI receptor cross-linking 
involved in IgE-mediated stimulation of human basophils.[221]  
To confirm that basophil activation was IgE mediated, we analyzed the WTM inhibitory 
effect at 1 µM [221]. This was used with the positive control (α-IgE) and the different 
haptens and synthetized structures at the same concentrations described previously. 
Protocol was the same as for BAT, but after peripheral blood sample incubation with 
stimulation buffer, 2.5 µL of 50 µM WTM were added and samples incubated swinging 
for 5 minutes at 37 ˚C. Then, 100 µL of hapten, washing buffer as negative  control  or  
α-IgE  as  positive  control  were  added  and  protocol  described  in previous point was 
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followed. 
1.9. Statistics for Basophil Activation Test 
Continuous variable results were expressed as mean ± standard statistical error. 
Comparisons of quantitative variables without a normal distribution were done by the 
Mann-Whitney test for two variables and Kruskall-Wallis test for cases with more than 
two independent variables. Comparisons of qualitative variables were done by means 
of the χ2 test. All reported P-values represent two-tailed tests, with values ≤ 0.05 
considered statistically significant. 
2. Study for identification of carrier proteins
2.1. Synthesis of Biotinylated Derivatives of CLV 
Synthesis of CLV-B 
Methyl biotinate: Reported procedure was followed [267]. Thionyl chloride (45 L) was 
added slowly to a suspension of biotin (50 mg, 0.204 mmol) in methanol (1.2 mL) and 
the mixture was stirred at ambient temperature for one hour. The reaction mixture was 
concentrated in vacuo to give quantitatively the methyl ester as a white solid (52 mg). 
Spectral data are in agreement with those reported in the literature [268]. 
Biotinol: Reported procedure was followed [267]. To a suspension of methyl biotinate 
(52 mg, 0.204 mmol) in dry THF (2 mL) was added carefully LiAlH4 (31 mg, 0.816 mmol) 
and stirred at room temperature overnight. The reaction mixture was quenched with 
MeOH (1 mL) and water (1 mL). MgSO4 was added to the mixture and it was stirred for 
additional twenty minutes. Then, the reaction mixture was concentrated in vacuo, 
filtered and washed with 1:4 MeOH/CH2Cl2 (10 mL). The filtrate was concentrated in 
HN NH
S
O
HH
O
OMe
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vacuo to give quantitatively the target product as a white solid (47 mg). Spectral data 
are in agreement with those reported in the literature [269]. 
Biotin tosylate: Reported procedure was followed [267]. Tosyl chloride (47 mg, 0.245 
mmol) was added to a suspension of biotinol (47 mg, 0.204) in dry pyridine (1.0 mL) in 
an ice bath. The reaction mixture was stirred at zero degrees for one hour and at 
ambient temperature overnight. Then, it was diluted with CH2Cl2 (5 mL) and washed 
with aqueous HCl 1M (5 mL), aqueous saturated NaHCO3 (5 mL), water (5 mL) and brine 
(5 mL). The organic layer was dried over anhydrous MgSO4, filtered, concentrated in 
vacuo and purified by flash chromatography eluting with 5% methanol in CH2Cl2 to give 
a white solid (29%). Spectral data are in agreement with those reported in the literature 
[270]. 
Biotin iodide: Reported procedure was followed [271]. Biotin tosylate (75 mg, 0.196 
mmol) and NaI (60 mg, 0.391 mmol) were stirred at reflux in acetone (10 mL) for 24 h. 
The solvent was removed under reduced pressure and the residue was dissolved in 
CH2Cl2 and the organic layer was successively washed with aqueous saturated sodium 
thiosulfate (10 mL) and water, dried over anhydrous Mg2SO4, and concentrated under 
vacuum. Purification of the crude material by flash chromatography eluting with 5% 
MeOH in CH2Cl2 gave the target compound as a white solid (52 mg, 78%). Spectral data 
are in agreement with those reported in the literature [271]. 
2-Biotin clavulanate (CLV-B): Reported procedure was followed [272]. Commercially 
available potassium clavulanate (44 mg, 0.173 mmol) and previously synthesized biotin 
iodide (49 mg, 0.144 mmol) under nitrogen atmosphere were stirred in dry DMF (2 mL) 
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at ambient temperature overnight. The solvent was removed under vacuum and the 
crude was purified by flash chromatography eluting with 5% methanol in CH2Cl2 to give 
the target compound as a white solid (35 mg, 60%).  
1H-NMR (400 MHz, DMSO-d6): δ  6.43 (1H, s, NH), 6.36 (1H, s, NH), 5.69 (1H, d, J = 2.7 
Hz, H5), 5.18 (1H, s, H2), 4.73 (1H, t, J = 6.8 Hz, H1´´),  4.30 (1H, t, J = 7.3 Hz, H12´), 4.14- 
3.94 (5H, m, H8´+ H2´ + H2´´), 3.62 (1H, dd, J = 16.8, 2.7 Hz, H6, diastereotopic protons), 
3.13-3.09 (2H, m, H6 + H7´), 2.82 (1H, dd, J = 12.5, 5.1 Hz, H13´, diastereotopic protons), 
2.58 (1H, d, J = 12.5 Hz, H13´), 1.60-1.23 (8H, m, H6´ + H5´ +  H4´ + H3´); 13C-NMR (400 
MHz, DMSO-d6): δ 175.5 (C7), 167.2 (C1’), 162.7 (C10’), 150.4 (C3), 101.2 (C1’), 87.5 
(C5), 65.5 (C2’), 61.0 (C8’), 69.9 (C2), 59.2 (C12’), 55.5 (C2’’), 55.4 (C7’), 46.0 (C6), 28.14, 
28.11, 27.7 (C5’, C4’, C3’), 25.2 (C6’). C13’ signal coincides with DMSO-d6 solvent signal 
(see HSQC). HRMS (C18H25N3O6S-H, 410.1385), found: 410.1385.   
Synthesis of CLV-TEG-B 
1-iodo-2-(2-(2-(2-iodoethoxy)ethoxy)ethoxy)ethane was prepared as follows: 
Tetraethylenglycol was first tosylated and this ditosylate was then subjected to reaction 
with NaI in acetone at reflux for 24h. Both reactions proceeded smoothly and 
quantitatively. Spectral data are in agreement with those reported by commercial firms. 
2-(2-(2-(2-Iodoethoxy)ethoxy)ethoxy)ethyl biotinate: Reported procedure was 
followed [230]. DMSO (5 mL) was added into a 25-mL Schlenk containing Biotin (244 mg, 
1.0 mmol) under nitrogen atmosphere at room temperature. Then, NaH (44 mg, 1.1 
mmol, 60% dispersion in mineral oil) was added under N2 atmosphere and the reaction 
mixture was allowed to stir for 10 minutes. Then, previously prepared 1-iodo-2-(2-(2-(2-
iodoethoxy)ethoxy)ethoxy)ethane (555 mg, 1.4 mmol) in DMSO (2 mL) was added to 
the reaction and the mixture was stirred at room temperature overnight. Then, 
saturated aqueous NH4Cl was added. Subsequently, it was extracted with EtOAc (3 x 10 
mL) and the combined organic phases were dried over anhydrous MgSO4, filtered and 
Experimental
221 
concentrated in vacuo. The crude was purified by flash chromatography eluting with 5% 
methanol in CH2Cl2 to give the target compound as a white solid (184 mg, 35%). 
1H-NMR (400 MHz, CDCl3): δ 6.29 (1H, s, NH), 5.83 (1H, s, NH), 4.38-4.35 (1H, m, H8), 
4.18-4.15 (1H, m, H4), 4.10-4.07 (2H, m, H6’), 3.62 (2H, t, J = 6.7 Hz, H12’),  3.57 (2H, t, J = 
4.9 Hz, H7’), 3.53 (s, 8H, H8’, H9’, H10’, H11’, H12’), 3.13 (2H, t, J = 7.0 Hz, H13’), 3.04-2.99 
(1H, m, H5), 2.76 (1H, dd, J = 12.8, 5.0 Hz, H7, diastereotopic protons), 2.61 (1H, d, J = 
12.7 Hz, H7), 2.24 (2H, t, J = 7.6 Hz, H4’), 1.64-1.48 (4H, m, H1’, H3’), 1.36-1.27 (2H, m, 
H2’). 13C-NMR (400 MHz, CDCl3): δ 173.6 (C5’), 164.0 (C2), 71.8, 70.5, 70.46, 70.40, 70.07, 
69.04 (C7’, C8’, C9’, C10’, C11’, C12’), 63.3 (C6’), 61.8 (C8), 60.0 (C4), 55.5 (C5), 40.4 
(C7),33.7 (C4’), 28.26, 28.11 (C2’, C3’), 24.6 (C1’), 3.1 (C13’). HRMS (C18H31IN2O6S+H, 
531.1020), found: 531.1015.   
2-Tetraoxadodecane-biotin clavulanate (CLV-TEG-B): Reported procedure was 
followed [272]. Commercially available potassium clavulanate (53 mg, 0.223 mmol) and 
previously synthesized 2-(2-(2-(2-Iodoethoxy)ethoxy)ethoxy)ethyl biotinate (130 mg, 
0.246 mmol) under nitrogen atmosphere were stirred in dry DMF (2 mL) at ambient 
temperature overnight.  The solvent was removed under vacuum and the crude was 
purified by flash chromatography eluting with 5% methanol in CH2Cl2 to give the target 
compound as a colorless oil (20.0 mg, 15%).  
1H-NMR (400 MHz, CDCl3): δ 5.90 (1H, s, NH), 5.68 (1H, d, J = 2.3 Hz, H5), 5.35 (1H, s, NH), 
5.05 (1H, d, J = 1.1 Hz, H2), 4.97 (1H, dt,  J = 6.9, 1.3 Hz, H1’’), 4.51-4.47 (1H, m, H16’), 
4.31-4.19 (7H, m, H20’, H2’, H2’’, H9’),  3.71-3.58 (12H, m, H3’, H4’, H5’, H6’, H7’, H8’), 3.48 
(1H, dd, J = 16.7, 2.8 Hz, H6, diastereotopic protons), 3.16-3.11 (1H, m, H15’), 3.08 (1H, d, 
J = 16.7 Hz, H6), 2.89 (1H, dd, J = 12.8, 5.0 Hz, H21’, diastereotopic protons), 2.74 (1H, d, 
J = 12.8 Hz, H21’), 2.36 (2H, t, J = 7.3 Hz, H11’), 1.74-1.63 (4H, m, H12’, H14’), 1.48-1.39 (2H, 
m, H13’). 13C-NMR (400 MHz, CDCl3): δ 174.8, 173.8, 167.3, 163.7 (C=O), 152.0 (C3), 101.0 
(C1’’), 87.9 (C5), 70.8, 70.6, 70.4, 69.3, 69.8 (oxygenated chain), 63.51, 63.49 (C2’, C9’), 
62.0 (C20’), 61.7 (oxygenated chain), 60.5, 60.2 (C2, C16’), 57.2 (C2’’), 55.6 (C15’), 46.5 
(C6), 40.6(C21’), 33.9 (C11’), 28.4, 28.3 (C12’, C13’), 24.8 (C14’). HRMS (C26H40N3O11S+H, 
602.2378), found: 602.2378. 
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2.2. Human serum proteins in vitro modification by CLV 
HSA in vitro modification by CLV 
Some solutions were prepared with different concentrations of CLV in PBS1X (pH 7.4). 
These solutions were incubated with an equivalent volume of HSA 20 mg/mL prepared 
in PBS1X (pH 7.4) for 16 hours at 37˚C. HSA final concentration was 10 mg/mL (0.15 mM) 
in every case and CLV final concentrations were from 0.36 to 11.52 mg/mL (1.5 to 48 
mM) to include molar ratio protein/drug from 1:10 to 1:320. In order to eliminate 
unbound -lactam after conjugation, Amicon Filters (Merck Millipore) were used. 
Several washing steps were performed with milliQ water and filtrates were collected, 
freeze-dried and analyzed by 1H-NMR. Conjugates were considered clean when NMR 
evidence of no drug left in filtrates.   
HSA in vitro modification by CLV-B and CLV-TEG-B 
Solutions of each biotynilated derivative, CLV-B and CLV-TEG-B, were prepared at 180 
mM in DMSO and PBS1X (pH 7.4), respectively. Nine decreasing fivefold dilutions of each 
solution were prepared in PBS1X (pH 7.4) and these solutions were incubated for 16 
hours at 37˚C with an equivalent volume of HSA 20 mg/mL prepared in PBS1X (pH 7.4). 
HSA final concentration was 10 mg/mL (0,15 mM) in every case and final concentrations 
of CLV biotynilated derivatives were from 1:600 to 1:3,1·10-4 molar ratio protein/drug.  
Also, HSA-CLV-TEG-B conjugates were prepared at 1:1, 1:10 and 1:100 protein/drug 
molar ratio. They were purified by dialysis filtration using Amicon filters (Merck-
Millipore).  
Resulting conjugates were analyzed by monodimensional SDS-PAGE followed by 
modification detection with streptavidin-HRP and ECL and/or MALDI-TOF MS. 
In vitro modification of a HSA peptide by CLV-TEG-B 
CLV-TEG-B was dissolved in PBS1X (pH 7.4) at 0.30 mM [88] and incubated with an 
equivalent volume of 27 mM 182-195HSA peptide (MW = 1518.68 Da) in PBS1X (pH 7.4) 
for 24 hours at 37˚C. Final peptide/ CLV-TEG-B ratio was 1:90. Resulting conjugate was 
purified using PD G-10 Desalting Columns (GE Healthcare) and analyzed by MALDI-TOF 
MS. 
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Human serum in vitro modification by CLV-TEG-B 
Total amount of protein in tree human sera obtained from healthy donors was 
quantified by Bradford. CLV-TEG-B was dissolved in PBS1X (pH 7.4) to get the needed 
concentration and was incubated with an equivalent volume of serum for 16 hours at 
37 ˚ C. Conditions chosen for incubation were total protein/CLV-TEG-B ratios 1:0.192 
and 1:0.00768 since a good signal was obtained in these conditions, without 
saturation. Resulting conjugates were analyzed by monodimensional SDS-PAGE as well 
as by 2D-electrophoresis followed by modification detection with streptavidin-HRP and 
ECL and proteins identification by MS (peptidic fingerprint). 
2.3. Enrichment of biotynilated fraction 
- Soft Link release Avidin, Promega 
-Pull-down 
First, NeutrAvidin-Agarose resin (Thermo Scientific) was equilibrated. 200 µL of resin 
slurry (corresponding to 100 µL of settled resin) were washed 5 times with mild 
homogenization buffer (50 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.2% NP-40 
and 0.1% SDS). Each washing step consisting on stirring for some seconds, centrifuging 
at 500 g and 4˚C for 1 minute and discarding the supernatant. 100 µL of mild 
hogenization buffer were added to the resulting 100 µL of dried beads in order to have 
a 1:1 (v/v) resin slurry.  
Purification of an HSA-CLV-TEG-B 1:10 and control HSA aliquots were carried out in 
parallel. 
Sample was diluted with mild homogenization buffer to 0.4 µg/µL (input) and 50 µL (20 
µg) were added to 50 µL resin slurry (25 µL dried resin) and volume completed up to 200 
µL with mild homogenization buffer. Samples were incubated stirring for two hours at 
room temperature. Then, samples were centrifuged at 500 g and 4˚C for 1 minute and 
supernatant volume recovered and kept (not bound). Resin was washed four times with 
500 µL strong buffer (50 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGTA, 1% NP-40 and 
0.5% SDS) stirring for some seconds, centrifuging at 500 g and 4˚C for 1 minute and 
discarding the supernatant. A fifth washing was made with 200 µL strong buffer and, 
after centrifugation, supernatant volume recovered and kept (last washing). 
HSA-CLV-TEG-B 1:10 was purified with SoftLink Soft Release Avidin Resin (Promega) 
following manufacturer´s instructions. 
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In order to release biotynilated protein from the resin, 100 µL of sample buffer 1X (1/5 
dilution of 1g SDS, 5 mL glycerol, 4 mL 1 M Tris-HCl pH 6.8, 2.5 mL β-mercaptoethanol 
and bromophenol blue) were added over the dried resin, the slurry was stirred for some 
minutes at room temperature and then, heated at 95˚C for 5 minutes. After a “short 
spin” supernatant was recovered and kept (elution) and dried resin was discarded. 
2 µg of samples and a molecular weight marker were loaded in a SDS-polyacrylamide gel 
(10%, 1.5 mm) in a final volume of 50 µL (sample volume completed up to 40 µL with 
mild homogenizing buffer and 10 µL sample buffer 5X) as follows: 
InputHSA/Not boundHSA/Last washingHSA/ElutedHSA//ElutedHSA-CLV-B/Last washingHSA-CLV-B/Not boundHSA-CLV-B/InputHSA-CLV-B 
2.4. Characterization of modified proteins by SDS-PAGE techniques 
Monodimensional SDS-PAGE characterization of proteins conjugated with CLV 
biotynilated derivatives general procedure  
After conjugation, HSA or human sera modified in vitro by CLV derivatives were 
denaturalized by adding Laemmli buffer and heating at 96˚C for 5 minutes. Eppendorf 
tubes containing denaturalized samples were centrifuged for some seconds (were given 
a short spin) and quickly cold in ice bath to avoid renaturalization. 2-4 µg of protein from 
each sample were loaded in 12% SDS-polyacrilamide gel and electrophoresis system was 
connected to a power supply with a 80 V current until samples pass through stacking gel 
and 120 V for separation since samples reached running (resolving) gel.  
Once finished electrophoresis, proteins were transferred to a PVDF membrane (Trans-
Blot Turbo Mini PVDF Transfer Packs, Bio-Rad) using Trans-Blot Turbo Transfer System 
from Bio-Rad following manufacturer´s indications. Membranes were blocked for 1 hour 
at room temperature with 1X blocking solution in H2O milliQ (prepared from 10X 
Blocking Buffer, SIGMA) and washed three times for 10 minutes with PBS-Tween 20 
0,05% (v/v). Then, membranes were incubated with streptavidin-horseradish 
peroxidase (HRP) conjugate (Amersham, GE Biosciences) dilution 1/1000 in 1% BSA 
(w/v) in PBS-Tween20 0.05% (v/v) and washed three times for 10 minutes with PBS-
Tween 20 0,05% (v/v). Chemiluminiscence was used for detection (Clarity Western ECL 
Substrate, Bio-Rad) and images were analyzed using ImageQuant LAS4000, GE 
Healthcare. 
Identification of modified serum proteins by 2D-electrophoresis 
For two-dimensional electrophoresis, aliquots of control and CLV-TEG-B-treated human 
serum, with protein/drug ratio 1:0,192, containing 20 µg of protein were precipitated 
with cold acetone stirring overnight at 4˚C. Then, acetone was decanted and the pellet 
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completely dried using a Speedvac system. The dried pellet was resuspended in 278.4 
µL of IEF simple buffer (4% CHAPS, 2 M thiourea, 7 M urea, 100 mM DTT) and 1.5 µL of 
Bio-lyte ampholytes pH range 3-10 and 2 µL of bromophenol blue added.  
Sample was then divided in two aliquots and loaded on two ReadyStrip IPG Strips (pH 
3–10 lineal, 7 cm, Bio-Rad) placed in a Protean IEF cell (Bio-Rad) and rehydrated for 12 
hours at 50 V and 20˚C, 50 µA per strip before six steps isoelectrofocusing: 1) 250 V for 
1 hour; 2) 500 V for 1 hour; 3) 1000 V for 1 hour; 4) 2000 V for 1 hour; 5) 8000 V for 1 
hour and 6) 8000 V for 1 hour. After isoelectrofocusing, strips were washed with milliQ 
water and equilibrated in two fifteen-minute steps stirring at room temperature in the 
dark with equilibration buffer (6 M urea, 2% SDS, 0.375 M Tris-HCl pH 8.8, 20% glycerol 
and bromophenol blue) containing 130 mM DTT for first step and 135 M iodoacetamide 
for second step. 
Equilibrated strips were loaded in duplicate in SDS-polyacrilamide gels (10%, 1.5 mm) 
using 0,5% agarose to fix them to the gels, which were run in duplicate. One of them 
was stained with SYPRO Ruby (Bio-Rad) for total protein pattern and the other one 
transferred to a PVDF membrane to detect proteins modified by CLV-TEG-B with 
streptavidin-HRP and chemiluminiscent detection (Clarity Western ECL Substrate, Bio-
Rad).  
Figure E.8. Representation of 2D SDS-PAGE procedure. Adapted from Laborde et al. [273] 
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Determination of the Extent of Biotinylation in HSA conjugates 
Estimation of the incorporation of CLV-B in HSA conjugates (1:1, 1:10 and 1:100) was 
made by comparison with a biotinylated BSA standard (Pierce). A known amount of 
conjugates (2 pmol) and six increasing amounts of biotinylated BSA (from 0.006 to 6 
pmol) were subjected to SDS-PAGE and transferred to a PVDF membrane following the 
general procedure.  
First of all, HSA conjugates correct load was checked. Membranes were blocked for 1 
hour at room temperature with 1X blocking solution in H2O milliQ (10X Blocking Buffer, 
SIGMA) and washed three times for 10 minutes with PBS-Tween 20 0,05% (v/v). After 
that, membranes were incubated with 1 µg/mL α-HSA primary antibody (ALB(F- 
10):sc-271605, Santa Cruz Biotechnology) in 1% BSA (w/v) in PBS-Tween20 0,05% (v/v), 
washed three times for 10 minutes with PBS-Tween 20 0,05% (v/v) and incubated with 
1/2000 dilution polyclonal rabbit α-mouse IgG conjugated with HRP (P0260, DAKO) in 
1% BSA (w/v) in PBS-Tween20 0,05% (v/v) and finally washed three times for 10 
minutes with PBS-Tween 20 0,05% (v/v) and detected by chemiluminiscence (Clarity 
Western ECL Substrate, Bio-Rad) and images were analyzed using ImageQuant 
LAS4000, GE Healthcare. 
For detection of biotinylation, stripping of the membranes was necessary. Membranes 
were washed three times for 5 minutes with milliQ water and incubated with HCl 
guanidine 8M for 15 min at room temperature. After three five-minute washings with 
milliQ water, membranes were incubated with streptavidin-HRP (Amersham, GE 
Biosciences) dilution 1/1000 in 1% BSA (w/v) in PBS-Tween20 0,05% (v/v) and washed 
three times for 10 minutes with PBS-Tween 20 0,05% (v/v). Chemiluminiscence was used 
for detection (Clarity Western ECL Substrate, Bio-Rad) and images were analyzed using 
ImageQuant LAS4000, GE Healthcare. 
We analyzed images obtained with ImageJ software (National Institutes of Health) for 
three replicates and expressed the results as pmol biotin/pmol HSA.  
Competition between CLV and CLV-TEG-B for HSA modification 
A solution of HSA 20 mg/mL and solutions of CLV 160, 1600, 16000, 24000, 48000, 
96000, 160000 and 192000 µM were prepared in PBS 1X pH 7.4. HSA was preincubated 
overnight at 37˚C with equivalent volumes of the indicated increasing concentrations of 
CLV, and only with PBS 1X pH 7.4 as control. The final concentration of HSA was 10 
mg/mL in every case and the final concentration of CLV was 80, 800, 8000, 12000, 24000, 
48000, 80000 and 96000 µM, respectively. 
After preincubation, CLV-TEG-B was added to each conjugate to have a final 
concentration of 80 µM. They were incubated for 2 hours at 37 ˚C. 
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CLV molar excess in conjugates with respect to CLV-TEG-B was: 0X, 1X, 10X, 100X, 150X, 
300X, 600X, 1000X and 1200X (Table E.2). 
Table E.2. CLV and CLV-TEG-B concentrations used for comprtitions experiments. 
[HSA]0 [HSA]f [CLV]0 [CLV]f [CLV-TEG-B]f Vf 
CLV 0 
20 mg/mL 
0,3 mM 
10 
mg/mL 
0,15 mM 
0 mg/mL 
0 M 
0 mg/mL 
0 M 
80 M 200 L 
CLV 1X 3,80·10
-2 mg/mL 
160 M 
1,90·10-2 mg/mL 
80 M 
CLV 10X 3,80·10
-1 mg/mL 
1600 M 
1,90·10-1 mg/mL 
800 M 
CLV 100X 
3,80 mg/mL 
16000 M 
1,90 mg/mL 
8000 M 
CLV 150X 
5,69 mg/mL 
24000 M 
2,85 mg/mL 
12000 
CLV 300X 
11,39 mg/mL 
48000 M 
5,69 mg/mL 
24000 M 
CLV 600X 22,78 mg/mL 
96000 M 
11,40 mg/mL 
48000 M 
CLV 1000X 37,96 mg/mL 
160000 M 
19,00 mg/mL 
80000 M 
CLV 1200X 45,55 mg/mL 
192000 M 
22,80 mg/mL 
96000 M 
SDS-PAGE of 2 µg aliquots from the incubation was carried out. After transfer to a PVDF 
membrane, incorporation of CLV-B was assessed by detection with HRP-streptavidin 
followed by ECL.  
2.5. Mass spectrometry 
MALDI-TOF of protein conjugates 
The MALDI-TOF mass spectra of complete protein were acquired at SCAI, UMA, 
Proteomic Unit, using a MALDI TOF TOF Bruker UtraFlextreme and were recorded by 
dissolving conjugates in milliQ water containing 0.1% trifluoroacetic acid (TFA) and using 
sinapinic acid (SPA) or α-cyano-4-hydroxycinamic acid (CHCA) as the matrix for proteins 
or peptides, respectively. 
Binding sites identification 
These experiments were carried out at University Hospital Vall d´Hebron Research 
Institute Proteomic Laboratory.  
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Figure E.9. Scheme of experimental procedure used for binding sites identification. 
- Liquid chromatography-Mass spectrometric analysis (Orbitrap): 
Control HSA as well as HSA modified with ten molar excess of CLV (HSA-CLV 1:10), were 
digested with Arg-C, Trypsin and chymotrypsin, and then analyzed on an LTQ Velos-
Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany), coupled to a 
nano-HPLC system (Proxeon, Denmark) and an Impact HD high resolution Q-TOF 
spectrometer (Bruker, Bremen), coupled to a nano-HPLC system (Proxeon, Denmark). 
Peptide mixtures were initially concentrated on a 100 µm ID, 2cm Proxeon nanotrapping 
column packed with Reprosil C18, 5 mm particle size (Proxeon, Denmark), and 
subsequently separated on the analytical nano reverse phase column, as indicated 
below. 
- Orbitrap analysis: an EASY-column, 75 mm ID, 10 cm long and packed with 
Reprosil, 3 µm particle size (Proxeon, Denmark) was used as analytical column. An 
acetonitrile gradient (5-35% ACN/0.1% formic acid in water, in 22 min, flow rate ca. 300 
nL/min) was used to elute the peptides through a stainless steel nano-bore emitter 
(Proxeon, Denmark) onto the nanospray ionization source of the LTQ Velos-Orbitrap 
mass spectrometer. MS/MS fragmentation (200 ms, 100–2800 m/z) of twenty of the 
most intense ions when their intensity exceeded a minimum threshold of 1000 counts 
was carried out, as detected from a 500 ms MS survey scan (300–1500 m/z), using a 
dynamic exclusion time of 20 sec for precursor selection and excluding single-charged 
ions. 
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- Impact QTOF analysis: a 75 µm ID, 15 cm Acclaim PepMap column (Dionex) 
was used for separation. Chromatography was run using a 0.1% formic acid- 
acetonitrile gradient (5-35% in 22 min; flow rate 300 nL/min). The column was coupled 
to the mass spectrometer inlet through a Captive Spray (Bruker) ionization source. MS 
acquisition was set to cycles of MS (1Hz), followed by MS/MS (0.5-2Hz) of the 8 most 
intense precursor ions with an intensity threshold for fragmentation of 5000 counts 
and using a dynamic exclusion time of 0.5 min and exclusion of single charged ions. All 
spectra were acquired in the range 100-2200 Da. LC-MS/MS data was analyzed using 
the Data Analysis 4.2 software (Bruker). 
- Peptide identification: Proteins were identified using Mascot (Matrix Science, 
London UK) to search against the sequence of isoform 1 of HSA; ALBU_HUMAN. MS/MS 
spectra were searched with a precursor mass tolerance of 10 ppm, fragment tolerance 
of 0.7 Da (Orbitrap) or 0.05 Da (Impact), and the corresponding enzyme specificity. 
Cysteine carbamidomethylation was set as fixed modification and methionine oxidation, 
as well as the CLV modifications, were set as variable modifications. The specificity for 
the CLV fragment modifications was defined in Cys, Hys and Lys as well as in the protein 
N-terminal. 
Peptidic fingerprint 
This proteomic analysis or identification of serum poteins modified by CLV-TEG-B was 
performed in the Proteomics Unit of Complutense University of Madrid that belongs to 
ProteoRed, PRB2-ISCIII, supported by grant PT13/0001.  
First step was 2D-electrophoresis of samples. The spots of interest were then manually 
excised from gels. Proteins selected for analysis were in-gel reduced, alkylated and 
digested with trypsin according to Sechi et al. Briefly, the samples were reduced with 10 
mM dithioerytritol in 25 mM ammonium bicarbonate for 30 min at 56˚C and 
subsequently alkylated with 25 mM iodoacetamide in 25 mM ammonium bicarbonate 
for 15 min in the dark. Finally, samples were digested with 12.5 ng/μl sequencing grade 
trypsin (Roche Molecular Biochemicals) in 25 mM ammonium bicarbonate (pH 8.5) 
overnight at 37˚C.  
After digestion, the supernatant was collected and 1μl was spotted onto a MALDI target 
plate and allowed to air-dry at room temperature. Then, 0.6 μl of a 3 mg/ml of α-cyano-
4-hydroxy-cinnamic acid matrix (Sigma) in 50% acetonitrile were added to the dried 
peptide digest spots and allowed again to air-dry at room temperature.  
MALDI-TOF MS analyses were performed in a 4800 Plus Proteomics Analyzer MALDI-
TOF/TOF mass spectrometer (Applied Biosystems, MDS Sciex, Toronto, Canada). The 
MALDI-TOF/TOF operated in positive reflector mode with an accelerating voltage of 
Experimental
230 
20000 V. All mass spectra were calibrated internally using peptides from the auto 
digestion of trypsin.  
For protein identification SwissProt 20170116 (553231 sequences; 197953409 residues) 
with taxonomy restriction to human was searched using MASCOT 2.3 
(www.matrixscience.com) through the software Global Protein Server v 3.6 (ABSciex). 
Search parameters were:  
-Carbamidomethyl Cystein as fixed modification and oxidized methionine as variable 
modification  
-Peptide mass tolerance, 50 ppm (PMF) 
-1 missed trypsin cleavage site 
In all protein identification, the probability scores were greater than the score fixed by 
mascot as significant with a p-value minor than 0.05. 
Figure E.10. Schamatic representation of procedure for proteins identification by peptidic fingerprint. 
Adapted from Laborde et al. [273]. 
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2.6. Molecular modeling 
In order to obtain further insights into the observed adducted Lys, molecular modeling 
studies were performed, exploring the regions surrounding the modified residues. 
The crystal structures of HSA and CLV, considered in its carboxylate form (CLV), were 
obtained from RCSB Protein Data Bank (PDB ID: 1AO6 and PDB ID: J01) [274]. The 
relaxation of the chain-A from HSA was performed with AMBER 12 MD software 
package [275] and the parm99 force field, using a full atomistic simulation. To preserve 
the charge neutrality, an appropriate number of chloride counterions were added. 
Then, the protein was solvated in a truncated octahedral cell, with a minimum of 10 Å 
solvation shell around the structure, and the TIP3P water model [276]. To retain the 
experimental folding, the solvated structure was minimized keeping fixed the backbone 
atoms during the initial cycle of conjugated gradient minimization. The optimized 
structure obtained was used in the docking analysis. 
For each recognized site of addition, a docking search was performed using the 
AutoDock 4.2 software [277] and a 14 Å  sphere around the adducted lysines (in their 
neutral form) was considered. CLV was docked into this grid with the Lamarckian 
algorithm and the ligand flexible bonds were left free to rotate. The genetic-based 
algorithm generated 100 poses and the other parameters were left at default settings. 
The obtained complexes were ranked considering both the docking scores and the 
distance between the lysine's amino group and the CLV β-lactam carbonyl group. 
3. Labeling of secondary antibodies
3.1. Radioactive labeling 
Labeling optimization 
α-Human IgG Fc clone SG-11 (ICN Biomedicals Inc) was diluted at 1 mg/mL with PBS 1X. 
An aliquot of 15 µL (15 µg) was separated from the stock solution and volume completed 
up to 45 µL with PBS 1X. Previous mixture was added to the bottom of a Pierce Pre-
Coated Iodination Tube (Thermo Fisher Scientific) and, immediately after, NaI125 
(NEZ033A001MC, Perkin Elmer) of 103, 23 mCi/mL concentration and 17 Ci/mg specific 
activity incorporated to the reaction. Two experiments were carried out in parallel with 
different amount of NaI125. In Experiment 1, 0.7 µL (75 µCi) of NaI125 were added, and in 
Experiment 2, 2.4 µL (250 µCi). The following steps were the same for each of them.  
Antibody solution and NaI125 in iodinating tubes were left to react at room temperature 
for 15 minutes, moving softly the mixture for 10 seconds every minute. After this time, 
the mixture was taken out of the iodination tube and the volume completed with PBS1X 
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up to 500 µL to stop the reaction (stop solution). We kept 5 µL to measure the maximum 
as reference for calculations.  
For antibody purification, a sephadex PD Minitrap G-25 (GE Healthcare Life Sciences) 
column was used. First, top and bottom caps were removed and column storage solution 
discarded. Then, column was equilibrated with 8 mL of PBS 1X, discarding the flow-
through. When all equilibration buffer had entered completely the packed bed, the 500 
µL of stop solution were immediately loaded in the column. The sample was allowed to 
enter the packed bed completely and the flow-through collected as fraction number 
one. Then, PBS 1X was added and 15 more 0.5 mL fractions were collected in 15 
eppendorfs (separately).  
As many measurement solutions as fractions collected were prepared adding 5 µL of the 
fraction to 4 mL of scintilliating liquid. Maximum solutions were prepared the same way. 
Radioactivity was measured using a HIDEX 300 SL gamma counter for identification of 
fractions containing radiolabeled IgG for both Experiment 1 and Experiment 2.  
Radioactivity values obtained for fractions and maximums by measurement in gamma 
counter are collected in Table E.3. 
Table E.3. Radioactivity results for fractions collected during purification step in optimization 
experiments. Cpm: counts per minute; dpm: desintegrations per minute; TDCR: Triple-to-double 
coincidence ratio. *Values of 1/2 dilution since direct measurement leaded to detector saturation. 
75 µCi 250 µCi 
cpm dpm TDCR cpm dpm TDCR 
Maximum 432515 627685 0,689 1590000* 2280000* 0,696* 
Fraction 1 419 12594 0,033 747 23301 0,032 
Fraction 2 50097 79930 0,626 468582 737185 0,653 
Fraction 3 138510 218914 0,632 1250000 1960000 0,639 
Fraction 4 12062 19497 0,618 83203 128487 0,647 
Fraction 5 20637 32473 0,635 131147 199934 0,655 
Fraction 6 24623 38486 0,639 190406 289038 0,658 
Fraction 7 17239 27132 0,635 400 7653 0,052 
Fraction 8 10784 17178 0,627 50562 77511 0,652 
Fraction 9 6133 10378 0,59 33249 51693 0,643 
Fraction 10 4672 8059 0,579 21014 32966 0,637 
Fraction 11 3394 6203 0,547 16641 25974 0,64 
Fraction 12 2689 5301 0,507 11116 17412 0,638 
Fraction 13 2424 4819 0,503 8342 12838 0,649 
Fraction 14 1809 3623 0,499 6961 11166 0,623 
Fraction 15 1809 4089 0,442 5251 8513 0,616 
Fraction 16 1873 4410 0,424 4491 7156 0,627 
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Antibody containing fractions were combined and iodination yield, incorporated activity 
and specific activity calculated as follows for each experiment.  
Iodination yield (%) =
Labeled IgG counts
Total counts
· 100
Incorporated activity (µCi) =
Iodination yield (%) ·  I125 initial activity
100
I125 initial activity = 75 or 250 µCi added in Experiment 1 and Experiment 2, respectively 
Specific activity (µCi/µg) =
Incorporated activity (µCi)
Labeled IgG mass
Labeling of -human IgE monoclonal antibody with I125 
Once optimized the amount of NaI125 that leaded to a better specific activity, we labeled 
a high specific mix of -human IgE monoclonal antibodies kindly provided by Phadia. 
Protocol described for optimization was used, employing 2.4 µL (250 µCi) of NaI125 
(optimization Experiment 2 conditions). Iodination yield, incorporated activity and 
specific activity were calculated for combination of fractions 2 and 3 (Table E.4) using 
equations in previous point. 
Table E.4. Radioactivity results for fractions collected during purification step. In bold, fractions 
containing labeled antibody. *Values of 1/2 dilution since direct measurement leaded to detector 
saturation. 
cpm dpm TDCR 
Maximum 1350000* 1860000* 0,728* 
Fraction 1 842 37395 0,022 
Fraction 2 274745 378274 0,726 
Fraction 3 1570000 2150000 0,73 
Fraction 4 130447 182347 0,715 
Fraction 5 87764 120273 0,729 
Fraction 6 48081 75982 0,632 
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Complete recovery was considered, thus having 15 µg of protein in 1 mL (combination 
of two 0.5 mL fractions). Finally, a hundred-fold dilution of the I125 labeled antibody was 
prepared in 1.5% (w/v) BSA in PBS 1X pH 7.4-Tween 0,1% so we have it in similar 
conditions to the old Phadia commercial antibody (0.15 µg/mL antibody concentration, 
1.065 µCi/mL activity per volume, 7.1 mCi/mg specific activity). 
Labeled IgG sensitivity evaluation by Radio Allergo Sorbent Test (RAST) 
Radiolabeled α-human IgE was subjected to immunological validation by RAST. Success 
in labeling was proved by comparison of RAST % results obtained with data acquired 
previously using other batches or kind of antibody used (Tables E.5 and E.6). 
Table E.5. % RAST results obtained for AX positive patients, using different I125 labeled antibodies. Solid 
phase used in RAST assays was AX-PLL. 
 
 
 
 
 
 
 
 
% RAST 
Phadia 
% RAST   
Chelatec labeling 
% RAST  
Our labeling protocol 
Case 1 29,80 25,96 59,78 
Case 2 16,22 16,31 26,07 
Case 3 18,74 16,00 27,41 
Case 4 41,52 50,51 80,49 
Case 5 25,79 29,62 38,43 
Case 6 20,14 16,17 27,11 
Control 1 - - 1,72 
Control 2 - - 2,34 
Control 3 - - 3,04 
Control 4 - - 2,71 
Control 5 - - 0 
Control 6 - - 2,95 
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Table E.6. % RAST results obtained for patients presenting allergic reactions to cefaclor, using different 
I125 labeled antibodies. Solid phase used in RAST assays was cefaclor-PLL. (-): not determined. 
% RAST 
Phadia 
% RAST 
ALK-Abelló 
% RAST  
Chelatec labeling 
% RAST  
Our labeling protocol 
Case 1 - - - 33,37 
Case 2 - - - 1,45 
Case 3 2,48 1,25 0,56 1,67 
Case 4 2,06 3,65 10,20 15,36 
Case 5 6,99 6,95 19,69 20,55 
Case 6 - - - 1,96 
Case 7 11,17 4,84 17,19 19,44 
Case 8 2,94 4,45 10,49 16,18 
Case 9 13,59 6,06 17,76 21,43 
Case 10 9,62 7,04 17,89 14,92 
Case 11 - - - 1,74 
Case 12 - - - 1,68 
Case 13 - - - 1,04 
Case 14 - - - 4,86 
Case 15 - 1,59 0,00 0,00 
Case 16 - 1,80 0,83 2,54 
Case 17 - 1,03 0,00 0,97 
Case 18 - 1,44 1,98 6,96 
Case 19 - - - 0,59 
Case 20 - 1,02 0,00 0,00 
Case 21 - 0,99 0,00 1,34 
Case 22 - 3,54 7,24 11,17 
Case 23 - 0,66 0,52 0,21 
Case 24 - 1,49 1,28 1,47 
Case 25 - - - 2,14 
Case 26 - 1,22 0,91 0,69 
Case 27 - 1,20 0,51 0,41 
Case 28 - 1,00 0,66 0,36 
Case 29 - 0,64 0,62 0,57 
Case 30 - 0,85 0,00 0,68 
Case 31 - 4,43 7,02 34,56 
Case 32 - 1,21 0,64 1,28 
Case 33 - 1,04 1,60 3,48 
Case 34 - 2,75 8,62 7,69 
Case 35 - 1,12 0,67 1,91 
Case 36 - 4,25 24,63 11,67 
Case 37 - 3,78 1,75 1,79 
Case 38 - 0,49 0,00 0,74 
Case 39 - 3,02 0,69 0,58 
Case 40 - 1,51 0,93 2,89 
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3.2. Fluorescent labeling 
Materials 
All chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA), Merck 
(Hohenbrunn, Germany), VWR (Fontenay-sous-Bois, France) and Lumiprobe (Hunt 
Valley, Maryland USA) and used as received unless otherwise stated.  
Nomenclature 
Dendrons are abbreviated as “Focal functionality”-”Spacer”-“Generation”-“Peripheral 
functionality”. For example, a third generation dendron with a benzylidene protected 
TEG spacer and an acetonide protected periphery is denoted as Bz-TEG-G3-Acetonide, 
and the same generation dendron, but with hydrazine functionalization at the focal 
point and Cy5 decorated in the periphery is named hydrazine-succinic-TEG-G3-Cy5. 
MALDI-TOF 
MALDI-TOF spectra were obtained using an UltraFlex MALDI-TOF with SCOUT-MTP Ion 
Source (Bruker Daltonics, Bremen, Germany) equipped with a nitrogen laser (337 nm), 
a gridless ion source and a reflector. The instrument was calibrated using SpheriCal™ 
calibrants. Samples were prepared by mixing 5 µL of 1 mg/mL analyte in EtOAc or MeOH 
with 5 µL of a 1 mg/mL counter-ion solution of sodium trifluoroacetate (NaTFA) in 
tetrahydrofuran (THF) and 20 µL of a matrix solution of 10 mg/mL in THF and applying 1 
µL this mixture to a stainless steel sample plate using the dried droplet method. The 
matrix used depended on the sample polarity and was either trans-2-[3-(4-tert-
butylphenyl)-2-methyl-2-propenylidene]-malononitrile (DCTB) or 2,5-dihydroxybenzoic 
acid (DHB). The obtained spectra were analyzed with FlexAnaysis version 2.2 from 
Bruker Daltonics. 
1H- and 13C-NMR 
1H-NMR (400 MHz) and 13C-NMR (101 MHz) were acquired using a Bruker Avance 
instrument (Bruker Biospin, Rheinstetten, Germany). The spectra were processed and 
analyzed with Mestre Nova version 9.0.0-12821 from Mestrelab Research (Santiago de 
Compostela, Spain). 
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3.2.1. Synthesis of fluorescent dendrons 
Diboc-hydrazine. Boc2O (8.046 g, 36.9 mmol, 2.5 eq.) was dissolved in 5 mL of 
dichloromethane (DCM) in an ice bath and 2-hydroxyethylhydrazine (1.123 g (1 mL), 
14.76 mmol, 1 eq.) was added dropwise. The mixture was left to reach room 
temperature and stirred overnight. After elimination of the solvent by rotoevaporation, 
the crude was purified by silica chromatography using heptane/EtOAc mixtures to afford 
the product (4.078 g, 9.51 mmol, 65%) as a white solid. 1H-NMR (400 MHz, CDCl3)  
(ppm) 6.67 (1H, s), 3.63 (s, 2H, CH2OH b), 3.53 (s, 2H, NCH2CH2 a), 1.46-1.40 (broad s, 
18H, 6xCH3 Boc). 13C-NMR (100 MHz, CDCl3)  (ppm) 157.2, 155.4, 82.1, 81.7, 59.5, 54.0, 
52.8, 28.2. 
TEG-Bz, (Dend1). Synthesized as previously reported.[151] 
Succinic-TEG-Bz, (Dend2). Monobenzylated tetraethylene glycol (TEG-Bz) (300 mg, 1.06 
mmol, 1eq.), pyridine (62.9 mg (64 L), 0,795 mmol, 0.75 eq.) and 4-
(Dimethylamino)pyridine (DMAP) (25.9 mg, 0.212 mmol, 0.2 eq.) were dissolved in 10 
mL of DCM in an ice bath and succinic anhydride (127.5 mg, 1.27 mmol, 1.2 eq.) was 
added slowly. The mixture was left to reach room temperature and stirred overnight. 
Once there was no Bz-TEG left (1H-NMR evidence), water was added for quenching of 
remaining succinic anhydride (1H-NMR evidence) and the reaction was washed with 
NaHSO4 10% and deionized water, dried over MgSO4, filtered and rotoevaporated to 
afford the product (328 mg, 0.853 mmol, 81%) as a colorless syrup. 1H-NMR (400 MHz, 
CDCl3)  (ppm) 7.35-7.32 (m, 5H, C6H5-CH2 Ar), 4.57 (s, 2H, C6H5-CH2 m), 4.28-4.26 (m, 
2H, CH2OCO e), 3.73-3.59 (m, 14H, OCH2CH2OCO f + 2xOCH2CH2O g,h,i,j + C6H5-
CH2OCH2CH2O k + C6H5-CH2OCH2 l), 2.68-2.58 (m, 4H, OCOCH2CH2COOH c+d). 13C-NMR 
(100 MHz, CDCl3)  (ppm) 175.7, 172.1, 138.1, 128.2, 127.7, 127.5, 73.1, 72.4, 70.5, 70.4, 
70.2, 69.3, 68.9, 63.7, 61.4, 29.0, 28.8. MALDI: m/z calc. 384.18 Da. Found [M + Na]+ 
406.04 Da. 
HO
O
O
O
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Diboc-hydrazine-succinic-TEG-Bz, (Dend3). Succinic-TEG-Bz (2) (248 mg, 0.646 mmol, 
1.5 eq.) was dissolved in EtOAc to a 1M concentration and CDI (104.65 mg, 0.646 mmol, 
1.5 eq.) was added and stirred at 50˚C about 1 hour. Once imidazolide-activated acid 
formation finished (1H-NMR evidence), diboc-hydrazine (135 mg, 0.50 mmol, 1 eq.) and 
catalytic amount of CsF were added and left to react overnight. Water was added to 
quench activated acid (1H-NMR evidence) and then, the reaction mixture was washed 
with NaHSO4 10% and NaHCO3 10%, dried over MgSO4, filtered and rotoevaporated to 
afford the product (313 mg, 0.487 mmol, 97%) as a colorless syrup. 1H-NMR (400 MHz, 
CDCl3)  (ppm) 7.35-7.32 (m, 5H, C6H5-CH2 Ar), 6.62 (s, H, NH-Boc), 4.56 (s, 2H, C6H5-CH2 
m), 4.30-4.21 (m, 4H, 2xCH2OCO b+e), 3.70-3.60 (m, 16H, NCH2CH2 a + OCH2CH2OCO f + 
2xOCH2CH2O g,h,i,j + C6H5-CH2OCH2CH2O k + C6H5-CH2OCH2 l), 2.68-2.58 (m, 4H, 
OCOCH2CH2COOCH2 c+d), 1.50-1.42 (broad s, 18H, 6xCH3 Boc). MALDI: m/z calc. 642.34 
Da. Found [M + Na]+ 668.17 Da. 
Diboc-hydrazine-succinic-TEG-OH, (Dend4). In a round bottom flask, Diboc-hydrazine-
succinic-TEG-Bz (3) (313 mg, 0.487 mmol, 1 eq.) was dissolved in a mixture of 20 mL of 
DCM and 2 mL of MeOH and palladium on carbon (10 wt % loaded, 15.7 mg, 5 wt %) was 
suspended in the mixture. The flask was evacuated and hydrogen gas was introduced. 
The reaction was carried out for one hour under heavy stirring (complete deprotection 
confirmed with MALDI), the palladium on carbon was filtered off and the solvent was 
rotoevaporated, affording the product (209 mg, 0.378 mmol, 76%) as a colorless syrup. 
1H-NMR (400 MHz, CDCl3)  (ppm) 6.67 (s, H, NH-Boc), 4.23-4.17 (m, 4H, 2xCH2OCO b+e), 
3.68-3.58 (m, 16H, NCH2CH2 a + OCH2CH2OCO f + 2xOCH2CH2O g,h,i,j + HOCH2CH2O k), 
3.57-3.52 (m, 2H, CH2OH  l), 2.62-2.54 (m, 4H, OCOCH2CH2COOCH2 c+d), 1.44-1.32 
(broad s, 18H, 6xCH3 Boc). 13C-NMR (100 MHz, CDCl3)  (ppm) 172.3, 155.0, 81.2, 72.6, 
70.6, 70.3, 69.0, 63.9, 61.5, 48.2, 29.1, 28.2. MALDI: m/z calc. 552.29 Da. Found [M + 
Na]+ 576.18 Da. 
Diboc-hydrazine-succinic-TEG-G0-Alkyne, (Dend5). 4-pentinoic acid (22.9 mg, 0.233 
mmol, 1.5 eq.) was dissolved in EtOAc to a 1M concentration and CDI (37.7 mg, 0.233 
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mmol, 1.5 eq.) was added and stirred at 50˚C about 1 hour. Once imidazolide-activated 
acid formation finished (1H-NMR evidence), Diboc-hydrazine-succinic-TEG-OH (Dend4) 
(85.65 mg, 0.155 mmol, 1 eq.) and catalytic amount of CsF were added and left to react 
overnight. Water was added to quench activated acid (1H-NMR evidence) and then, the 
reaction mixture was washed with NaHSO4 10% and NaHCO3 10%, dried over MgSO4, 
filtered and rotoevaporated to afford the product (93 mg, 0.147 mmol, 95%) as a 
colorless syrup. 1H-NMR (400 MHz, CDCl3)  (ppm) 6.64 (s, 1H, NH-Boc), 4.26-4.18 (m, 
6H, 3xCH2OCO b+e+l), 3.70-3.60 (m, 14H, NCH2CH2 a + OCH2CH2OCO f + 2xOCH2CH2O 
g,h,i,j + COOCH2CH2O k), 2.65-2.57 (m, 4H, OCOCH2CH2COOCH2 c+d), 2.56-2.52 (m, 2H, 
CHCCH2CH2COO n), 2.50-2.44 (m, 2H, CHCCH2 o), 1.95 (t  J=2.6Hz, 1H, CCH q), 1.47-1.37 
(broad s, 18H, 6xCH3 Boc). 13C-NMR (100 MHz, CDCl3)  (ppm) 172.4, 171.8, 155.0, 82.5, 
81.3, 70.7, 69.2, 69.1, 63.9, 61.6, 48.3, 33.3, 29.1, 28.1, 14.4. MALDI: m/z calc. 632.32 
Da. Found [M + Na]+ 658.14 Da. 
Diboc-hydrazine-succinic-TEG-G0-Cy5, (Dend6). 
Procedure 1; Alkyne-TEG-succinic-diboc-hydrazine (Dend5) (16 mg, 0.0253 mmol, 1 eq.) 
and sulfo-Cy5-azide (Lumiprobe) (20.77 mg, 0.0278 mmol, 1.1 eq.) were dissolved in 100 
L THF/H2O 1:1 and Na ascorbate (1.614 mg, 0.01012 mmol, 0,4 eq.) and CuSO4 (1.002 
mg, 0.00506 mmol, 0.2 eq.) were added. The mixture is left to react overnight at 50° 
protected from light. Once there was no alkyne left (MALDI evidence), solvents were 
eliminated and the product Dend10 was isolated by preparative TLC using EtOAc:MeOH 
1:1 (35 mg, 0.0253 mmol, quantitative yield) as a brilliant blue solid.  
Procedure 2; Alkyne-TEG-succinic-diboc-hydrazine (Dend5) (10 mg, 0.0158 mmol, 1 eq.) 
and sulfo-Cy5-azide (Lumiprobe) (14.16 mg, 0.0190 mmol, 1.2 eq.) were dissolved in 500 
L DMSO and PMDTA (5.48 mg (6.6 L), 0.0316 mmol, 2 eq.) was added. Immediately, 
after three cycles of freeze/pump thaw, CuBr (4.53 mg, 0.0316 mmol, 2 eq.) was added 
and the mixture was left to react overnight under Ar atmosphere at room temperature. 
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The product Dend10 was isolated by preparative TLC using EtOAc:MeOH 1:1 (38 mg, 
0.0275 mmol, quantitative yield) as a brilliant blue solid. 
1H-NMR (400 MHz, MeOD)  (ppm) 8.38-8.28 (t J= 11.7 Hz, 2H, CHCHCHCHCH 16+18) 
7.93-7.88 (m, 3H, Ar), 7.84 (s, 1H, C=CHN p), 7.36 (dd J1= 8.6Hz, J2= 2.4 Hz, 2H, Ar), 6.68 
(t J= 12.5 Hz, 2H, CHCHCHCHCH 17), 6.35 (dd J1=13.6, J2=5.7 Hz, 2H, CHCHCHCHCH 
19+15), 4.42-4.36 (t J=6.8 Hz, 2H, CH2NN 1), 4.28-4.12 (m, 8H, 3xCH2OCO b+e+l + CH2N+ 
9), 3.72-3.62 (m, 17H, N-CH3 20 + NCH2CH2 a + OCH2CH2OCO f + 2xOCH2CH2O g,h,i,j + 
COOCH2CH2O k), 3.17-3.11 (m, 2H, CH2NHCO 3), 3.02 (t J=7.3 Hz, 2H, CH2C=CN o), 2.75 
(t J=7.3 Hz , 2H, CH2CH2NN 2), 2.68-2.62 (m, 6H, OCOCH2CH2COOCH2 c+d, NCCH2CH2COO 
n), 2.26-2.12 (m, 2H, CH2CONH 5), 1.79-1.75 (m, 18H, N+CH2(CH2)3CH2CONH 6,7,8 + 
4xCH3 13+13´+14+14´), 1.50-1.40 (broad s, 18H, 6xCH3 Boc). MALDI: m/z calc. 1378.57 
Da. Found [M]+ 1378.520 Da; [M–Na+H]+ 1356.550 Da. 
G0-Cy5. Boc protected G0-Cy5 was dissolved in TFA/DCM (1:1) and left to react for 2h 
at room temperature. TFA was eliminated by rotoevaporation to afford deprotected 
product (see Figure S4 for 1H-NMR evidence) as TFA salt as a blue solid. 1H-NMR (400 
MHz, MeOD)  (ppm) 8.38-8.28 (t J= 11.7 Hz, 2H, CHCHCHCHCH 16+18) 7.93-7.88 (m, 
3H, Ar), 7.85 (s, 1H, C=CHN p), 7.36 (dd J1= 8.6Hz, J2= 2.4 Hz, 2H, Ar), 6.68 (t J= 12.5 Hz, 
2H, CHCHCHCHCH 17), 6.35 (dd J1=13.6, J2=5.7 Hz, 2H, CHCHCHCHCH 19+15), 4.42-4.36 
(t J=6.8 Hz, 2H, CH2NN 1), 4.28-4.12 (m, 8H, 3xCH2OCO b+e+l + CH2N+ 9), 3.72-3.62 (m, 
17H, N-CH3 20 + NCH2CH2 a + OCH2CH2OCO f + 2xOCH2CH2O g,h,i,j + COOCH2CH2O k), 
3.17-3.11 (m, 2H, CH2NHCO 3), 3.02 (t J=7.3 Hz, 2H, CH2C=CN o), 2.75 (t J=7.3 Hz , 2H, 
CH2CH2NN 2), 2.68-2.62 (m, 6H, OCOCH2CH2COOCH2 c+d, NCCH2CH2COO n), 2.26-2.12 
(m, 2H, CH2CONH 5), 1.79-1.75 (m, 18H, N+CH2(CH2)3CH2CONH 6,7,8 + 4xCH3 
13+13´+14+14´). MALDI: m/z calc. 1178.46 Da. Found [M]+ 1178.626 Da; [M–Na+H]+ 
1156.595. 
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Diboc-hydrazine-succinic-TEG-G1-Acetonide, (Dend7). Acetonide protected bis-MPA 
(52.74 mg, 0.303 mmol, 1.5 eq.) was dissolved in EtOAc to a 1M concentration and CDI 
(49.1 mg, 0.303 mmol, 1.5 eq.) was added and stirred at 50˚C about 1 hour. Once 
imidazolide-activated acid formation finished (1H-NMR evidence), Diboc-hydrazine-
succinic-TEG-OH (Dend4) (111.63 mg, 0.202 mmol, 1 eq.) and catalytic amount of CsF 
were added and left to react overnight. Water was added to quench activated acid (1H-
NMR evidence) and then, the reaction mixture was washed with NaHSO4 10% and 
NaHCO3 10%, dried over MgSO4, filtered and rotoevaporated to afford the product (111 
mg, 0.157 mmol, 78%) as a colorless syrup. 1H-NMR (400 MHz, CDCl3) d (ppm) 4.35-4.25 
(m, 6H, 3xCH2OCO b+e+l), 4.22 (d J= 11.8 Hz, 2xCHH´O s1+t1), 3.75-3.59 (m, 16H, 
NCH2CH2 a + OCH2CH2OCO f + 2xOCH2CH2O g,h,i,j + COOCH2CH2O k + 2xCHH´O s2+t2), 
2.69-2.59 (m, 4H, OCOCH2CH2COOCH2 c+d), 1.48-1.44 broad s, 18H, 2xBoc), 1.43 (s, 3H, 
OCCH3 u), 1.39 (s, 3H, OCCH3´ v), 1.22 (s, 3H, OCH2CCH3 r). 13C-NMR (100 MHz, CDCl3) d 
(ppm) 174.0, 172.2, 154.9, 97.9, 81.1, 72.4, 70.5, 70.4, 70.2, 68.9, 65.8, 63.8, 61.6, 61.4, 
48.1, 41.7, 28.9, 28.1, 24.1, 23.0, 18.6. MALDI: m/z calc. 708.37 Da. Found [M + Na]+ 
735.23 Da. 
Diboc-hydrazine-succinic-TEG-G1-OH, (Dend8). Diboc-hydrazine-succinic-TEG-G1-
Acetonide (7) (106 mg, 0.149 mmol, 1 eq.) was dissolved in 500 L of MeOH and DOWEX 
(26.5 mg, 25% wt) was added and stirred at room temperature for 2 hours. When 
complete deprotection was confirmed with MALDI, the solution was filtered off to 
remove DOWEX and the solvent was rotoevaporated, affording the product (100.5 mg, 
0.150 mmol, quantitative yield) as a colorless syrup. 1H-NMR (400 MHz, CDCl3)  (ppm) 
4.32-4.28 (m, 2H, CH2OCO(CH2)2COO e), 4.25-4.19 (m, 4H, CH2OCOCCH3 b + 
OCH2CH2OCOCCH3 l), 3.78 (d J= 11.3 Hz, 2H, 2xCHH´OH s1+t1), 3.72-2.52 (m, 16H, 
NCH2CH2 a + OCH2CH2OCO f + 2xOCH2CH2O g,h,i,j + COOCH2CH2O k + 2xCHH´OH s2+t2), 
2.65-2.55 (m, 4H, OCOCH2CH2COOCH2 c+d), 1.46-1.38 (broad s, 18H, 2xBoc), 1.07 (s, 3H, 
CH2CCH3 r). 13C-NMR (100 MHz, CDCl3)  (ppm) 175.7, 172.4, 155.1, 81.3, 72.6, 70.6, 
70.5, 70.4, 69.1, 68.8, 67.4, 63.9, 63.4, 61.7, 61.6, 49.8, 48.3, 29.1, 28.3, 17.2. MALDI: 
m/z calc. 668.34 Da. Found [M + Na]+ 694.19 Da. 
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Diboc-hydrazine-succinic-TEG-G1-Alkyne, (Dend9). 4-pentinoic acid (78.83 mg, 0.803 
mmol, 3.0 eq.) was dissolved in EtOAc to a 1M concentration and CDI (130.2 mg, 0.803 
mmol, 3.0 eq.) was added and stirred at 50˚C about 1 hour. Once imidazolide-activated 
acid formation finished (1H-NMR evidence), Diboc-hydrazine-succinic-TEG-G1-OH (180 
mg, 0.269 mmol, 1 eq.) and catalytic amount of CsF were added and left to react 
overnight. Water was added to quench activated acid (1H-NMR evidence) and then, the 
reaction mixture was washed with NaHSO4 10% and NaHCO3 10%, dried over MgSO4, 
filtered and rotoevaporated to afford the product (134 mg, 0.162 mmol, 60%) as a 
colorless syrup. 1H-NMR (400 MHz, CDCl3)  (ppm) 4.34-4.22 (m, 10H, 5xCH2OCO 
b+e+l+s+t), 3.74-3.62 (m, 14H, NCH2CH2 a + OCH2CH2OCO f + 2xOCH2CH2O g,h,i,j + 
COOCH2CH2O k), 2.68-2.60 (m, 4H, OCOCH2CH2COOCH2 c+d), 2.58-2.52 (m, 4H, 
2xCHCCH2CH2COO n), 2.52-2.46 (m, 4H, 2xCHCCH2 o), 1.98 (t J= 2.5Hz , 2H, 2xCCH q), 
1.50-1.42 (broad s, 18H, 2xBoc), 1.27 (s, 3H, CH2CCH3 r). 13C-NMR (100 MHz, CDCl3)  
(ppm) 172.4, 172.2, 171.6, 171.0, 157.9, 82.2, 81.0, 70.5, 70.4, 69.3, 69.1, 68.9, 68.7, 
65.3, 64.1, 63.7, 61.4, 49.4, 48.1, 46.2, 33.1, 28.9, 28.1, 17.7, 14.2. MALDI: m/z calc. 
828.39 Da. Found [M + Na]+ 855.28 Da. 
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Diboc-hydrazine-succinic-TEG-G1-Cy5, (Dend10). Diboc-hydrazine-succinic-TEG-G1-
Alkyne (9) (14 mg, 0.0170 mmol, 1 eq.) and sulfo-Cy5-azide (Lumiprobe) (26.9 mg, 
0.0360 mmol, 2.1 eq.) were dissolved in 500 L DMSO and PMDTA (11.74 mg (14.1 L), 
0.064 mmol, 4 eq.) was added. Immediately, after three cycles of freeze/pump thaw, 
CuBr (5.76 mg, 0.064 mmol, 4 eq.) was added and the mixture was left to react overnight 
under Ar atmosphere at room temperature. Presence of triazol ring was confirmed by 
1H-NMR (MeOD) of reaction crude. 1KDa dialysis membrane was used to get rid of sulfo-
Cy5-azide excess and DMSO, affording the product (35 mg, 0.0149 mmol, 88%) as a 
brilliant blue solid. 1H-NMR (400 MHz, MeOD)  (ppm) 8.38-8.28 (t J= 13.6 Hz, 4H, 
CHCHCHCHCH 16+18), 8.00-7.84 (m, 6H, Ar), 7.80 (s, 2H, C=CHN p), 7.40-7.30 (m, 4H, 
Ar), 6.67 (t J= 12.8 Hz, 4H, CHCHCHCHCH 17), 6.40-6.28 (m, 4H, CHCHCHCHCH 19+15), 
4.40-4.30 (m, 4H, CH2NN 1), 4.27-4.07 (m, 10H, 3xCH2OCO b+e+l + CH2N+ 9), 3.75-3.55 
(m, 17H, N-CH3 20 + NCH2CH2 a + OCH2CH2OCO f + 2xOCH2CH2O g,h,i,j + COOCH2CH2O 
k), 3.18-3.10 (m, 4H, CH2NHCO 3), 3.02-2.92 (m, 4H, CH2C=CN o), (CH2CH2NN 2), 
(OCOCH2CH2COOCH2 c+d, NCCH2CH2COO n), 2.25-2.15 (t J=6.8 Hz, 4H, CH2CONH 5), 
1.78-1.70 (m, 36H, N+CH2(CH2)3CH2CONH 6,7,8 + 4xCH3 13+13´+14+14´),  1.50-1.40 (m, 
18H, 6xCH3 Boc), 1.18 (s, 3H, CH3 bis-MPA r).  
G1-Cy5. Boc protected G1-Cy5 was dissolved in TFA/DCM (1:1) and left to react for 2h 
at room temperature. TFA was eliminated by rotoevaporation to afford deprotected 
product (see Figure S6 for 1H-NMR evidence) as TFA salt as a blue solid. 1H-NMR (400 
MHz, MeOD)  (ppm) 8.38-8.28 (t J= 13.6 Hz, 4H, CHCHCHCHCH 16+18), 8.00-7.84 (m, 
8H, Ar + C=CHN p), 7.40-7.30 (m, 4H, Ar), 6.67 (t J= 12.8 Hz, 4H, CHCHCHCHCH 17), 6.40-
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6.28 (m, 4H, CHCHCHCHCH 19+15), 4.40-4.30 (m, 4H, CH2NN 1), 4.27-4.07 (m, 10H, 
3xCH2OCO b+e+l + CH2N+ 9), 3.75-3.55 (m, 17H, N-CH3 20 + NCH2CH2 a + OCH2CH2OCO f 
+ 2xOCH2CH2O g,h,i,j + COOCH2CH2O k), 3.18-3.10 (m, 4H, CH2NHCO 3), 3.02-2.92 (m, 
4H, CH2C=CN o), (CH2CH2NN 2), (OCOCH2CH2COOCH2 c+d, NCCH2CH2COO n), 2.25-2.15 
(t J=6.8 Hz, 4H, CH2CONH 5), 1.78-1.70 (m, 36H, N+CH2(CH2)3CH2CONH 6,7,8 + 4xCH3 
13+13´+14+14´), 1.18 (s, 3H, CH3 bis-MPA r).  
Diboc-hydrazine-succinic. Diboc-hydrazine (2.543 g, 9.203 mmol, 1 eq.), pyridine 
(545,95 mg (556 L), 6.902 mmol, 0.75 eq) and 4-(Dimethylamino)pyridine (DMAP) (672 
mg, 5.523 mmol, 0.6 eq.) were dissolved in 70 mL of DCM in an ice bath and succinic 
anhydride (1.101 g, 11.044 mmol, 1.2 eq.) was added slowly. The mixture was left to 
reach room temperature and stirred until no diboc-hydrazine was left (TLC evidence). 
Then, water was added for quenching of remaining succinic anhydride (1H-NMR 
evidence) and the reaction was washed with NaHSO4 10% and Brine, dried over MgSO4, 
filtered and rotoevaporated to afford the product (3.179 g, 8.445 mmol, 92%) as a white 
solid. 1H-NMR (400 MHz, CDCl3)  (ppm) 4.21 (s, 2H, CH2OCO b), 3.66 (s, 2H, NCH2CH2 
a), 2.65-2.55 (m, 4H, OCOCH2CH2COOH c+d), 1.50-1.35 (broad s, 18H, 6xCH3 Boc). 13C-
NMR (100 MHz, CDCl3)  (ppm) 176.9, 176.6, 172.5, 155.4, 82.2, 81.5, 61.9, 61.6, 53.5, 
49.4, 48.1, 29.0, 28.2.  
Bz-TEG-G3-acetonide, (Dend11). Synthesized as previously reported [151]. 
H
N
N
O
Boc
Boc O
O
OH
O O O O O
O O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
Experimental
245 
HO-TEG-G3-acetonide, (Dend12). Bz-TEG-G3-acetonide (11) (253 mg, 0.201 mmol, 
1eq.), was dissolved in 20 mL of EtOAc, palladium on carbon (10 wt % loaded, 25 mg, 10 
wt %) was suspended and 3 mL of DCM added. The flask was evacuated and hydrogen 
gas was introduced. The reaction was carried out for 35 minutes under heavy stirring 
(complete deprotection confirmed with MALDI), the palladium on carbon was filtered 
off and the solvent was rotoevaporated, affording the product (225 mg, 0.192 mmol, 
96%) as a colorless syrup. 1H-NMR (400 MHz, CDCl3)  (ppm) 4.33-4.25 (m, 14H, 
OCH2CH2OCO l, 6xCH2O (G1+G2) s+t+2xs´+2xt´), 4.18-4.11 (d J=12Hz, 8H, 2x(4xCHH´O) 
(G3) 4xs1” + 4xt1”), 3.74-3.18 (m, 22H, CH2OH e + OCH2CH2OH f + 2xOCH2CH2O g,h,i,j + 
OCH2CH2OCO k + 2x(4xCHH´O) (G3) 4xs2” + 4xt2”), 1.41 (s, 12H, 4xOCCH3 u”), 1.35 (s, 
12H, 4xOCCH3 v”), 1.28 (s, 9H, 3xCOCCH3 (G1+G2) r+2xr2), 1.15 (s, 12H, 4xCOCCH3 (G3) 
r3). 13C-NMR (100 MHz, CDCl3)  (ppm) 173.6, 172.2, 172.0, 98.2, 72.6, 70.7, 70.6, 70.5, 
70.4, 68.9, 66.1, 66.0, 65.0, 64.5, 61.8, 47.0, 46.7, 42.1, 25.3, 22.2, 18.6, 17.8, 17.7. 
MALDI: m/z calc. 1166.57 Da. Found [M + Na]+ 1194.88 Da. 
Diboc-hydrazine-succinic-TEG-G3-acetonide, (Dend13). Diboc-hydrazine-succinic 
(114.15 mg, 0.303 mmol, 1.5 eq.) was dissolved in EtOAc to a 1M concentration and CDI 
(49.1 mg, 0.303 mmol, 1.5 eq.) was added and stirred at 50˚C about 1 hour. Once 
imidazolide-activated acid formation finished (1H-NMR evidence), OH-TEG-G3-
acetonide (Dend12) (236 mg, 0.202 mmol, 1 eq.) and catalytic amount of CsF were 
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added and left to react overnight. Water was added to quench activated acid (1H-NMR 
evidence) and then, the reaction mixture was washed with NaHSO4 10% and NaHCO3 
10%, dried over MgSO4, filtered and rotoevaporated to afford the product (300 mg, 
0.197 mmol, 97%) as a colorless syrup. 1H-NMR (400 MHz, CDCl3)  (ppm) 6.65 (s, 1H, 
NH), 4.36-4.23 (m, 18H, 3xCH2OCO b+e+l + 6xCH2O (G1+G2) s+t+2xs´+2xt´), 4.18-4.12 (d 
J=12Hz, 8H, 2x(4xCHH´O) (G3) 4xs1” + 4xt1”), 3.74-3.58 (m, 22H, NCH2CH2 a + 
OCH2CH2OCO f + 2xOCH2CH2O g,h,i,j + OCH2CH2OCO k + 2x(4xCHH´O) (G3) 4xs2” + 4xt2”), 
2.70-2.60 (m, 4H, OCOCH2CH2COOH c+d), 1.50-1.44 (broad s, 18H, 2xBoc), 1.37 (s, 12H, 
4xOCCH3 u”), 1.31 (s, 12H, 4xOCCH3 v”), 1.26 (s, 9H, 3xCOCCH3 (G1+G2) r+2xr2), 1.15 (s, 
12H, 4xCOCCH3 (G3) r3). 13C-NMR (100 MHz, CDCl3)  (ppm) 173.6, 172.4, 172.2, 172.0, 
98.2, 70.7, 70.7, 70.6, 70.5, 69.2, 68.9, 66.1, 66.0, 65.9, 65.0, 64.5, 64.0, 61.7, 47.0, 46.7, 
12.2, 29.1, 28.3, 25.3, 22.2, 18.6, 17.8, 17.7. MALDI: m/z calc. 1556.81 Da. Found [M + 
Na]+ 1548.97 Da. 
Diboc-hydrazine-succinic-TEG-G3-OH, (Dend14). Diboc-hydrazine-succinic-TEG-G3-
acetonide (13) (60 mg, 0.039 mmol, 1 eq.) was dissolved in 15 mL of MeOH and DOWEX 
(15mg, 25% wt) was added and stirred at room temperature and after 2 hours, DOWEX 
was filtered off and an aliquot was assayed by MALDI (x6). When complete deprotection 
was confirmed with MALDI, the solution was filtered off to remove DOWEX and the 
solvent was rotoevaporated, affording the product (41 mg, 0.030 mmol, 77%) as a 
yellowish syrup. 1H-NMR (400 MHz, CDCl3)  (ppm) 6.65 (s, 1H, NH), 4.37-4.18 (m, 18H, 
3xCH2OCO b+e+l + 6xCH2O (G1+G2) s+t+s´+t´), 3.79-3.54 (m, 30H, NCH2CH2 a + 
OCH2CH2OCO f + 2xOCH2CH2O g,h,i,j + OCH2CH2OCO k + 8xCH2OH 4xs” + 4xt”) 2.68-2.56 
(m, 4H, OCOCH2CH2COOH c+d), 1.50-1.40 (broad s, 18H, 2xBoc), 1.25 (s, 9H, 3xCOCCH3 
(G1+G2) r+2xr2), 1.07 (s, 12H, 4xCOCCH3 (G3) r3). MALDI: m/z calc. 1366.98 Da. Found 
[M + Na]+ 1393.61 Da. 
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Diboc-hydrazine-succinic-TEG-G3-Alkyne, (Dend15). 4-pentinoic acid (35.32 mg, 0.36 
mmol, 12.0 eq.) was dissolved in EtOAc to a 1M concentration and CDI (58.32 mg, 0.36 
mmol, 12.0 eq.) was added and stirred at 50˚C about 1 hour. Once imidazolide-activated 
acid formation finished (1H-NMR evidence), diboc-hydrazine-succinic-TEG-G3-OH 
(Dend14) (41 mg, 0.030 mmol, 1 eq.) and catalytic amount of CsF were added and left 
to react overnight. Water was added to quench activated acid (1H-NMR evidence) and 
then, the reaction mixture was washed with NaHSO4 10% and NaHCO3 10%, dried over 
MgSO4, filtered and rotoevaporated to afford the product (30 mg, 0.015 mmol, 50%) as 
a brownish syrup. 1H-NMR (400 MHz, CDCl3)  (ppm) 6.59 (s, 1H, NH), 4.37-4.10 (m, 34H, 
3xCH2OCO b+e+l + 14xCH2O (G1+G2+G3) s+t+2xs´+2xt´+4xs”+4xt”), 3.80-3.50 (m, 14H, 
NCH2CH2 a + OCH2CH2OCO f + 2xOCH2CH2O g,h,i,j + OCH2CH2OCO k), 2.66-2.58 (m, 4H, 
OCOCH2CH2COOH c+d), 2.58-2.51 (m, 16H, 8xCHCCH2CH2COO n), 2.50-2.43 (m, 16H, 
8xCHCCH2 o), 2.00 (t J= 2.5Hz, 8H, 8xCCH q), 1.52-1.36 (broad s, 18H, 2xBoc), 1.24 (s, 
21H, 7xCOCCH3 (G1+G2+G3) r+2xr2+4xr3). 13C-NMR (100 MHz, CDCl3)  (ppm) 172.4, 
172.0, 171.5, 171.2, 82.4, 70.7, 70.6, 70.6, 70.5, 69.4, 69.1, 68.9, 66.2, 65.4, 64.5, 46.8, 
46.7, 46.5, 33.2, 29.8, 29.1, 28.3, 17.9, 17.7, 14.4. MALDI: m/z calc. 2004.89 Da. Found 
[M + Na]+ 2036.10 Da. 
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Diboc-hydrazine-succinic-TEG-G3-Cy5, (Dend16). Diboc-hydrazine-succinic-TEG-G3-
Alkyne (15) (7 mg, 0.00349 mmol, 1 eq.) was dissolved in 150 L THF and sulfo-Cy5-azide 
(Lumiprobe) (25 mg, 0.0335 mmol, 9.6 eq.) in 150 L H2O and Na ascorbate (2.67 mg, 
0.0167 mmol, 4,8 eq.) and CuSO4 (1.659 mg, 0.00837 mmol, 2.4 eq.) were added. Some 
drops of DMF were added as well to solubilize better the reagents. The mixture is left to 
react for two nights at 50° protected from light. The solvents were eliminated and the 
crude dissolved in 500 µL H2O and purified by sephadex using PD Minitrap G-25 columns 
(GE Healthcare) to afford after freeze-drying the product (16 mg, 0.002 mmol, 57%) as 
a brilliant blue solid. 1H-NMR (400 MHz, MeOD)  (ppm) 8.37-8.19 (m, 16H, 
CHCHCHCHCH 16+18), 7.99 (s, 8H, C=CHN p), 7.91-7.81 (m, 24H, Ar), 7.37-7.28 (m, 16H, 
Ar), 6.68 (t J= 12.4 Hz, 16H, CHCHCHCHCH 17), 6.85-6.25 (m, 16H, CHCHCHCHCH 19+15), 
4.42-4.27 (m, 16H, CH2NN 1), 4.27-4.00 (m, 10H, 3xCH2OCO b+e+l, 14xCH2O (G1+G2+G3) 
s+t+2xs´+2xt´+4xs”+4xt, CH2N+ 9), 3.68-3.52 (m, 38H, N-CH3 20 + NCH2CH2 a + 
OCH2CH2OCO f + 2xOCH2CH2O g,h,i,j + COOCH2CH2O k), 3.25-3.17 (m, 16H, CH2NHCO 3), 
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3.16-3.05 (m, 16H, CH2C=CN o), 2.70 (m, 16H, CH2CH2NN 2), 2.64-2.54 (m, 20H, 
OCOCH2CH2COOCH2 c+d, NCCH2CH2COO n), 2.25-2.10 (m J=6.8 Hz, 16H, CH2CONH 5), 
1.91-1.57 (m, 36H, N+CH2(CH2)3CH2CONH 6,7,8 + 4xCH3 13+13´+14+14´),  1.48-1.38 
(broad s, 18H, 6xCH3 Boc), 1.29 (s, 21H, 7xCH3 bis-MPA (G1+G2+G3) r, r2, r3)  
G3-Cy5. Boc protected G3-Cy5 was dissolved in pure TFA and left to react for 20 min at 
room temperature. The acid was eliminated by rotoevaporation to afford the 
deprotected product (see Figure S9 for 1H-NMR evidence) as TFA salt as a blue solid. 1H-
NMR (400 MHz, MeOD)  (ppm) 8.37-8.19 (m, 16H, CHCHCHCHCH 16+18), 7.91-7.81 (m, 
24H, Ar), 7.80 (s, 8H, C=CHN p), 7.37-7.28 (m, 16H, Ar), 6.68 (t J= 12.4 Hz, 16H, 
CHCHCHCHCH 17), 6.85-6.25 (m, 16H, CHCHCHCHCH 19+15), 4.42-4.27 (m, 16H, CH2NN 
1), 4.27-4.00 (m, 10H, 3xCH2OCO b+e+l, 14xCH2O (G1+G2+G3) s+t+2xs´+2xt´+4xs”+4xt, 
CH2N+ 9), 3.68-3.52 (m, 38H, N-CH3 20 + NCH2CH2 a + OCH2CH2OCO f + 2xOCH2CH2O 
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g,h,i,j + COOCH2CH2O k), 3.25-3.17 (m, 16H, CH2NHCO 3), 3.16-3.05 (m, 16H, CH2C=CN 
o), 2.70 (m, 16H, CH2CH2NN 2), 2.64-2.54 (m, 20H, OCOCH2CH2COOCH2 c+d, 
NCCH2CH2COO n), 2.25-2.10 (m J=6.8 Hz, 16H, CH2CONH 5), 1.91-1.57 (m, 36H, 
N+CH2(CH2)3CH2CONH 6,7,8 + 4xCH3 13+13´+14+14´), 1.29 (s, 21H, 7xCH3 bis-MPA 
(G1+G2+G3) r, r2, r3). 
3.2.2. IgG labeling with Cy5 decorated dendrons 
The protocol used for IgG labeling was the one registered in Bioconjugate techniques  
[160]. The two steps necessary are described in the two following points. 
Activation of antibodies with sodium periodate (NaIO3) 
IgG chosen for labeling procedure optimization was α-Human IgG Fc clone SG-11 (ICN 
Biomedicals Inc). Protein main concentration was determined by Bradford. 
IgG (20 mg/mL, 4 mg, 1 eq., 2.67.10-5 mol) was dissolved at a concentration of 10 mg/mL 
in 0.01 M Na3PO4, 0.15 M NaCl, pH 7.2 and 40 µL (100 µL per mL of IgG) of freshly 
prepared 0.1 M NaIO3 were added. After homogenization, the mixture was left to react 
in the dark for 20 min in a swinging tray. Then, 1 mg of Na2SO3 was added to quench 
remaining NaIO3 and left to react in the dark for 30 min in a swinging tray. Meanwhile, 
a PD MiniTrap G-25 sephadex desalting column (GE Healthcare) was equilibrated with 
8 mL of chromatography buffer (Na3PO4 0.1M, NaCl 0.15 M, pH 7.2).  
After quenching, the reaction mixture was completed to 500 µL with chromatography 
buffer (Na3PO4 0.1M, NaCl 0.15 M, pH 7.2) and introduced in the desalting column once 
the buffer used for equilibration entered the packed bed completely. The 500 µL that 
come out of the column after adding sample volume were discarded and then, 1 mL of 
chromatography buffer was added and the flow through collected. After removing NaIO3 
excess by desalting step, IgG concentration was 4 mg/mL.  
Amicon ultra 0.5 mL 30K centrifugal filters (Merck Millipore) were used to reduce 
volume to 400 µL for having a final antibody concentration of 10 mg/mL. The oxidized 
antibody was used immediately. 
Conjugation of periodate-oxidized antibodies with Cy5 decorated dendrons 
This is the general procedure for labeling, used for the conjugation of each of three 
dendrons. Two to ten milligrams of the hydrazine containing molecule were weighted 
and dissolved in the amount of milliQ water necessary so that in 25 µL we have the 
amount corresponding to a 15-fold molar excess (4.24·10-4 mol) over the amount of 
antibody present. The fluorescent probe solution was added to the 400 µL of oxidized 
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antibody in chromatography buffer and left to react in the dark for 2 hours in a swinging 
tray.  
All following steps were carried out in a fume hood. In order to stabilize the hydrazine 
bond formed, 4 µL of 5 M NaBH3CN in 1M NaOH (10 µL per mL of conjugation solution) 
were added and left to react for 30 minutes in the dark in a swinging tray. Unreacted 
aldehyde sites were blocked by addition of 20 µL of ethanolamine 1M pH 9.6 (50 µL per 
mL of conjugation solution), 30 min reaction in the dark. Purification from excess of 
reactants was made in case of IgG-G0-Cy5 and IgG-G1-Cy5 by gel filtration, using a PD 
MiniTrap G-25 sephadex desalting column (GE Healthcare) as described in purification 
step after oxidation, using this time 0.01 M Na3PO4, 0.15 M NaCl, pH 7.0 as 
chromatography buffer (chromatography buffer after labeling). Amicon ultra 0.5 mL 
30K centrifugal filters (Merck Millipore) was used for IgG-G3-Cy5 purification. 
In order to make sure that no excess of the fluorescent probe was still remaining, we 
further filtrated the conjugated antibody with Amicon ultra 4 mL 30K centrifugal filters 
(Merck Millipore) and washed it with milliQ water as many times as necessary to get a 
crystal clear filtrate.  
After filtration, we completed each labeled IgG volume up to a 1 mL with 0.01 M Na3PO4, 
0.15 M NaCl, pH 7.0 (chromatography buffer after labeling) and considered complete 
recovery after all labeling and purification steps. 
3.2.3. SDS-PAGE characterization of Cy5 labeled IgG 
After conjugation, control IgG and Cy5 labeled IgG samples were denaturalized by 
adding Laemmli buffer and heating at 96˚C for 5 minutes. Eppendorf tubes containing 
denaturalized samples were centrifuged for some seconds (were given a short spin) and 
quickly cool down in ice bath to avoid renaturalization. Four decreasing amounts of 
control IgG (4, 2, 1, 0.5 µg), 4 µg of each of three IgG-Cy5 samples and a molecular weight 
marker (Precision Plus Protein Standards Dual color, Bio-Rad) were loaded in 12% SDS-
polyacrilamide gel and electrophoresis system was connected to a power supply with a 
80 V current until samples pass through stacking gel and 120 V since samples reached 
running gel.  
Once electrophoresis finished, gels were analyzed with Molecular Imager Pharos FX and, 
after fluorescence registration, stained with Coomassie and digitalized with ChemiDoc 
Imaging Systems (Bio-Rad). 
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3.2.4. Spectroscopic Characterization of Dendrons and Labeled IgG 
Boc-deprotected dendrons G0-Cy5, G1-Cy5 and G3-Cy5 were dissolved in in 0.01 M 
Na3PO4, 0.15 M NaCl, pH 7.0 (chromatography buffer after labeling) at 3.8·10-7 M and 
solutions of control IgG and labeled IgG (IgG-G0-Cy5, IgG-G1-Cy5 and IgG-G3-Cy5) were 
prepared using the same solvent at 10-6 M. Absorbance was measured in an Agilent 8453 
UV-Visible Spectroscopy System and fluorescence in an Edinburgh Instruments FLS 920 
fluorimeter. Data were processed with GraphPad Prism 5.01 (GraphPad Software, Inc., 
California). 
For cited solvent, knowing the solutions concentration we calculated the molar 
extinction coefficient, ε, from absorbance obtained at absorption maximum wavelength 
(646 nm) by using Lambert Beer Law (A= ε·b·c). Qantum yield (φ) was calculated as 
described in [280] using sulfo-Cy5 as standard dye, and relative brightness (ε·φ) [254] 
was also calculated. The quenching-dequenching characteristics of IgG-G3-Cy5 were 
studied by adding to the conjugates 1% SDS to disassociate any molecular interaction 
between fluorophores. 
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INTRODUCCIÓN 
Según la Organización Mundial de la Salud (OMS), las reacciones adversas a fármacos se 
definen como “todas aquellas respuestas nocivas y no intencionadas, o cualquier otro 
efecto perjudicial no deseado que ocurre tras la administración de una dosis 
habitualmente utilizada del fármaco en la especie humana para la profilaxis, diagnóstico 
y tratamiento de una enfermedad o para la modificación de una función biológica”. Las 
reacciones de hipersensibilidad a fármacos pertenecen al grupo B de las reacciones 
alérgicas a fármacos y se definen como los efectos adversos de las formulaciones 
farmacéuticas (incluyendo el principio activo y los excipientes) que clínicamente 
recuerdan una alergia. En función del mecanismo implicado se clasifican en dos grupos. 
Las reacciones alérgicas están mediadas por mecanismos inmunológicos específicos y 
las no alérgicas por mecanismos no inmunológicos (Figura R.1). Las reacciones alérgicas 
representan entre el 5-10% de las reacciones tipo B. 
A su vez las reacciones alérgicas a antibióticos betalactámicos pueden clasificarse en 
función del mecanismo inmunológico implicado (Gell y Coombs) o del tiempo 
transcurrido desde la toma del fármaco hasta que aparece la reacción.  
Las reacciones inmediatas a antibióticos betalactámicos, mediadas por anticuerpos IgE, 
constituyen el objeto de estudio de esta tesis doctoral.  
Todas las reacciones adversas a fármacos con base inmunológica requieren un período 
de previo sensibilización tras la primera exposición al antígeno, en el que se producen 
anticuerpos IgE específicos implicados en el desarrollo de una respuesta alérgica 
después de una nueva exposición a dicho antígeno (Figura R.2).  
El modelo actual más aceptado por la comunidad científica para explicar el modo en el 
que el sistema inmune reconoce a los fármacos está basado en la hipótesis del hapteno 
formulada por Landsteiner en 1935 (Figura R.3). Un hapteno es una especie de bajo peso 
molecular (< 1000 Da), químicamente reactiva y demasiado pequeña para inducir una 
respuesta inmunológica por sí misma, pero que sí alcanza el tamaño suficiente para 
inducirla cuando se une covalentemente a macromoléculas, proceso que se denomina 
haptenización.  
Según esta hipótesis, después de la unión covalente del hapteno a una macromolécula, 
el conjugado hapteno-molécula portadora puede ser procesado y presentado por las 
células presentadoras de antígenos a los linfocitos para la producción de anticuerpos 
específicos que pueden reaccionar contra el determinante antigénico, formado por el 
hapteno y posiblemente por algunas regiones de la molécula portadora.  
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Figura R.1. Clasificación inmunológica y clínica de las reacciones alérgicas a fármacos con base 
inmunológica. RAF: Reacciones adversas a fármacos.  
Figura R.2. Secuencia de acontecimientos de las reacciones alérgicas inmediatas: fase de sensibilización 
y desarrollo de la respuesta alérgica inmediata. CPA: célula presentadora de antígenos. FcεRI: receptor 
celular de alta afinidad.  
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Figura R.3. Hipótesis del hapteno propuesta por Landsteiner. 
Las reacciones alérgicas inmediatas a antibióticos betalactámicos son las reacciones con 
base inmunológica más frecuentes y pueden ser inducidas por cualquiera de las 
estructuras de betalactámicos disponibles. Aparecen normalmente en un intervalo de 
tiempo inferior a una hora tras de la administración del fármaco y están mediadas por 
anticuerpos IgE que reconocen específicamente estas estructuras. Dentro de los 
antibióticos betalactámicos, las penicilinas han sido los fármacos más estudiados y de 
los que se conoce bien su inmunoquímica, empleándose como modelo para estudio de 
las reacciones alérgicas a otros medicamentos. 
Los antibióticos betalactámicos se clasifican en función de su estructura química en seis 
grupos: penicilinas, cefalosporinas, carbapanemas, clavamas y monobactamas (Figura 
R.4). Dentro de esta clasificación, las penicilinas y las cefalosporinas son los dos grupos 
principales. 
La estructura general de todos los betalactámicos (Figura R.4) consiste en un anillo β-
lactámico que, a excepción de las monobactamas, está fusionado a otro anillo: de 
tiazolidina en el caso de las penicilinas, de dihidrotiazina en el caso de cefalosporinas, 
de dihidropirrol en carbapenemas y de oxazolidina en clavamas. Cada tipo de antibiótico 
betalactámico presenta diferentes cadenas laterales o sustituyentes R, unidos al anillo 
de β-lactama (R or R1), excepto en las clavamas, o al otro anillo (R2, R3) excepto en 
penicilinas y monobactamas. Hay una gran variedad de estructuras de cadenas laterales, 
que pueden ser similares o idénticas entre miembros de los diferentes grupos de 
betalactámicos. 
Los antibióticos betalactámicos son estructuras de bajo peso molecular que actúan 
como haptenos en el reconocimiento por el sistema inmune, por lo que es necesario 
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que se unan a estructuras macromoleculares para poder inducir una respuesta 
inmunológica.  
Figura R.4. Diferentes antibióticos betalactámicos con detalles de su estructura general. 
Todos los antibióticos betalactámicos son químicamente reactivos sin necesidad de un 
proceso metabólico previo y tienen la capacidad de unirse de forma espontánea a 
proteínas exógenas o endógenas que pueden ser procesadas y reconocidas por el 
sistema inmune. Estos antibióticos se unen covalentemente a las proteínas mediante 
el ataque nucleofílico al grupo carbonilo en el anillo β-lactámico por un grupo amino 
primario de los residuos aminoacídicos de la proteína, con formación de un enlace tipo 
amida.  
Las penicilinas son los antibióticos betalactámicos mejor estudiados y dentro de este 
grupo, la bencilpenicilina fue el primer hapteno del que se estudió su inmunoquímica en 
detalle y que tradicionalmente ha sido considerado como el hapteno modelo para el 
estudio de las reacciones alérgicas a fármacos. Durante muchos años, el determinante 
antigénico mejor conocido ha sido el bencilpeniciloil (BPO), estructura estable que se 
forma por la unión del grupo carbonilo resultante de la apertura nucleofílica del anillo 
β-lactámico con un grupo amino libre de una proteína (Figura R.5). El mismo proceso de 
formación del determinante BPO se ha observado con la amoxicilina (Figura R.5) y la 
ampicilina para la formación de sus determinantes equivalentes amoxiciloil (AXO) y 
ampiciloil (APO), respectivamente,  y por extensión se asume que este tipo de 
determinante “peniciloil” se pueden generar con el resto de penicilinas. A partir de la 
obtención de anticuerpos frente a penicilinas empleando como inmunógeno el fármaco 
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conjugado a una macromolécula portadora se ha observado que tanto la naturaleza de 
la molécula portadora como la del hapteno pueden influir en el reconocimiento por los 
anticuerpos IgE específicos. 
Figura R.5. Formación del determinante antigénico para amoxicilina y ácido clavulánico. 
Carbapenemas y monobactamas también forman determinantes antigénicos estables 
tras la formación de enlace amida entre los grupos amino de las proteínas y el carbonilo 
del anillo β-lactámico. Sin embargo, la inestabilidad del conjugado formado por la unión 
covalente entre proteína y cefalosporinas o ácido clavulánico, y una reactividad química 
más compleja de estos fármacos, ha impedido que se conozca con exactitud la 
estructura del determinante antigénico responsable de las reacciones alérgicas a estos 
antibióticos betalactámicos.  
Una aproximación general para la evaluación y el diagnóstico de sujetos que han sufrido 
una reacción de hipersensibilidad inmediata tras la administración de antibióticos 
betalactámicos se ha descrito por la Academia Europea de Alergia e Inmunología Clínica 
(EAACI). El algoritmo diagnóstico propuesto comprende la realización de una historia 
clínica plausible y de diferentes pruebas diagnósticas entre las que se incluyen las 
pruebas cutáneas, inmunoensayos, ensayos celulares y la administración controlada del 
fármaco (Figura R.6). 
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Figura R.6. Algoritmo diagnóstico para la evaluación de las reacciones alérgicas inmediatas a antibióticos 
betalactámicos. BP-OL: bencilpeniciloil-octalisina. MD: determinante menor (ácido bencilpeniloico). 
El primer paso para realizar un diagnóstico clínico correcto es establecer una historia 
clínica plausible, en la que los síntomas descritos tienen que ser compatibles con este 
tipo de reacciones y aparecer en un intervalo de tiempo inferior a 1 hora tras la 
administración del fármaco.  
A continuación, se realizan pruebas cutáneas, dentro de las cuales se realizan pruebas 
intracutáneas (o prick), y si los resultados obtenidos son negativos se realizan las 
pruebas intradérmicas. Las pruebas cutáneas son muy específicas (97%), sin embargo, 
su sensibilidad ha ido variando a lo largo del tiempo aunque sin superar el 70%.  
En caso de pruebas cutáneas y pruebas in vitro negativas, y sólo en pacientes que no 
presenten ningún factor de riesgo y en los sea imprescindible obtener un diagnóstico 
confirmado, se realiza la administración controlada del fármaco. Estudios recientes 
muestran que, debido a una sensibilidad no óptima de las pruebas cutáneas e in vitro, 
más del 30% de los pacientes con reacciones alérgicas inmediatas a antibióticos 
betalactámicos no podrán ser diagnosticados correctamente si no se someten a una 
administración controlada de fármaco. 
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Los inmunoensayos son los métodos que se emplean en la detección de anticuerpos IgE 
específicos frente a betalactámicos. En estos ensayos se usa una fase sólida (sefarosa, 
discos de celulosa) a la que está unida una molécula portadora (poli-L-lisina, albúmina 
sérica humana (HSA), aminoespaciadores), a la que se conjuga el antibiótico 
betalactámico de interés. En las determinaciones de rutina se emplea una plataforma 
comercial de fluoroinmunoensayo (FEIA) (“ImmunoCAP”, Phadia) que permite un 
análisis automatizado. La especificidad de este método está comprendida entre 83-
100% y la sensibilidad entre el 0-50%. Existen estudios recientes que muestran una 
tendencia general a la disminución de la sensibilidad de esta técnica, posiblemente 
relacionada con la relevancia que están adquiriendo nuevas estructuras betalactámicos 
en el desarrollo de las reacciones alérgicas inmediatas. En algunos laboratorios de 
investigación también se realiza un radioinmunoensayo (RIA) no comercial para la 
determinación de anticuerpos IgE específicos conocido como prueba 
radioalergoabsorbente (RAST). En este método se emplean como fase sólida discos de 
celulosa activados con bromuro de cianógeno a los que se une una molécula portadora 
conjugada con el hapteno de interés. Los valores de especificidad del RAST están 
comprendidos entre el 68-83% y los de sensibilidad se sitúan alrededor del 43-75%. En 
comparación con el inmunoCAP, el RAST presenta mayor sensibilidad/especificidad, 
pero carece de automatización y necesita de método de detección radiactivo para el que 
se necesitan instalaciones especiales y personal con formación específica, no disponibles 
en todos los laboratorios. Con objeto de mejorar la sensibilidad de estas pruebas se 
están realizando estudios basados en la aplicación de la nanotecnología, fundamental 
para la mejora de los métodos diagnósticos en biomedicina. Así, se ha dedicado mucho 
esfuerzo en la incorporación de diferentes haptenos/determinantes en la construcción 
de sistemas nanométricos capaces de emular in vitro el reconocimiento que ocurre in 
vivo. En este sentido, se han utilizado estructuras dendriméricas como moléculas 
portadoras a las que se conjugan antibióticos betalactámicos. Además se han 
desarrollado diferentes métodos de anclaje a la fase sólida, incluyendo el empleo de 
espaciadores para aumentar la accesibilidad de los conjugados por la IgE, con un 
consecuente aumento de sensibilidad.  Otros estudios están encaminados al empleo de 
nuevas fases sólidas diferentes a los tradicionales discos de celululosa como 
nanopartículas de sílice, zeolitas o láminas de oro. 
Entre los ensayos celulares, el uso del test de activación de basófilos (BAT) está 
aumentando de forma progresiva en el diagnóstico de las reacciones alérgicas 
inmediatas. Se basa en la capacidad de los basófilos activados, tras su estimulación con 
el fármaco, de expresar en su superficie marcadores de activación, que pueden ser 
detectados mediante citometría de flujo. Este método tiene una sensibilidad del 49% y 
una especificidad del 93% con los antibióticos betalactámicos.  
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JUSTIFICACIÓN E HIPÓTESIS 
La alergia a antibióticos betalactámicos constituye actualmente un problema de salud 
importante que necesita un diagnóstico rápido y preciso para poder instaurar una 
terapia antibiótica apropiada, incrementar la seguridad del paciente y reducir costes al 
sistema sanitario. De entre las diferentes  reacciones alérgicas,  las reacciones 
inmediatas (mediadas por IgE) a antibióticos betalactámicos constituyen las más 
frecuentes. El diagnóstico in vitro de este tipo de reacciones es objeto de estudio de esta 
tesis. 
El hecho de poder diagnosticar correctamente la alergia a fármacos es muy importante 
para realizar una adecuada prescripción de medicamentos y evitar riesgos para el 
paciente. La primera aproximación para evaluar al paciente consiste en una historia 
clínica detallada, lo cual es a veces muy difícil de conseguir. La siguiente opción 
considera frecuentemente las pruebas cutáneas y, si son negativas, las pruebas de 
administración controlada. Debido al alto riesgo que supone la realización de estas 
pruebas in vivo, los métodos in vitro representan la alternativa ideal para el diagnóstico. 
Las dos técnicas in vitro más empleadas consisten en inmunoensayos, basados en el 
reconocimiento por la IgE específica del fármaco o un metabolito unido a una fase sólida, 
y el BAT, basado en la cuantificación de la activación del basófilo tras su estimulación 
con el fármaco. Entre los inmunoensayos, el InmunoCAP es el único método comercial 
y está sólo disponible para algunos antibióticos betalactámicos, presentando poca 
sensibilidad. El RAST presenta una mayor sensibilidad pero su principal inconveniente es 
la necesidad del uso de un anticuerpo radioactivo. El BAT permite el diagnóstico en el 
50%. Varios factores pueden influir en la falta de sensibilidad de esta técnica, entre los 
que se encuentra: (i) la no inclusión, en la prueba in vitro, del metabolito o derivado del 
fármaco que indujo la reacción in vivo; o (ii) que la molécula portadora empleada no 
exponga al fármaco en una conformación o número óptimo para ser reconocido por la 
IgE. 
Sin duda, comprender el mecanismo mediante el cual la molécula del fármaco se 
metaboliza después de la conjugación con la proteína portadora y el conocimiento de 
los metabolitos exactos que interaccionan con el sistema inmune e inducen la respuesta 
alérgica, es clave para poder evaluar estas reacciones mediante test diagnósticos tanto 
in vivo como in vitro. La estructura del fármaco que permanece unida al portador se 
llama determinante antigénico. Los estudios dirigidos hacia la identificación de 
determinantes antigénicos de fármacos y los conjugados hapteno-portador resultan 
muy complejos y no se han abordado con éxito para prototipos importantes de 
fármacos, como cefaclor, cefadroxilo y ácido clavulánico. Esto implica una dificultad 
añadida para la realización de un diagnóstico de alergia, ya que hasta la fecha sólo 
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existen pruebas cutáneas, que en el caso concreto de estos fármacos no están 
estandarizadas, e implican un riesgo.  
Con el fin de entender el mecanismo de degradación de los fármacos tras su unión con 
las proteínas, es necesario proponer cuales son estos mecanismos y realizar la síntesis 
de una serie de estructuras candidatas para su evaluación en la activación y/o 
reconocimiento molecular por el sistema inmune. Partimos de la base de que podemos 
identificar estos nuevos determinantes antigénicos y que su incorporación a los 
materiales diagnósticos implicaría un gran avance.  
Otra causa que con probabilidad también influye en la baja sensibilidad de los métodos 
diagnósticos in vitro de alergia a fármacos, además del desconocimiento de los 
determinantes antigénicos implicados, es la escasa cantidad de IgE específica 
(femtogramos o menos) asociada a este tipo de alergias. El marcaje con fluorescencia 
de un anticuerpo secundario altamente específico serviría para afrontar el 
inconveniente de la detección con radioactividad del RAST, pudiéndose emplear en 
inmunoensayos convencionales. Las plataformas de microarray permiten la evaluación 
en paralelo de múltiples fármacos con una mínima cantidad de muestra y podrían 
afrontar la necesidad de gran cantidad de muestra así como la capacidad de analizar un 
limitado número de fármacos de los métodos actuales. El marcaje mencionado 
permitiría conseguir un método de detección compatible con los escáneres empleados 
en los microarray.  
El uso de dendrones como nanoestructuras para el marcaje de anticuerpos secundarios 
permite aumentar el número de unidades fluorescentes en la sonda debido a su 
multivalencia. Un correcto diseño de estas nanoestructuras permitiría el marcaje 
específico del anticuerpo en regiones que no afecten al reconocimiento, así como la 
amplificación de la señal de detección sin incrementar las uniones inespecíficas del 
inmunoensayo, llegando a un compromiso óptimo entre el número de unidades 
fluorescentes y la emisión de fluorescencia.  
Los resultados obtenidos de los estudios de identificación de determinantes antigénicos 
y de metodologías para la amplificación de la señal fluorescente podrían ser de 
importancia para el desarrollo y mejora de métodos de diagnóstico in vitro de alergias a 
antibióticos betalactámicos, con lo que se podrían conseguir avances importantes con 
repercusión en el sistema sanitario.  
OBJETIVOS  
El objetivo general de esta tesis está dirigido hacia la identificación de determinantes 
antigénicos y el marcaje fluorescente de anticuerpos secundarios para mejorar el 
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diagnóstico in vitro de reacciones alérgicas antibióticos betalactámicos de tipo 
inmediatas. 
Como objetivos concretos se presentan los siguientes: 
1- Sínteis y evaluación inmunológica de determinantes antigénicos potenciales de α-
aminocefalosporinas mediante una aproximación de estudio SAR, utilizando RAST 
como inmunoensayo para evaluar el reconocimiento IgE específico.  
2- Estudio de los determinantes antigénicos de ácido clavulánico mediate varias 
aproximaciones. (i) Estudios SAR: sínteis y evaluación inmunológica de determinantes 
antigénicos potenciales. (ii) Estudios de proteómica: identificación de fragmento 
anclado a HSA e identificación de los sitios de unión, así como identificación de proteínas 
séricas dianas de haptenización mediante el uso de un derivado biotinilado del ácido 
clavulánico.  
3- Síntesis y caracterización de una serie de dendrones fluorescentes y comprobación 
de la validez para su anclaje quimioselectivo a anticuerpos y amplificación de la señal 
fluorescente.  
RESULTADOS Y DISCUSIÓN 
I. Estudio de los Determinantes Antigénicos de α-aminocefalosporinas 
Las cefalosporinas son betalactámicos de uso creciente, no existiendo en la actualidad 
test con suficiente sensibilidad para detectar anticuerpos IgE específicos en pacientes 
con reacciones alérgicas. Para su diagnóstico in vitro se necesita incluir las estructuras 
químicas de los determinante antigénicos implicados, que aún no han sido identificados. 
Los estudios estructurales de los conjugados de cefalosporinas con proteínas resultan 
muy complicados y nunca se han realizado con éxito. Se ha postulado como producto 
inicial un determinante, el cefalosporoílo (CPO), que aparece como consecuencia de la 
aminolisis de cefalosporinas, que posteriormente sufre fragmentaciones sucesivas en el 
núcleo de dihidrotiazina, durante las cuales generalmente se pierde la cadena lateral R2. 
Sobre la base de esta hipótesis, y dada la inestabilidad y dificultad de aislamiento del 
CPO intermedio y de sus productos de degradación, en estudios previos del grupo de 
investigación, se abordó este estudio mediante una aproximación sintética. De modo 
que la relación entre la estructura química del determinante antigénico sintético y el 
reconocimiento molecular por IgE se determinó mediante el estudio de estructuras 
definidas (I, II, III y IV) mostradas en la Figura R.7 que corresponden a los 
determinantes propuestos de diferentes cefalosporinas. Los resultados indicaron que 
los determinantes antigénicos retienen el sustituyente R1 de las cefalosporinas y 
alguna porción del anillo de dihidrotiazina, aunque sin incluir el átomo de azufre.  
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La especificidad está relacionada principalmente con la cadena lateral R1 y la 
diferente funcionalización en el carbono puente refinan el reconocimiento molecular 
con la IgE.  
Figura R.7. Hipótesis de degradación de cefalosporinas (A) y α-aminocefalosporinas (B). 
Aunque en este sentido se ha avanzado considerablemente en el conocimiento de las 
estructuras antigénicas de cefalosporinas, todavía no existen fases sólidas que incluyan 
estas moléculas ancladas adecuadamente para llevar a cabo los inmunoensayos en la 
clínica rutinaria. Por otro lado, otras aminocefalosporinas como el cefaclor y el 
cefadroxilo muestran patrones de reconocimiento diferentes, que todavía no han sido 
estudiados en detalle, y la evaluación clínica de un producto de degradación con un 
núcleo de pirazina (V), Figura R.7B y Figura R.8, podría ser necesaria para realizar este 
diagnóstico. En este trabajo, abordamos también desde una aproximación sintética el 
estudio del reconocimiento molecular de derivados cíclicos (pirazinonas) de cefaclor y 
cefadroxilo por las IgE específicas.  
La estrategia sintética empleada para la síntesis de los potenciales determinantes 
antigénicos con estructura cíclica de cefaclor y cefadroxilo fue 
Ugi/Desprotección/Ciclación (UDC), cuyo esquema se muestra en la Figura R.8. En 
primer lugar, se llevó a cabo la reacción multicomponente de Ugi (U-4CR), en la que se 
emplean simultáneamente un aldehído o cetona, un isocianuro, una amina y un ácido 
carboxílico para dar lugar a una bisamida (aducto de Ugi). Hay que destacar que, para el 
diseño de las estructuras finales (V), los productos de partida se eligieron de tal forma 
que permitiese tener en el aducto de Ugi el aldehído y los grupos amino adecuadamente 
protegidos. En segundo lugar, la eliminación de los grupos protectores y aromatización, 
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dio lugar a las estructuras tipo pirazinona deseadas. El método empleado es bastante 
eficiente puesto que la molécula objetivo se consigue tras sólo dos pasos sintéticos y 
una etapa de purificación. Además, todos los productos de partida son comerciales.  
Figura R.8. Esquema sintético de las estructuras tipo pirazinona (V) para cefaclor y cefadroxilo, mediante 
la estrategia UDC. 
Se evaluó el reconocimiento inmunológico de estas nuevas estructuras tipo pirazinona 
(V), junto con los determinantes sintéticos anteriormente descritos (II) y los conjugados 
monoméricos con butilamina mediante inhibición del RAST empleando suero de 
pacientes alérgicos a betalactamas. El ensayo consiste en una competición entre el 
reconocimiento de la IgE por la fase sólida (poli-L-lisina-betalactámico) vs los inhibidores 
en fase fluída. De esta manera se comparó el reconocimiento de las estructuras 
sintéticas perfectamente definidas (II y V) y la mezcla de compuestos resultante de la 
conjugación cefalosporina-butilamina. 
La evaluación inmunológica de las estructuras derivadas de cefaclor (Cef1, Cef3 y Cef5) 
se realizó a dos concentraciones (de 100 y 10 mM) con 8 sueros de pacientes alérgicos 
a cefaclor. Los resultados de inhibición de RAST se muestran en la Figura R.9.  
En la mayoría de los casos, para la mayor concentración de inhibidor (100 mM), el 
porcentaje de inhibición obtenido para la pirazinona Cef1 fue mayor que para la 
estructura Cef3, indicando un mayor reconocimiento de la estructura cíclica. Asimismo, 
importantes diferencias fueron encontradas al evaluar la positividad (cuando el 
porcentaje de inhibición es mayor del 50%), puesto que el 63% de los pacientes alérgicos 
a cefaclor reconocieron la estructura Cef1 mientras que solo el 12% reconocieron la 
estructura Cef3. En cuanto a cefaclor-butilamina (Cef5), sólo en dos pacientes (casos 5 y 
8) el reconocimiento fue mayor que para las estructuras sintéticas Cef1 y Cef3, lo que
está de acuerdo con el hecho de que cefaclor-butilamina (Cef5) puede contener todos 
Reacción de UGI
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los tipos de estructuras de degradación posibles pero en una baja concentración de cada 
una, aumentando el uso de los nuevos determinantes sintéticos la sensibilidad del 
ensayo.  
Figura R.9. Resultados de inhibición del RAST utilizando como fase sólida poli-L-lisina-cefaclor y como 
inhibidores estructuras derivadas de cefaclor (A) y comparación de la positividad obtenida para cada 
inhibidor (B). 
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Puesto que amoxicilina y cefadroxilo comparten la misma cadena lateral R1, el 
reconocimiento de los epítopes sintéticos propuestos para cefadroxilo (Cef2 y Cef4) se 
evaluó en nueve pacientes alérgicos a amoxicilina (Figura R.10) para estudiar la 
reactividad cruzada con penicilinas.  
Como resultado, la mayoría de los sueros mostraron el mismo reconocimiento por la IgE 
específica de los pacientes de ambas estructuras Cef2 y Cef4 (Figura R.10A). De hecho, 
se observó un reconocimiento positivo (% inhibición del RAST >50%) similar para Cef2 y 
Cef4 (reactividad cruzada in vitro) en el 44% de los pacientes alérgicos a amoxicilina 
(casos 10, 12, 13 y 17). También se obtuvieron los mismos valores de positividad para 
Cef2 y Cef4 (Figura R.10B), reconociendo cada determinante antigénico derivado de 
cefadroxilo un 56% de los pacientes. Teniendo en cuenta que el fármaco responsible de 
la respuesta alérgica es amoxicilina, estos resultados pueden ser de ayuda para la 
elucidación del determinante antigénico implicado en la alergia a cefadroxilo, además 
de para el studio de la reactividad cruzada entre penicilinas y cefalosporinas.  
También, hay que destacar el hecho de que los resultados de inhibición con las 
estructuras sintéticas concuerdan con los resultados de las pruebas in vivo, puesto que 
la inhibición fue positiva en todos los casos que presentaron skin test positivo a 
cefadroxilo (casos 9, 10, 11 y 13), bien con una de las estructuras (inhibición positiva con 
Cef2 en caso 9 y con Cef4 en caso 11) o con las dos (inhibición positiva con Cef2 y Cef4 
en casos 10 y 13). Además, en tres de estos cuatro casos con inhibición del RAST y skin 
test a cefadroxilo positivos, los resultados de RAST directo utilizando poli-L-lisina-
cefadroxilo en la fase sólida habían sido negativos, lo que confirma la aplicación 
potencial de las estructuras sintéticas para la mejora de la sensibilidad de los tests in 
vitro dirigidos a estudiar la reactividad cruzada amoxicilina/cefadroxilo. 
El hecho de que cefadroxilo-butilamina (Cef6) fuese reconocido mejor que las 
estructuras sintéticas Cef2 y Cef4 en la mayoría de los casos estaría de acuerdo con el 
hecho de que otros determinantes antigénicos podrían estar también implicados en el 
desarrollo de la respuesta alérgica.  
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Figura R.10. Resultados de inhibición del RAST utilizando como fase sólida poli-L-lisina-amoxicilina y como 
inhibidores estructuras derivadas de cefadroxilo (A) y comparación de la positividad obtenida para cada 
inhibidor (B).  
Como resumen, se han sintetizado nuevos determinantes de α-aminocefalosporinas de 
estructura cíclica (Cef1 y Cef2) que son reconocidos por la IgE específica de pacientes 
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alérgicos a antibióticos betalactámicos. El anclaje de estas estructuras a fase sólida 
podría incrementar la sensibilidad de los inmunoensayos. Además, las estructuras 
sintetizadas pueden ser de uso en el diagnóstico de alergia a cefalosporinas que 
comparten la misma cadena lateral R1 como cefprozilo, con la misma R1 que cefadroxilo, 
o cefalexina y cefaloglicina, con la misma R1 que cefaclor.
II. Elucidación de la Estructura de Determinantes Antigénicos del Ácido
Clavulánico 
Los nuevos hábitos de prescripción están modificando los patrones alérgicos de 
especificidad debido a la aparición de nuevos determinantes antigénicos, fenómeno que 
en la actualidad está ocurriendo en muchos países con la combinación amoxicilina-ácido 
clavulánico. El desconocimiento de la estructura del determinante antigénico del ácido 
clavulánico conduce a un diagnóstico incompleto cuando esta combinación está 
implicada en las reacciones alérgicas. Se ha descrito que el ácido clavulánico puede 
generar productos estables de una estructura intermedia resultante de la apertura de 
los anillos de β-lactama  y de oxazolidina (Figura R.11), a través de un mecanismo similar 
a la formación de aductos con betalactamasas. Estas estructuras derivadas podrían estar 
implicadas en el reconocimiento molecular de la IgE en reacciones selectivas, aunque 
para llegar a ciertas conclusiones sería necesario profundizar con estudios que 
impliquen el empleo de estructuras bien definidas, lo que incluimos como hipótesis de 
trabajo.  
Los dos determinantes antigénicos principales propuestos para ácido clavulánico, AD-I 
(compuesto 1,3-dicarbonílico) y AD-II (compuesto monocarbonílico), son estructuras de 
bajo peso molecular con sólo tres átomos de carbono. Mientras que AD-I puede ser 
reactivo frente a proteínas debido al aldehído que comprende en su estructura, la 
reactividad de AD-II es limitada. Hay que destacar que el resto de estructuras 
intermedias también pueden ser determinantes antigénicos responsables de la alergia 
a ácido clavulánico. El análisis del reconocimiento molecular por IgE específicas de 
estructuras sintéticas bien definidas derivadas de ácido clavulánico daría información de 
los grupos químicos responsables del desarrollo de la respuesta alérgica y la 
identificación de los determinantes antigénicos más relevantes podría ayudar a mejorar 
los procedimientos diagnósticos actuales.  
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Figura R.11. Mecanismo de reacción propuesto para la unión covalente de ácido clavulánico a proteínas 
y diferentes vías de degradación que pueden dar lugar a diferentes posibles determinantes antigénicos.  
En este trabajo, abordamos también mediante una aproximación sintética la evaluación 
del reconocimiento inmunológico de distintas estructuras derivadas de AD-I y AD-II.  
Como primera aproximación, análogos sintéticos de AD-I y AD-II así como la molécula 
completa de ácido clavulánico, tanto cerrada como con el anillo β-lactámico abierto, 
fueron ancladas a diferentes superficies sólidas (celulosa y nanopartículas de sílice) y se 
sometieron a evaluación inmunológica mediante RAST utilizando sueros de pacientes 
alérgicos selectivos a ácido clavulánico. Los resultados no fueron satisfactorios, 
poniéndose de esta forma de manifiesto la dificultad para la evaluación de la 
inmunogenicidad de los derivados de ácido clavulánico, quizá debida a su pequeño 
tamaño. 
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Como segunda aproximación, seis análogos sintéticos, cuya estructura se representa en 
la Figura R.12, fueron sintetizados, purificados y caracterizados para su posterior 
evaluación inmunológica mediante BAT.  
Figura R.12. Determinantes sintéticos correspondientes a AD-I (Clav1-Clav3) y AD-II (Clav4-Clav6). 
Todos los análogos sintéticos de ácido clavulánico y el mismo ácido clavulánico fueron 
evaluados en 29 pacientes con alergia selectiva a ácido clavulánico y 25 controles con 
tolerancia confirmada a amoxicilina-ácido clavulánico. La concentración óptima para el 
estudio de la activación de basófilos se seleccionó tras la elaboración de curvas dosis-
respuesta y resultó ser de 8 mM para ácido clavulánico, Clav2 y Clav3, mientras que el 
resto de estructuras sintéticas no mostraron diferencia significativa entre pacientes y 
controles.  
El mecanismo IgE mediado se confirmó mediante la inhibición de los basófilos con 
Wortmanina, inhibidor de unas enzimas parte del proceso de señalización, puesto que 
en todos los casos este tratamiento redujo notablemente el porcentaje de expresión de 
CD63 comparado con el ensayo sin Wortmanina.  
Se observó que de los pacientes con BAT positivo a ácido clavulánico, el 75% era 
también positivo a Clav2 y el 33,3% a Clav3. Algo más interesante, es el hecho de que 
en los casos con BAT negativo a ácido clavulánico, el 47.1% presentó resultados 
positivos con Clav2 y el 23.5% con Clav3 (Figura R.13A). El porcentaje de pacientes con 
BAT positivo aumentó notablemente cuando se combinaron los resultados obtenidos 
con ácidco clavulánico y  Clav2 comparado con ácido clavulánico solo pero no aumentó 
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al incluir también Clav3 (Figura R.13B). 
Figura R.13. Resultados de BAT positivo en pacientes alérgicos. A, Comparación del porcentaje de 
resultados de BAT positivo para Clav2 y Clav3 en casos de BAT positivo o negativo a ácido clavulánico. B, 
Comparación del porcentaje de positividad de BAT combinando los resultados con ácido clavulánico, 
Clav2 o Clav3. Diferencias significativas se indicant en la gráfica (* p<0.01). 
Por otro lado, puesto que la unión de antibióticos betalactámicos a proteínas juega un 
papel importante en el desarrollo de alergia, en primer lugar nos propusimos el estudio 
de la haptenización in vitro por ácido clavulánico, tomando la HSA como proteína 
modelo. El análisis mediante MALDI-TOF de los conjugados preparados (relación molar 
proteína/fármaco de 1:10 a 1:320) utilizando concentraciones crecientes de ácido 
clavulánico, tuvo como resultado un incremento en la masa de la proteína proporcional 
a la concentración de fármaco utilizada en la incubación.    
Para posteriores estudios, elegimos el conjugado de relación molar proteína/fármaco 
1:10, por ser el más próximo a las condiciones terapéuticas. Los residuos de HSA 
modificados se identificaron tras la digestión del conjugado con arginina C seguida del 
análsis  por cromatografía líquida acoplada a espectrometría de masas (LC-MS/MS) de 
los péptidos resultantes. La molécula de áci do clavulánico   completa no se encontró 
pero se encontraron dos residuos de lisina (lisinas 195 y 475) con un incremento de 
masa de 70 Da, que concuerda con la adición de un fragmento de ácido  clavulánico  de 
masa 71 y la posterior pérdida de un átomo de hidrógeno. La reactividad de estos 
residuos fue confirmada mediante estudios de modelización molecular, y es 
determinada tanto por el entorno de los residuos como por la accesibilidad del 
residuo. La adición de 70 Da es compatible con nuestra hipótesis de la formación de un 
determinante antigénico con la estructura de AD-I (Figura R.11) y con los resultados 
obtenidos con el BAT, lo que confirmaría que el determinante antigénico derivado de
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AD-I que es específicamente reconocido forma parte del conjugado HSA-ácido 
clavulánico. 
Una vez comprobada la capacidad de haptenización de ácido clavulánico, la 
identificación de las proteínas séricas diana de haptenización por este betalactámico 
podría  suponer un gran avance pero la inexistencia de anticuerpos monoclonales α-
ácido clavulánico  hace que este estudio no sea viable. La interacción avidina-biotina es 
de gran afinidad y sensibilidad y permite la combinación de la modificación de 
proteínas con compuestos biotinilados con métodos de detección, purificación e 
imagen. Por ello, nos propusimos la síntesis de un derivado biotinilado de á cido 
clavulánico  para su uso en la detección de aductos con proteínas séricas. 
En primer lugar, se sintetizó un derivado biotinilado de ácido  clavulánico  que 
comprende la introducción de espaciador de tetraetilenglicol (TEG) entre ácido 
clavulánico  y la biotina mediante un proceso sintético de dos pasos (Figura R.14) que 
permitió la obtención del derivado CLV-TEG-B  con un rendimiento medio del 62%. El 
espaciador hidrofílico proporciona solubilidad en agua así como flexibilidad y espacio 
que permite a la biotina estar más  accessible para su interacción con la estreptavidina 
y por tanto, más eficiencia en la detección.  
Figura R.14. Síntesis del derivado biotinilado CLV-TEG-B. 
Tras la comprobación mediante RMN de la capacidad de reacción con nucleófilos de 
CLV-TEG-B, el siguiente paso fue el estudio de su capacidad de haptenización in vitro de 
la HSA. Se prepararon conjugados HSA-CLV-TEG-B utilizando varias relaciones molares 
proteína/betalactámico y tras su separación mediante SDS-PAGE se transfirieron a una 
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membrana de polifluoruro de vinilideno (PVDF) y se detectaron utilizando 
estreptavidina-peroxidasa de rábano(HRP) y reactivo de   ECL (Figura R.15).  
Se observó no sólo que la modificación era concentración-dependiente, sino la alta 
sensibilidad de la detección, puesto que incluso el conjugado preparado con una baja 
concentración de CLV-TEG-B es visible tras la detección.  
Figura R.15. Detección con estreptavidina-HRP de HSA modificada utilizando diferentes relaciones 
molares HSA/CLV-TEG-B. En cada calle, se sembraron 2 µg de conjugado.  
El siguiente experimento, fue diseñado para comparar el comportamiento de 
haptenización de ácido clavulánico y CLV-TEG-B e intentar entender el mecanismo 
implicado. En un ensayo competitivo, se incubó HSA durante dos horas con CLV-TEG-B 
80 mM tras la preincubación durante 16 horas con diferentes concentraciones de ácido 
clavulánico per se (de 0 a 10X) y los conjugados resultantes se purificaron mediante 
dodecil sulfato sódico-electroforesis en gel de poliacrilamida (SDS-PAGE), se 
transfirieron a una membrana de PVDF y se realizó la detección con SDS-PAGE y reactivo 
de ECL. Los resultados (Figura R.16) indican que la incubación de HSA en presencia de 
un exceso de ácido clavulánico, reduce la formación de aductos con CLV-TEG-B, lo que 
significa que ambos compuestos compiten por su unión a HSA y sugiere que pueden 
unirse a los mismos sitios de unión de la proteína.  
Para estudiar la haptenización de proteínas séricas por CLV-TEG-B, suero humano fue 
conjugado usando dos concentraciones del derivado biotinilado y alícuotas de 4 µg de 
la incubación se purificaron mediante SDS-PAGE junto con un control de HSA, 
transferidas y detectadas con estreptavidina-HRP y reactivo de ECL (Figura R.17). La 
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detección de proteína total con Coomassie confirma que la diferencia de intensidad 
observada en las bandas en el revelado con estreptavidina-HRP es debido únicamente a 
la biotinilación y el hecho de que no se observe banda para el control de HSA confirma 
la especificidad de la detección.  
Figura R.16. Resultados de los ensayos de competición entre ácido clavulánico y CLV-TEG-B. 
Figura R.17. Detección de proteínas séricas biotiniladas (arriba) y patron de proteínas totales con tinción 
de Coomassie (abajo). 
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Con este ensayo queda demostrado que CLV-TEG-B se une covalentemente a varias 
proteínas séricas pero para la identificación de estas proteínas se require su separación 
mediante 2D-SDS-PAGE y su análisis por huella peptídica. La Figura R.18  muestra el 
análisis mediante 2D-SDS-PAGE de un suero control y de un suero modificado con CLV-
TEG-B a una relación molar proteína/ CLV-TEG-B 1:0.192 tras su transferencia y 
detección con estreptavidina-HRP, a la izquierda, y el patrón de proteínas totales en el 
suero modificado y los puntos de interés elegidos, a la derecha. Los puntos de interés 
señalados fueron recortados del gel, digeridos con tripsina y analizados mediante huella 
peptídica utilizando espectrometría de masas de desorción/ionización láser asistida por 
matriz-tiempo de vuelo (MALDI-TOF-TOF MS) (Tabla R.1). 
Figura R.18. Análisis de las proteínas séricas diana de haptenización por CLV-TEG-B mediante 2D-SDS-
PAGE. 
Las proteínas séricas modificadas por CLV-TEG-B identificadas en este experimento 
fueron HSA, haptoglobina y las cadenas ligeras y pesadas de las inmunoglobulinas (Ig). 
Aunque la inexistencia de un anticuerpo monoclonal α-ácido clavulánico impide 
comprobar si estas mismas proteínas son haptenizadas por ácido clavulánico per se, 
nuestra aproximación da información sobre el proceso de haptenización mediante el 
uso de un método de detección de alta sensibilidad.  
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Tabla R.1. Resultado de la identificación por huella peptídica mediante digestion tríptica y analisis por 
MADI-TOF-TOF de las proteínas séricas modificadas por CLV-TEG-B. 
Para la elucidación de la estructura derivada de CLV-TEG-B que queda unida a la 
proteína tras la conjugación, como primera aproximación se incubó el péptido 
182-195HSA de secuencia LDELRDEGKASSAK con un exceso molar del derivado 
biotinilado y tras su purificación por cromatografía de exclusión, se añalizó por 
MALDI-TOF tanto el péptido modificado como el péptido control sin incubar. Al 
analizar los resultados (Figura R.19) se observó un pico que pertenecía al péptido sin 
conjugar (1518.686 Da) y un pico muy bajo (2118.898 Da) correspondiente al péptido 
modificado con un incremento de masa de 600.2 Da.  
Spot Número de 
acceso 
Nombre de la 
proteína 
Puntuación 
total 
Puntuación 
límite 
Peso 
molecular 
(Da) 
pI Péptidos emparejados 
Cobertura 
(%) 
1 P02768 HSA 470 56 71317 5.92 43 69 
2 P01857 Ig gamma-1 chain C region human 119 56 36596 
8.46 13 52 
3 P01857 Ig gamma-1 chain C region human 197 56 36596 
8.46 18 66 
4 P00738 Haptoglobin human 128 56 45861 6.13 18 35 
5 P00738 Haptoglobin human 102 56 45861 6.13 16 33 
6 P01834 Ig kappa chain C region human 86 56 11773 5.58 7 76 
7 P01834 Ig kappa chain C region human 66 56 11773 5.58 6 76 
Como segunda aproximación, para caracterizar la estructura que queda unida a la HSA 
completa se preparó el conjugado HSA-CLV-TEG-B 1:10 y se analizó mediante LC-MS/
MS tras digestion enzimática del conjugado formado. Su análisis resultó complicado, no 
obteniéndose péptidos modificados cuando se utilizó el modo de fragmentación CID. 
Además del modo de fragmentación, la baja proporción de conjugación observada en 
el experimento anterior (Figura R.19) puede ser la causa de la dificultad encontrada en 
el análisis. Al utilizar disociación por transferencia de electrones (ETD) como modo de 
fragmentación, método más suave que conserva modificaciones postraduccionales, se 
encontró el péptido 404-430HSA, de secuencia QNALLVRYTKKVPQVSTPTLVEVSRNL, 
modificado con una masa de 600.22 Da, que coincide con el incremento de masa 
encontrado para tras el análisis por MALDI-TOF del péptido utilizado como primera 
aproximación.  
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Figura R.19. MALDI-TOF MS análisis de 182-195HSA tras su conjugación con CLV-TEG-B (arriba) y sin 
conjugar (abajo). 
III. Marcaje de Anticuerpos Secundarios para la Detección de IgE Específica
en Alergia a Fármacos 
La sensibilidad y especificidad de la detección de sIgE deben estar aseguradas en los 
inmunoensayos empleados el diagnóstico in vitro de alergia a fármacos. Para ello, se 
require el marcaje de los anticuerpos secundarios empleados en los ensayos con 
radioisótopos, luminóforos o fluorescentes. El empleo de anticuerpos marcados con 
radioisótopos sigue siendo necesario para la detección de sIgE en alergia a fármacos 
puesto que el RAST es el único ensayo disponible en muchos casos. El marcaje con 
fluorescescencia, puede ser una buena alternativa a los radioisótopos pero sería 
necesaria la amplificación de la señal para obtener la sensibilidad requerida para la 
detección de sIgE en alergia a fármacos.  
Este capítulo está dedicado a la optimización de métodos de marcaje de anticuerpos 
secundarios para su utilización en los test in vitro empleados en el diagnóstico de alergia 
a fármacos. Por un lado, se ha optimizado el marcaje radiactivo de un anticuerpo α-
human IgE altamente específico para su utilización en RAST caseros. Por otro lado, se ha 
diseñado, sintetizado y caracterizado una serie de dendrones fluorescentes con una o 
Monocharged 182-195HSA
Purified control 182-195HSA
Purified 182-195HSA-CLV-TEG-B
Monocharged 182-195HSA
182-195HSA-CLV-TEG-B
Δ= 600.2
m/z
monocargada
monocargada
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varias moléculas de fluorescente y se ha probado su adecuación para el marcaje 
específico de anticuerpos secundarios para su futuro uso en plataformas de microarray. 
Para el marcaje del anticuerpo con I125 en condiciones acuosas se utilizaron tubos con 
IodoGen como reactivo de yodación. En primer lugar, se optimizó la cantidad de NaI125 
para la que se obtenía un mayor marcaje utilizando un anticuerpo de prueba y, una vez 
optimizada (250 µCi), se repitió el protocolo para marcar el anticuerpo altamente 
específico. La concentración y actividad por volumen finales del anticuerpo específico 
marcado fueron 0.15µg/mL 1.57 µCi/mL, incluso mayor que para un anticuerpo 
comercializado por Phadia hace años (1.06 µCi/mL).  
La eficacia del marcaje se comprobó mediante la comparación de los resultados de RAST 
obtenidos para sueros de pacientes alérgicos a amoxicilina y controles previamente 
analizados utilizando diferentes anticuerpos radiactivos, obteniéndose mejores 
resultados con el anticuerpo marcado con nuestro protocolo optimizado (Figura R.20).   
Figura R.20. Comparación de resultados de RAST obtenidos con diferentes marcajes radiactivos. 
Los dendrones son moléculas monodispersas con forma de cuña que poseen varios 
grupos funcionales terminales y un único grupo funcional en el punto focal, por lo que 
pueden ser de utilidad para el marcaje selectivo de anticuerpos. Los fluoróforos tipo 
cianina son de los más prometedores en la región del infrarrojo cercano, ideales para 
imagen tanto in vivo como in vitro. Entre ellos, Cy5 parece ser el mejor, puesto que su 
longitud de onda de absorción superior a 600 nm reduce la interferencia por 
autofluorescencia de las células, si se compara con otros fluoróforos de ese espectro. 
Además, los escáneres de microarray presentan la posibilidad de detección de Cy5.  
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En este trabajo presentamos la síntesis de una serie de nuevas sondas que presentan 
funcionalidad hidracina en el punto focal y una o varias unidades fluorescentes en la 
periferia (Figura R.21). La multivalencia viene dada por la incorporación de dendrones 
basados en el monómero bis-MPA a la estructura. 
Figura R.21. Sondas mono o multivalentes con un grupo hidracina como conector para bioconjugación, 
un espaciador hidrofílico tipo tetraetilenglicol y una o varias unidades fluorescentes. 
Los dendrones G0-Cy5, G1-Cy5 y G3-Cy5 fueron sintetizados y posteriormente utilizados 
para la bioconjugación a un anticuerpo. En primer lugar, los precursores se diseñaron 
para albergar las funcionalizaciones ortogonales adecuadas: hidracina protegida en el 
punto focal y funcionalización alquino en la periferia para posterior funcionalización con 
el fluorerscente mediante química click. El esquema sintético completo se muestra en 
el Esquema R.1.  
Espaciador hidrofílico
Fluorescente
G1
Fluorescente
G0-Cy5
G1-Cy5
Conector
G1
G3G3
G2
G3-Cy5
Fluorescente
Espaciador hidrofílico
Espaciador hidrofílico
Conector
Conector
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Esquema R.1. Síntesis de los dendrones fluorescentes. A) Síntesis del espaciador basada en la 
derivatización de una cadena de tetraetilenglicol con una molécula que contiene hidracina diprotegida 
con Boc. B) Síntesis de G0-Cy5, con una unidad fluorescente. C) Síntesis del dendrón G1-Cy5, con dos 
unidades fluorescentes. D) Síntesis del dendrón G3-Cy5, con ocho moléculas fluorescentes. 
Las molécuas fueron caracterizadas mediante 1H y 13C-RMN y MALDI-TOF, y G0-Cy5, G1-
Cy5 y G3-Cy5 se caracterizaron además mediante espectroscopía UV-Vis y de 
fluorescencia (Figura R.22).   
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Figura R.22. Caracterización de los dendrones. A) De derecha a izquierda, monitorización mediante 
MALDI-TOF de la síntesis de los dendrones con funcionalización alquino en la periferia. B) 
Caracterización mediante 1H-RMN de G0-Cy5. C) Espectroscopía UV-visible de los dendrones G0-Cy5, 
G1-Cy5 and G3-Cy5. D) Emisión de fluorescencia de los dendrones G0-Cy5, G1-Cy5 y G3-Cy5. 
Una vez caracterizados las dendrones fluorescentes, se comprobó su utilidad como 
sondas para el marcaje de anticuerpos. La metodología usada para el marcaje está 
basada en el marcaje específico del anticuerpo a través de dos pasos Figura R.23: (i) 
oxidación suave con NaIO4 de los 1,2-dioles del ácido siálico presente en las cadenas de 
carbohidratos ancladas en la región cristalizable (Fc) de las cadenas pesadas del 
anticuerpo; (ii) reacción selectiva del grupo hidracina presente en los dendrones (G0-
Cy5, G1-Cy5 y G3-Cy5) con los aldehídos generados mediante enlace hidrazona. Este 
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marcaje no afecta a la actividad del acticuerpo o a su reconocimiento ni provoca un 
mayor daño oxidativo. Tras el marcaje, los anticuerpos fueron purificados con sephadex 
G-25 y lavados adicionales usando filtros de diálisis para asegurar la eliminación del 
exceso de fluorescente.  
Figura R.23. Esquema del proceso empleado para el marcaje del anticuerpo. La concentración de las 
disoluciones del anticuerpo mostradas en la figura es de aproximadamente 8 mg/mL. 
La unión covalente de las sondas fluorescentes al anticuerpo se confirmó mediante SDS-
PAGE. A la derecha de la Figura R.24 se puede observar la detección fluorescente 
selectiva en los casos en los que el anticuerpo estaba marcado con los dendrones 
fluorescentes, no observándose señal para el anticuerpo sin marcar. A la izquierda de la 
Figura R.24, se muestra la tinción del gel con Coomassie, en la que se observa que la 
recuperación fue similar en los tres casos para el anticuerpo marcado tras su 
purificación.  
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Figura R.24. Caracterización mediante SDS-PAGE del anticuerpo marcado con las sondas fluorescentes. 
Se cargó en el gel un marcador de peso molecular (calle 1), cuatro concentraciones decrecientes de 
anticuerpo sin marcar (calles 2-5) y los conjugados IgG-G0-Cy5, IgG-G1-Cy5 e IgG-G3-Cy5 (calles 6-8). 
Tinción con Commassie (izquierda) y detección fluorescente (derecha). 
La absorbancia del anticuerpo marcado con las sondas fluorescentes presenta una 
banda a 646 nm cuya intensidad aumenta con el número de unidades de fluorescente. 
Los valores de absortividad molar (ε646) fueron 49667, 274985 y 2280894 M-1·cm-1 para 
IgG-G0-Cy5, IgG-G1-Cy5 e IgG-G3-Cy5, respectivamente (Figura R.25 arriba). En el caso 
de IgG-G3-Cy5 se observa una banda también a 600 nm, comportamiento previamente 
recogido en la literatura y debido a la formación de agregados paralelos entre moléculas 
de Cy5 (dímeros H) y que se reduce al añadir dodecil sulfato sódico (SDS) como se 
observa en la Figura R.25 abajo.  
Las propiedades fluorescentes del anticuerpo marcado resultaron en una emisión 
fluorescencia un orden de magnitud mayor para IgG-G1-Cy5 (φ= 0.25, ε·φ= 67891) que 
para IgG-G0-Cy5 (φ= 0.41; ε·φ= 20473) como se observa en la Figura R.26 izquierda. 
Por el contrario, IgG-G3-Cy5 resultó ser apenas fluorescente con un valor 
extremadamente bajo de rendimiento cuántico (φ= 0.02), lo que significaría que la 
mayoría de los fotones absorbidos se desactivan mediante procesos no radiativos. La 
caída de fluorescencia del anticuerpo marcado con respecto a la sonda fluorescente 
libre (G3-Cy5) podría ser debido a un entorno más restringido cuando se incorpora al 
anticuerpo, con las unidades de Cy5 probablemente más cercanas entre sí, lo que 
favorecería la formación de dímeros H. La adición de SDS una disolución de IgG-G3-Cy5 
tuvo como consecuencia un aumento en la fluorescencia Figura R.26 derecha, 
probablemente debido al desdoblamiento de la proteína en presencia del detergente. 
Este último argumento está en concordancia con el resultado del SDS-PAGE (en el paso 
de desnaturalización se utiliza SDS y  -mercaptoetanol, afectando la conformación de 
la proteína), en el que se detectó fluorescencia para IgG-G3-Cy5 a pesar de apenas 
presentar fluorescencia en disolución acuosa.  
Resumen
286 
Figura R.25. Espectro de absorbancia obtenido para el anticuerpo marcado (IgG-G0-Cy5, IgG-G1-Cy5, 
IgG-G3-Cy5) (arriba izquierda). Comparación de la forma diferente del espectro para IgG-G3-Cy5 (arriba 
derecha). Cambio en la absorbancia fluorescencia 90 minutos después de añadir SDS (1%) (abajo). 
Figura R.26. Resultados de emisión de fluorescencia obtenidos para el anticuerpo marcado (IgG-G0-Cy5, 
IgG-G1-Cy5, IgG-G3-Cy5) (izquierda) y cambio en la fluorescencia 90 minutos después de añadir SDS 
(1%) (derecha). 
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De todos estos resultados se concluye que IgG-G1-Cy5, con dos unidades fluorescentes, 
es el que más amplifica la señal fluorescente y, por tanto, podría utilizarse para 
aumentar la sensibilidad de la detección en los inmunoensayos dirigidos al diagnóstico 
de alergia a fármacos. Estos resultados están en concordancia con unos estudios 
anteriores publicados por Gruber y Hahn que aseguraban que el número de Cy5 por 
molécula para el cual se obtiene una óptima fluorescencia es de dos. Sin embargo, para 
nuestro conocimiento, esta es la primera vez que se utilizan sondas solubles en agua con 
funcionalidad ortogonal para el marcaje selectivo de anticuerpos utilizando una 
metodología mediante la cual el sitio de unión al antígeno no se ve afectado.  
CONCLUSIONES 
1. De la síntesis de estructuras tipo pirazinona V (Cef1 y Cef2), derivadas de cefaclor y
cefadroxilo, y de su reconocimiento inmunológico, se deduce que este fragmento
ciclado de la α-aminocefalosporina es reconocido específicamente por anticuerpos
IgE de pacientes que han presentado un episodio alérgico a las correspondientes
cefalosporinas o a otras penicilinas con la misma cadena lateral R1.
La pirazinona Cef1 parece implicar una mejora en el reconocimiento por IgE
específico a cefaclor, comparada con el determinante sintético Cef3.
La pirazinona Cef2 junto con el determinante sintético Cef4 han resultado útiles para
el estudio de reactividad cruzada entre penicilinas y cefalosporinas.
2. De la síntesis de estructuras bien definidas derivadas de ácido clavulánico, se
concluye que su capacidad de activación de los basófilos de pacientes con alergia
selectiva a este betalactámico está influenciada por su estructura química y su
capacidad de unión a proteínas. Clav2, derivado de AD-I, permite aumentar el
porcentaje de pacientes con BAT positivo comparado con el ácido clavulánico.
Asimismo, la estructura de 70 Da identificada, AD-I, que modifica los residuos de
lisina 195 y 475 de la HSA in vitro, confirma los resultados obtenidos mediante SAR.
3. Se ha llevado a cabo el diseño y síntesis de un derivado biotinilado del ácido
clavulánico (CLV-TEG-B) que presenta solubilidad en agua y se ha probado su
capacidad de haptenización de proteínas, que es dependiente de la concentración
del derivado.
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Del estudio de la haptenización de proteínas séricas con CLV-TEG-B, se deduce que 
éste es una herramienta útil para la  identificación de proteínas candidatas. 
4. Tres dendrones (Dend5, Dend9, and Dend15), con características ortogonales se han
funcionalizado con 1, 2 u 8 unidades del fluorescente sulfo-Cy5 en su periferia, y un
grupo hidrazina en el punto focal (G0-Cy5, G1-Cy5 y G3-Cy5). De los estudios
espectroscópicos se deduce que tanto absorbancia como fluorescencia aumentan
con el número de unidades fluorescentes.
De la prueba de concepto que ha consistido en el uso de G0-Cy5, G1-Cy5 y G3-Cy5
como sondas fluorescentes para el marcaje de biomoléculas, se deduce que son
óptimos para el marcaje selectivo de anticuerpos, utilizando α-Human IgG Fc como
modelo.
La señal óptima de amplificación se ha obtenido para el anticuerpo marcado con dos
unidades de sulfo-Cy5 (IgG-G1-Cy5), con una emission de fluorescencia un orden de
magnitud mayor que IgG-G0-Cy5, con una única unidad fluorescente, lo que
convierte al dendrón G1-Cy5 en un valioso candidato para el marcaje de
macromoléculas para aplicaciones tales como la amplificación de la señal de
detección en inmunoensayos.
Por el contrario, se ha observado un enorme fenómeno de quencheo para IgG-G3-
Cy5, que apenas es fluorescente.
De hecho, HSA, haptoglobina y las cadenas pesadas y ligeras de las 
inmunoglubulinas han sido identificadas como potenciales dianas de haptenización 
por CLV.   
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